PMID-sentid	Pub_year	Sent_text	comp_official_name	comp_offset	protein_name	organism	prot_offset
33148174-2	2020	Mechanical loading negatively regulates sclerostin expression, and sclerostin has been shown to induce RANKL synthesis in osteocytes.	sclerostin	67-77	TNF superfamily member 11	Homo sapiens	103-108
33148174-8	2020	This is the first study to report that administration of Scl-Ab has the ability to revert osteocyte-mediated osteoclastogenesis and resorption by decreasing RANKL/OPG ratio expression and increasing WISP1 expression in estrogen deficient osteocytes.	scl-ab	57-63	TNF superfamily member 11	Homo sapiens	157-162
33140671-13	2022	Moreover, TET inhibited the levels of MMP-9, PPAR-gamma, RANKL, beta-CTX and TRACP-5b, and increased the levels of OPG, ALP and osteocalcin (OC) in osteoporosis.	tetrandrine	10-13	TNF superfamily member 11	Homo sapiens	57-62
33140671-16	2022	Besides, TET reversed RANKL-induced osteoclasts proliferation, p65 phosphorylation, and the expression changes of RANKL, Ki67, PPAR-gamma, ALP, OPG.	tetrandrine	9-12	TNF superfamily member 11	Homo sapiens	22-27
33140671-16	2022	Besides, TET reversed RANKL-induced osteoclasts proliferation, p65 phosphorylation, and the expression changes of RANKL, Ki67, PPAR-gamma, ALP, OPG.	tetrandrine	9-12	TNF superfamily member 11	Homo sapiens	114-119
32769069-0	2020	Blockade of RANKL/RANK signaling pathway by epigallocatechin gallate alleviates mast cell-mediated inflammatory reactions.	epigallocatechin gallate	44-68	TNF superfamily member 11	Homo sapiens	12-17
32976685-4	2020	METHODS: We examined the effect of Asperolide A (AA), a marine-derived agent, on osteolysis and RANKL-induced phosphoinositide 3-kinase (PI3K)/AKT/mTOR/c-FOS/nuclear factor-activated T cell 1 (NFATc1) pathway activation, F-actin ring formation, and reactive oxygen species (ROS) generation in vitro.	Reactive Oxygen Species	249-272	TNF superfamily member 11	Homo sapiens	96-101
32976685-4	2020	METHODS: We examined the effect of Asperolide A (AA), a marine-derived agent, on osteolysis and RANKL-induced phosphoinositide 3-kinase (PI3K)/AKT/mTOR/c-FOS/nuclear factor-activated T cell 1 (NFATc1) pathway activation, F-actin ring formation, and reactive oxygen species (ROS) generation in vitro.	Reactive Oxygen Species	274-277	TNF superfamily member 11	Homo sapiens	96-101
32769069-4	2020	Here we investigated the immuno-regulatory effects and its molecular mechanisms of epigallocatechin gallate (EGCG) in RANKL-stimulated human mast cell line, HMC-1 cells.	epigallocatechin gallate	83-107	TNF superfamily member 11	Homo sapiens	118-123
32769069-4	2020	Here we investigated the immuno-regulatory effects and its molecular mechanisms of epigallocatechin gallate (EGCG) in RANKL-stimulated human mast cell line, HMC-1 cells.	epigallocatechin gallate	109-113	TNF superfamily member 11	Homo sapiens	118-123
32769069-5	2020	In this study, EGCG prevented expression of PI3 Kinase and phosphorylation of mitogen-activated protein (MAP) Kinases in RANKL-stimulated HMC-1 cells.	epigallocatechin gallate	15-19	TNF superfamily member 11	Homo sapiens	121-126
32769069-6	2020	EGCG prevented caspase-1 activity and decreased transcriptional activity of nuclear factor (NF)-kappaB by suppressing inhibitory protein kappaBalpha phosphorylation in RANKL-stimulated HMC-1 cells.	epigallocatechin gallate	0-4	TNF superfamily member 11	Homo sapiens	168-173
32769069-7	2020	EGCG has been shown to prevent production and mRNA expression of TSLP, interleukin (IL)-1beta, IL-6, and IL-8 by RANKL without cytotoxicity.	epigallocatechin gallate	0-4	TNF superfamily member 11	Homo sapiens	113-118
32769069-8	2020	Furthermore, EGCG prevented degranulation of mast cell in RANKL-stimulated HMC-1 cells.	epigallocatechin gallate	13-17	TNF superfamily member 11	Homo sapiens	58-63
32769069-9	2020	Overall, these results suggest that EGCG acts as a natural agent for preventing and treating RANKL-mediated inflammatory diseases by targeting PI3 Kinase, MAP Kinase, caspase-1, and NF-kappaB signaling cascade in mast cells.	epigallocatechin gallate	36-40	TNF superfamily member 11	Homo sapiens	93-98
32955874-4	2020	Through a systematic screening of 39 analogs of SPD-304, a dual inhibitor of TNF and RANKL trimerization, we identified 4 compounds (1b, 3b, 4a, and 4c) that selectively inhibited RANKL-induced osteoclastogenesis in a dose-dependent manner, without affecting TNF activity or osteoblast differentiation.	SPD-304	48-55	TNF superfamily member 11	Homo sapiens	85-90
32921410-0	2020	Corrigendum to "25-hydroxycholesterol promotes RANKL-induced osteoclastogenesis through coordinating NFATc1 and Sp1 complex in the transcription of miR-139-5p .	25-hydroxycholesterol	16-37	TNF superfamily member 11	Homo sapiens	47-52
32939977-4	2020	The present results showed that Maackiain could restrain receptor activator of nuclear factor-kappaB ligand (RANKL)-stimulated osteoclast formation and hydroxyapatite resorption dose-dependently, and interrupt the structures of F-actin belts in the mature osteoclasts.	Durapatite	152-166	TNF superfamily member 11	Homo sapiens	109-114
32939977-6	2020	Furthermore, Maackiain could inhibit RANKL-stimulated NF-kappaB and calcium signalling pathways, and dampen Nuclear factor of activated T cell cytoplasmic 1 activity, protein expression and translocation into the nucleus.	inermin	13-22	TNF superfamily member 11	Homo sapiens	37-42
32939977-6	2020	Furthermore, Maackiain could inhibit RANKL-stimulated NF-kappaB and calcium signalling pathways, and dampen Nuclear factor of activated T cell cytoplasmic 1 activity, protein expression and translocation into the nucleus.	Calcium	68-75	TNF superfamily member 11	Homo sapiens	37-42
33105546-9	2020	In gene plot analysis, marked increases in receptor activator of nuclear factor kappa-Beta ligand (RANKL) expression were seen in TC-treated cells over time.	Technetium	130-132	TNF superfamily member 11	Homo sapiens	99-104
32955874-4	2020	Through a systematic screening of 39 analogs of SPD-304, a dual inhibitor of TNF and RANKL trimerization, we identified 4 compounds (1b, 3b, 4a, and 4c) that selectively inhibited RANKL-induced osteoclastogenesis in a dose-dependent manner, without affecting TNF activity or osteoblast differentiation.	SPD-304	48-55	TNF superfamily member 11	Homo sapiens	180-185
33081167-5	2020	GSPE strongly suppressed receptor activator of nuclear factor kappa-B ligand (RANKL)-induced osteoclast differentiation and bone resorption activity of mature osteoclasts by decreasing the RANKL-induced nuclear factor-kappaB transcription activity.	gspe	0-4	TNF superfamily member 11	Homo sapiens	25-76
33081167-5	2020	GSPE strongly suppressed receptor activator of nuclear factor kappa-B ligand (RANKL)-induced osteoclast differentiation and bone resorption activity of mature osteoclasts by decreasing the RANKL-induced nuclear factor-kappaB transcription activity.	gspe	0-4	TNF superfamily member 11	Homo sapiens	78-83
33081167-5	2020	GSPE strongly suppressed receptor activator of nuclear factor kappa-B ligand (RANKL)-induced osteoclast differentiation and bone resorption activity of mature osteoclasts by decreasing the RANKL-induced nuclear factor-kappaB transcription activity.	gspe	0-4	TNF superfamily member 11	Homo sapiens	189-194
33066388-2	2020	Additionally, the RANKL/RANK axis is a significant mediator of progesterone-driven mammary epithelial cell proliferation, potentially contributing to breast cancer initiation and progression.	Progesterone	63-75	TNF superfamily member 11	Homo sapiens	18-23
32673666-4	2020	Phorbol-12-myristate-13-acetate (PMA) was used to induce THP-1 cells to differentiate into macrophages, followed by induction to osteoclasts using macrophage colony-stimulating factor (M-CSF) and receptor activator of NF-kappaB ligand (RANKL).	Tetradecanoylphorbol Acetate	0-31	TNF superfamily member 11	Homo sapiens	236-241
33117342-9	2020	Leonurine significantly inhibited TAZ-mediated expression of RANKL, and RANK and IL-6 in synovial fibroblasts.	leonurine	0-9	TNF superfamily member 11	Homo sapiens	61-66
32738656-6	2020	Such electrospun PLGA@ASA nanofiber coatings could promote proliferation and osteogenic differentiation of bone mesenchymal stem cells (BMSCs) as well as inhibit M1 polarization and RANKL-induced osteoclast differentiation of macrophages in vitro.	Aspirin	22-25	TNF superfamily member 11	Homo sapiens	182-187
32589777-10	2020	Both CBM concentrations inhibited the production of osteolytic Receptor Activator of Nuclear Factor Kappa-Beta Ligand (RANKL), dose dependently (p<0.005 and p<0.01, respectively).	N-(4-chlorobenzoyl)melatonin	5-8	TNF superfamily member 11	Homo sapiens	63-117
32589777-10	2020	Both CBM concentrations inhibited the production of osteolytic Receptor Activator of Nuclear Factor Kappa-Beta Ligand (RANKL), dose dependently (p<0.005 and p<0.01, respectively).	N-(4-chlorobenzoyl)melatonin	5-8	TNF superfamily member 11	Homo sapiens	119-124
32673666-4	2020	Phorbol-12-myristate-13-acetate (PMA) was used to induce THP-1 cells to differentiate into macrophages, followed by induction to osteoclasts using macrophage colony-stimulating factor (M-CSF) and receptor activator of NF-kappaB ligand (RANKL).	Tetradecanoylphorbol Acetate	33-36	TNF superfamily member 11	Homo sapiens	196-234
32673666-4	2020	Phorbol-12-myristate-13-acetate (PMA) was used to induce THP-1 cells to differentiate into macrophages, followed by induction to osteoclasts using macrophage colony-stimulating factor (M-CSF) and receptor activator of NF-kappaB ligand (RANKL).	Tetradecanoylphorbol Acetate	33-36	TNF superfamily member 11	Homo sapiens	236-241
32546661-10	2020	We found that co-administration of LY294002 or Rapamycin with Dexamethasone protected skin against Dexamethasone-induced atrophy, and normalized RANKL/OPG ratio indicating a reduction of Dexamethasone-induced osteoporosis.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	35-43	TNF superfamily member 11	Homo sapiens	145-150
32973207-7	2020	Moreover, quantitative expression analysis of OPG and RANKL revealed altered levels in mechanically stimulated PA-treated HPdLF.	Protactinium	111-113	TNF superfamily member 11	Homo sapiens	54-59
32731089-4	2020	OFB suppressed receptor activator of nuclear factor-kappaB (RANKL)-induced formation of tartate-resistant acid phosphatase-positive multinuclear cells without cytotoxicity.	tartate	88-95	TNF superfamily member 11	Homo sapiens	60-65
32899435-5	2020	Quercetin was shown to inhibit RANKL-mediated osteoclastogenesis, osteoblast apoptosis, oxidative stress and inflammatory response while promoting osteogenesis, angiogenesis, antioxidant expression, adipocyte apoptosis and osteoclast apoptosis.	Quercetin	0-9	TNF superfamily member 11	Homo sapiens	31-36
32649040-8	2020	Importantly, the addition of resveratrol upregulated the proliferation of HPLF cells, while osteoclastogenesis of BMM cells treated with mCSF-RANKL was significantly downregulated by celastrol.	celastrol	183-192	TNF superfamily member 11	Homo sapiens	142-147
32899248-0	2020	Dual Oxidase Maturation Factor 1 Positively Regulates RANKL-Induced Osteoclastogenesis via Activating Reactive Oxygen Species and TRAF6-Mediated Signaling.	Reactive Oxygen Species	102-125	TNF superfamily member 11	Homo sapiens	54-59
32899248-1	2020	Receptor activator of NF-kappaB ligand (RANKL) induces generation of intracellular reactive oxygen species (ROS), which act as second messengers in RANKL-mediated osteoclastogenesis.	Reactive Oxygen Species	83-106	TNF superfamily member 11	Homo sapiens	0-38
32899248-1	2020	Receptor activator of NF-kappaB ligand (RANKL) induces generation of intracellular reactive oxygen species (ROS), which act as second messengers in RANKL-mediated osteoclastogenesis.	Reactive Oxygen Species	83-106	TNF superfamily member 11	Homo sapiens	40-45
32899248-1	2020	Receptor activator of NF-kappaB ligand (RANKL) induces generation of intracellular reactive oxygen species (ROS), which act as second messengers in RANKL-mediated osteoclastogenesis.	Reactive Oxygen Species	83-106	TNF superfamily member 11	Homo sapiens	148-153
32899248-1	2020	Receptor activator of NF-kappaB ligand (RANKL) induces generation of intracellular reactive oxygen species (ROS), which act as second messengers in RANKL-mediated osteoclastogenesis.	Reactive Oxygen Species	108-111	TNF superfamily member 11	Homo sapiens	0-38
32899248-1	2020	Receptor activator of NF-kappaB ligand (RANKL) induces generation of intracellular reactive oxygen species (ROS), which act as second messengers in RANKL-mediated osteoclastogenesis.	Reactive Oxygen Species	108-111	TNF superfamily member 11	Homo sapiens	40-45
32899248-1	2020	Receptor activator of NF-kappaB ligand (RANKL) induces generation of intracellular reactive oxygen species (ROS), which act as second messengers in RANKL-mediated osteoclastogenesis.	Reactive Oxygen Species	108-111	TNF superfamily member 11	Homo sapiens	148-153
32899248-7	2020	Furthermore, knockdown of Duoxa1 decreased the RANKL-induced ROS production.	Reactive Oxygen Species	61-64	TNF superfamily member 11	Homo sapiens	47-52
32899248-9	2020	Overall, our data indicate that Duoxa1 plays a crucial role in osteoclastogenesis via regulating RANKL-induced intracellular ROS production and activating TRAF6-mediated signaling.	Reactive Oxygen Species	125-128	TNF superfamily member 11	Homo sapiens	97-102
32608081-0	2020	A marine fungus-derived nitrobenzoyl sesquiterpenoid suppresses RANKL-induced osteoclastogenesis and attenuates inflammatory bone destruction.	nitrobenzoyl sesquiterpenoid	24-52	TNF superfamily member 11	Homo sapiens	64-69
32546661-10	2020	We found that co-administration of LY294002 or Rapamycin with Dexamethasone protected skin against Dexamethasone-induced atrophy, and normalized RANKL/OPG ratio indicating a reduction of Dexamethasone-induced osteoporosis.	Sirolimus	47-56	TNF superfamily member 11	Homo sapiens	145-150
32546661-10	2020	We found that co-administration of LY294002 or Rapamycin with Dexamethasone protected skin against Dexamethasone-induced atrophy, and normalized RANKL/OPG ratio indicating a reduction of Dexamethasone-induced osteoporosis.	Dexamethasone	62-75	TNF superfamily member 11	Homo sapiens	145-150
32874068-9	2020	Quantification analysis of RANKL revealed significantly higher IRS and intensity scores (p < 0.05) in areas containing titanium.	Titanium	119-127	TNF superfamily member 11	Homo sapiens	27-32
33108714-9	2020	Furthermore, SKH significantly increased the expression of osteoprotegerin and downregulated receptor activator of nuclear factor kappa B ligand and phosphorylation of c-jun N-terminal kinases in the bones of the OVX model.	skh	13-16	TNF superfamily member 11	Homo sapiens	93-144
32922141-12	2020	Collectively, these findings led to the assumption that the downregulation of IL-6/JAK2/STAT3 signaling by cinnamaldehyde, tadalafil, and aliskiren could alleviate joint destruction by MMP-3 and RANKL, reduce iNOS, and enhance eNOS expressions.	cinnamaldehyde	107-121	TNF superfamily member 11	Homo sapiens	195-200
32922141-12	2020	Collectively, these findings led to the assumption that the downregulation of IL-6/JAK2/STAT3 signaling by cinnamaldehyde, tadalafil, and aliskiren could alleviate joint destruction by MMP-3 and RANKL, reduce iNOS, and enhance eNOS expressions.	Tadalafil	123-132	TNF superfamily member 11	Homo sapiens	195-200
32922141-0	2020	Aliskiren, tadalafil, and cinnamaldehyde alleviate joint destruction biomarkers; MMP-3 and RANKL; in complete Freund"s adjuvant arthritis model: Downregulation of IL-6/JAK2/STAT3 signaling pathway.	aliskiren	0-9	TNF superfamily member 11	Homo sapiens	91-96
32922006-8	2020	Results: The results of this study demonstrated that although CeO2NPs were capable of scavenging ROS in acellular environments, they facilitated the production of ROS in the acidic cellular environment during receptor activator of nuclear factor kappa-Beta ligand (RANKL)-dependent osteoclast differentiation of bone marrow-derived macrophages (BMMs).	ceo2nps	62-69	TNF superfamily member 11	Homo sapiens	265-270
32687309-8	2020	Noticeably, the results indicated a concomitant reduction of bone regeneration potential assessed as reduced Runx2 and PINP expression when bone resorptive RANKL and CTX-I levels were reduced by Sr supplementation.	Strontium	195-197	TNF superfamily member 11	Homo sapiens	156-161
32922141-12	2020	Collectively, these findings led to the assumption that the downregulation of IL-6/JAK2/STAT3 signaling by cinnamaldehyde, tadalafil, and aliskiren could alleviate joint destruction by MMP-3 and RANKL, reduce iNOS, and enhance eNOS expressions.	aliskiren	138-147	TNF superfamily member 11	Homo sapiens	195-200
32485573-0	2020	GSH attenuates RANKL-induced osteoclast formation in vitro and LPS-induced bone loss in vivo.	Glutathione	0-3	TNF superfamily member 11	Homo sapiens	15-20
32764823-8	2020	Histamine increased the expression of H1R, H2R and H4R as well as of interleukin-6, cyclooxygenase-2, and prostaglandin-E2 secretion even without pressure application and induced receptor activator of NF-kB ligand (RANKL) protein expression with unchanged osteoprotegerin secretion.	Histamine	0-9	TNF superfamily member 11	Homo sapiens	215-220
32764823-11	2020	Increased histamine concentration was associated with enhanced expression of proinflammatory mediators and RANKL, suggesting an inductive effect of histamine on PDLF-mediated osteoclastogenesis and orthodontic tooth movement.	Histamine	10-19	TNF superfamily member 11	Homo sapiens	107-112
32764823-11	2020	Increased histamine concentration was associated with enhanced expression of proinflammatory mediators and RANKL, suggesting an inductive effect of histamine on PDLF-mediated osteoclastogenesis and orthodontic tooth movement.	Histamine	148-157	TNF superfamily member 11	Homo sapiens	107-112
32376366-0	2020	Dolichosin A, a coumestan isolated from Glycine tabacina, inhibits IL-1beta-induced inflammation in SW982 human synovial cells and suppresses RANKL-induced osteoclastogenesis: From network pharmacology to experimental pharmacology.	dolichosin a	0-12	TNF superfamily member 11	Homo sapiens	142-147
32376366-7	2020	Anti-arthritic effects of DoA and predicted mechanisms were further validated using IL-1beta-induced SW982 human synovial cell model and RANKL-induced osteoclastogenesis model.	dioctyl adipate	26-29	TNF superfamily member 11	Homo sapiens	137-142
32376366-11	2020	DoA also suppressed RANKL-induced osteoclastogenesis in vitro, as evidenced by decreased number of TRAP-positive multinucleated osteoclasts and reduced TRAP activity.	dioctyl adipate	0-3	TNF superfamily member 11	Homo sapiens	20-25
32764823-8	2020	Histamine increased the expression of H1R, H2R and H4R as well as of interleukin-6, cyclooxygenase-2, and prostaglandin-E2 secretion even without pressure application and induced receptor activator of NF-kB ligand (RANKL) protein expression with unchanged osteoprotegerin secretion.	Histamine	0-9	TNF superfamily member 11	Homo sapiens	179-213
32485573-2	2020	Reactive oxygen species (ROS), as a signaling messenger, plays an important role in the receptor activator nuclear factor kappaB ligand (RANKL) signal pathway during osteoclast differentiation.	Reactive Oxygen Species	0-23	TNF superfamily member 11	Homo sapiens	88-135
32485573-2	2020	Reactive oxygen species (ROS), as a signaling messenger, plays an important role in the receptor activator nuclear factor kappaB ligand (RANKL) signal pathway during osteoclast differentiation.	Reactive Oxygen Species	0-23	TNF superfamily member 11	Homo sapiens	137-142
32485573-2	2020	Reactive oxygen species (ROS), as a signaling messenger, plays an important role in the receptor activator nuclear factor kappaB ligand (RANKL) signal pathway during osteoclast differentiation.	Reactive Oxygen Species	25-28	TNF superfamily member 11	Homo sapiens	88-135
32485573-2	2020	Reactive oxygen species (ROS), as a signaling messenger, plays an important role in the receptor activator nuclear factor kappaB ligand (RANKL) signal pathway during osteoclast differentiation.	Reactive Oxygen Species	25-28	TNF superfamily member 11	Homo sapiens	137-142
32485573-4	2020	This study aimed to investigate whether GSH can as a protective agent against the RANKL-stimulated osteoclastogenesis by suppressing intracellular ROS.	Glutathione	40-43	TNF superfamily member 11	Homo sapiens	82-87
32485573-4	2020	This study aimed to investigate whether GSH can as a protective agent against the RANKL-stimulated osteoclastogenesis by suppressing intracellular ROS.	Reactive Oxygen Species	147-150	TNF superfamily member 11	Homo sapiens	82-87
32485573-6	2020	GSH suppressed RANKL-induced ROS generation and subsequent ROS-induced NF-kappaB signaling pathways within BMMs during osteoclastogenesis.	Glutathione	0-3	TNF superfamily member 11	Homo sapiens	15-20
32485573-6	2020	GSH suppressed RANKL-induced ROS generation and subsequent ROS-induced NF-kappaB signaling pathways within BMMs during osteoclastogenesis.	Reactive Oxygen Species	29-32	TNF superfamily member 11	Homo sapiens	15-20
32602250-0	2020	Niclosamide and its derivative DK-520 inhibit RANKL-induced osteoclastogenesis.	Niclosamide	0-11	TNF superfamily member 11	Homo sapiens	46-51
32602250-5	2020	Treatment with either Niclosamide or DK-520 did not affect the viability of osteoclast precursors (OCPs), but significantly inhibited RANKL-induced trans-differentiation of macrophages into OCPs, particularly in the early stage of osteoclastogenesis.	Niclosamide	22-33	TNF superfamily member 11	Homo sapiens	134-139
32602250-5	2020	Treatment with either Niclosamide or DK-520 did not affect the viability of osteoclast precursors (OCPs), but significantly inhibited RANKL-induced trans-differentiation of macrophages into OCPs, particularly in the early stage of osteoclastogenesis.	CHEMBL3604905	37-43	TNF superfamily member 11	Homo sapiens	134-139
30902523-7	2020	These beneficial properties of berberine are mediated in part through its ability to target multiple signaling pathways, including PKA, p38 MAPK, Wnt/beta-catenin, AMPK, RANK/RANKL/OPG, PI3K/Akt, NFAT, NF-kappaB, Hedgehog, and oxidative stress signaling.	Berberine	31-40	TNF superfamily member 11	Homo sapiens	175-180
32371216-0	2020	Vitamin D status influences transcriptional levels of RANKL and inflammatory biomarkers which are associated with activation of PBMC.	Vitamin D	0-9	TNF superfamily member 11	Homo sapiens	54-59
31907393-0	2020	Dual targeting of SREBP2 and ERRalpha by carnosic acid suppresses RANKL-mediated osteoclastogenesis and prevents ovariectomy-induced bone loss.	salvin	41-54	TNF superfamily member 11	Homo sapiens	66-71
32660129-8	2020	We showed that the inhibition of MEK by the U0126 inhibitor rescued the osteoclast development of RAW264.7 induced by RANKL in a co-culture system with CK2.3.	U 0126	44-49	TNF superfamily member 11	Homo sapiens	118-123
32388216-0	2020	Isoalantolactone inhibits RANKL-induced osteoclast formation via multiple signaling pathways.	isoalantolactone	0-16	TNF superfamily member 11	Homo sapiens	26-31
32523732-6	2020	Furthermore, it was found that Sr-SBG might suppress osteoclastogenesis by the combined effect of strontium and silicon released through inhibition of RANKL-induced activation of p38 and NF-kappaB pathway.	Silicon	112-119	TNF superfamily member 11	Homo sapiens	151-156
32523732-0	2020	Strontium-substituted sub-micron bioactive glasses inhibit ostoclastogenesis through suppression of RANKL-induced signaling pathway.	Strontium	0-9	TNF superfamily member 11	Homo sapiens	100-105
32488754-6	2020	Also, serum RANKL concentration reduced significantly up to 17% in the soy isoflavone group at the end of week 8 compared to baseline (P = 0.03).	Isoflavones	75-85	TNF superfamily member 11	Homo sapiens	12-17
32488754-9	2020	CONCLUSION: This study indicates that daily administration of 100 mg soy isoflavone supplement to PD patients reduces serum N-telopeptide and RANKL which are two bone resorption markers.	Isoflavones	69-83	TNF superfamily member 11	Homo sapiens	142-147
32109361-1	2020	Medication-related osteonecrosis of the jaw (MRONJ) is a rare intraoral lesion that occurs in patients undergoing long-term and/or high-dose therapy with nitrogen-containing bisphosphonates, a RANKL inhibitor, antiangiogenic agents, or mTOR inhibitors.	Nitrogen	154-162	TNF superfamily member 11	Homo sapiens	193-198
32523732-7	2020	These results elaborated the effect of Sr-SBG-based materials on osteoclastogenesis through RANKL-induced downstream pathway and might represent a significant guidance for designing better bone repair materials.	sr-sbg	39-45	TNF superfamily member 11	Homo sapiens	92-97
32523732-4	2020	Herein, we studied the potential impact and underling mechanism of strontium-substituted sub-micron bioactive glass (Sr-SBG) on RANKL-induced osteoclast activation and differentiation in vitro.	sr-sbg	117-123	TNF superfamily member 11	Homo sapiens	128-133
32398744-4	2020	In detail, inhibition of ASM by fluoxetine reduces the sphingosine-1-phosphate (S1P) level in bone marrow adipocytes, leading to the increase of receptor activator of nuclear factor-kappa-Beta ligand (RANKL) secretion, a key regulator for the activation of osteoclastogenesis and bone loss, through the upregulation of cyclooxygenase-2 and its enzymatic product prostaglandin E2 (COX-2/PGE2).	Fluoxetine	32-42	TNF superfamily member 11	Homo sapiens	145-199
32523732-5	2020	As expected, Sr-SBG inhibited RANKL-mediated osteoclastogenesis significantly with the experimental performance of decreased mature osteoclasts formation and downregulation of osteoclastogenesis-related gene expression.	sr-sbg	13-19	TNF superfamily member 11	Homo sapiens	30-35
32523732-6	2020	Furthermore, it was found that Sr-SBG might suppress osteoclastogenesis by the combined effect of strontium and silicon released through inhibition of RANKL-induced activation of p38 and NF-kappaB pathway.	sr-sbg	31-37	TNF superfamily member 11	Homo sapiens	151-156
32435453-0	2020	Effect of GNAQ alteration on RANKL-induced osteoclastogenesis in human non-small-cell lung cancer.	gnaq	10-14	TNF superfamily member 11	Homo sapiens	29-34
32435453-11	2020	Conclusion: The present study reveals that the alterations of GNAQ activate NF-kappaB pathway in cancers, which increase RANKL and M-CSF expression and induce osteoclastogenesis in cancers.Cite this article: Bone Joint Res.	gnaq	62-66	TNF superfamily member 11	Homo sapiens	121-126
32477461-1	2020	The role of RANKL-RANK pathway in progesterone-driven mammary carcinogenesis and triple negative breast cancer tumorigenesis has been well characterized.	Progesterone	34-46	TNF superfamily member 11	Homo sapiens	12-17
32398744-4	2020	In detail, inhibition of ASM by fluoxetine reduces the sphingosine-1-phosphate (S1P) level in bone marrow adipocytes, leading to the increase of receptor activator of nuclear factor-kappa-Beta ligand (RANKL) secretion, a key regulator for the activation of osteoclastogenesis and bone loss, through the upregulation of cyclooxygenase-2 and its enzymatic product prostaglandin E2 (COX-2/PGE2).	Fluoxetine	32-42	TNF superfamily member 11	Homo sapiens	201-206
32398744-4	2020	In detail, inhibition of ASM by fluoxetine reduces the sphingosine-1-phosphate (S1P) level in bone marrow adipocytes, leading to the increase of receptor activator of nuclear factor-kappa-Beta ligand (RANKL) secretion, a key regulator for the activation of osteoclastogenesis and bone loss, through the upregulation of cyclooxygenase-2 and its enzymatic product prostaglandin E2 (COX-2/PGE2).	sphingosine 1-phosphate	55-78	TNF superfamily member 11	Homo sapiens	201-206
32398744-4	2020	In detail, inhibition of ASM by fluoxetine reduces the sphingosine-1-phosphate (S1P) level in bone marrow adipocytes, leading to the increase of receptor activator of nuclear factor-kappa-Beta ligand (RANKL) secretion, a key regulator for the activation of osteoclastogenesis and bone loss, through the upregulation of cyclooxygenase-2 and its enzymatic product prostaglandin E2 (COX-2/PGE2).	Dinoprostone	362-378	TNF superfamily member 11	Homo sapiens	145-199
32398744-4	2020	In detail, inhibition of ASM by fluoxetine reduces the sphingosine-1-phosphate (S1P) level in bone marrow adipocytes, leading to the increase of receptor activator of nuclear factor-kappa-Beta ligand (RANKL) secretion, a key regulator for the activation of osteoclastogenesis and bone loss, through the upregulation of cyclooxygenase-2 and its enzymatic product prostaglandin E2 (COX-2/PGE2).	Dinoprostone	362-378	TNF superfamily member 11	Homo sapiens	201-206
32398744-4	2020	In detail, inhibition of ASM by fluoxetine reduces the sphingosine-1-phosphate (S1P) level in bone marrow adipocytes, leading to the increase of receptor activator of nuclear factor-kappa-Beta ligand (RANKL) secretion, a key regulator for the activation of osteoclastogenesis and bone loss, through the upregulation of cyclooxygenase-2 and its enzymatic product prostaglandin E2 (COX-2/PGE2).	Dinoprostone	386-390	TNF superfamily member 11	Homo sapiens	145-199
32398744-4	2020	In detail, inhibition of ASM by fluoxetine reduces the sphingosine-1-phosphate (S1P) level in bone marrow adipocytes, leading to the increase of receptor activator of nuclear factor-kappa-Beta ligand (RANKL) secretion, a key regulator for the activation of osteoclastogenesis and bone loss, through the upregulation of cyclooxygenase-2 and its enzymatic product prostaglandin E2 (COX-2/PGE2).	Dinoprostone	386-390	TNF superfamily member 11	Homo sapiens	201-206
32398744-5	2020	In contrast, overexpression of ASM by cisplatin normalizes fluoxetine-induced RANKL overproduction.	Cisplatin	38-47	TNF superfamily member 11	Homo sapiens	78-83
32398744-5	2020	In contrast, overexpression of ASM by cisplatin normalizes fluoxetine-induced RANKL overproduction.	Fluoxetine	59-69	TNF superfamily member 11	Homo sapiens	78-83
33455339-4	2020	This work explored the potential of RIS@ZIF-8 nanoparticles, which could not only enhance ATP production, induce extracellular matrix (ECM) mineralization, and upregulate the expression levels of osteogenic genes but also effectively inhibit the formation of multinucleated giant osteocasts and decrease the Rankl/Opg ratio.	Adenosine Triphosphate	90-93	TNF superfamily member 11	Homo sapiens	308-313
32143118-8	2020	ARS compounds selectively inhibit osteoclast differentiation by downregulation of pathways involved in receptor activator of nuclear factor kappa-B ligand (RANKL) -induced osteoclastogenesis, and have no effect on osteogenic differentiation of osteoblasts.	artemisinin	0-3	TNF superfamily member 11	Homo sapiens	103-154
32143118-8	2020	ARS compounds selectively inhibit osteoclast differentiation by downregulation of pathways involved in receptor activator of nuclear factor kappa-B ligand (RANKL) -induced osteoclastogenesis, and have no effect on osteogenic differentiation of osteoblasts.	artemisinin	0-3	TNF superfamily member 11	Homo sapiens	156-161
31648414-10	2020	Only in hOBs, PMMA decreased RANKL/OPG ratio.	Polymethyl Methacrylate	14-18	TNF superfamily member 11	Homo sapiens	29-34
32332865-4	2020	SM-164 also inhibited expression of RANKL, which mediates interactions between metastatic BC and host microenvironment cells and induces osteoclast-mediated osteolysis.	SM 164	0-6	TNF superfamily member 11	Homo sapiens	36-41
31910292-10	2020	This RANKL upregulation in bystander osteocytes was prevented by blocking Pannexin 1 channels as well as its ATP receptor.	Adenosine Triphosphate	109-112	TNF superfamily member 11	Homo sapiens	5-10
31910292-11	2020	ATP alone caused comparable RANKL upregulation in bystander osteocytes.	Adenosine Triphosphate	0-3	TNF superfamily member 11	Homo sapiens	28-33
31910292-13	2020	These findings point to extracellular ATP, released from apoptotic osteocytes via Panx1 channels, as a major signal for triggering bystander osteocyte RANKL expression and activating bone remodeling.	Adenosine Triphosphate	38-41	TNF superfamily member 11	Homo sapiens	151-156
32027437-8	2020	RESULTS: Cells cultured under 2% O2 exhibited decreased A20 expression and increased RANKL/OPG (R/O) ratio.	Superoxides	33-35	TNF superfamily member 11	Homo sapiens	85-90
32337233-6	2020	The RANKL inhibitor, scutellarin, inhibited these effects in PC3-hFOB1.19 cocultures.	scutellarin	21-32	TNF superfamily member 11	Homo sapiens	4-9
31986066-8	2020	Also, active vitamin D3 induced the expression of RANKL, a major key factor for osteoclastogenesis, equally in osteoblastic cells derived from control and PFE-iPSCs.	Cholecalciferol	13-23	TNF superfamily member 11	Homo sapiens	50-55
32183159-5	2020	Mammary stem cells guarantee differentiation of the epithelial mammary cells, the growth of which is regulated by the progesterone-induced RANKL signaling pathway.	Progesterone	118-130	TNF superfamily member 11	Homo sapiens	139-144
31846839-0	2020	Vinpocetine inhibits RANKL-induced osteoclastogenesis and attenuates ovariectomy-induced bone loss.	vinpocetine	0-11	TNF superfamily member 11	Homo sapiens	21-26
31846839-8	2020	In this study, we found that Vinp significantly inhibited receptor activator of NF-kappaB ligand (RANKL)-induced osteoclast and F-actin formation and decreased osteoclastic bone resorption in vitro.	vinpocetine	29-33	TNF superfamily member 11	Homo sapiens	58-96
31846839-8	2020	In this study, we found that Vinp significantly inhibited receptor activator of NF-kappaB ligand (RANKL)-induced osteoclast and F-actin formation and decreased osteoclastic bone resorption in vitro.	vinpocetine	29-33	TNF superfamily member 11	Homo sapiens	98-103
31846839-11	2020	Animal experiments consistently demonstrated that Vinp treatment significantly attenuated ovariectomy-induced bone loss with a decrease in the osteoclast number and decreases in serum levels of RANKL, TRAP, interleukin-1beta, and tumor necrosis factor-alpha, as well as increased serum levels of osteoprotegerin.	vinpocetine	50-54	TNF superfamily member 11	Homo sapiens	194-199
31953640-7	2020	Mechanical loading and unloading modulate the osteocytic release of NO, PGE2, and ATPs that regulates multiple cellular signaling such as Wnt/beta-catenin, RANKL/OPG, BMPs, PTH, IGF1, VEGF, sclerostin, and others.	Adenosine Triphosphate	82-86	TNF superfamily member 11	Homo sapiens	156-161
31965715-0	2020	Dracorhodin perchlorate inhibits osteoclastogenesis through repressing RANKL-stimulated NFATc1 activity.	dracorhodin	0-23	TNF superfamily member 11	Homo sapiens	71-76
31965715-5	2020	We have found that D.P inhibited RANKL-induced osteoclast formation and resorbed pits of hydroxyapatite-coated plate in a dose-dependent manner.	dracorhodin	19-22	TNF superfamily member 11	Homo sapiens	33-38
31965715-7	2020	Further, D.P was able to suppress RANKL-activated JNK, NF-kappaB and Ca2+ signalling pathways and reduces the expression level of NFATc1 as well as the nucleus translocation of NFATc1.	dracorhodin	9-12	TNF superfamily member 11	Homo sapiens	34-39
31654098-10	2020	At the end of the culture period of M-CSF + RANKL-stimulated CD14+ PBMCs, there was a correlation between the secretion of TRAP 5a and 5b proteins with CTX-I.	ciguatoxin 1B (CTX 1B)	152-157	TNF superfamily member 11	Homo sapiens	44-49
31859389-6	2020	RESULTS: Both in hGFs and hPDLCs, 1,25OH2 D3 could significantly induce the mRNA and protein expression of RANKL, and FF genotype had significantly higher induction than the other genotypes, however, neither 1,25OH2 D3 nor VDR-FokI had significant influence on the OPG expression.	25-hydroxyvitamin D3-bromoacetate	34-44	TNF superfamily member 11	Homo sapiens	107-112
31859389-6	2020	RESULTS: Both in hGFs and hPDLCs, 1,25OH2 D3 could significantly induce the mRNA and protein expression of RANKL, and FF genotype had significantly higher induction than the other genotypes, however, neither 1,25OH2 D3 nor VDR-FokI had significant influence on the OPG expression.	25-hydroxyvitamin D3-bromoacetate	208-218	TNF superfamily member 11	Homo sapiens	107-112
31859389-7	2020	As a result, the RANKL/OPG ratio was significantly elevated under 1,25OH2 D3 stimulation and FF genotype had the most remarkable elevation.	25-hydroxyvitamin D3-bromoacetate	66-76	TNF superfamily member 11	Homo sapiens	17-22
31859389-9	2020	CONCLUSION: The strongest transcriptional activity of FF genotype might contribute to the strongest enhancement of RANKL expression and RANKL/OPG ratio in hGFs and hPDLCs stimulated by 1,25OH2 D3 , which might help to reveal the mechanisms of the correlation between FF genotype and susceptibility to periodontitis.	25-hydroxyvitamin D3-bromoacetate	185-195	TNF superfamily member 11	Homo sapiens	115-120
31859389-9	2020	CONCLUSION: The strongest transcriptional activity of FF genotype might contribute to the strongest enhancement of RANKL expression and RANKL/OPG ratio in hGFs and hPDLCs stimulated by 1,25OH2 D3 , which might help to reveal the mechanisms of the correlation between FF genotype and susceptibility to periodontitis.	25-hydroxyvitamin D3-bromoacetate	185-195	TNF superfamily member 11	Homo sapiens	136-141
32075617-0	2020	Polyphyllin VII attenuated RANKL-induced osteoclast differentiation via inhibiting of TRAF6/c-Src/PI3K pathway and ROS production.	polyphyllin VII	0-15	TNF superfamily member 11	Homo sapiens	27-32
32075617-0	2020	Polyphyllin VII attenuated RANKL-induced osteoclast differentiation via inhibiting of TRAF6/c-Src/PI3K pathway and ROS production.	Reactive Oxygen Species	115-118	TNF superfamily member 11	Homo sapiens	27-32
32075617-6	2020	RESULTS: RANKL + M-CSF significantly increased TRAP activity, number of osteoclasts, number and area of lacunae, intracellular content of ROS, protein levels of Nox1, TRAF6, c-Src and p-PI3K, as well as the content of activated GTP-Rac1, which were significantly blocked by polyphyllin VII in a concentration-dependent manner.	Reactive Oxygen Species	138-141	TNF superfamily member 11	Homo sapiens	9-14
32075617-6	2020	RESULTS: RANKL + M-CSF significantly increased TRAP activity, number of osteoclasts, number and area of lacunae, intracellular content of ROS, protein levels of Nox1, TRAF6, c-Src and p-PI3K, as well as the content of activated GTP-Rac1, which were significantly blocked by polyphyllin VII in a concentration-dependent manner.	polyphyllin VII	274-289	TNF superfamily member 11	Homo sapiens	9-14
32102511-6	2020	Moreover, logistic regression analysis showed that RANKL had the highest differentiation power in the discrimination of MBC from NMBC.	nmbc	129-133	TNF superfamily member 11	Homo sapiens	51-56
31606424-8	2020	Bisphosphonate (P &lt; .001) and mixed necrosis (P = .002) demonstrated more RANKL- and TRAP-positive osteoclasts.	Diphosphonates	0-14	TNF superfamily member 11	Homo sapiens	77-82
31309556-7	2020	RANKL stimulation inhibited terminal deoxynucleotidyl transferase dUTP nick end labeling positive staining in TRAIL-treated cells.	deoxyuridine triphosphate	66-70	TNF superfamily member 11	Homo sapiens	0-5
31947859-0	2020	Evaluation of Isoflavones as Bone Resorption Inhibitors upon Interactions with Receptor Activator of Nuclear Factor-kappaB Ligand (RANKL).	Isoflavones	14-25	TNF superfamily member 11	Homo sapiens	79-129
31996227-10	2020	CONCLUSIONS: Lycopene activates the WNT/beta-catenin and ERK1/2 pathways, upregulates RUNX2, alkaline phosphatase, COL1A and downregulates RANKL Saos-2.	lycopene	13-21	TNF superfamily member 11	Homo sapiens	139-144
31991837-6	2020	Tartrate-resistant acid phosphatase (TRAP) staining, as well as bone resorption assays, revealed that TGFbeta1 suppressed RANKL-mediated human osteoclast development.	Tartrates	0-8	TNF superfamily member 11	Homo sapiens	122-127
31678610-5	2020	Curcumin could also abate RANKL"s stimulatory effect on OCP autophagy and osteoclastogenesis.	Curcumin	0-8	TNF superfamily member 11	Homo sapiens	26-31
31947859-0	2020	Evaluation of Isoflavones as Bone Resorption Inhibitors upon Interactions with Receptor Activator of Nuclear Factor-kappaB Ligand (RANKL).	Isoflavones	14-25	TNF superfamily member 11	Homo sapiens	131-136
31947859-5	2020	The aim of the study was to verify the hypothesis that isoflavones can form complexes with RANKL limiting binding of the cytokine to its receptor.	Isoflavones	55-66	TNF superfamily member 11	Homo sapiens	91-96
31947859-6	2020	Interactions of five isoflavones with RANKL were investigated by isothermal titration calorimetry (ITC), by in silico docking simulation and on Saos-2 cells.	Isoflavones	21-32	TNF superfamily member 11	Homo sapiens	38-43
31947859-7	2020	Daidzein and biochanin A showed the highest affinity for RANKL.	daidzein	0-8	TNF superfamily member 11	Homo sapiens	57-62
31947859-8	2020	Among studied isoflavones coumestrol, formononetin and biochanin A showed the highest potential for Saos-2 mineralization and were able to regulate the expression of RANKL and OPG at the mRNA levels, as well as osteogenic differentiation markers: alkaline phosphatase (ALP), collagen type 1, and Runt-related transcription factor 2 (Runx2).	Isoflavones	14-25	TNF superfamily member 11	Homo sapiens	166-171
31947859-8	2020	Among studied isoflavones coumestrol, formononetin and biochanin A showed the highest potential for Saos-2 mineralization and were able to regulate the expression of RANKL and OPG at the mRNA levels, as well as osteogenic differentiation markers: alkaline phosphatase (ALP), collagen type 1, and Runt-related transcription factor 2 (Runx2).	Coumestrol	26-36	TNF superfamily member 11	Homo sapiens	166-171
31947859-8	2020	Among studied isoflavones coumestrol, formononetin and biochanin A showed the highest potential for Saos-2 mineralization and were able to regulate the expression of RANKL and OPG at the mRNA levels, as well as osteogenic differentiation markers: alkaline phosphatase (ALP), collagen type 1, and Runt-related transcription factor 2 (Runx2).	formononetin	38-50	TNF superfamily member 11	Homo sapiens	166-171
31787342-0	2020	Diterpenoids from the aerial parts of Flueggea acicularis and their activity against RANKL-induced osteoclastogenesis.	ent-7beta,11alpha,14-trihydroxy-18-aldehyde-11beta-20-epoxy-kaur-16-en15-one	0-12	TNF superfamily member 11	Homo sapiens	85-90
31823791-0	2019	OPG/RANK/RANKL signaling axis in patients with type I diabetes: Associations with parathormone and vitamin D.	Vitamin D	99-108	TNF superfamily member 11	Homo sapiens	9-14
33268671-0	2020	(-)-Epigallocatechin-3-gallate inhibits RANKL-induced osteoclastogenesis via downregulation of NFATc1 and suppression of HO-1-HMGB1-RAGE pathway.	epigallocatechin gallate	0-30	TNF superfamily member 11	Homo sapiens	40-45
31724123-0	2020	RANKL treatment of vascular endothelial cells leading to paracrine pro-calcific signaling involves ROS production.	Reactive Oxygen Species	99-102	TNF superfamily member 11	Homo sapiens	0-5
31724123-4	2020	In the current paper, we investigate the possibility that RANKL leads to ROS signaling within the endothelial layer as part of the RANKL-driven VC signaling cascade.	Reactive Oxygen Species	73-76	TNF superfamily member 11	Homo sapiens	58-63
31724123-4	2020	In the current paper, we investigate the possibility that RANKL leads to ROS signaling within the endothelial layer as part of the RANKL-driven VC signaling cascade.	Reactive Oxygen Species	73-76	TNF superfamily member 11	Homo sapiens	131-136
31724123-7	2020	Treatment of HAECs with RANKL-induced robust ROS production.	Reactive Oxygen Species	45-48	TNF superfamily member 11	Homo sapiens	24-29
31724123-12	2020	In summary, RANKL elicits ROS generation in HAECs with direct consequences for generation of paracrine pro-calcific signals known to effect calcification in underlying VSMCs.	Reactive Oxygen Species	26-29	TNF superfamily member 11	Homo sapiens	12-17
31323160-8	2020	By blocking RANKL signalling, either via neutralizing antibodies, genetic alterations or the RANKL receptor inhibitor SPD304, the survival advantage provided by osteoblasts could be overcome.	SPD-304	118-124	TNF superfamily member 11	Homo sapiens	12-17
31820176-5	2020	In vitro, PGE2 can directly stimulate osteoblast differentiation and, indirectly via stimulation of RANKL in osteoblastic cells, stimulate the differentiation of osteoclasts.	Dinoprostone	10-14	TNF superfamily member 11	Homo sapiens	100-105
31654668-6	2019	In this study, by using Bone Marrow-derived macrophages (BMMs) as osteoclast precursors (OCPs), we found that RANKL-induced TRAF3 degradation was significantly suppressed by JNK inhibitor (SP600125), which was restored by overexpression of Beclin1 (key autophagic protein).	pyrazolanthrone	189-197	TNF superfamily member 11	Homo sapiens	110-115
31369791-0	2019	Effect of bergenin on RANKL-induced osteoclast differentiation in the presence of methylglyoxal.	bergenin	10-18	TNF superfamily member 11	Homo sapiens	22-27
31369791-0	2019	Effect of bergenin on RANKL-induced osteoclast differentiation in the presence of methylglyoxal.	Pyruvaldehyde	82-95	TNF superfamily member 11	Homo sapiens	22-27
31615565-0	2019	Puerarin inhibits the osteoclastogenesis by inhibiting RANKL-dependent and -independent autophagic responses.	puerarin	0-8	TNF superfamily member 11	Homo sapiens	55-60
31707778-9	2019	ST5 reduction caused a decrease in RANKL-evoked calcium oscillation and inhibited translocation of NFATc1 into the nucleus.	Calcium	48-55	TNF superfamily member 11	Homo sapiens	35-40
31694210-8	2019	Moreover, the addition of both Si and Zn positively regulate the osteoprotegerin: receptor activator of nuclear factor k-beta ligand (OPG:RANKL) ratio at 21-days for Si-TCP and Zn-TCP scaffolds.	Silicon	31-33	TNF superfamily member 11	Homo sapiens	138-143
31694210-8	2019	Moreover, the addition of both Si and Zn positively regulate the osteoprotegerin: receptor activator of nuclear factor k-beta ligand (OPG:RANKL) ratio at 21-days for Si-TCP and Zn-TCP scaffolds.	Zinc	38-40	TNF superfamily member 11	Homo sapiens	138-143
31694210-8	2019	Moreover, the addition of both Si and Zn positively regulate the osteoprotegerin: receptor activator of nuclear factor k-beta ligand (OPG:RANKL) ratio at 21-days for Si-TCP and Zn-TCP scaffolds.	Silicon	166-168	TNF superfamily member 11	Homo sapiens	138-143
31694210-8	2019	Moreover, the addition of both Si and Zn positively regulate the osteoprotegerin: receptor activator of nuclear factor k-beta ligand (OPG:RANKL) ratio at 21-days for Si-TCP and Zn-TCP scaffolds.	tricalcium phosphate	169-172	TNF superfamily member 11	Homo sapiens	138-143
31694210-9	2019	These results demonstrate the effects of Si and Zn doped porous beta-TCP scaffolds on the upregulation of osteoblast marker gene expression including OPG, RANKL, BMP-2, and Runx2, indicating the role of trace elements on the effective regulation of late-stage osteoblast cell differentiation markers.	Silicon	41-43	TNF superfamily member 11	Homo sapiens	155-160
31694210-9	2019	These results demonstrate the effects of Si and Zn doped porous beta-TCP scaffolds on the upregulation of osteoblast marker gene expression including OPG, RANKL, BMP-2, and Runx2, indicating the role of trace elements on the effective regulation of late-stage osteoblast cell differentiation markers.	Zinc	48-50	TNF superfamily member 11	Homo sapiens	155-160
31694210-9	2019	These results demonstrate the effects of Si and Zn doped porous beta-TCP scaffolds on the upregulation of osteoblast marker gene expression including OPG, RANKL, BMP-2, and Runx2, indicating the role of trace elements on the effective regulation of late-stage osteoblast cell differentiation markers.	tricalcium phosphate	69-72	TNF superfamily member 11	Homo sapiens	155-160
30856080-10	2019	These studies demonstrated that vitamin E, especially tocotrienol, was able to alleviate IL-1, IL-6, RANKL, iNOS and hs-CRP levels in relation to bone metabolism.	Vitamin E	32-41	TNF superfamily member 11	Homo sapiens	101-106
30856080-10	2019	These studies demonstrated that vitamin E, especially tocotrienol, was able to alleviate IL-1, IL-6, RANKL, iNOS and hs-CRP levels in relation to bone metabolism.	Tocotrienols	54-65	TNF superfamily member 11	Homo sapiens	101-106
30949254-2	2019	Osteonecrosis of the jaw similar to that occurring with BPs is also produced with the anti-receptor activator of nuclear factor kappa-Beta ligand (RANKL) antibody denosumab, a bone resorption inhibitor that has a different mode of action from BPs, and there is also a report of osteonecrosis of the jaw related to bevacizumab, an angiogenic inhibitor.	Diphosphonates	56-59	TNF superfamily member 11	Homo sapiens	86-145
30949254-2	2019	Osteonecrosis of the jaw similar to that occurring with BPs is also produced with the anti-receptor activator of nuclear factor kappa-Beta ligand (RANKL) antibody denosumab, a bone resorption inhibitor that has a different mode of action from BPs, and there is also a report of osteonecrosis of the jaw related to bevacizumab, an angiogenic inhibitor.	Diphosphonates	56-59	TNF superfamily member 11	Homo sapiens	147-152
30949254-2	2019	Osteonecrosis of the jaw similar to that occurring with BPs is also produced with the anti-receptor activator of nuclear factor kappa-Beta ligand (RANKL) antibody denosumab, a bone resorption inhibitor that has a different mode of action from BPs, and there is also a report of osteonecrosis of the jaw related to bevacizumab, an angiogenic inhibitor.	Diphosphonates	243-246	TNF superfamily member 11	Homo sapiens	86-145
30949254-2	2019	Osteonecrosis of the jaw similar to that occurring with BPs is also produced with the anti-receptor activator of nuclear factor kappa-Beta ligand (RANKL) antibody denosumab, a bone resorption inhibitor that has a different mode of action from BPs, and there is also a report of osteonecrosis of the jaw related to bevacizumab, an angiogenic inhibitor.	Diphosphonates	243-246	TNF superfamily member 11	Homo sapiens	147-152
31549110-5	2019	The expression of the receptor activator of NF-kappaB ligand (RANKL)-induced osteoclast marker gene and protein was also reduced by sclareol treatment.	sclareol	132-140	TNF superfamily member 11	Homo sapiens	22-60
31549110-5	2019	The expression of the receptor activator of NF-kappaB ligand (RANKL)-induced osteoclast marker gene and protein was also reduced by sclareol treatment.	sclareol	132-140	TNF superfamily member 11	Homo sapiens	62-67
31549110-6	2019	Mechanistically, we found that sclareol inhibits RANKL-induced NF-kappaB and MAPK/ERK pathway activation.	sclareol	31-39	TNF superfamily member 11	Homo sapiens	49-54
31704842-1	2019	AIM: This study aimed to evaluate the antitumor effects of cyclolinopeptide (CL), which suppresses receptor activator of nuclear factor-kappaB ligand (RANKL) signalling on giant-cell tumours of the bone (GCTB) cells.	cyclolinopeptide A	59-75	TNF superfamily member 11	Homo sapiens	99-149
31704842-1	2019	AIM: This study aimed to evaluate the antitumor effects of cyclolinopeptide (CL), which suppresses receptor activator of nuclear factor-kappaB ligand (RANKL) signalling on giant-cell tumours of the bone (GCTB) cells.	cyclolinopeptide A	59-75	TNF superfamily member 11	Homo sapiens	151-156
31764838-2	2019	Blockade of receptor activator of nuclear factor kappa-B ligand (RANKL) improves osteoporosis, but might also improve glucose tolerance through reduction of hepatic insulin resistance.	Glucose	118-125	TNF superfamily member 11	Homo sapiens	12-63
31764838-2	2019	Blockade of receptor activator of nuclear factor kappa-B ligand (RANKL) improves osteoporosis, but might also improve glucose tolerance through reduction of hepatic insulin resistance.	Glucose	118-125	TNF superfamily member 11	Homo sapiens	65-70
31635168-6	2019	PPOA-N-Ac-2-Cl affected the expression of osteoclast-specific marker genes, such as TRAF6, c-fos, DC-STAMP, NFATc1, MMP9, CtsK, and TRAP (Acp5), during RANKL-mediated osteoclastogenesis.	ppoa-n-ac-2-cl	0-14	TNF superfamily member 11	Homo sapiens	152-157
31615565-8	2019	What"s more, RANKL could promote the autography of OCPs, which was recovered by Puerarin treatment.	puerarin	80-88	TNF superfamily member 11	Homo sapiens	13-18
31615565-10	2019	CONCLUSION: In conclusion, Puerarin could inhibit the OCP autophagy in the presence or absence of RANKL, which blocked the OCP proliferation and osteoclast differentiation respectively.	puerarin	27-35	TNF superfamily member 11	Homo sapiens	98-103
31596733-0	2019	Disulfiram suppressed ethanol promoted RANKL-induced osteoclastogenesis in vitro and ethanol-induced osteoporosis in vivo via ALDH1A1-NFATc1 axis.	Disulfiram	0-10	TNF superfamily member 11	Homo sapiens	39-44
31596733-2	2019	Disulfiram inhibits receptor activator of nuclear factor kappa-B ligand (RANKL)-induced osteoclastogenesis; however, whether it can be used for ethanol-induced osteoclastogenesis and its underlying mechanism are still unclear.	Disulfiram	0-10	TNF superfamily member 11	Homo sapiens	20-71
31614564-6	2019	Also, linear regression analysis showed a significant correlation between 18F-choline uptake and the number of vimentin, RANKL, VDR, or PTX3 positive prostate cancer cells.	Choline	78-85	TNF superfamily member 11	Homo sapiens	121-126
31596733-0	2019	Disulfiram suppressed ethanol promoted RANKL-induced osteoclastogenesis in vitro and ethanol-induced osteoporosis in vivo via ALDH1A1-NFATc1 axis.	Ethanol	22-29	TNF superfamily member 11	Homo sapiens	39-44
31596733-2	2019	Disulfiram inhibits receptor activator of nuclear factor kappa-B ligand (RANKL)-induced osteoclastogenesis; however, whether it can be used for ethanol-induced osteoclastogenesis and its underlying mechanism are still unclear.	Disulfiram	0-10	TNF superfamily member 11	Homo sapiens	73-78
31632268-3	2019	However, the underlying molecular mechanism by which puerarin interacts with receptor activator of nuclear factor kappa-B ligand (RANKL)-mediated osteoclast formation in vitro and wear particle-stimulated osteolysis in vivo has not been reported.	puerarin	53-61	TNF superfamily member 11	Homo sapiens	77-128
31596733-3	2019	In this study, we demonstrated that ethanol promoted RANKL-induced osteoclast formation and bone resorption, whereas, disulfiram suppressed ethanol-induced osteoclastogenesis by abrogating the expression of nuclear factor of activated T cell c1 (NFATc1) in vitro.	Ethanol	36-43	TNF superfamily member 11	Homo sapiens	53-58
31226530-7	2019	RESULTS: PA decreases RANKL, DKK1 and sclerostin expression in osteocytes.	Palmitic Acid	9-11	TNF superfamily member 11	Homo sapiens	22-27
31377240-9	2019	High doses (10 and 100 nM) of 1,25(OH)2vitamin D also increased the ratio of RANKL/OPG expression in CKD osteoblasts.	1,25(oh)2vitamin d	30-48	TNF superfamily member 11	Homo sapiens	77-82
31254476-8	2019	The 40 mM concentration of NaCl also enhanced receptor activator of nuclear factor kappa-B ligand (RANKL) but reduced that of osteoprotegerin (OPG), resulting in upregulated PDLF-mediated osteoclastogenesis.	Sodium Chloride	27-31	TNF superfamily member 11	Homo sapiens	46-97
31254476-8	2019	The 40 mM concentration of NaCl also enhanced receptor activator of nuclear factor kappa-B ligand (RANKL) but reduced that of osteoprotegerin (OPG), resulting in upregulated PDLF-mediated osteoclastogenesis.	Sodium Chloride	27-31	TNF superfamily member 11	Homo sapiens	99-104
31632268-3	2019	However, the underlying molecular mechanism by which puerarin interacts with receptor activator of nuclear factor kappa-B ligand (RANKL)-mediated osteoclast formation in vitro and wear particle-stimulated osteolysis in vivo has not been reported.	puerarin	53-61	TNF superfamily member 11	Homo sapiens	130-135
31632268-6	2019	Additionally, puerarin inhibited RANKL-induced osteoclast activation, bone resorption ability, and F-actin ring formation in vitro as puerarin concentration increased.	puerarin	14-22	TNF superfamily member 11	Homo sapiens	33-38
31632268-6	2019	Additionally, puerarin inhibited RANKL-induced osteoclast activation, bone resorption ability, and F-actin ring formation in vitro as puerarin concentration increased.	puerarin	134-142	TNF superfamily member 11	Homo sapiens	33-38
31632268-7	2019	Furthermore, mechanistic investigation indicated that reduced RANKL-stimulated MEK/ERK/NFATc1 signaling cascades might regulate the protective effect of puerarin.	puerarin	153-161	TNF superfamily member 11	Homo sapiens	62-67
31572609-2	2019	Recent retrospective clinical studies in patients with advanced melanoma and lung cancer suggest the addition of anti-RANKL antibody to ICI increases the overall response rate relative to ICI treatment alone.	2-I-ICI-H	136-139	TNF superfamily member 11	Homo sapiens	118-123
31569368-5	2019	Subsequently, the cultures of human osteoblasts with PhIP-stimulated condition medium of 786-O increased the expression of the macrophage colony-stimulating factor (M-CSF) and receptor activator of nuclear factor kappa-B ligand (RANKL), and decreased the expression of osteoprotegerin (OPG).	2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine	53-57	TNF superfamily member 11	Homo sapiens	176-227
31569368-5	2019	Subsequently, the cultures of human osteoblasts with PhIP-stimulated condition medium of 786-O increased the expression of the macrophage colony-stimulating factor (M-CSF) and receptor activator of nuclear factor kappa-B ligand (RANKL), and decreased the expression of osteoprotegerin (OPG).	2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine	53-57	TNF superfamily member 11	Homo sapiens	229-234
31572609-2	2019	Recent retrospective clinical studies in patients with advanced melanoma and lung cancer suggest the addition of anti-RANKL antibody to ICI increases the overall response rate relative to ICI treatment alone.	2-I-ICI-H	188-191	TNF superfamily member 11	Homo sapiens	118-123
31595160-0	2019	Umbelliferone Prevents Lipopolysaccharide-Induced Bone Loss and Suppresses RANKL-Induced Osteoclastogenesis by Attenuating Akt-c-Fos-NFATc1 Signaling.	Umbelliferones	0-13	TNF superfamily member 11	Homo sapiens	75-80
31595160-7	2019	In addition, Umb suppressed RANKL-induced osteoclast differentiation and abrogated bone resorption.	Umbelliferones	13-16	TNF superfamily member 11	Homo sapiens	28-33
31595160-8	2019	We found that the anti-osteoclastic and anti-resorptive activities of Umb are mediated via suppression of the RANKL-induced Akt-c-Fos-NFATc1 signaling pathway and the attenuation of osteoclast-specific genes, such as TRAP, OSCAR, ATP6v0d2, and CtsK.	Umbelliferones	70-73	TNF superfamily member 11	Homo sapiens	110-115
31595160-8	2019	We found that the anti-osteoclastic and anti-resorptive activities of Umb are mediated via suppression of the RANKL-induced Akt-c-Fos-NFATc1 signaling pathway and the attenuation of osteoclast-specific genes, such as TRAP, OSCAR, ATP6v0d2, and CtsK.	Ser-Phe-Phe-Leu-Arg-Asn	217-221	TNF superfamily member 11	Homo sapiens	110-115
31291555-5	2019	As illustrated by tartrate-resistant acid phosphatase staining, TCP was capable of inhibiting osteoclastogenesis induced by receptor activators of the NF-kappaB ligand (RANKL) in bone marrow-derived macrophage cells without any cytotoxicity.	Tranylcypromine	64-67	TNF superfamily member 11	Homo sapiens	169-174
31555218-0	2019	Hexane Fraction of Turbo brunneus Inhibits Intermediates of RANK-RANKL Signaling Pathway and Prevent Ovariectomy Induced Bone Loss.	Hexanes	0-6	TNF superfamily member 11	Homo sapiens	65-70
31238000-12	2019	Similar to the findings of MS-mediated regulation, the A23187-mediated [Ca2+]i uptake resulted in the up-regulation of receptor activator of NF-kappaB ligand (Rankl) and Sost along with increased sclerostin immunoreactivity, suggesting that [Ca2+]i signaling networks may be involved in bone remodeling.	Calcimycin	55-61	TNF superfamily member 11	Homo sapiens	119-157
31238000-12	2019	Similar to the findings of MS-mediated regulation, the A23187-mediated [Ca2+]i uptake resulted in the up-regulation of receptor activator of NF-kappaB ligand (Rankl) and Sost along with increased sclerostin immunoreactivity, suggesting that [Ca2+]i signaling networks may be involved in bone remodeling.	Calcimycin	55-61	TNF superfamily member 11	Homo sapiens	159-164
31211955-0	2019	Nirogacestat suppresses RANKL-Induced osteoclast formation in vitro and attenuates LPS-Induced bone resorption in vivo.	nirogacestat	0-12	TNF superfamily member 11	Homo sapiens	24-29
30793311-0	2019	Vitexin suppresses RANKL-induced osteoclastogenesis and prevents lipopolysaccharide (LPS)-induced osteolysis.	vitexin	0-7	TNF superfamily member 11	Homo sapiens	19-24
31304802-14	2019	RANKL -643 C/T was significantly associated with DPN alone while -693 C/G was significantly associated with both DPN and CN.	NAD	49-52	TNF superfamily member 11	Homo sapiens	0-5
31582866-2	2019	The aim of this study was to analyze the Osteoprotegerin (OPG) and Receptor Activator of NF-Kappab ligand (RANKL) expression after the application of Hydroxyapatite scaffold and SHED.	Hydroxyapatites	150-164	TNF superfamily member 11	Homo sapiens	67-105
31582866-2	2019	The aim of this study was to analyze the Osteoprotegerin (OPG) and Receptor Activator of NF-Kappab ligand (RANKL) expression after the application of Hydroxyapatite scaffold and SHED.	Hydroxyapatites	150-164	TNF superfamily member 11	Homo sapiens	107-112
31582866-15	2019	Conclusion: Hydroxyapatite scaffold and SHED increase Osteoprotegerin and decrease Receptor Activator of NF-kappaB Ligand expression with high potential as an effective agent in alveolar bone defect regeneration.	Hydroxyapatites	12-26	TNF superfamily member 11	Homo sapiens	83-121
31496878-7	2019	In addition, we found that HN significantly decreased the levels of RANKL-induced reactive oxygen species in BMMs.	Reactive Oxygen Species	82-105	TNF superfamily member 11	Homo sapiens	68-73
31161369-4	2019	Here, we found that receptor activator of nuclear factor kappa B ligand (RANKL) induced PI3Kdelta protein expression, and idelalisib inhibited RANKL-induced osteoclast differentiation.	idelalisib	122-132	TNF superfamily member 11	Homo sapiens	143-148
31161369-5	2019	Next, the inhibitory effect of idelalisib on RANKL-induced activation of the Akt-c-Fos/NFATc1 signaling cascade was confirmed by western blot analysis and real-time PCR.	idelalisib	31-41	TNF superfamily member 11	Homo sapiens	45-50
31261037-0	2019	Berberine coated mannosylated liposomes curtail RANKL stimulated osteoclastogenesis through the modulation of GSK3beta pathway via upregulating miR-23a.	Berberine	0-9	TNF superfamily member 11	Homo sapiens	48-53
31261037-3	2019	Accordingly, the present study was designed to examine the therapeutic effect of berberine coated mannosylated liposomes (ML-BBR) on RANKL (100 ng/ml) stimulated bone marrow-derived monocytes/macrophages (BMMs) via altering miR-23a expression.	Berberine	81-90	TNF superfamily member 11	Homo sapiens	133-138
31319381-10	2019	Of note, RANKL treatment inhibited Homer proteins interaction with NFATc1, but it was restored by cyclosporine A treatment to inhibit calcineurin.	Cyclosporine	98-112	TNF superfamily member 11	Homo sapiens	9-14
31194990-1	2019	Triiodothyronine (T3) and estrogen (E2) play important roles in the bone remodeling process and signaling of receptor activator of the nuclear factor-kappa beta (RANKL) and osteoprotegerin (OPG) expressed by osteoblasts.	Triiodothyronine	0-16	TNF superfamily member 11	Homo sapiens	162-167
31225720-7	2019	Moreover, DHE inhibited the RANKL-induced phosphorylation of NF-kappaB, mitigated bone erosion in vivo in lipopolysaccharide-induced inflammatory bone loss model and particle-induced calvarial osteolysis model.	dehydrocostus lactone	10-13	TNF superfamily member 11	Homo sapiens	28-33
31109651-7	2019	In vitro cellular analyses showed that Vx-11e inhibited osteoclast formation from BMM precursors in response to RANKL, as well as bone resorption by mature osteoclasts.	VX-11e	39-45	TNF superfamily member 11	Homo sapiens	112-117
31109651-8	2019	Mechanistically, Vx-11e impaired RANKL-induced ERK1/2 signaling by inhibiting its kinase activity thereby blocking the phosphorylation of downstream substrates.	VX-11e	17-23	TNF superfamily member 11	Homo sapiens	33-38
31062421-3	2019	The aim of this study was to explore the effects of dietary calcium to available phosphorus ratios (Ca/AP) on bone metabolism and osteoclast activity of the osteoprotegerin (OPG)/receptor activator of nuclear factor kappa B ligand (RANKL) signalling pathway in piglets.	Calcium	60-67	TNF superfamily member 11	Homo sapiens	179-230
31367247-0	2019	Loureirin B suppresses RANKL-induced osteoclastogenesis and ovariectomized osteoporosis via attenuating NFATc1 and ROS activities.	loureirin B	0-11	TNF superfamily member 11	Homo sapiens	23-28
31150804-0	2019	RANKL-induced osteoclastogenesis in bone marrow-derived macrophages is suppressed by cisapride.	Cisapride	85-94	TNF superfamily member 11	Homo sapiens	0-5
30548260-0	2019	Hesperetin suppresses RANKL-induced osteoclastogenesis and ameliorates lipopolysaccharide-induced bone loss.	hesperetin	0-10	TNF superfamily member 11	Homo sapiens	22-27
30548260-7	2019	Hesperetin effectively suppressed RANKL-induced osteoclastogenesis, osteoclastic bone resorption, and F-actin ring formation in a dose-dependent manner.	hesperetin	0-10	TNF superfamily member 11	Homo sapiens	34-39
30548260-10	2019	Consistent with in vitro results, hesperetin effectively ameliorated LPS-induced bone loss, reduced osteoclast numbers, and decreased the RANKL/OPG ratio in vivo.	hesperetin	34-44	TNF superfamily member 11	Homo sapiens	138-143
31217507-0	2019	A Selective FGFR inhibitor AZD4547 suppresses RANKL/M-CSF/OPG-dependent ostoclastogenesis and breast cancer growth in the metastatic bone microenvironment.	AZD4547	27-34	TNF superfamily member 11	Homo sapiens	46-51
31150804-4	2019	Cisapride significantly inhibited tartrate-resistant acid phosphatase (TRAP)-positive multinuclear osteoclasts and F-actin ring formation during receptor activator of NF-kappaB ligand (RANKL)-induced osteoclastogenesis.	Cisapride	0-9	TNF superfamily member 11	Homo sapiens	145-183
31150804-4	2019	Cisapride significantly inhibited tartrate-resistant acid phosphatase (TRAP)-positive multinuclear osteoclasts and F-actin ring formation during receptor activator of NF-kappaB ligand (RANKL)-induced osteoclastogenesis.	Cisapride	0-9	TNF superfamily member 11	Homo sapiens	185-190
31150804-6	2019	Cisapride also suppressed RANKL-induced expression of NF-ATc1, TRAP, and cathepsin K genes in BMMs.	Cisapride	0-9	TNF superfamily member 11	Homo sapiens	26-31
31231214-0	2019	Deacylcynaropicrin Inhibits RANKL-Induced Osteoclastogenesis by Inhibiting NF-kappaB and MAPK and Promoting M2 Polarization of Macrophages.	deacylcynaropicrin	0-18	TNF superfamily member 11	Homo sapiens	28-33
31231214-8	2019	In conclusion, these results demonstrated that DAC suppressed RANKL-induced inflammation and osteoclastogenesis and therefore it can be used as a potential treatment for osteoporosis, arthritis, osteolysis, and aseptic loosening of artificial prostheses.	deacylcynaropicrin	47-50	TNF superfamily member 11	Homo sapiens	62-67
31231214-2	2019	Here, we aimed to investigate the inhibitory effects of deacylcynaropicrin (DAC) on osteoclastogenesis and bone resorption induced by RANKL.	deacylcynaropicrin	56-74	TNF superfamily member 11	Homo sapiens	134-139
31231214-2	2019	Here, we aimed to investigate the inhibitory effects of deacylcynaropicrin (DAC) on osteoclastogenesis and bone resorption induced by RANKL.	deacylcynaropicrin	76-79	TNF superfamily member 11	Homo sapiens	134-139
30951948-0	2019	S-amlodipine improves endothelial dysfunction via the RANK/RANKL/OPG system by regulating microRNA-155 in hypertension.	Amlodipine	2-12	TNF superfamily member 11	Homo sapiens	59-64
30902820-6	2019	BI 655064 was associated with greater changes in CD40-CD40L pathway-related markers, including reductions in inflammatory and bone resorption markers (interleukin-6, matrix metalloproteinase-3, receptor activator of nuclear factor-kappaB ligand), concentration of autoantibodies (immunoglobulin [Ig]G rheumatoid factor [RF], IgM RF, IgA RF) and CD95+ activated B-cell subsets.	BI 655064	0-9	TNF superfamily member 11	Homo sapiens	166-244
30951948-3	2019	Specifically, we investigated if S-amlodipine regulates RANK/RANKL/OPG and micro-RNA 155 (miR-155) levels.	Amlodipine	33-45	TNF superfamily member 11	Homo sapiens	61-66
30951948-7	2019	In human umbilical vein endothelial cells (HUVECs), miR-155, RANK, and RANKL levels were significantly decreased, while OPG mRNA levels were significantly increased in the S-amlodipine group.	Sulfur	172-173	TNF superfamily member 11	Homo sapiens	71-76
30355436-0	2019	CCAAT/enhancer-binding protein beta (C/EBPbeta) is an important mediator of 1,25 dihydroxyvitamin D3 (1,25D3)-induced receptor activator of nuclear factor kappa-B ligand (RANKL) expression in osteoblasts.	Calcitriol	76-100	TNF superfamily member 11	Homo sapiens	118-169
30951948-10	2019	S-amlodipine significantly inhibited RANKL expression and NF-kappaB phosphorylation, and there were no significant differences in response to the NF-kappaB inhibitor (Bay110785).	Amlodipine	2-12	TNF superfamily member 11	Homo sapiens	37-42
30951948-13	2019	Our results indicate that S-amlodipine inhibits inflammation and protects against endothelial dysfunction, likely via regulating the RANK/RANKL/OPG pathway, which appears to be downstream of miR-155.	Amlodipine	26-38	TNF superfamily member 11	Homo sapiens	138-143
30737962-11	2019	Furthermore, dexamethasone alleviated RANKL-induced inflammatory reactions in AR models.	Dexamethasone	13-26	TNF superfamily member 11	Homo sapiens	38-43
30355436-0	2019	CCAAT/enhancer-binding protein beta (C/EBPbeta) is an important mediator of 1,25 dihydroxyvitamin D3 (1,25D3)-induced receptor activator of nuclear factor kappa-B ligand (RANKL) expression in osteoblasts.	Calcitriol	76-100	TNF superfamily member 11	Homo sapiens	171-176
30355436-1	2019	Receptor activator of nuclear factor kappa B ligand (RANKL) expression in osteoblasts is regulated by 1,25-dihydroxyvitamin D3 (1,25D3).	Calcitriol	102-126	TNF superfamily member 11	Homo sapiens	0-51
30355436-1	2019	Receptor activator of nuclear factor kappa B ligand (RANKL) expression in osteoblasts is regulated by 1,25-dihydroxyvitamin D3 (1,25D3).	Calcitriol	102-126	TNF superfamily member 11	Homo sapiens	53-58
30715395-9	2019	Higher kynurenine concentrations were significantly associated with higher TRAP-5b and RANKL levels, but not with BSALP and OPG levels, in BM plasma.	Kynurenine	7-17	TNF superfamily member 11	Homo sapiens	87-92
31211043-1	2019	Objective: This study aimed to examine the effects of PGE2 on RANKL expression in response to vibration and vibration in combination with compressive stress and characterise this transduction pathway in periodontal ligament (PDL) cells.	Dinoprostone	54-58	TNF superfamily member 11	Homo sapiens	62-67
31211043-3	2019	To investigate whether the expression of RANKL and PGE2 was COX-dependent, PDL cells were treated with indomethacin prior to the onset of mechanical stimulation.	Indomethacin	103-115	TNF superfamily member 11	Homo sapiens	41-46
31211043-8	2019	Indomethacin abolished induction of RANKL and downregulated OPG in response to all mechanical stresses.	Indomethacin	0-12	TNF superfamily member 11	Homo sapiens	36-41
30895561-0	2019	Roles of SP600125 in expression of JNK, RANKL and OPG in cultured dental follicle cells.	pyrazolanthrone	9-17	TNF superfamily member 11	Homo sapiens	40-45
30895561-7	2019	Significant decrease was noticed in the RANKL protein expression with the elevation of SP600125.	pyrazolanthrone	87-95	TNF superfamily member 11	Homo sapiens	40-45
30895561-9	2019	After SP600125 treatment, the expression of RANKL and JNK showed a trend of decrease, and the expression of OPG showed gradual increase followed by gradual decrease.	pyrazolanthrone	6-14	TNF superfamily member 11	Homo sapiens	44-49
31292059-11	2019	Nevertheless, unlike the IL-17 group, IL-17 combined with inhibitor SB203580 decreased the expression of RANKL mRNA and protein and increased OPG mRNA.	SB 203580	68-76	TNF superfamily member 11	Homo sapiens	105-110
30914204-0	2019	Accumulation of hyaluronic acid in stromal cells modulates osteoclast formation by regulation of receptor activator of nuclear factor kappa-B ligand expression.	Hyaluronic Acid	16-31	TNF superfamily member 11	Homo sapiens	97-148
31123462-13	2019	Conclusions: These findings indicate that the interaction of TRAF6 with c-Cbl causes lysine 48-linked polyubiquitination for both negative feedback regulation and signaling cross-talk between RANKL and IFN-gamma.	Lysine	85-91	TNF superfamily member 11	Homo sapiens	192-197
31384515-10	2019	Serum levels of osteopontin and RANKL were correlated to serum levels of BAP and disease extension.	benzylaminopurine	73-76	TNF superfamily member 11	Homo sapiens	32-37
30914204-2	2019	In this study, we investigated the effect and underlying mechanisms of HA accumulation on the expression of receptor activator of nuclear factor kappa-B ligand (RANKL) induced by 1alpha,25(OH)2D3 and dexamethasone in stromal cells, which support osteoclastogenesis.	25(oh)2d3	186-195	TNF superfamily member 11	Homo sapiens	108-159
30914204-2	2019	In this study, we investigated the effect and underlying mechanisms of HA accumulation on the expression of receptor activator of nuclear factor kappa-B ligand (RANKL) induced by 1alpha,25(OH)2D3 and dexamethasone in stromal cells, which support osteoclastogenesis.	25(oh)2d3	186-195	TNF superfamily member 11	Homo sapiens	161-166
30914204-2	2019	In this study, we investigated the effect and underlying mechanisms of HA accumulation on the expression of receptor activator of nuclear factor kappa-B ligand (RANKL) induced by 1alpha,25(OH)2D3 and dexamethasone in stromal cells, which support osteoclastogenesis.	Dexamethasone	200-213	TNF superfamily member 11	Homo sapiens	108-159
30914204-2	2019	In this study, we investigated the effect and underlying mechanisms of HA accumulation on the expression of receptor activator of nuclear factor kappa-B ligand (RANKL) induced by 1alpha,25(OH)2D3 and dexamethasone in stromal cells, which support osteoclastogenesis.	Dexamethasone	200-213	TNF superfamily member 11	Homo sapiens	161-166
30914204-4	2019	Down-regulation of hyaluronan synthase 2 (HAS2) expression by siRNA also stimulated RANKL expression induced by 1alpha,25(OH)2D3 and dexamethasone.	Dexamethasone	133-146	TNF superfamily member 11	Homo sapiens	84-89
30914204-6	2019	In contrast, transforming growth factor-beta1 (TGF-beta1), which stimulates HAS2 expression and HA synthesis, down-regulated RANKL expression induced by 1alpha,25(OH)2D3 and dexamethasone.	oh)2d3	163-169	TNF superfamily member 11	Homo sapiens	125-130
30914204-6	2019	In contrast, transforming growth factor-beta1 (TGF-beta1), which stimulates HAS2 expression and HA synthesis, down-regulated RANKL expression induced by 1alpha,25(OH)2D3 and dexamethasone.	Dexamethasone	174-187	TNF superfamily member 11	Homo sapiens	125-130
30753461-5	2019	We further showed that treatment with FK506 (tacrolimus) possibly inhibits the increase in IL-8 levels in RA patients with anti-RANKL Ab, and in vitro assay confirmed that FK506 suppressed IL-8 production in pre-OCLs.	Tacrolimus	38-43	TNF superfamily member 11	Homo sapiens	128-133
31198358-1	2019	Purpose: The aim of this study was to estimate the Receptor activator of nuclear factor kappa-B ligand (RANKL) and Osteoprotegrin (OPG) levels in gingival crevicular fluid (GCF) after placement of collagen membrane with simvastatin in intrabony defects.	Simvastatin	220-231	TNF superfamily member 11	Homo sapiens	51-102
31198358-11	2019	Conclusion: Simvastatin-loaded collagen membrane expressed increased OPG and decreased RANKL levels, which could have a potential role in periodontal regeneration.	Simvastatin	12-23	TNF superfamily member 11	Homo sapiens	87-92
31076346-7	2019	Infusion of GMSC to CIA significantly attenuated the severity of arthritis, pathology scores, frequency of osteoclasts, particularly bone erosion, as well as a decreased expression of RANKL in synovial tissues in vivo.	gmsc	12-16	TNF superfamily member 11	Homo sapiens	184-189
31223608-14	2019	EFV reduced RANKL-mediated osteoclast formation and activation by inhibiting expression of nuclear factor of activated T cells 1, a key factor of osteoclastogenesis.	efavirenz	0-3	TNF superfamily member 11	Homo sapiens	12-17
30753461-5	2019	We further showed that treatment with FK506 (tacrolimus) possibly inhibits the increase in IL-8 levels in RA patients with anti-RANKL Ab, and in vitro assay confirmed that FK506 suppressed IL-8 production in pre-OCLs.	Tacrolimus	45-55	TNF superfamily member 11	Homo sapiens	128-133
30753461-5	2019	We further showed that treatment with FK506 (tacrolimus) possibly inhibits the increase in IL-8 levels in RA patients with anti-RANKL Ab, and in vitro assay confirmed that FK506 suppressed IL-8 production in pre-OCLs.	Tacrolimus	172-177	TNF superfamily member 11	Homo sapiens	128-133
30850163-7	2019	In presence of RANKL, the autophagy capacity of OCPs and the differentiation from OCPs into mature osteoclasts were significantly enhanced by 1alpha,25-(OH)2D3, while the suppression of autophagy with spautin-1 or 3-MA downregulated the osteoclastogenesis capacity.	ocps	48-52	TNF superfamily member 11	Homo sapiens	15-20
30850163-7	2019	In presence of RANKL, the autophagy capacity of OCPs and the differentiation from OCPs into mature osteoclasts were significantly enhanced by 1alpha,25-(OH)2D3, while the suppression of autophagy with spautin-1 or 3-MA downregulated the osteoclastogenesis capacity.	Calcitriol	142-159	TNF superfamily member 11	Homo sapiens	15-20
30992059-4	2019	RESULTS: We show here that treating RANKL-induced osteoclast progenitor (OCP) cells with the DNMT inhibitor 5-Aza-2"-deoxycytidine (5-Aza-CdR) induces CpG island hypomethylation and facilitates MMP-9 transcription.	Decitabine	108-130	TNF superfamily member 11	Homo sapiens	36-41
30850163-7	2019	In presence of RANKL, the autophagy capacity of OCPs and the differentiation from OCPs into mature osteoclasts were significantly enhanced by 1alpha,25-(OH)2D3, while the suppression of autophagy with spautin-1 or 3-MA downregulated the osteoclastogenesis capacity.	spautin-1	201-210	TNF superfamily member 11	Homo sapiens	15-20
30850163-7	2019	In presence of RANKL, the autophagy capacity of OCPs and the differentiation from OCPs into mature osteoclasts were significantly enhanced by 1alpha,25-(OH)2D3, while the suppression of autophagy with spautin-1 or 3-MA downregulated the osteoclastogenesis capacity.	3-methyladenine	214-218	TNF superfamily member 11	Homo sapiens	15-20
30850163-8	2019	In summary, 1alpha,25-(OH)2D3 can directly suppress OCPs autophagy, which negatively regulates the proliferation of OCPs without RANKL.	Calcitriol	12-29	TNF superfamily member 11	Homo sapiens	129-134
30850163-9	2019	1alpha,25-(OH)2D3 can indirectly upregulate the autophagy response of OCPs, thereby enhancing the osteoclasts formation in presence of RANKL.	Calcitriol	0-17	TNF superfamily member 11	Homo sapiens	135-140
30850163-9	2019	1alpha,25-(OH)2D3 can indirectly upregulate the autophagy response of OCPs, thereby enhancing the osteoclasts formation in presence of RANKL.	ocps	70-74	TNF superfamily member 11	Homo sapiens	135-140
30979019-3	2019	Unsaturated fatty acids (UFA) are known to inhibit osteoclastogenesis by targeting RANKL signalling.	Fatty Acids, Unsaturated	0-23	TNF superfamily member 11	Homo sapiens	83-88
30979019-3	2019	Unsaturated fatty acids (UFA) are known to inhibit osteoclastogenesis by targeting RANKL signalling.	Fatty Acids, Unsaturated	25-28	TNF superfamily member 11	Homo sapiens	83-88
30826055-0	2019	CDDO-Me, Sulforaphane and tBHQ attenuate the RANKL-induced osteoclast differentiation via activating the NRF2-mediated antioxidant response.	bardoxolone methyl	0-7	TNF superfamily member 11	Homo sapiens	45-50
31024321-3	2019	In the present study, we found that a novel imidazole derivative, KP-A038, suppressed receptor activator of nuclear factor-kappaB ligand (RANKL)-mediated osteoclastogenesis and bone-resorbing activity in vitro and attenuated lipopolysaccharide (LPS)-induced bone destruction in vivo.	imidazole	44-53	TNF superfamily member 11	Homo sapiens	138-143
30826055-0	2019	CDDO-Me, Sulforaphane and tBHQ attenuate the RANKL-induced osteoclast differentiation via activating the NRF2-mediated antioxidant response.	sulforaphane	9-21	TNF superfamily member 11	Homo sapiens	45-50
30826055-0	2019	CDDO-Me, Sulforaphane and tBHQ attenuate the RANKL-induced osteoclast differentiation via activating the NRF2-mediated antioxidant response.	2-tert-butylhydroquinone	26-30	TNF superfamily member 11	Homo sapiens	45-50
30826055-2	2019	During OC differentiation, intracellular reactive oxygen species (ROS) stimulated by receptor activator of nuclear factor kappa-B ligand (RANKL) can serve as the signaling molecules to promote osteoclastic genes expression.	Reactive Oxygen Species	41-64	TNF superfamily member 11	Homo sapiens	85-136
30826055-2	2019	During OC differentiation, intracellular reactive oxygen species (ROS) stimulated by receptor activator of nuclear factor kappa-B ligand (RANKL) can serve as the signaling molecules to promote osteoclastic genes expression.	Reactive Oxygen Species	41-64	TNF superfamily member 11	Homo sapiens	138-143
30826055-2	2019	During OC differentiation, intracellular reactive oxygen species (ROS) stimulated by receptor activator of nuclear factor kappa-B ligand (RANKL) can serve as the signaling molecules to promote osteoclastic genes expression.	Reactive Oxygen Species	66-69	TNF superfamily member 11	Homo sapiens	85-136
30826055-2	2019	During OC differentiation, intracellular reactive oxygen species (ROS) stimulated by receptor activator of nuclear factor kappa-B ligand (RANKL) can serve as the signaling molecules to promote osteoclastic genes expression.	Reactive Oxygen Species	66-69	TNF superfamily member 11	Homo sapiens	138-143
30826055-5	2019	By treating RAW cells with three compounds, we found that NRF2 was activated and its downstream antioxidant genes were upregulated, and the RANKL-induced intracellular ROS production and osteoclastogenesis were impaired.	Reactive Oxygen Species	168-171	TNF superfamily member 11	Homo sapiens	140-145
30826055-8	2019	Taken together, these results suggest that CDDO-Me, SFN and tBHQ attenuate RANKL-induced osteoclastogenesis via activation of NRF2-mediated antioxidant response.	bardoxolone methyl	43-50	TNF superfamily member 11	Homo sapiens	75-80
30826055-8	2019	Taken together, these results suggest that CDDO-Me, SFN and tBHQ attenuate RANKL-induced osteoclastogenesis via activation of NRF2-mediated antioxidant response.	sulforaphane	52-55	TNF superfamily member 11	Homo sapiens	75-80
30826055-8	2019	Taken together, these results suggest that CDDO-Me, SFN and tBHQ attenuate RANKL-induced osteoclastogenesis via activation of NRF2-mediated antioxidant response.	2-tert-butylhydroquinone	60-64	TNF superfamily member 11	Homo sapiens	75-80
31001202-3	2019	The aim of this study is to evaluate the antioxidant effect of vitamin E added to UHMWPE on oxidative stress induced osteolysis, focusing in particular on the oxidative stress response in correlation with the production of osteoimmunological markers, Sclerostin and DKK-1, and the RANKL/OPG ratio compared to conventional UHMWPE wear debris.	Vitamin E	63-72	TNF superfamily member 11	Homo sapiens	281-286
31001202-8	2019	Vitamin E-stabilized UHMWPE induced a decrease of RANKL/OPG ratio compared to UHMWPE without Vitamin E, and the same effect was observed for Sclerostin, while DKK-1 was not significantly affected.	Vitamin E	0-9	TNF superfamily member 11	Homo sapiens	50-55
30270544-0	2019	The effects of fatty acids consumption on OPG/RANKL/RANK system in cardiovascular diseases: Current status and future perspectives for the impact of diet-gene interaction.	Fatty Acids	15-26	TNF superfamily member 11	Homo sapiens	46-51
31929726-6	2019	Receptor Activator of NF-kappaB Ligand (RANKL)/ Osteoprotegerine (OPG) ratio is elevated in favor of RANKL in a time-dependent manner, and further RANKL production is caused by upregulation of Interleukin-6 (IL-6) and the inflammation pathway.	osteoprotegerine	48-64	TNF superfamily member 11	Homo sapiens	0-38
31929726-6	2019	Receptor Activator of NF-kappaB Ligand (RANKL)/ Osteoprotegerine (OPG) ratio is elevated in favor of RANKL in a time-dependent manner, and further RANKL production is caused by upregulation of Interleukin-6 (IL-6) and the inflammation pathway.	osteoprotegerine	48-64	TNF superfamily member 11	Homo sapiens	40-45
31929726-6	2019	Receptor Activator of NF-kappaB Ligand (RANKL)/ Osteoprotegerine (OPG) ratio is elevated in favor of RANKL in a time-dependent manner, and further RANKL production is caused by upregulation of Interleukin-6 (IL-6) and the inflammation pathway.	osteoprotegerine	48-64	TNF superfamily member 11	Homo sapiens	101-106
31929726-6	2019	Receptor Activator of NF-kappaB Ligand (RANKL)/ Osteoprotegerine (OPG) ratio is elevated in favor of RANKL in a time-dependent manner, and further RANKL production is caused by upregulation of Interleukin-6 (IL-6) and the inflammation pathway.	osteoprotegerine	48-64	TNF superfamily member 11	Homo sapiens	101-106
31929726-6	2019	Receptor Activator of NF-kappaB Ligand (RANKL)/ Osteoprotegerine (OPG) ratio is elevated in favor of RANKL in a time-dependent manner, and further RANKL production is caused by upregulation of Interleukin-6 (IL-6) and the inflammation pathway.	SCHEMBL12347590	66-69	TNF superfamily member 11	Homo sapiens	0-38
31929726-6	2019	Receptor Activator of NF-kappaB Ligand (RANKL)/ Osteoprotegerine (OPG) ratio is elevated in favor of RANKL in a time-dependent manner, and further RANKL production is caused by upregulation of Interleukin-6 (IL-6) and the inflammation pathway.	SCHEMBL12347590	66-69	TNF superfamily member 11	Homo sapiens	40-45
31929726-6	2019	Receptor Activator of NF-kappaB Ligand (RANKL)/ Osteoprotegerine (OPG) ratio is elevated in favor of RANKL in a time-dependent manner, and further RANKL production is caused by upregulation of Interleukin-6 (IL-6) and the inflammation pathway.	SCHEMBL12347590	66-69	TNF superfamily member 11	Homo sapiens	101-106
31929726-6	2019	Receptor Activator of NF-kappaB Ligand (RANKL)/ Osteoprotegerine (OPG) ratio is elevated in favor of RANKL in a time-dependent manner, and further RANKL production is caused by upregulation of Interleukin-6 (IL-6) and the inflammation pathway.	SCHEMBL12347590	66-69	TNF superfamily member 11	Homo sapiens	101-106
31929726-10	2019	Conclusion: Suppressing the expression of fusion genes such as syncytine-A which acts independently of RANKL, could be possible future therapeutic targets for microgravity side effects.	syncytine-a	63-74	TNF superfamily member 11	Homo sapiens	103-108
30378146-5	2019	In this study, our study showed that daidzin significantly inhibited receptor activator of nuclear factor-kB ligand (RANKL)-induced osteoclast differentiation of bone marrow macrophages and the hydroxyapatite-resorbing activity of mature osteoclasts by inhibiting RANKL-induced NF-kB signaling pathway.	daidzin	37-44	TNF superfamily member 11	Homo sapiens	69-115
30378146-5	2019	In this study, our study showed that daidzin significantly inhibited receptor activator of nuclear factor-kB ligand (RANKL)-induced osteoclast differentiation of bone marrow macrophages and the hydroxyapatite-resorbing activity of mature osteoclasts by inhibiting RANKL-induced NF-kB signaling pathway.	daidzin	37-44	TNF superfamily member 11	Homo sapiens	117-122
30378146-5	2019	In this study, our study showed that daidzin significantly inhibited receptor activator of nuclear factor-kB ligand (RANKL)-induced osteoclast differentiation of bone marrow macrophages and the hydroxyapatite-resorbing activity of mature osteoclasts by inhibiting RANKL-induced NF-kB signaling pathway.	daidzin	37-44	TNF superfamily member 11	Homo sapiens	264-269
30378146-5	2019	In this study, our study showed that daidzin significantly inhibited receptor activator of nuclear factor-kB ligand (RANKL)-induced osteoclast differentiation of bone marrow macrophages and the hydroxyapatite-resorbing activity of mature osteoclasts by inhibiting RANKL-induced NF-kB signaling pathway.	Durapatite	194-208	TNF superfamily member 11	Homo sapiens	69-115
30378146-5	2019	In this study, our study showed that daidzin significantly inhibited receptor activator of nuclear factor-kB ligand (RANKL)-induced osteoclast differentiation of bone marrow macrophages and the hydroxyapatite-resorbing activity of mature osteoclasts by inhibiting RANKL-induced NF-kB signaling pathway.	Durapatite	194-208	TNF superfamily member 11	Homo sapiens	117-122
30378146-8	2019	Together our data demonstrated that daidzin inhibits RANKL-induced osteoclastogenesis through suppressing NF-kB signaling pathway and that daidzin is a promising agent in the treatment of osteolytic diseases.	daidzin	36-43	TNF superfamily member 11	Homo sapiens	53-58
30903656-13	2019	Finally, iNKT cell activation by the prototypal glycolipid ligand alpha-galactosylceramide increased by 8 times their RANKL expression.	alpha-galactosylceramide	66-90	TNF superfamily member 11	Homo sapiens	118-123
30703706-1	2019	The purpose of this study was to determine the direct effects of phenobarbital (PB) on receptor activator of nuclear factor kappa-B ligand (RANKL) induced osteoclast differentiation and function in vitro and in vivo.	Phenobarbital	65-78	TNF superfamily member 11	Homo sapiens	140-145
30703706-1	2019	The purpose of this study was to determine the direct effects of phenobarbital (PB) on receptor activator of nuclear factor kappa-B ligand (RANKL) induced osteoclast differentiation and function in vitro and in vivo.	Phenobarbital	80-82	TNF superfamily member 11	Homo sapiens	140-145
30703706-2	2019	Here, PB significantly inhibited osteoclast formation and bone resorption ability induced by RANKL in vitro.	Phenobarbital	6-8	TNF superfamily member 11	Homo sapiens	93-98
30378146-0	2019	Daidzin inhibits RANKL-induced osteoclastogenesis in vitro and prevents LPS-induced bone loss in vivo.	daidzin	0-7	TNF superfamily member 11	Homo sapiens	17-22
30729671-7	2019	Exogenous Pros1 inhibited p.g-LPS-induced production of TNF-alpha, IL-6, IL-1beta, MMP9/2 and RANKL in a Tyro3-dependent manner as revealed by PCR, Western blot analysis, ELISA and gelatin zymography.	p.g-lps	26-33	TNF superfamily member 11	Homo sapiens	94-99
30486961-0	2019	Au Nanoparticles Attenuate RANKL-Induced Osteoclastogenesis by Suppressing Pre-Osteoclast Fusion.	Gold	0-2	TNF superfamily member 11	Homo sapiens	27-32
30826495-7	2019	Lastly, inhibition of PLCgamma by pharmacological inhibitor U73122 abrogates Sema6A-stimulated NFATc1 activation and RANKL-induced osteoclastogenesis, thus demonstrating that the PLCgamma-mediated NFATc1 activation accounts for the promotive role of Sema6A-plexin-A2 axis in RANKL-induced osteoclastogenesis.	1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione	60-66	TNF superfamily member 11	Homo sapiens	117-122
30270544-4	2019	However, there have been few studies on the impact of diet-gene interaction for effects of fatty acids consumption on the OPG/RANKL/RANK system in CVD.	Fatty Acids	91-102	TNF superfamily member 11	Homo sapiens	126-131
30270544-5	2019	This review focuses on the effects of fatty acids on OPG/RANKL/RANK in CVD.	Fatty Acids	38-49	TNF superfamily member 11	Homo sapiens	57-62
30633253-0	2019	Effect of the Wnt signal-RANKL/OPG axis on the enhanced osteogenic integration of a lithium incorporated surface.	Lithium	84-91	TNF superfamily member 11	Homo sapiens	25-30
30597617-7	2019	Mechanistically, by activating melatonin receptor 2 (MT2), melatonin upregulates the gene expression of alkaline phosphatase (ALP), bone morphogenetic protein 2 (BMP2), BMP6, osteocalcin, and osteoprotegerin to promote osteogenesis while inhibiting the receptor activator of NF-kB ligand (RANKL) pathway to suppress osteolysis.	Melatonin	31-40	TNF superfamily member 11	Homo sapiens	253-287
30597617-7	2019	Mechanistically, by activating melatonin receptor 2 (MT2), melatonin upregulates the gene expression of alkaline phosphatase (ALP), bone morphogenetic protein 2 (BMP2), BMP6, osteocalcin, and osteoprotegerin to promote osteogenesis while inhibiting the receptor activator of NF-kB ligand (RANKL) pathway to suppress osteolysis.	Melatonin	31-40	TNF superfamily member 11	Homo sapiens	289-294
30840811-0	2019	N-acetyl-l-cysteine controls osteoclastogenesis through regulating Th17 differentiation and RANKL production in rheumatoid arthritis.	Acetylcysteine	0-19	TNF superfamily member 11	Homo sapiens	92-97
30703868-0	2019	Calcium-Phosphate Crystals Promote RANKL Expression via the Downregulation of DUSP1.	calcium phosphate	0-17	TNF superfamily member 11	Homo sapiens	35-40
30703868-5	2019	The calcium-containing crystals upregulated the expression of RANKL and increased the differentiation of osteoclasts significantly as a result.	Calcium	4-11	TNF superfamily member 11	Homo sapiens	62-67
30703868-11	2019	These findings suggest that calcium-containing crystals may play a crucial role in promoting RANKL-induced osteoclastogenesis via DUSP1.	Calcium	28-35	TNF superfamily member 11	Homo sapiens	93-98
30732873-7	2019	The augmentation of ROS level activated the RANKL dependent osteoclasts differentiation pathways resulted in the promotion of osteoclastogenesis, while anions associated with cerium(III) cation have no effects on the differentiation of osteoclasts.	Reactive Oxygen Species	20-23	TNF superfamily member 11	Homo sapiens	44-49
30659666-7	2019	However, the RANKL/OPG ratio was significantly higher in fluoride toothpaste-treated sites when compared to triclosan/fluoride-treated sites at the end of period without mechanical toothbrushing, on the 21st day (p = 0.041).	Fluorides	57-65	TNF superfamily member 11	Homo sapiens	13-18
30813507-7	2019	On nanofunctionalized titanium specimens, the osteoclast-specific TRAP5b protein was monitored and showed a significantly decreased amount on cDMAB-titanium in PBMCs + RANKL/MCSF.	Titanium	22-30	TNF superfamily member 11	Homo sapiens	168-173
30813507-7	2019	On nanofunctionalized titanium specimens, the osteoclast-specific TRAP5b protein was monitored and showed a significantly decreased amount on cDMAB-titanium in PBMCs + RANKL/MCSF.	Titanium	148-156	TNF superfamily member 11	Homo sapiens	168-173
30659666-8	2019	CONCLUSION: Triclosan-containing toothpaste favorably modulated osteo-immunoinflammatory mediators during the experimental peri-implant mucositis in smokers, decreasing the ratio of RANKL/OPG.	Triclosan	12-21	TNF superfamily member 11	Homo sapiens	182-187
30696596-1	2019	Unraveling the vitamin D - RANKL association.	Vitamin D	15-24	TNF superfamily member 11	Homo sapiens	27-32
30596535-6	2019	We found that IL-17 stimulated RA-FLS to produce RANKL and quercetin decreased the IL-17-induced RANKL protein levels.	Quercetin	59-68	TNF superfamily member 11	Homo sapiens	97-102
30596535-8	2019	When monocytes were stimulated with IL-17, macrophage colony-stimulating factor or RANKL, mature osteoclasts were formed, and quercetin decreased this osteoclastogenesis.	Quercetin	126-135	TNF superfamily member 11	Homo sapiens	83-88
30596535-11	2019	Quercetin inhibits IL-17-stimulated RANKL production in RA-FLS and IL-17-stimulated osteoclast formation.	Quercetin	0-9	TNF superfamily member 11	Homo sapiens	36-41
30696596-3	2019	The discovery of receptor activator of nuclear factor kB (RANK) and RANK binding ligand (RANKL) uncovered the bone homeostasis and molecular mechanism by which multiple compounds (including vitamin D) regulated osteoclast differentiation; a function mediated by osteoblastic cells and osteoclast-precursor cells.	Vitamin D	190-199	TNF superfamily member 11	Homo sapiens	68-87
30696596-3	2019	The discovery of receptor activator of nuclear factor kB (RANK) and RANK binding ligand (RANKL) uncovered the bone homeostasis and molecular mechanism by which multiple compounds (including vitamin D) regulated osteoclast differentiation; a function mediated by osteoblastic cells and osteoclast-precursor cells.	Vitamin D	190-199	TNF superfamily member 11	Homo sapiens	89-94
30696596-4	2019	HYPOTHESIS: In a country burdened by vitamin D deficiency, causal relation between hypovitaminosis D and GCTB was hypothesized based on the vitamin D mediated RANKL expression and osteoclastogenesis, as India is also a population with higher incidence of GCTB as compared to Western populations described in the literature.	gctb	105-109	TNF superfamily member 11	Homo sapiens	159-164
30696596-4	2019	HYPOTHESIS: In a country burdened by vitamin D deficiency, causal relation between hypovitaminosis D and GCTB was hypothesized based on the vitamin D mediated RANKL expression and osteoclastogenesis, as India is also a population with higher incidence of GCTB as compared to Western populations described in the literature.	Vitamin D	140-149	TNF superfamily member 11	Homo sapiens	159-164
30696596-5	2019	The possibility of vitamin D regulated osteoclastogenesis in GCTB is postulated on the evidence from molecular research linking it to the RANK/RANKL/OPG pathway.	Vitamin D	19-28	TNF superfamily member 11	Homo sapiens	143-148
30696596-11	2019	DISCUSSION: The differential expression of RANKL and OPG in response to levels of vitamin D has been established.	Vitamin D	82-91	TNF superfamily member 11	Homo sapiens	43-48
30696596-12	2019	The stromal cells of osteolytic GCTB express high levels of RANKL, which is a key signal regulator in development of this disease and bone destruction typical of GCTBs.	gctbs	162-167	TNF superfamily member 11	Homo sapiens	60-65
30713497-0	2018	20(S)-Protopanaxadiol Inhibits Titanium Particle-Induced Inflammatory Osteolysis and RANKL-Mediated Osteoclastogenesis via MAPK and NF-kappaB Signaling Pathways.	protopanaxadiol	2-21	TNF superfamily member 11	Homo sapiens	85-90
30397855-3	2019	The amount of 8-nitro-cGMP in Ocy454 cells increased during incubation with parathyroid hormone or prostaglandin E2, both of which are known to upregulate receptor activator of nuclear factor-kappaB ligand (RANKL) mRNA expression in osteocytes.	8-nitro	14-21	TNF superfamily member 11	Homo sapiens	155-205
30394316-4	2019	SREBP-2 expression was found to be induced during the early stages of osteoclast formation under the control of the RANKL/cAMP-response element binding protein (CREB) signaling cascade.	Cyclic AMP	122-126	TNF superfamily member 11	Homo sapiens	116-121
30043156-7	2019	In a genotype-phenotype correlation analysis using 24 normal left atrial appendage samples, increasing gradients of atrial RANKL expression levels positively correlated with atrial collagen volume fraction were identified in samples with CC, CG and GG genotypes.	cysteinylglycine	242-244	TNF superfamily member 11	Homo sapiens	123-128
30621730-4	2019	In turn, RANKL controls cell proliferation in breast epithelium under physiological conditions typically associated with higher serum progesterone levels, such as luteal phase of the menstrual cycle and pregnancy.	Progesterone	134-146	TNF superfamily member 11	Homo sapiens	9-14
30397855-3	2019	The amount of 8-nitro-cGMP in Ocy454 cells increased during incubation with parathyroid hormone or prostaglandin E2, both of which are known to upregulate receptor activator of nuclear factor-kappaB ligand (RANKL) mRNA expression in osteocytes.	8-nitro	14-21	TNF superfamily member 11	Homo sapiens	207-212
30397855-3	2019	The amount of 8-nitro-cGMP in Ocy454 cells increased during incubation with parathyroid hormone or prostaglandin E2, both of which are known to upregulate receptor activator of nuclear factor-kappaB ligand (RANKL) mRNA expression in osteocytes.	Cyclic GMP	22-26	TNF superfamily member 11	Homo sapiens	155-205
30397855-3	2019	The amount of 8-nitro-cGMP in Ocy454 cells increased during incubation with parathyroid hormone or prostaglandin E2, both of which are known to upregulate receptor activator of nuclear factor-kappaB ligand (RANKL) mRNA expression in osteocytes.	Cyclic GMP	22-26	TNF superfamily member 11	Homo sapiens	207-212
30397855-3	2019	The amount of 8-nitro-cGMP in Ocy454 cells increased during incubation with parathyroid hormone or prostaglandin E2, both of which are known to upregulate receptor activator of nuclear factor-kappaB ligand (RANKL) mRNA expression in osteocytes.	ocy454	30-36	TNF superfamily member 11	Homo sapiens	155-205
30397855-3	2019	The amount of 8-nitro-cGMP in Ocy454 cells increased during incubation with parathyroid hormone or prostaglandin E2, both of which are known to upregulate receptor activator of nuclear factor-kappaB ligand (RANKL) mRNA expression in osteocytes.	ocy454	30-36	TNF superfamily member 11	Homo sapiens	207-212
30397855-3	2019	The amount of 8-nitro-cGMP in Ocy454 cells increased during incubation with parathyroid hormone or prostaglandin E2, both of which are known to upregulate receptor activator of nuclear factor-kappaB ligand (RANKL) mRNA expression in osteocytes.	Dinoprostone	99-115	TNF superfamily member 11	Homo sapiens	155-205
30397855-3	2019	The amount of 8-nitro-cGMP in Ocy454 cells increased during incubation with parathyroid hormone or prostaglandin E2, both of which are known to upregulate receptor activator of nuclear factor-kappaB ligand (RANKL) mRNA expression in osteocytes.	Dinoprostone	99-115	TNF superfamily member 11	Homo sapiens	207-212
30562925-17	2018	In conclusion, higher concentrations of butyric acid generated by periodontal and root canal microorganisms may potentially induce bone destruction and impair bone repair by the alteration of OPG/RANKL expression/secretion, 8-isoprostane, MMP-2 and OPN secretion, and affect cell viability.	Butyric Acid	40-52	TNF superfamily member 11	Homo sapiens	196-201
30338925-0	2019	Madecassoside inhibits estrogen deficiency-induced osteoporosis by suppressing RANKL-induced osteoclastogenesis.	madecassoside	0-13	TNF superfamily member 11	Homo sapiens	79-84
30218207-0	2019	Cynaropicrin from Cynara scolymus L. suppresses Porphyromonas gingivalis LPS-induced production of inflammatory cytokines in human gingival fibroblasts and RANKL-induced osteoclast differentiation in RAW264.7 cells.	cynaropicrin	0-12	TNF superfamily member 11	Homo sapiens	156-161
30377251-9	2018	In summary, in the osteoblast, the effects of PTH(1-34), PTHrP(1-36), and ABL on Rankl are mediated by differential stimulation of cAMP/PKA signaling and by their downstream effects on SIK2 and -3, PP1/PP2A, and CRTC3.	Cyclic AMP	131-135	TNF superfamily member 11	Homo sapiens	81-86
30522105-0	2019	Taxifolin Inhibits Receptor Activator of NF-kappaB Ligand-Induced Osteoclastogenesis of Human Bone Marrow-Derived Macrophages in vitro and Prevents Lipopolysaccharide-Induced Bone Loss in vivo.	taxifolin	0-9	TNF superfamily member 11	Homo sapiens	19-57
30522105-2	2019	In our research, the inhibition effects of taxifolin on the osteoclastogenesis of human bone marrow-derived macrophages (BMMs) induced by receptor activator of NF-kappaB ligand (RANKL) as well as the protection effects in lipopolysaccharide-induced bone lysis mouse model have been demonstrated.	taxifolin	43-52	TNF superfamily member 11	Homo sapiens	138-176
30522105-2	2019	In our research, the inhibition effects of taxifolin on the osteoclastogenesis of human bone marrow-derived macrophages (BMMs) induced by receptor activator of NF-kappaB ligand (RANKL) as well as the protection effects in lipopolysaccharide-induced bone lysis mouse model have been demonstrated.	taxifolin	43-52	TNF superfamily member 11	Homo sapiens	178-183
30522105-3	2019	In vitro, taxifolin inhibited RANKL-induced osteoclast differentiation of human BMMs without cytotoxicity.	taxifolin	10-19	TNF superfamily member 11	Homo sapiens	30-35
30522105-4	2019	Moreover, taxifolin significantly suppressed RANKL-induced gene expression, including tartrate-resistant acid phosphatase, matrix metalloproteinase-9 nuclear factor of activated T cells 1 and cathepsin K, and F-actin ring formation.	taxifolin	10-19	TNF superfamily member 11	Homo sapiens	45-50
30562925-0	2018	Butyrate Stimulates Histone H3 Acetylation, 8-Isoprostane Production, RANKL Expression, and Regulated Osteoprotegerin Expression/Secretion in MG-63 Osteoblastic Cells.	Butyrates	0-8	TNF superfamily member 11	Homo sapiens	70-75
30562925-12	2018	Twenty-four hours of exposure to butyrate stimulated RANKL protein expression, whereas it inhibited OPG protein expression.	Butyrates	33-41	TNF superfamily member 11	Homo sapiens	53-58
30352839-6	2018	Furthermore, because RANKL levels in mammary tissue are modulated by progesterone, we stratified analyses by progesterone levels.	Progesterone	69-81	TNF superfamily member 11	Homo sapiens	21-26
30627063-8	2018	Noteworthy, PET/CT analysis showed higher uptake of 18F-choline in BM+ lesions with high positivity (&gt;=300/500 cells) for RUNX2 and/or RANKL immunostaining.	fluoromethylcholine	52-63	TNF superfamily member 11	Homo sapiens	138-143
30316078-3	2018	In a previous study, we reported that Tatarinan O, a lignin-like compound, suppressed RANKL-induced osteoclastogenesis.	tatarinan o	38-49	TNF superfamily member 11	Homo sapiens	86-91
30316078-3	2018	In a previous study, we reported that Tatarinan O, a lignin-like compound, suppressed RANKL-induced osteoclastogenesis.	Lignin	53-59	TNF superfamily member 11	Homo sapiens	86-91
30059597-6	2018	In the in vitro study, RepSox inhibited the receptor activator of nuclear factor kappaB ligand (RANKL)-induced osteoclast differentiation and bone resorption activity.	RepSox	23-29	TNF superfamily member 11	Homo sapiens	44-94
30059597-6	2018	In the in vitro study, RepSox inhibited the receptor activator of nuclear factor kappaB ligand (RANKL)-induced osteoclast differentiation and bone resorption activity.	RepSox	23-29	TNF superfamily member 11	Homo sapiens	96-101
30059166-3	2018	In vivo and ex vivo bone organ cultures have demonstrated that excess retinoids increase osteoclast formation due to increased receptor activator of nuclear factor kappa B-ligand (RANKL) expression.	Retinoids	70-79	TNF superfamily member 11	Homo sapiens	127-178
30637345-4	2018	Methods: BMMs were cultured with macrophage colony-stimulating factor (M-CSF) alone or M-CSF plus receptor activator of nuclear factor kappa B ligand (RANKL) in the presence of propofol (0-50 microM) for 4 days.	Propofol	177-185	TNF superfamily member 11	Homo sapiens	151-156
30637345-11	2018	However, SB203580, a p38 inhibitor, significantly suppressed the propofol/RANKL-induced increase in mRNA expression of DC-STAMP.	SB 203580	9-17	TNF superfamily member 11	Homo sapiens	74-79
30059166-3	2018	In vivo and ex vivo bone organ cultures have demonstrated that excess retinoids increase osteoclast formation due to increased receptor activator of nuclear factor kappa B-ligand (RANKL) expression.	Retinoids	70-79	TNF superfamily member 11	Homo sapiens	180-185
30637345-11	2018	However, SB203580, a p38 inhibitor, significantly suppressed the propofol/RANKL-induced increase in mRNA expression of DC-STAMP.	Propofol	65-73	TNF superfamily member 11	Homo sapiens	74-79
30059166-8	2018	ATRA inhibited physiologically induced (RANKL) osteoclast formation of human peripheral blood monocytes and mouse BMM as well as human monocytes stimulated with the pro-inflammatory compounds, TNF-alpha and LPS.	Tretinoin	0-4	TNF superfamily member 11	Homo sapiens	40-45
29486220-10	2018	We found HG and PA enhanced osteoclast differentiation, decreased SIRT1 and OPG expression, and increased levels of RANK, RANKL, NFATc1, TRAP, and c-fos.	Palmitates	16-18	TNF superfamily member 11	Homo sapiens	122-127
30483128-6	2018	Taxifolin also prevented reactive oxygen species (ROS) production following RANKL stimulation.	taxifolin	0-9	TNF superfamily member 11	Homo sapiens	76-81
30483128-6	2018	Taxifolin also prevented reactive oxygen species (ROS) production following RANKL stimulation.	Reactive Oxygen Species	25-48	TNF superfamily member 11	Homo sapiens	76-81
30483128-6	2018	Taxifolin also prevented reactive oxygen species (ROS) production following RANKL stimulation.	Reactive Oxygen Species	50-53	TNF superfamily member 11	Homo sapiens	76-81
30483128-7	2018	In addition, taxifolin alleviated ovariectomized-induced bone loss by repressing osteoclast activity and decreasing serum levels of tumor necrosis factor-alpha, interleukin-1beta, interleukin-6 and receptor activator of nuclear factor-kappaB ligand (RANKL) in vivo.	taxifolin	13-22	TNF superfamily member 11	Homo sapiens	250-255
30483128-8	2018	Our results indicated that taxifolin inhibits osteoclastogenesis via regulation of modulation of several RANKL signaling pathways.	taxifolin	27-36	TNF superfamily member 11	Homo sapiens	105-110
29891857-10	2018	In addition, ICA treatment recovered the decreased bone-related gene expression, including alkaline phosphatase (ALP), bone glaprotein (BGP), and osteoprotegerin/receptor activator of the NF-kappaB ligand ratio (OPG/RANKL), in the tibia and the decreased bone resorption marker TRACP-5b levels in serum caused by simulated microgravity.	icariin	13-16	TNF superfamily member 11	Homo sapiens	216-221
30006289-4	2018	This study investigated in vitro how vitamin E-blended-UHMWPE wear debris might affect osteoblast-mediated osteolysis and the production of RANKL, OPG, Sclerostin and DKK-1, compared to conventional UHMWPE wear debris.	Vitamin E	37-46	TNF superfamily member 11	Homo sapiens	140-145
30388885-3	2018	We found that N,N"-1,4-butanediylbis[3-(2-chlorophenyl)acrylamide] (BCPA) inhibited receptor activator of nuclear factor kappa-B ligand (RANKL)-induced osteoclastogenesis in a dose-dependent manner without cytotoxicity.	n,n"-1,4-butanediylbis[3-(2-chlorophenyl)acrylamide	14-65	TNF superfamily member 11	Homo sapiens	84-135
30388885-3	2018	We found that N,N"-1,4-butanediylbis[3-(2-chlorophenyl)acrylamide] (BCPA) inhibited receptor activator of nuclear factor kappa-B ligand (RANKL)-induced osteoclastogenesis in a dose-dependent manner without cytotoxicity.	n,n"-1,4-butanediylbis[3-(2-chlorophenyl)acrylamide	14-65	TNF superfamily member 11	Homo sapiens	137-142
30388885-3	2018	We found that N,N"-1,4-butanediylbis[3-(2-chlorophenyl)acrylamide] (BCPA) inhibited receptor activator of nuclear factor kappa-B ligand (RANKL)-induced osteoclastogenesis in a dose-dependent manner without cytotoxicity.	bcpa	68-72	TNF superfamily member 11	Homo sapiens	84-135
30388885-3	2018	We found that N,N"-1,4-butanediylbis[3-(2-chlorophenyl)acrylamide] (BCPA) inhibited receptor activator of nuclear factor kappa-B ligand (RANKL)-induced osteoclastogenesis in a dose-dependent manner without cytotoxicity.	bcpa	68-72	TNF superfamily member 11	Homo sapiens	137-142
30076654-6	2018	To further investigate the underlying mechanism, we found that DMY inhibits osteoclast (OC) differentiation and bone resorption activity through blocking the RANKL-induced activation of the NF-kappaB and MAPKs signaling pathways and then downregulated c-Fos and NFATc1, which is essential for OC differentiation.	dihydromyricetin	63-66	TNF superfamily member 11	Homo sapiens	158-163
30379236-6	2018	RANKL expression was higher in CGCL than in PGCL (p = 0.04) and all recurrent lesions showed higher RANKL and OPG expressions than nonrecurrent lesions.	cgcl	31-35	TNF superfamily member 11	Homo sapiens	0-5
30379236-6	2018	RANKL expression was higher in CGCL than in PGCL (p = 0.04) and all recurrent lesions showed higher RANKL and OPG expressions than nonrecurrent lesions.	pgcl	44-48	TNF superfamily member 11	Homo sapiens	0-5
29940143-0	2018	The inhibition of RANKL expression in fibroblasts attenuate CoCr particles induced aseptic prosthesis loosening via the MyD88-independent TLR signaling pathway.	cocr	60-64	TNF superfamily member 11	Homo sapiens	18-23
30338210-0	2018	Rosiglitazone suppresses RANKL-induced NFATc1 autoamplification by disrupting the physical interaction between NFATc1 and PPARgamma.	Rosiglitazone	0-13	TNF superfamily member 11	Homo sapiens	25-30
30338210-2	2018	Because NFATc1 expression is autoamplified, we investigated the molecular mechanism by which peroxisome proliferator-activated receptor gamma (PPARgamma) activation by the thiazolidinedione drug rosiglitazone decreases NFATc1 expression during RANKL stimulation.	2,4-thiazolidinedione	172-189	TNF superfamily member 11	Homo sapiens	244-249
30338210-2	2018	Because NFATc1 expression is autoamplified, we investigated the molecular mechanism by which peroxisome proliferator-activated receptor gamma (PPARgamma) activation by the thiazolidinedione drug rosiglitazone decreases NFATc1 expression during RANKL stimulation.	Rosiglitazone	195-208	TNF superfamily member 11	Homo sapiens	244-249
30338210-3	2018	Western blotting demonstrated that rosiglitazone attenuated the increase in NFATc1 protein level induced by RANKL without affecting that of PPARgamma.	Rosiglitazone	35-48	TNF superfamily member 11	Homo sapiens	108-113
30338210-4	2018	Immunofluorescence data indicated that rosiglitazone tended to suppress RANKL-induced NFATc1 nuclear translocation, partly by reducing calcineurin activity, as reflected by the observed decrease in nuclear NFATc1 abundance.	Rosiglitazone	39-52	TNF superfamily member 11	Homo sapiens	72-77
30338210-5	2018	On coimmunoprecipitation, the intensity of the physical interaction between NFATc1 and PPARgamma was unexpectedly higher in the RANKL-stimulated group than in the control, but rosiglitazone reduced this to basal levels.	Rosiglitazone	176-189	TNF superfamily member 11	Homo sapiens	128-133
30338210-8	2018	These findings suggest that PPARgamma activation by rosiglitazone blocks NFATc1 from binding to its own promoter, thereby reducing RANKL-induced NFATc1 autoamplification.	Rosiglitazone	52-65	TNF superfamily member 11	Homo sapiens	131-136
29856998-0	2018	Go6983 attenuates titanium particle-induced osteolysis and RANKL mediated osteoclastogenesis through the suppression of NFkappaB/JNK/p38 pathways.	2-(1-(3-dimethylaminopropyl)-5-methoxyindol-3-yl)-3-(1H-indol-3-yl)maleimide	0-6	TNF superfamily member 11	Homo sapiens	59-64
30206967-0	2018	Daphnetin inhibits RANKL-induced osteoclastogenesis in vitro.	daphnetin	0-9	TNF superfamily member 11	Homo sapiens	19-24
29856998-5	2018	In vitro, Go6983 inhibited RANKL-stimulated osteoclast formation and function by inhibiting the RANKL-stimulated nuclear factor-kappaB/JNK/p38 signaling pathway.	2-(1-(3-dimethylaminopropyl)-5-methoxyindol-3-yl)-3-(1H-indol-3-yl)maleimide	10-16	TNF superfamily member 11	Homo sapiens	27-32
30206967-7	2018	In addition, daphnetin prevented the RANKL-induced activation of NF-kappaB and Akt/GSK-3beta pathways in BMMs.	daphnetin	13-22	TNF superfamily member 11	Homo sapiens	37-42
29856998-5	2018	In vitro, Go6983 inhibited RANKL-stimulated osteoclast formation and function by inhibiting the RANKL-stimulated nuclear factor-kappaB/JNK/p38 signaling pathway.	2-(1-(3-dimethylaminopropyl)-5-methoxyindol-3-yl)-3-(1H-indol-3-yl)maleimide	10-16	TNF superfamily member 11	Homo sapiens	96-101
30206967-8	2018	These findings indicated that daphnetin exhibited an inhibitory effect on RANKL-induced osteoclastogenesis in vitro.	daphnetin	30-39	TNF superfamily member 11	Homo sapiens	74-79
29782843-6	2018	At physiological concentrations, active vitamin D maintains a normal rate of bone resorption and formation through the RANKL/OPG signal.	Vitamin D	40-49	TNF superfamily member 11	Homo sapiens	119-124
29920835-9	2018	As a result, LMHF reduced the RANKL/OPG mRNA ratio in iliac osteoblasts but did not alter the RANKL/OPG mRNA ratio in mandible osteoblasts.	lmhf	13-17	TNF superfamily member 11	Homo sapiens	30-35
30181310-0	2018	Retraction: Zerumbone Abolishes RANKL-Induced NF-kappaB Activation, Inhibits Osteoclastogenesis, and Suppresses Human Breast Cancer-Induced Bone Loss in Athymic Nude Mice.	zerumbone	12-21	TNF superfamily member 11	Homo sapiens	32-37
29786751-5	2018	In addition, fraxetin was demonstrated to suppress receptor activator of nuclear factor-kappaB ligand (RANKL)-mediated osteoclast differentiation and bone resorption in vitro in a dose-dependent manner.	fraxetin	13-21	TNF superfamily member 11	Homo sapiens	51-101
29465363-0	2018	Inhibitory effect and mechanism of 1,25-dihydroxy vitamin D3 on RANKL expression in fibroblast-like synoviocytes and osteoclast-like cell formation induced by IL-22 in rheumatoid arthritis.	Calcitriol	35-60	TNF superfamily member 11	Homo sapiens	64-69
29465363-1	2018	OBJECTIVES: To explore the inhibitory effect and mechanism of 1,25-dihydroxy vitamin D3 (l,25(OH)2D3) on receptor activator of nuclear factor-kappaB ligand (RANKL) expression in fibroblast-like synoviocytes (FLSs) and osteoclastogenesis induced by interleukin (IL)-22 in patients with rheumatoid arthritis (RA).	Calcitriol	62-87	TNF superfamily member 11	Homo sapiens	105-155
29465363-1	2018	OBJECTIVES: To explore the inhibitory effect and mechanism of 1,25-dihydroxy vitamin D3 (l,25(OH)2D3) on receptor activator of nuclear factor-kappaB ligand (RANKL) expression in fibroblast-like synoviocytes (FLSs) and osteoclastogenesis induced by interleukin (IL)-22 in patients with rheumatoid arthritis (RA).	Calcitriol	62-87	TNF superfamily member 11	Homo sapiens	157-162
29465363-1	2018	OBJECTIVES: To explore the inhibitory effect and mechanism of 1,25-dihydroxy vitamin D3 (l,25(OH)2D3) on receptor activator of nuclear factor-kappaB ligand (RANKL) expression in fibroblast-like synoviocytes (FLSs) and osteoclastogenesis induced by interleukin (IL)-22 in patients with rheumatoid arthritis (RA).	l,25(oh)2d3	89-100	TNF superfamily member 11	Homo sapiens	105-155
29465363-1	2018	OBJECTIVES: To explore the inhibitory effect and mechanism of 1,25-dihydroxy vitamin D3 (l,25(OH)2D3) on receptor activator of nuclear factor-kappaB ligand (RANKL) expression in fibroblast-like synoviocytes (FLSs) and osteoclastogenesis induced by interleukin (IL)-22 in patients with rheumatoid arthritis (RA).	l,25(oh)2d3	89-100	TNF superfamily member 11	Homo sapiens	157-162
29465363-10	2018	CONCLUSIONS: 1,25(OH)2D3 may exert inhibitory effect on osteoclastogenesis of RA-FLSs by down-regulating RANKL expression, which could be mediated by IL-22 through JAK-2/STAT-3 and p38 MAPK/NF-kappaB signalling.	Calcitriol	13-24	TNF superfamily member 11	Homo sapiens	105-110
29786751-5	2018	In addition, fraxetin was demonstrated to suppress receptor activator of nuclear factor-kappaB ligand (RANKL)-mediated osteoclast differentiation and bone resorption in vitro in a dose-dependent manner.	fraxetin	13-21	TNF superfamily member 11	Homo sapiens	103-108
29911332-3	2018	However, the effects of myricitrin on nuclear factor-kappaB ligand (RANKL)-stimulated osteoclastogenesis have not yet been further investigated.	myricitrin	24-34	TNF superfamily member 11	Homo sapiens	68-73
29911332-4	2018	The current study was aimed to demonstrating the inhibitory effects of myricitrin on RANKL-stimulated osteoclastogenesis and relevant mechanisms.	myricitrin	71-81	TNF superfamily member 11	Homo sapiens	85-90
29911332-5	2018	We found myricitrin significantly suppressed osteoclastogenesis suggesting that it may acts on RANKL/RANK induced downstream signal cross cascading in osteoclast precursors.	myricitrin	9-19	TNF superfamily member 11	Homo sapiens	95-100
30055205-0	2018	Inhibitory effect of vanillin on RANKL-induced osteoclast formation and function through activating mitochondrial-dependent apoptosis signaling pathway.	vanillin	21-29	TNF superfamily member 11	Homo sapiens	33-38
30055205-5	2018	In this study, we found that the inhibitory effect of vanillin on RANKL-induced multinucleated osteoclast formation and bone resorption (concentration of 0.25 mM-2.5 mM).	vanillin	54-62	TNF superfamily member 11	Homo sapiens	66-71
30055205-7	2018	Vanillin could significantly inhibit bone resorption and promote the early apoptosis rate during RANKL-induced osteoclastogenesis.	vanillin	0-8	TNF superfamily member 11	Homo sapiens	97-102
30015970-7	2018	Nystatin, a lipid raft inhibitor, inhibited the activation of Cav-1 and markedly reversed RANKL-induced gastric cancer cell migration.	Nystatin	0-8	TNF superfamily member 11	Homo sapiens	90-95
29996622-4	2018	In this study, we demonstrated that Curcuma xanthorrhiza supercritical extract (CXS) and its active compound, xanthorrhizol (XAN), exhibit anti-inflammatory effects on lipopolysaccharide (LPS)-treated human gingival fibroblast-1 cells and anti-osteoclastic effects on receptor activator of nuclear factor kappa B ligand (RANKL)-treated RAW264.7 cells.	xanthorrhizol	110-123	TNF superfamily member 11	Homo sapiens	268-319
30127998-8	2018	The AhR antagonist CH-223191, blocks the effects on TCDD-induced RANKL, COX-2, PGE2 and CXCR4 changes.	Polychlorinated Dibenzodioxins	52-56	TNF superfamily member 11	Homo sapiens	65-70
30127998-8	2018	The AhR antagonist CH-223191, blocks the effects on TCDD-induced RANKL, COX-2, PGE2 and CXCR4 changes.	2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide	19-28	TNF superfamily member 11	Homo sapiens	65-70
29996622-4	2018	In this study, we demonstrated that Curcuma xanthorrhiza supercritical extract (CXS) and its active compound, xanthorrhizol (XAN), exhibit anti-inflammatory effects on lipopolysaccharide (LPS)-treated human gingival fibroblast-1 cells and anti-osteoclastic effects on receptor activator of nuclear factor kappa B ligand (RANKL)-treated RAW264.7 cells.	xanthorrhizol	110-123	TNF superfamily member 11	Homo sapiens	321-326
29996622-4	2018	In this study, we demonstrated that Curcuma xanthorrhiza supercritical extract (CXS) and its active compound, xanthorrhizol (XAN), exhibit anti-inflammatory effects on lipopolysaccharide (LPS)-treated human gingival fibroblast-1 cells and anti-osteoclastic effects on receptor activator of nuclear factor kappa B ligand (RANKL)-treated RAW264.7 cells.	xanthorrhizol	125-128	TNF superfamily member 11	Homo sapiens	268-319
29996622-4	2018	In this study, we demonstrated that Curcuma xanthorrhiza supercritical extract (CXS) and its active compound, xanthorrhizol (XAN), exhibit anti-inflammatory effects on lipopolysaccharide (LPS)-treated human gingival fibroblast-1 cells and anti-osteoclastic effects on receptor activator of nuclear factor kappa B ligand (RANKL)-treated RAW264.7 cells.	xanthorrhizol	125-128	TNF superfamily member 11	Homo sapiens	321-326
30082761-0	2018	Nano-sized Al2O3 particle-induced autophagy reduces osteolysis in aseptic loosening of total hip arthroplasty by negative feedback regulation of RANKL expression in fibroblasts.	Aluminum Oxide	11-16	TNF superfamily member 11	Homo sapiens	145-150
29803792-5	2018	In addition, DTF was more potent than etanercept in decreasing the ratio of RANKL/OPG in the serum and rebalancing the population ratio of Treg/Th17 cells in the spleens.	dtf	13-16	TNF superfamily member 11	Homo sapiens	76-81
30082761-5	2018	We determined the levels of RANKL and autophagy in fibroblasts treated with Al2O3 particles in vitro while using shBECN-1 interference lentivirus vectors to block the autophagy pathway and BECN-1 overexpression lentivirus vectors to promote autophagy.	Aluminum Oxide	76-81	TNF superfamily member 11	Homo sapiens	28-33
30082761-11	2018	Al2O3 particles induced fibroblast autophagy, which reduced RANKL expression.	Aluminum Oxide	0-5	TNF superfamily member 11	Homo sapiens	60-65
29803913-0	2018	Combination of 4-hydroperoxy cyclophosphamide and methotrexate inhibits IL-6/sIL-6R-induced RANKL expression in fibroblast-like synoviocytes via suppression of the JAK2/STAT3 and p38MAPK signaling pathway.	perfosfamide	15-45	TNF superfamily member 11	Homo sapiens	92-97
29782859-1	2018	Previous studies have indicated that paeonol inhibits RANKL-induced osteoclastogenesis by inhibiting the ERK, p38, and NF-kappaB pathway.	paeonol	37-44	TNF superfamily member 11	Homo sapiens	54-59
29803913-0	2018	Combination of 4-hydroperoxy cyclophosphamide and methotrexate inhibits IL-6/sIL-6R-induced RANKL expression in fibroblast-like synoviocytes via suppression of the JAK2/STAT3 and p38MAPK signaling pathway.	Methotrexate	50-62	TNF superfamily member 11	Homo sapiens	92-97
29879658-0	2018	A flavonoids compound inhibits osteoclast differentiation by attenuating RANKL induced NFATc-1/c-Fos induction.	Flavonoids	2-12	TNF superfamily member 11	Homo sapiens	73-78
29803913-4	2018	Using western blotting, real-time polymerase chain reaction, enzyme-linked immunosorbent assays, and immunofluorescent staining, we demonstrated that the combination of 4-hydroperoxy CTX (4-H-CTX) and MTX inhibited the expression of receptor activator of nuclear factor-kappaB ligand (RANKL) in fibroblast-like synoviocytes (FLS) treated with the interleukin (IL)-6/soluble IL-6 receptor (sIL-6R) complex.	Methotrexate	201-204	TNF superfamily member 11	Homo sapiens	233-283
29803913-4	2018	Using western blotting, real-time polymerase chain reaction, enzyme-linked immunosorbent assays, and immunofluorescent staining, we demonstrated that the combination of 4-hydroperoxy CTX (4-H-CTX) and MTX inhibited the expression of receptor activator of nuclear factor-kappaB ligand (RANKL) in fibroblast-like synoviocytes (FLS) treated with the interleukin (IL)-6/soluble IL-6 receptor (sIL-6R) complex.	Methotrexate	201-204	TNF superfamily member 11	Homo sapiens	285-290
29879658-3	2018	We initially found pectolinarigenin inhibited receptor activator of nuclear factor-kappa B ligand (RANKL) induced osteoclast formation during the bone marrow-derived macrophages (BMMs) cultures, suggesting that this natural product could act on osteoclast precursors by inhibiting the down signaling cascades of RANKL signaling.	pectolinarigenin	19-35	TNF superfamily member 11	Homo sapiens	99-104
29803913-6	2018	The results showed that IL-6/sIL-6R-induced RANKL upregulation required phosphorylation-mediated activation of STAT3 and p38 signaling, and that 4-H-CTX and/or MTX inhibited RANKL expression in IL-6/sIL-6R-stimulated FLS by suppressing JAK2/STAT3 and p38MAPK signaling.	Methotrexate	160-163	TNF superfamily member 11	Homo sapiens	44-49
29879658-3	2018	We initially found pectolinarigenin inhibited receptor activator of nuclear factor-kappa B ligand (RANKL) induced osteoclast formation during the bone marrow-derived macrophages (BMMs) cultures, suggesting that this natural product could act on osteoclast precursors by inhibiting the down signaling cascades of RANKL signaling.	pectolinarigenin	19-35	TNF superfamily member 11	Homo sapiens	312-317
29879658-4	2018	Moreover, mechanistical investigation showed pectolinarigenin inhibits RANKL-mediated osteoclastogenesis by attenuating the nuclear factor of activated T cells cytoplasmic 1 (NFATc-1) and c-Fos following the Akt and mitogen activated protein kinases (MAPKs) signaling costimulatory.	pectolinarigenin	45-61	TNF superfamily member 11	Homo sapiens	71-76
29803913-6	2018	The results showed that IL-6/sIL-6R-induced RANKL upregulation required phosphorylation-mediated activation of STAT3 and p38 signaling, and that 4-H-CTX and/or MTX inhibited RANKL expression in IL-6/sIL-6R-stimulated FLS by suppressing JAK2/STAT3 and p38MAPK signaling.	Methotrexate	160-163	TNF superfamily member 11	Homo sapiens	174-179
30186567-4	2018	Results: Our results showed that 0.2-1.2 microm and 1.2-10 microm titanium particles up-regulate CD147 to activate autophagy, which increase the level of soluble RANKL to promote osteoclastogenesis.	Titanium	66-74	TNF superfamily member 11	Homo sapiens	162-167
30186567-6	2018	In addition, CQ could dramatically reduce particle-induced soluble RANKL expression.	Chloroquine	13-15	TNF superfamily member 11	Homo sapiens	67-72
30151060-6	2018	RANKL was expressed higher in the epithelium (p = 0.0002) and in the stroma (p = 0.0004) of UA.	ulmoside A	92-94	TNF superfamily member 11	Homo sapiens	0-5
29750753-0	2018	Immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy alone versus immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy in combination with anti-RANKL denosumuab in malignant melanoma: a retrospective analysis at a tertiary care center.	denosumuab	166-176	TNF superfamily member 11	Homo sapiens	160-165
30123059-9	2018	Summarizing, zoledronic acid treatment is associated to decreases in plasma levels of ALP, RANKL, sclerostin and P1GF in active PDB patients.	Zoledronic Acid	13-28	TNF superfamily member 11	Homo sapiens	91-96
29620154-0	2018	[Corrigendum] Inhibition of RANKL-induced osteoclastogenesis through the suppression of the ERK signaling pathway by astragaloside IV and attenuation of titanium-particle-induced osteolysis.	astragaloside A	117-133	TNF superfamily member 11	Homo sapiens	28-33
29016746-9	2018	PGE2 and RANKL, but not OPG, were increased in groups V, C, and VC, thus increasing the RANKL/OPG ratio.	Dinoprostone	0-4	TNF superfamily member 11	Homo sapiens	88-93
29620154-0	2018	[Corrigendum] Inhibition of RANKL-induced osteoclastogenesis through the suppression of the ERK signaling pathway by astragaloside IV and attenuation of titanium-particle-induced osteolysis.	Titanium	153-161	TNF superfamily member 11	Homo sapiens	28-33
28555075-10	2018	Ketamine significantly increased both the OPG/RANKL ratio and plasma OPN levels, and significantly decreased RANKL levels.	Ketamine	0-8	TNF superfamily member 11	Homo sapiens	46-51
28555075-10	2018	Ketamine significantly increased both the OPG/RANKL ratio and plasma OPN levels, and significantly decreased RANKL levels.	Ketamine	0-8	TNF superfamily member 11	Homo sapiens	109-114
29058810-13	2018	Overexpression of miR-302a-3p could decrease RANKL expression during PGE2 stimulation.	Dinoprostone	69-73	TNF superfamily member 11	Homo sapiens	45-50
29730290-10	2018	Application of the H2S donor GYY4137 increased the number of RANKL-induced osteoclasts, the number of osteoclasts in periodontal tissues and tooth movement distance in CSE-/- mice.	Hydrogen Sulfide	19-22	TNF superfamily member 11	Homo sapiens	61-66
29730290-10	2018	Application of the H2S donor GYY4137 increased the number of RANKL-induced osteoclasts, the number of osteoclasts in periodontal tissues and tooth movement distance in CSE-/- mice.	GYY 4137	29-36	TNF superfamily member 11	Homo sapiens	61-66
29401617-3	2018	Because MMP9 and CX3CR1 reportedly participate in receptor activator of nuclear factor-kappaB ligand (RANKL)-induced osteoclastogenesis, we inferred that REV-ERBs might play a role in osteoclastogenesis.	rev-erbs	154-162	TNF superfamily member 11	Homo sapiens	50-100
29401617-3	2018	Because MMP9 and CX3CR1 reportedly participate in receptor activator of nuclear factor-kappaB ligand (RANKL)-induced osteoclastogenesis, we inferred that REV-ERBs might play a role in osteoclastogenesis.	rev-erbs	154-162	TNF superfamily member 11	Homo sapiens	102-107
29058810-10	2018	When PGE2 stimulated RANKL in HMOBs, miR-302a-3p was lower than baseline level.	Dinoprostone	5-9	TNF superfamily member 11	Homo sapiens	21-26
29058810-11	2018	However, upregulation of miR-302a-3p is observed when IFNgamma suppressed RANKL expression in PGE2 -stimulated HMOBs.	Dinoprostone	94-98	TNF superfamily member 11	Homo sapiens	74-79
29058810-14	2018	In contrast, silencing of miR-302a-3p by its inhibitor increased RANKL expression in PGE2 -IFNgamma conditioned HMOBs.	Dinoprostone	85-89	TNF superfamily member 11	Homo sapiens	65-70
29058810-15	2018	miR-302a-3p regulates RANKL expression in HMOBs within PGE2 -IFNgamma regulatory network.	Dinoprostone	55-59	TNF superfamily member 11	Homo sapiens	22-27
29807539-3	2018	RESULTS: We show that H3 monomethylation at lysine 27 (H3K27me1) is essential for MMP-9-dependent H3NT proteolysis during RANKL-induced osteoclast differentiation.	Lysine	44-50	TNF superfamily member 11	Homo sapiens	122-127
29525694-9	2018	On the other hand, SrHA inhibited osteoclastogenesis and osteoclast differentiation, as demonstrated by the observed increase of the osteoprotegerin/RANKL ratio and decrease of the number of TRAP-positive multinucleated cells when increasing SrHA amount in the coatings.	srha	19-23	TNF superfamily member 11	Homo sapiens	149-154
29430796-1	2018	BACKGROUND: RANKL is a key regulator of bone resorption that may also modulate glucose metabolism.	Glucose	79-86	TNF superfamily member 11	Homo sapiens	12-17
29799160-6	2018	As subchondral bone remodelling is involved in OA progression, and osteoclasts are a unique cell type in bone resorption, we investigated the effects of OMT on osteoclastogenesis, and the results demonstrated that OMT suppresses RANKL-induced osteoclastogenesis by suppressing the RANKL-induced NFATc1 and c-fos signalling pathway in vitro.	oxymatrine	214-217	TNF superfamily member 11	Homo sapiens	229-234
29799160-6	2018	As subchondral bone remodelling is involved in OA progression, and osteoclasts are a unique cell type in bone resorption, we investigated the effects of OMT on osteoclastogenesis, and the results demonstrated that OMT suppresses RANKL-induced osteoclastogenesis by suppressing the RANKL-induced NFATc1 and c-fos signalling pathway in vitro.	oxymatrine	214-217	TNF superfamily member 11	Homo sapiens	281-286
30231385-5	2018	We also review the state of the art in treatment of MM bone disease (MMBD) and the role of bisphosphonates and denosumab, a monoclonal antibody that binds and blocks the activity of receptor activator of nuclear factor-kappa B ligand (RANKL), which was recently approved by the U.S. Food and Drug Administration for MMBD.	Diphosphonates	91-106	TNF superfamily member 11	Homo sapiens	182-233
29430796-12	2018	It remains to be determined whether blockade of RANKL has a clinically important effect on glucose metabolism.	Glucose	91-98	TNF superfamily member 11	Homo sapiens	48-53
30603558-0	2018	Remifentanil Negatively Regulates RANKL-Induced Osteoclast Differentiation and Bone Resorption by Inhibiting c-Fos/NFATc1 Expression.	Remifentanil	0-12	TNF superfamily member 11	Homo sapiens	34-39
28705683-16	2018	In contrast to the osteoclastogenesis results, the RANKL/OPG ratio was higher in the presence of GW788388, only in FOP cultures.	4-(4-(3-(pyridin-2-yl)-1H-pyrazol-4-yl)pyridin-2-yl)-N-(tetrahydro-2H-pyran-4-yl)benzamide	97-105	TNF superfamily member 11	Homo sapiens	51-56
29432759-9	2018	BPA interrupts the bone metabolism via RANKL, apoptosis and Wnt/beta-catenin signaling pathways.	bisphenol A	0-3	TNF superfamily member 11	Homo sapiens	39-44
29285799-5	2018	In layered but not transwell cocultures, melatonin increased OPG:RANKL ratios by inhibiting RANKL, suggesting that contact with osteoclasts during osteoblastogenesis inhibits RANKL secretion.	Melatonin	41-50	TNF superfamily member 11	Homo sapiens	65-70
29285799-5	2018	In layered but not transwell cocultures, melatonin increased OPG:RANKL ratios by inhibiting RANKL, suggesting that contact with osteoclasts during osteoblastogenesis inhibits RANKL secretion.	Melatonin	41-50	TNF superfamily member 11	Homo sapiens	92-97
29285799-5	2018	In layered but not transwell cocultures, melatonin increased OPG:RANKL ratios by inhibiting RANKL, suggesting that contact with osteoclasts during osteoblastogenesis inhibits RANKL secretion.	Melatonin	41-50	TNF superfamily member 11	Homo sapiens	92-97
29378912-4	2018	In this study, we identified an ER-bound transcription factor, cAMP response element-binding protein H (CREBH), as a downstream effector of ER stress during RANKL-induced osteoclast differentiation.	Cyclic AMP	63-67	TNF superfamily member 11	Homo sapiens	157-162
29241742-2	2018	The RANKL inhibitor denosumab, when used for the treatment of GCTB, leads to histological changes such as new bone formation and giant cell depletion.	gctb	62-66	TNF superfamily member 11	Homo sapiens	4-9
28771720-0	2018	Cyanidin Chloride inhibits ovariectomy-induced osteoporosis by suppressing RANKL-mediated osteoclastogenesis and associated signaling pathways.	cyanidin	0-17	TNF superfamily member 11	Homo sapiens	75-80
28771720-3	2018	In this study, we showed that Cyanidin Chloride inhibits osteoclast formation, hydroxyapatite resorption, and receptor activator of NF-kappaB ligand (RANKL)-induced osteoclast marker gene expression; including ctr, ctsk, and trap.	cyanidin	30-47	TNF superfamily member 11	Homo sapiens	110-148
28771720-3	2018	In this study, we showed that Cyanidin Chloride inhibits osteoclast formation, hydroxyapatite resorption, and receptor activator of NF-kappaB ligand (RANKL)-induced osteoclast marker gene expression; including ctr, ctsk, and trap.	cyanidin	30-47	TNF superfamily member 11	Homo sapiens	150-155
28771720-4	2018	Further investigation revealed that Cyanidin Chloride inhibits RANKL-induced NF-kappaB activation, suppresses the degradation of IkappaB-alpha and attenuates the phosphorylation of extracellular signal-regulated kinases (ERK).	cyanidin	36-53	TNF superfamily member 11	Homo sapiens	63-68
28771720-5	2018	In addition, Cyanidin Chloride abrogated RANKL-induced calcium oscillations, the activation of nuclear factor of activated T cells calcineurin-dependent 1 (NFATc1), and the expression of c-Fos.	cyanidin	13-30	TNF superfamily member 11	Homo sapiens	41-46
28771720-5	2018	In addition, Cyanidin Chloride abrogated RANKL-induced calcium oscillations, the activation of nuclear factor of activated T cells calcineurin-dependent 1 (NFATc1), and the expression of c-Fos.	Calcium	55-62	TNF superfamily member 11	Homo sapiens	41-46
28771720-7	2018	Together our findings suggest that Cyanidin Chloride is capable of inhibiting osteoclast formation, hydroxyapatite resorption and RANKL-induced signal pathways in vitro and OVX-induced bone loss in vivo, and thus might have therapeutic potential for osteolytic diseases.	cyanidin	35-52	TNF superfamily member 11	Homo sapiens	130-135
29107144-14	2018	Mechanistically, ET4 dose- and time-dependently blocked the RANKL-induced activation of ERK and c-Fos as well as the induction of NFATc1 which is essential for OC formation.	et4	17-20	TNF superfamily member 11	Homo sapiens	60-65
29378912-8	2018	In addition, inhibition of reactive oxygen species using N-acetylcysteine attenuated ER stress, expression of osteoclast-specific marker genes, and RANKL-induced CREBH activation.	Reactive Oxygen Species	27-50	TNF superfamily member 11	Homo sapiens	148-153
29378912-8	2018	In addition, inhibition of reactive oxygen species using N-acetylcysteine attenuated ER stress, expression of osteoclast-specific marker genes, and RANKL-induced CREBH activation.	Acetylcysteine	57-73	TNF superfamily member 11	Homo sapiens	148-153
29378912-10	2018	Taken together, our results suggest that reactive oxygen species/ER stress signaling-dependent CREBH activation plays an important role in RANKL-induced osteoclastogenesis.	Reactive Oxygen Species	41-64	TNF superfamily member 11	Homo sapiens	139-144
29463002-2	2018	In this study, we enzymatically synthesized purpurogallin from pyrogallol and investigated its role in receptor activator of nuclear factor-kappaB ligand (RANKL)-induced osteoclastogenesis.	purpurogallin	44-57	TNF superfamily member 11	Homo sapiens	103-153
29507818-6	2018	In co-culture, Lrp1-deficient osteoblasts stimulated osteoclastogenesis in a PDGFRbeta-dependent manner and in vivo treatment with the PDGFR tyrosine kinase inhibitor imatinib mesylate limited RANKL production and led to complete remission of the osteoporotic phenotype.	Imatinib Mesylate	167-184	TNF superfamily member 11	Homo sapiens	193-198
29328471-6	2018	The results of western blotting and reverse transcription-quantitative polymerase chain reaction demonstrated that the protein and the mRNA expression levels of MMP-2, MMP-9, RANKL and RUNX2 in PC-3 cells were significantly upregulated by treatment with PGE2, respectively, and knockdown of these proteins blocked PGE2-induced cell proliferation and invasion in PC-3 cells, as determined by Cell Counting Kit-8 and Matrigel invasion assays, respectively.	Dinoprostone	254-258	TNF superfamily member 11	Homo sapiens	175-180
29328471-6	2018	The results of western blotting and reverse transcription-quantitative polymerase chain reaction demonstrated that the protein and the mRNA expression levels of MMP-2, MMP-9, RANKL and RUNX2 in PC-3 cells were significantly upregulated by treatment with PGE2, respectively, and knockdown of these proteins blocked PGE2-induced cell proliferation and invasion in PC-3 cells, as determined by Cell Counting Kit-8 and Matrigel invasion assays, respectively.	Dinoprostone	314-318	TNF superfamily member 11	Homo sapiens	175-180
29328471-13	2018	In conclusion, the results of the present study indicate that PGE2 significantly upregulated the mRNA and protein expression levels of the MMP-2, MMP-9, RANKL and RUNX2, and the EP4 receptor was involved in the cell proliferation and invasion of PCa via the cAMP-PKA/PI3K-Akt signaling pathway.	Dinoprostone	62-66	TNF superfamily member 11	Homo sapiens	153-158
29463002-2	2018	In this study, we enzymatically synthesized purpurogallin from pyrogallol and investigated its role in receptor activator of nuclear factor-kappaB ligand (RANKL)-induced osteoclastogenesis.	purpurogallin	44-57	TNF superfamily member 11	Homo sapiens	155-160
29073497-3	2018	The receptor activator of nuclear factor kappa B ligand (RANKL) inhibitor denosumab and bisphosphonates (e.g. zoledronic acid) are approved in Europe for the prevention of skeletal-related events (pathologic fracture, radiation or surgery to bone, and spinal cord compression) in adults with bone metastases secondary to solid tumours.	Zoledronic Acid	110-125	TNF superfamily member 11	Homo sapiens	4-55
29073497-3	2018	The receptor activator of nuclear factor kappa B ligand (RANKL) inhibitor denosumab and bisphosphonates (e.g. zoledronic acid) are approved in Europe for the prevention of skeletal-related events (pathologic fracture, radiation or surgery to bone, and spinal cord compression) in adults with bone metastases secondary to solid tumours.	Zoledronic Acid	110-125	TNF superfamily member 11	Homo sapiens	57-62
29101208-1	2018	Recent studies have shown that progesterone receptor (PR)-expressing cells respond to progesterone in part through the induction of the receptor activator of NF-kappaB ligand (RANKL), which acts in a paracrine manner to induce expansion of a RANK-expressing luminal progenitor cell population.	Progesterone	31-43	TNF superfamily member 11	Homo sapiens	136-174
29174801-8	2018	Cabozantinib (60 mg/kg, 3 weeks) suppressed tumor growth in bone and reduced expression of RANKL and M-CSF and subsequent tumor-induced osteolysis.	cabozantinib	0-12	TNF superfamily member 11	Homo sapiens	91-96
29101208-1	2018	Recent studies have shown that progesterone receptor (PR)-expressing cells respond to progesterone in part through the induction of the receptor activator of NF-kappaB ligand (RANKL), which acts in a paracrine manner to induce expansion of a RANK-expressing luminal progenitor cell population.	Progesterone	31-43	TNF superfamily member 11	Homo sapiens	176-181
28681916-0	2018	Luteoloside prevents lipopolysaccharide-induced osteolysis and suppresses RANKL-induced osteoclastogenesis through attenuating RANKL signaling cascades.	luteolin-7-glucoside	0-11	TNF superfamily member 11	Homo sapiens	74-79
28407244-5	2018	It was observed that nicotine at low concentrations elicit an increase in osteoclast differentiation, but only in the presence of M-CSF and RANKL it was also able to significantly increase the resorbing ability of osteoclasts.	Nicotine	21-29	TNF superfamily member 11	Homo sapiens	140-145
28681916-0	2018	Luteoloside prevents lipopolysaccharide-induced osteolysis and suppresses RANKL-induced osteoclastogenesis through attenuating RANKL signaling cascades.	luteolin-7-glucoside	0-11	TNF superfamily member 11	Homo sapiens	127-132
28681916-6	2018	In addition, Luteoloside suppressed RANKL-induced osteoclast differentiation and abrogated bone resorption in a dose-dependent manner.	luteolin-7-glucoside	13-24	TNF superfamily member 11	Homo sapiens	36-41
28681916-7	2018	Further, we found that the anti-osteoclastic and anti-resorptive actions of Luteoloside are mediated via blocking NFATc1 activity and the attenuation of RANKL-mediated Ca2+ signaling as well as NF-kappaB and MAPK pathways.	luteolin-7-glucoside	76-87	TNF superfamily member 11	Homo sapiens	153-158
29342179-7	2018	However, sudachitin rather increased the expression of receptor activator of NF-kappaB ligand (RANKL), which is an important molecule triggering osteoclast differentiation, and the mRNA ratio of RANKL/osteoprotegerin that is a decoy receptor for RANKL, in the isolated osteoblasts, suggesting the presence of additional target cells.	sudachitin	9-19	TNF superfamily member 11	Homo sapiens	55-93
29342179-7	2018	However, sudachitin rather increased the expression of receptor activator of NF-kappaB ligand (RANKL), which is an important molecule triggering osteoclast differentiation, and the mRNA ratio of RANKL/osteoprotegerin that is a decoy receptor for RANKL, in the isolated osteoblasts, suggesting the presence of additional target cells.	sudachitin	9-19	TNF superfamily member 11	Homo sapiens	95-100
29342179-7	2018	However, sudachitin rather increased the expression of receptor activator of NF-kappaB ligand (RANKL), which is an important molecule triggering osteoclast differentiation, and the mRNA ratio of RANKL/osteoprotegerin that is a decoy receptor for RANKL, in the isolated osteoblasts, suggesting the presence of additional target cells.	sudachitin	9-19	TNF superfamily member 11	Homo sapiens	195-200
29342179-7	2018	However, sudachitin rather increased the expression of receptor activator of NF-kappaB ligand (RANKL), which is an important molecule triggering osteoclast differentiation, and the mRNA ratio of RANKL/osteoprotegerin that is a decoy receptor for RANKL, in the isolated osteoblasts, suggesting the presence of additional target cells.	sudachitin	9-19	TNF superfamily member 11	Homo sapiens	195-200
29342179-8	2018	When osteoclast formation was induced from osteoclast precursors derived from bone marrow cells in the presence of soluble RANKL and macrophage colony-stimulating factor, sudachitin inhibited osteoclastogenesis without influencing cell viability.	sudachitin	171-181	TNF superfamily member 11	Homo sapiens	123-128
29342179-10	2018	In addition, sudachitin decreased activation of MAPKs such as Erk and JNK and the ROS production evoked by RANKL in osteoclast lineage cells.	sudachitin	13-23	TNF superfamily member 11	Homo sapiens	107-112
29342179-10	2018	In addition, sudachitin decreased activation of MAPKs such as Erk and JNK and the ROS production evoked by RANKL in osteoclast lineage cells.	Reactive Oxygen Species	82-85	TNF superfamily member 11	Homo sapiens	107-112
29521042-10	2018	Additional application of dexamethasone to SCP-1 cells further increased the RANKL/OPG ratio 3-fold, but decreased IL-6 and IL-1beta expression to 10% and 50%, respectively.	Dexamethasone	26-39	TNF superfamily member 11	Homo sapiens	77-82
29269297-0	2018	Inhibitory activity of linarin on osteoclastogenesis through receptor activator of nuclear factor kappaB ligand-induced NF-kappaB pathway.	linarin	23-30	TNF superfamily member 11	Homo sapiens	61-111
29269297-7	2018	Western blot analysis further showed that linarin inhibited receptor activator of nuclear factor kappaB ligand (RANKL)-induced nuclear factor kappa B (NF-kappaB) p65 and NFATc1 activity.	linarin	42-49	TNF superfamily member 11	Homo sapiens	60-110
29269297-7	2018	Western blot analysis further showed that linarin inhibited receptor activator of nuclear factor kappaB ligand (RANKL)-induced nuclear factor kappa B (NF-kappaB) p65 and NFATc1 activity.	linarin	42-49	TNF superfamily member 11	Homo sapiens	112-117
29269297-8	2018	The present findings show that linarin exerted a potent inhibitory effect on osteoclastogenesis through RANKL-induced NF-kappaB signaling pathway.	linarin	31-38	TNF superfamily member 11	Homo sapiens	104-109
28294321-0	2018	Artesunate inhibits RANKL-induced osteoclastogenesis and bone resorption in vitro and prevents LPS-induced bone loss in vivo.	Artesunate	0-10	TNF superfamily member 11	Homo sapiens	20-25
30101837-5	2018	DHA inhibited receptor activator of nuclear factor kappa-B ligand (RANKL)-induced osteoclast formation and its bone resorbing activity.	artenimol	0-3	TNF superfamily member 11	Homo sapiens	14-65
30101837-5	2018	DHA inhibited receptor activator of nuclear factor kappa-B ligand (RANKL)-induced osteoclast formation and its bone resorbing activity.	artenimol	0-3	TNF superfamily member 11	Homo sapiens	67-72
30101837-8	2018	These results indicate that DHA represses RANKL-induced osteoclastogenesis of bone marrow macrophages through reduced NFATc1 expression and impaired phosphorylation of IkappaBalpha.	artenimol	28-31	TNF superfamily member 11	Homo sapiens	42-47
29412105-5	2018	The in vivo studies indicated that tocotrienols improve the bone health and reduce bone loss via inhibition of osteoclast formation and resorption activity, which could be through regulation of RANKL and OPG expression as seen from their levels in the sera.	Tocotrienols	35-47	TNF superfamily member 11	Homo sapiens	194-199
28294321-8	2018	Together our data demonstrated that Art inhibits RANKL-induced osteoclastogenesis by suppressing the NF-kappaB signaling pathway and that it is a promising agent for the treatment of osteolytic diseases.	Artesunate	36-39	TNF superfamily member 11	Homo sapiens	49-54
30587688-3	2018	In this study, the role of hypoxia-inducible factor-1 (HIF-1) signaling in the regulation of CCAAT (cytosine-cytosine-adenosine-adenosine-thymidine)/enhancer-binding protein-beta (C/EBPbeta) and the receptor activator of nuclear factor kappa-B ligand (RANKL) expressions in immortalized human periodontal ligament (PDL) cells was investigated.	Cytosine	100-108	TNF superfamily member 11	Homo sapiens	199-250
29932225-0	2018	Abietic acid attenuates RANKL induced osteoclastogenesis and inflammation associated osteolysis by inhibiting the NF-KB and MAPK signaling.	abietic acid	0-12	TNF superfamily member 11	Homo sapiens	24-29
29932225-6	2018	Mechanistically, AA abrogated RANKL-induced phosphorylation of IKKalpha/beta (ser 176/180), IkBalpha (ser 32), and inhibited the nuclear translocation of NF-kappaB.	Serine	78-81	TNF superfamily member 11	Homo sapiens	30-35
29932225-6	2018	Mechanistically, AA abrogated RANKL-induced phosphorylation of IKKalpha/beta (ser 176/180), IkBalpha (ser 32), and inhibited the nuclear translocation of NF-kappaB.	Serine	102-105	TNF superfamily member 11	Homo sapiens	30-35
30587688-3	2018	In this study, the role of hypoxia-inducible factor-1 (HIF-1) signaling in the regulation of CCAAT (cytosine-cytosine-adenosine-adenosine-thymidine)/enhancer-binding protein-beta (C/EBPbeta) and the receptor activator of nuclear factor kappa-B ligand (RANKL) expressions in immortalized human periodontal ligament (PDL) cells was investigated.	Cytosine	100-108	TNF superfamily member 11	Homo sapiens	252-257
30587688-3	2018	In this study, the role of hypoxia-inducible factor-1 (HIF-1) signaling in the regulation of CCAAT (cytosine-cytosine-adenosine-adenosine-thymidine)/enhancer-binding protein-beta (C/EBPbeta) and the receptor activator of nuclear factor kappa-B ligand (RANKL) expressions in immortalized human periodontal ligament (PDL) cells was investigated.	adenosine-thymidine	128-147	TNF superfamily member 11	Homo sapiens	199-250
30587688-3	2018	In this study, the role of hypoxia-inducible factor-1 (HIF-1) signaling in the regulation of CCAAT (cytosine-cytosine-adenosine-adenosine-thymidine)/enhancer-binding protein-beta (C/EBPbeta) and the receptor activator of nuclear factor kappa-B ligand (RANKL) expressions in immortalized human periodontal ligament (PDL) cells was investigated.	adenosine-thymidine	128-147	TNF superfamily member 11	Homo sapiens	252-257
30587688-6	2018	Treatment of the cells with dimethyloxaloylglycine, a competitive HIF prolyl hydroxylase inhibitor, significantly increased the expression of C/EBPbeta and RANKL mRNAs.	dimethyloxallyl glycine	28-50	TNF superfamily member 11	Homo sapiens	156-161
29635231-12	2018	These data suggest that HASMCs are a significant source of OPG within the vasculature but that RANKL, once present, downregulates this production and appears capable of preventing the "protective" upregulation of OPG seen with HASMCs exposed to physiological levels of cyclic strain.	hasmcs	227-233	TNF superfamily member 11	Homo sapiens	95-100
28213978-1	2017	We have recently demonstrated that RUNX2 promoted, and 17beta-Estradiol (E2) diminished, association of RANKL with the cell membrane in pre-osteoblast cultures.	Estradiol	55-71	TNF superfamily member 11	Homo sapiens	104-109
28302039-8	2018	The inflammatory cytokines and ROS influence osteoclast differentiation by regulating osteoclast-lineage cells or by acting on other cells to regulate the expression of RANKL and osteoprotegerin (OPG).	Reactive Oxygen Species	31-34	TNF superfamily member 11	Homo sapiens	169-174
29635231-11	2018	Exposing HASMCs to exogenous RANKL inhibited basal OPG production and completely abrogated the strain-mediated upregulation of OPG.	hasmcs	9-15	TNF superfamily member 11	Homo sapiens	29-34
27437760-6	2017	Furthermore, vitamin K2 reduces the pro-apoptotic proteins Fas and Bax in osteoblasts, and decreases osteoclast differentiation by increasing osteoprotegerin and reducing the receptor activator of nuclear factor kappa-B ligand.	Vitamin K 2	13-23	TNF superfamily member 11	Homo sapiens	175-226
28715096-8	2017	In the DMEM-F12 groups, RANKL expression increased, indicating there was a tendency for osteoclastogenic differentiation.	dmem	7-11	TNF superfamily member 11	Homo sapiens	24-29
29078090-0	2017	Swertiamarin, a natural steroid, prevent bone erosion by modulating RANKL/RANK/OPG signaling.	swertiamarin	0-12	TNF superfamily member 11	Homo sapiens	68-73
29078090-0	2017	Swertiamarin, a natural steroid, prevent bone erosion by modulating RANKL/RANK/OPG signaling.	Steroids	24-31	TNF superfamily member 11	Homo sapiens	68-73
29078090-3	2017	The swertiamarin treatment decreased the expression of TRAP, RANKL, and RANK levels and increased the levels of OPG levels significantly in both in vitro and in vivo models.	swertiamarin	4-16	TNF superfamily member 11	Homo sapiens	61-66
29078090-7	2017	In in silico analysis swertiamarin had affinity towards the proteins RANK, RANKL and OPG residues with low binding energy -4.5, -3.92 and -5.77kcal/mol respectively.	swertiamarin	22-34	TNF superfamily member 11	Homo sapiens	75-80
28213978-2	2017	Here we show that, similar to E2, dihydrotestosterone (DHT) diminishes association of RANKL, and transiently transfected GFP-RANKL with the pre-osteoblast membrane without decreasing total RANKL mRNA or protein levels.	Dihydrotestosterone	34-53	TNF superfamily member 11	Homo sapiens	86-91
28213978-2	2017	Here we show that, similar to E2, dihydrotestosterone (DHT) diminishes association of RANKL, and transiently transfected GFP-RANKL with the pre-osteoblast membrane without decreasing total RANKL mRNA or protein levels.	Dihydrotestosterone	55-58	TNF superfamily member 11	Homo sapiens	86-91
28213978-4	2017	A marked decrease in membrane-associated RANKL was observed after 30 min of either E2 or DHT treatment, and near-complete inhibition was observed by 1 hr, suggesting that the diminution of RANKL membrane association was mediated through non-genomic mechanisms.	Dihydrotestosterone	89-92	TNF superfamily member 11	Homo sapiens	41-46
28213978-6	2017	Finally, the inhibitory effect of E2 and DHT on RANKL membrane association was counteracted by the MMP inhibitor NNGH, and the effect of E2 (and not DHT) was antagonized by the Src inhibitor SU6656.	NNGH	113-117	TNF superfamily member 11	Homo sapiens	48-53
28385082-0	2017	Hyperbaric oxygen therapy modulates serum OPG/RANKL in femoral head necrosis patients.	Oxygen	11-17	TNF superfamily member 11	Homo sapiens	46-51
28213978-6	2017	Finally, the inhibitory effect of E2 and DHT on RANKL membrane association was counteracted by the MMP inhibitor NNGH, and the effect of E2 (and not DHT) was antagonized by the Src inhibitor SU6656.	Estradiol	34-36	TNF superfamily member 11	Homo sapiens	48-53
28213978-6	2017	Finally, the inhibitory effect of E2 and DHT on RANKL membrane association was counteracted by the MMP inhibitor NNGH, and the effect of E2 (and not DHT) was antagonized by the Src inhibitor SU6656.	Dihydrotestosterone	41-44	TNF superfamily member 11	Homo sapiens	48-53
29145718-2	2017	Lipopolysaccharide (LPS) induced autophagy, osteoclastogenesis, and cytoplasmic reactive oxygen species (ROS) in bone marrow-derived macrophages that were pre-stimulated with receptor activator of nuclear factor-kappaB ligand.	Reactive Oxygen Species	80-103	TNF superfamily member 11	Homo sapiens	175-225
29039565-12	2017	Additionally, the number of osteoclasts, the expression of RANKL, ALP, OCN and the ratio of RANKL/OPG were significantly up-regulated in the NaHS group.	sodium bisulfide	141-145	TNF superfamily member 11	Homo sapiens	59-64
29039565-12	2017	Additionally, the number of osteoclasts, the expression of RANKL, ALP, OCN and the ratio of RANKL/OPG were significantly up-regulated in the NaHS group.	sodium bisulfide	141-145	TNF superfamily member 11	Homo sapiens	92-97
29039565-13	2017	In contrast, PAG down-regulated the number of osteoclasts, the expression of RANKL, ALP, OCN and the ratio of RANKL/OPG.	propargylglycine	13-16	TNF superfamily member 11	Homo sapiens	77-82
29039565-13	2017	In contrast, PAG down-regulated the number of osteoclasts, the expression of RANKL, ALP, OCN and the ratio of RANKL/OPG.	propargylglycine	13-16	TNF superfamily member 11	Homo sapiens	110-115
29145718-2	2017	Lipopolysaccharide (LPS) induced autophagy, osteoclastogenesis, and cytoplasmic reactive oxygen species (ROS) in bone marrow-derived macrophages that were pre-stimulated with receptor activator of nuclear factor-kappaB ligand.	Reactive Oxygen Species	105-108	TNF superfamily member 11	Homo sapiens	175-225
29067128-0	2017	I-BET151 inhibits expression of RANKL, OPG, MMP3 and MMP9 in ankylosing spondylitis in vivo and in vitro.	GSK1210151A	0-8	TNF superfamily member 11	Homo sapiens	32-37
29145460-9	2017	Importantly, several RANKL actions (e.g. increased BMP-2 release from mono-cultured HAECs or increased ALP/Sox9 levels in co-cultured HASMCs) could be strongly blocked by co-incubation with TRAIL.	hasmcs	134-140	TNF superfamily member 11	Homo sapiens	21-26
28954509-4	2017	The bispecific antibody, Dmab-FvOn, showed a similar activity as Dmab in inhibiting RANKL as examined in an osteoclast differentiation assay.	dmab-fvon	25-34	TNF superfamily member 11	Homo sapiens	84-89
29055288-7	2017	Given that administration of Cyplexinol was found to improve density scores in both mild and severe cases, despite the extent of the patient"s history of documented bone loss, Cyplexinol has a more diverse range of applicability than prescription medications, suggesting the first, natural alternative to bisphosphonates, hormone replacement therapies and antireceptor activator of nuclear factor kappa-B ligand (anti-RANKL) agents.	cyplexinol	29-39	TNF superfamily member 11	Homo sapiens	418-423
29067128-9	2017	Conversely, levels of RANKL, OPG, MMP3 and MMP9 were significantly inhibited in cells or animals treated with I-BET151.	Iodine	110-111	TNF superfamily member 11	Homo sapiens	22-27
29149986-2	2017	The aim of this work was to study the effects of cyclosporine (CsA), tacrolimus (FK-506), and rapamycin (RAPA) on the release of three local factors directly implicated in bone-remodeling regulation and apoptosis of human osteoblasts: interleukin (IL)-6, osteoprotegerin, and receptor activator of nuclear factor kappabeta (RANKL).	Cyclosporine	49-61	TNF superfamily member 11	Homo sapiens	324-329
28901402-7	2017	CORM-3 attenuated the LPS- and nicotine-induced production of PGE2, COX-2 and RANKL in human PDLCs by releasing CO, and upregulated the expression of OPG.	Nicotine	31-39	TNF superfamily member 11	Homo sapiens	78-83
29149986-2	2017	The aim of this work was to study the effects of cyclosporine (CsA), tacrolimus (FK-506), and rapamycin (RAPA) on the release of three local factors directly implicated in bone-remodeling regulation and apoptosis of human osteoblasts: interleukin (IL)-6, osteoprotegerin, and receptor activator of nuclear factor kappabeta (RANKL).	Cyclosporine	63-66	TNF superfamily member 11	Homo sapiens	324-329
29149986-2	2017	The aim of this work was to study the effects of cyclosporine (CsA), tacrolimus (FK-506), and rapamycin (RAPA) on the release of three local factors directly implicated in bone-remodeling regulation and apoptosis of human osteoblasts: interleukin (IL)-6, osteoprotegerin, and receptor activator of nuclear factor kappabeta (RANKL).	Tacrolimus	69-79	TNF superfamily member 11	Homo sapiens	324-329
29149986-2	2017	The aim of this work was to study the effects of cyclosporine (CsA), tacrolimus (FK-506), and rapamycin (RAPA) on the release of three local factors directly implicated in bone-remodeling regulation and apoptosis of human osteoblasts: interleukin (IL)-6, osteoprotegerin, and receptor activator of nuclear factor kappabeta (RANKL).	Tacrolimus	81-87	TNF superfamily member 11	Homo sapiens	324-329
28885764-6	2017	Derivatives were screened, and the chlorin-macrocycle-containing pheophorbide A and purpurin 18 were found to bind recombinant RANKL, to inhibit RANK-RANKL interactions in the ELISA, and to suppress the RANKL-dependent activation of model cells and the differentiation of RANK-expressing precursors into osteoclasts.	chlorin	35-42	TNF superfamily member 11	Homo sapiens	150-155
28885764-6	2017	Derivatives were screened, and the chlorin-macrocycle-containing pheophorbide A and purpurin 18 were found to bind recombinant RANKL, to inhibit RANK-RANKL interactions in the ELISA, and to suppress the RANKL-dependent activation of model cells and the differentiation of RANK-expressing precursors into osteoclasts.	chlorin	35-42	TNF superfamily member 11	Homo sapiens	150-155
28885764-6	2017	Derivatives were screened, and the chlorin-macrocycle-containing pheophorbide A and purpurin 18 were found to bind recombinant RANKL, to inhibit RANK-RANKL interactions in the ELISA, and to suppress the RANKL-dependent activation of model cells and the differentiation of RANK-expressing precursors into osteoclasts.	chlorin	35-42	TNF superfamily member 11	Homo sapiens	127-132
28885764-6	2017	Derivatives were screened, and the chlorin-macrocycle-containing pheophorbide A and purpurin 18 were found to bind recombinant RANKL, to inhibit RANK-RANKL interactions in the ELISA, and to suppress the RANKL-dependent activation of model cells and the differentiation of RANK-expressing precursors into osteoclasts.	pheophorbide a	65-79	TNF superfamily member 11	Homo sapiens	127-132
28885764-6	2017	Derivatives were screened, and the chlorin-macrocycle-containing pheophorbide A and purpurin 18 were found to bind recombinant RANKL, to inhibit RANK-RANKL interactions in the ELISA, and to suppress the RANKL-dependent activation of model cells and the differentiation of RANK-expressing precursors into osteoclasts.	pheophorbide a	65-79	TNF superfamily member 11	Homo sapiens	150-155
28885764-6	2017	Derivatives were screened, and the chlorin-macrocycle-containing pheophorbide A and purpurin 18 were found to bind recombinant RANKL, to inhibit RANK-RANKL interactions in the ELISA, and to suppress the RANKL-dependent activation of model cells and the differentiation of RANK-expressing precursors into osteoclasts.	pheophorbide a	65-79	TNF superfamily member 11	Homo sapiens	150-155
28885764-6	2017	Derivatives were screened, and the chlorin-macrocycle-containing pheophorbide A and purpurin 18 were found to bind recombinant RANKL, to inhibit RANK-RANKL interactions in the ELISA, and to suppress the RANKL-dependent activation of model cells and the differentiation of RANK-expressing precursors into osteoclasts.	purpurin 18	84-95	TNF superfamily member 11	Homo sapiens	127-132
28885764-6	2017	Derivatives were screened, and the chlorin-macrocycle-containing pheophorbide A and purpurin 18 were found to bind recombinant RANKL, to inhibit RANK-RANKL interactions in the ELISA, and to suppress the RANKL-dependent activation of model cells and the differentiation of RANK-expressing precursors into osteoclasts.	purpurin 18	84-95	TNF superfamily member 11	Homo sapiens	150-155
28885764-6	2017	Derivatives were screened, and the chlorin-macrocycle-containing pheophorbide A and purpurin 18 were found to bind recombinant RANKL, to inhibit RANK-RANKL interactions in the ELISA, and to suppress the RANKL-dependent activation of model cells and the differentiation of RANK-expressing precursors into osteoclasts.	purpurin 18	84-95	TNF superfamily member 11	Homo sapiens	150-155
29022922-3	2017	Here, we report that receptor activator for nuclear factor-kappa B ligand (RANKL), secreted by human embryonic trophoblasts and maternal decidual stromal cells (DSCs), polarizes dMphi toward a M2 phenotype.	dmphi	178-183	TNF superfamily member 11	Homo sapiens	21-73
29022922-3	2017	Here, we report that receptor activator for nuclear factor-kappa B ligand (RANKL), secreted by human embryonic trophoblasts and maternal decidual stromal cells (DSCs), polarizes dMphi toward a M2 phenotype.	dmphi	178-183	TNF superfamily member 11	Homo sapiens	75-80
28861734-2	2017	Here, the effect of sesamin on human osteoclasts was investigated in terms of differentiation and function in M-CSF and RANKL induced human PBMCs.	sesamin	20-27	TNF superfamily member 11	Homo sapiens	120-125
29046637-7	2017	On the one hand, at the molecular level, meclizine attenuated RANKL-induced activation of c-Fos, NFATc1, nuclear factor-kappaB (NF-kappaB) and mitogen-activated protein kinase (MAPKs), including ERK and p38, but not JNK.	Meclizine	41-50	TNF superfamily member 11	Homo sapiens	62-67
29046637-10	2017	In conclusion, our results indicated that meclizine inhibits osteoclastogenesis via regulation of several RANKL signaling pathways and PXR was involved in the processes.	Meclizine	42-51	TNF superfamily member 11	Homo sapiens	106-111
29046637-5	2017	In the present study, we explored the effect of meclizine on RANKL-induced osteoclastogenesis both in vivo and in vitro.	Meclizine	48-57	TNF superfamily member 11	Homo sapiens	61-66
28708461-7	2017	The Co-Cr group showed the greatest PD, GCF volume, RANKL/OPG, RANKL, and calcium ion concentration, followed by the Au-Pt group.	co-cr	4-9	TNF superfamily member 11	Homo sapiens	52-57
28779592-5	2017	Moreover, the RANKL induced NF-kappaB/p65 phosphorylation and I-kappaB degradation were significantly inhibited by psoralidin.	psoralidin	115-125	TNF superfamily member 11	Homo sapiens	14-19
28779592-3	2017	By using both in vitro and in vivo studies, we observed psoralidin strongly inhibited RANKL induced osteoclast formation during preosteoclast cultures, suggesting that it acts on osteoclast precursors to inhibit RANKL/RANK signaling.	psoralidin	56-66	TNF superfamily member 11	Homo sapiens	86-91
28779592-3	2017	By using both in vitro and in vivo studies, we observed psoralidin strongly inhibited RANKL induced osteoclast formation during preosteoclast cultures, suggesting that it acts on osteoclast precursors to inhibit RANKL/RANK signaling.	psoralidin	56-66	TNF superfamily member 11	Homo sapiens	212-217
28708461-7	2017	The Co-Cr group showed the greatest PD, GCF volume, RANKL/OPG, RANKL, and calcium ion concentration, followed by the Au-Pt group.	co-cr	4-9	TNF superfamily member 11	Homo sapiens	63-68
28819671-0	2017	Fullerenol nanoparticles suppress RANKL-induced osteoclastogenesis by inhibiting differentiation and maturation.	fullerenol	0-10	TNF superfamily member 11	Homo sapiens	34-39
29047264-4	2017	A2BAR stimulation with its specific agonist BAY 60-6583 was sufficient to inhibit the activation of ERK1/2, p38 MAP kinases and NF-kappaB by RANKL as well as it abrogated cell-cell fusion in the late stage of osteoclast differentiation.	BAY 60-6583	44-55	TNF superfamily member 11	Homo sapiens	141-146
28391779-6	2017	In addition, Tusc2 induced the activation of RANKL-mediated NF-kappaB and calcium/calmodulin-dependent kinase IV (CaMKIV)/cAMP-response element (CRE)-binding protein CREB signaling cascades.	Cyclic AMP	122-126	TNF superfamily member 11	Homo sapiens	45-50
28667678-7	2017	RANK-L was significantly decreased at week 13 in the SRP + PDT group compared with the SRP group.	L-seryl-AMP	53-56	TNF superfamily member 11	Homo sapiens	0-6
28667678-7	2017	RANK-L was significantly decreased at week 13 in the SRP + PDT group compared with the SRP group.	L-seryl-AMP	87-90	TNF superfamily member 11	Homo sapiens	0-6
28528307-4	2017	Increased extracellular ATP (eATP) by interacting with P2x7 purinoreceptors, present on fibroblasts and osteoblasts, induces generation of receptor activator of nuclear factor kB ligand (RANKL) that further activates osteoclastic alveolar bone resorption and bone loss.	Adenosine Triphosphate	24-27	TNF superfamily member 11	Homo sapiens	139-185
28528307-4	2017	Increased extracellular ATP (eATP) by interacting with P2x7 purinoreceptors, present on fibroblasts and osteoblasts, induces generation of receptor activator of nuclear factor kB ligand (RANKL) that further activates osteoclastic alveolar bone resorption and bone loss.	Adenosine Triphosphate	24-27	TNF superfamily member 11	Homo sapiens	187-192
28819671-6	2017	In addition, fullerenol dose-dependently restricted the differentiation of bone marrow macrophage cells (BMMs) to form osteoclasts following treatment with macrophage colony-stimulating factor (M-CSF) and receptor activator of nuclear factor (NF)-kappaB (RANKL) to activate NF-kappaB and mitogen activating protein kinase (MAPK) signaling pathways.	fullerenol	13-23	TNF superfamily member 11	Homo sapiens	255-260
28869453-0	2017	Bortezomib could down-regulate the expression of RANKL, inhibit cell proliferation and induce cell apoptosis in the human myeloma cell line RPMI 8226 by activating casepase-3.	Bortezomib	0-10	TNF superfamily member 11	Homo sapiens	49-54
28869453-0	2017	Bortezomib could down-regulate the expression of RANKL, inhibit cell proliferation and induce cell apoptosis in the human myeloma cell line RPMI 8226 by activating casepase-3.	rpmi	140-144	TNF superfamily member 11	Homo sapiens	49-54
28869453-1	2017	OBJECTIVE: In spite of bortezomib being developed and demonstrated as a safe drug therapy for multiple myeloma (MM), the role of bortezomib-induced receptor activator of nuclear factor (NF)-kappaB ligand (RANKL) in the MM cell lines remains to be understood.	Bortezomib	129-139	TNF superfamily member 11	Homo sapiens	205-210
28869453-2	2017	Thus the present study aims to explore the impact of bortezomib on RANKL expression, cell growth and apoptosis in human myeloma cell line RPMI 8226.	Bortezomib	53-63	TNF superfamily member 11	Homo sapiens	67-72
28869453-9	2017	Compared with those treated with bortezomib (20 nmol/L and 40 nmol/L) for 6 h, the RANKL expression was down-regulated, cell inhibition rate was increased, cells at the S stage were reduced, cell apoptosis rate was enhanced, and caspase-3 activity elevated in the RPMI 8226 cells as treated with bortezomib for 24 h, with a dose- and time-dependent manner.	Bortezomib	33-43	TNF superfamily member 11	Homo sapiens	83-88
28869453-9	2017	Compared with those treated with bortezomib (20 nmol/L and 40 nmol/L) for 6 h, the RANKL expression was down-regulated, cell inhibition rate was increased, cells at the S stage were reduced, cell apoptosis rate was enhanced, and caspase-3 activity elevated in the RPMI 8226 cells as treated with bortezomib for 24 h, with a dose- and time-dependent manner.	rpmi	264-268	TNF superfamily member 11	Homo sapiens	83-88
28869453-9	2017	Compared with those treated with bortezomib (20 nmol/L and 40 nmol/L) for 6 h, the RANKL expression was down-regulated, cell inhibition rate was increased, cells at the S stage were reduced, cell apoptosis rate was enhanced, and caspase-3 activity elevated in the RPMI 8226 cells as treated with bortezomib for 24 h, with a dose- and time-dependent manner.	Bortezomib	296-306	TNF superfamily member 11	Homo sapiens	83-88
28869453-10	2017	CONCLUSIONS: Bortezomib could reduce the RANKL expression, inhibit cell proliferation and activate caspase-3 activity to induce cell apoptosis in RPMI 8266 cells.	Bortezomib	13-23	TNF superfamily member 11	Homo sapiens	41-46
28578884-12	2017	miR-335-5p promoted RANKL in HPDLFs regardless of whether or not it was under inflammatory conditions (P &lt; .05).	mir-335-5p	0-10	TNF superfamily member 11	Homo sapiens	20-25
28618255-7	2017	The global RANKL/OPG ratio in the spine after 8 months of steroid and dietary treatment was not different from that of the control.	Steroids	58-65	TNF superfamily member 11	Homo sapiens	11-16
28618255-8	2017	Interestingly, assessment of the osteocyte-specific RANKL/OPG ratio showed that the steroid-induced osteoporosis in its late progressive phase stimulates RANKL expression in osteocytes.	Steroids	84-91	TNF superfamily member 11	Homo sapiens	52-57
28618255-8	2017	Interestingly, assessment of the osteocyte-specific RANKL/OPG ratio showed that the steroid-induced osteoporosis in its late progressive phase stimulates RANKL expression in osteocytes.	Steroids	84-91	TNF superfamily member 11	Homo sapiens	154-159
28810648-9	2017	Moreover, alendronate or genistein used separately at higher concentrations suppressed the osteoclastic differentiation of RAW267.4 cells induced by receptor activator of nuclear factor-kappaB ligand (RANKL) in vitro.	Alendronate	10-21	TNF superfamily member 11	Homo sapiens	149-199
28810648-9	2017	Moreover, alendronate or genistein used separately at higher concentrations suppressed the osteoclastic differentiation of RAW267.4 cells induced by receptor activator of nuclear factor-kappaB ligand (RANKL) in vitro.	Alendronate	10-21	TNF superfamily member 11	Homo sapiens	201-206
28810648-9	2017	Moreover, alendronate or genistein used separately at higher concentrations suppressed the osteoclastic differentiation of RAW267.4 cells induced by receptor activator of nuclear factor-kappaB ligand (RANKL) in vitro.	Genistein	25-34	TNF superfamily member 11	Homo sapiens	149-199
28810648-9	2017	Moreover, alendronate or genistein used separately at higher concentrations suppressed the osteoclastic differentiation of RAW267.4 cells induced by receptor activator of nuclear factor-kappaB ligand (RANKL) in vitro.	Genistein	25-34	TNF superfamily member 11	Homo sapiens	201-206
28715463-9	2017	Non-cytotoxic K citrate concentrations were not sufficient to steadily neutralize the acidic medium, but a) inhibited the osteoclastogenesis, the collagen degradation, and the expression of genes involved in RANKL-mediated OC differentiation, b) enhanced OB proliferation and alkaline phosphatase expression, whereas it did not affect the in vitro mineralization, and c) were effective also in OC cultures resistant to alendronate, i.e. the positive control of osteoclastogenesis inhibition.	Potassium Citrate	14-23	TNF superfamily member 11	Homo sapiens	208-213
28666187-0	2017	Evaluation of the Prognostic Value of RANK, OPG, and RANKL mRNA Expression in Early Breast Cancer Patients Treated with Anthracycline-Based Adjuvant Chemotherapy.	Anthracyclines	120-133	TNF superfamily member 11	Homo sapiens	53-58
29228639-11	2017	But prolonged melatonin administration promoted the proteolytic cleavage of RANKL protein in the synovium, leading to severe subchondral bone erosion.	Melatonin	14-23	TNF superfamily member 11	Homo sapiens	76-81
28525946-5	2017	Here, we reported the role of ghrelin and its relationship with OPG/RANKL/RANK system in patients with diabetic foot amputation.	Ghrelin	30-37	TNF superfamily member 11	Homo sapiens	68-73
28525946-15	2017	In addition, ghrelin upregulated OPG expression and downregulated RANKL expression in VSMC calcification when anti-OPG antibody and RANKL were performed.	Ghrelin	13-20	TNF superfamily member 11	Homo sapiens	66-71
28525946-15	2017	In addition, ghrelin upregulated OPG expression and downregulated RANKL expression in VSMC calcification when anti-OPG antibody and RANKL were performed.	Ghrelin	13-20	TNF superfamily member 11	Homo sapiens	132-137
28387573-0	2017	Metformin inhibits RANKL and sensitizes cancer stem cells to denosumab.	Metformin	0-9	TNF superfamily member 11	Homo sapiens	19-24
28417335-11	2017	CONCLUSIONS: RANK and RANKL co-expression is associated with poor RFS and OS in patients with TNBC.	tnbc	94-98	TNF superfamily member 11	Homo sapiens	22-27
28387573-3	2017	Here we report that the biguanide metformin prevents BRCA1 haploinsufficiency-driven RANKL gene overexpression, thereby disrupting an auto-regulatory feedback control of RANKL-addicted cancer stem cell-like states within BRCA1mut/- cell populations.	Biguanides	24-33	TNF superfamily member 11	Homo sapiens	85-90
28387573-3	2017	Here we report that the biguanide metformin prevents BRCA1 haploinsufficiency-driven RANKL gene overexpression, thereby disrupting an auto-regulatory feedback control of RANKL-addicted cancer stem cell-like states within BRCA1mut/- cell populations.	Metformin	34-43	TNF superfamily member 11	Homo sapiens	85-90
28387573-6	2017	Our findings provide a rationale for new denosumab/metformin combinatorial strategies to clinically manage RANKL-related breast oncogenesis and metastatic progression.	Metformin	51-60	TNF superfamily member 11	Homo sapiens	107-112
28363435-9	2017	The potent antioxidant activity of CAPE is, at least in part, involved in its anti-apoptotic effects and modulation of RunX2 and RANKL/OPG signals.	caffeic acid phenethyl ester	35-39	TNF superfamily member 11	Homo sapiens	129-134
28363435-0	2017	Caffeic acid phenethyl ester protects against glucocorticoid-induced osteoporosis in vivo: Impact on oxidative stress and RANKL/OPG signals.	caffeic acid phenethyl ester	0-28	TNF superfamily member 11	Homo sapiens	122-127
28190118-7	2017	The concentration of RANKL was significantly higher in patients compared with controls, median (IQR) 0.56 (0.9) nmol/L and 0.20 (0.25) nmol/L (p &lt; 0.001), and in anti-CCP2-positive patients compared with sero-negative individuals.	sero	207-211	TNF superfamily member 11	Homo sapiens	21-26
28363435-7	2017	Co-administration of CAPE with DEX normalized RANKL/OPG ratio and Akt activation indicating a reduction in DEX-osteoclastogenesis.	caffeic acid phenethyl ester	21-25	TNF superfamily member 11	Homo sapiens	46-51
28363435-7	2017	Co-administration of CAPE with DEX normalized RANKL/OPG ratio and Akt activation indicating a reduction in DEX-osteoclastogenesis.	Dexamethasone	31-34	TNF superfamily member 11	Homo sapiens	46-51
28876039-4	2017	In this study, by adjusting and stabilizing the pH value of LB medium at 7.5, lowering the inducing temperature to 16 C and optimizing the lysis program, the yield of soluble hRANKL increased by approximately 5 to 12-fold over the non-adjusted group.	lb medium	60-69	TNF superfamily member 11	Homo sapiens	175-181
28288319-0	2017	Synthesis of heterocyclic ring-fused tricyclic diterpene analogs as novel inhibitors of RANKL-induced osteoclastogenesis and bone resorption.	Diterpenes	47-56	TNF superfamily member 11	Homo sapiens	88-93
28587149-4	2017	The presence of melatonin significantly reduced receptor activator of nuclear factor kappaB ligand (RANKL)-induced osteoclastogenesis and the siRNA-mediated knockdown of the melatonin receptor failed to overcome the anti-osteoclastogenic effect of melatonin.	Melatonin	16-25	TNF superfamily member 11	Homo sapiens	100-105
28446753-9	2017	Histamine, IL-17, and IL-22 stimulated RANKL expression in RA monocytes and JNJ7777120 reduced the RANKL expression.	Histamine	0-9	TNF superfamily member 11	Homo sapiens	39-44
28446753-9	2017	Histamine, IL-17, and IL-22 stimulated RANKL expression in RA monocytes and JNJ7777120 reduced the RANKL expression.	Histamine	0-9	TNF superfamily member 11	Homo sapiens	99-104
28044198-8	2017	By inhibiting prostaglandin synthesis, meloxicam seems to downregulate hPDL-mediated inflammation, RANKL-induced osteoclastogenesis and, consequently, tooth movement velocity by about 50%, thus limiting its suitability for analgesia during orthodontic therapy.	Meloxicam	39-48	TNF superfamily member 11	Homo sapiens	99-104
28256196-4	2017	In this study, afatinib significantly suppressed receptor activator of nuclear factor kappaB (RANK) ligand (RANKL)-induced osteoclast formation in bone marrow macrophages (BMMs).	Afatinib	15-23	TNF superfamily member 11	Homo sapiens	49-106
27796050-7	2017	Immunohistochemical staining of the distal femur demonstrated that %TNF-alpha+ , %IL-6+ , %RANKL+ , and %OPG+ osteocytes were elevated in cancellous bone in TNBS animals compared to vehicle.	Trinitrobenzenesulfonic Acid	157-161	TNF superfamily member 11	Homo sapiens	91-96
28263804-9	2017	A decrease in RANKL-induced osteoclastogenesis and resorption was also observed after beta-carotene treatment.	beta Carotene	86-99	TNF superfamily member 11	Homo sapiens	14-19
28263804-10	2017	beta-Carotene attenuated the NF-kB pathway activation by RANKL, with no effect on MAPK pathway.	beta Carotene	0-13	TNF superfamily member 11	Homo sapiens	57-62
28263804-11	2017	beta-Carotene suppressed the upregulation of NFATc1 and c-Fos by RANKL.	beta Carotene	0-13	TNF superfamily member 11	Homo sapiens	65-70
28161640-8	2017	Our results showed that gastrodin retarded RANKL-induced osteoclast differentiation efficiently by downregulating transcriptional and translational expression of nuclear factor of activated T cells cl (NFATc1), a major factor in RANKL-mediated osteoclastogenesis.	gastrodin	24-33	TNF superfamily member 11	Homo sapiens	43-48
28161640-8	2017	Our results showed that gastrodin retarded RANKL-induced osteoclast differentiation efficiently by downregulating transcriptional and translational expression of nuclear factor of activated T cells cl (NFATc1), a major factor in RANKL-mediated osteoclastogenesis.	gastrodin	24-33	TNF superfamily member 11	Homo sapiens	229-234
28161640-10	2017	And gastrodin prevented RANKL-induced osteoclastic bone erosion in vitro.	gastrodin	4-13	TNF superfamily member 11	Homo sapiens	24-29
27312515-5	2017	RANKL-induced osteoclastogenesis is regulated by the phosphoinositide (PI) signaling pathway, in which diacylglycerol (DG) serves as a second messenger in signal transduction.	Phosphatidylinositols	53-69	TNF superfamily member 11	Homo sapiens	0-5
27312515-5	2017	RANKL-induced osteoclastogenesis is regulated by the phosphoinositide (PI) signaling pathway, in which diacylglycerol (DG) serves as a second messenger in signal transduction.	Diglycerides	103-117	TNF superfamily member 11	Homo sapiens	0-5
28540268-3	2017	This study was done to compare the effects of high dose (5mg/day) and low dose (0.5 mg/day) folic acid in the RANKL/OPG ratio and Tumor Necrosis Factoralpha (TNFalpha) concentration during pregnancy.	Folic Acid	92-102	TNF superfamily member 11	Homo sapiens	110-115
28223547-5	2017	Cabozantinib treatment has no effect on osteoblast viability or differentiation, but increases osteoprotegerin mRNA (p=0.015) and protein levels (p=0.004) and down-modulates Receptor Activator of Nuclear Factor k B Ligand (RANKL) at both mRNA (p&lt;0.001) and protein levels (p=0.043).	cabozantinib	0-12	TNF superfamily member 11	Homo sapiens	174-221
28223547-5	2017	Cabozantinib treatment has no effect on osteoblast viability or differentiation, but increases osteoprotegerin mRNA (p=0.015) and protein levels (p=0.004) and down-modulates Receptor Activator of Nuclear Factor k B Ligand (RANKL) at both mRNA (p&lt;0.001) and protein levels (p=0.043).	cabozantinib	0-12	TNF superfamily member 11	Homo sapiens	223-228
28223547-6	2017	Direct cell-to-cell contact between cabozantinib pre-treated osteoblasts and untreated osteoclasts confirmed the indirect anti-resorptive effect of cabozantinib.We demonstrate that cabozantinib inhibits osteoclast functions "directly" and "indirectly" reducing the RANKL/osteoprotegerin ratio in osteoblasts.	cabozantinib	148-160	TNF superfamily member 11	Homo sapiens	265-270
28223547-6	2017	Direct cell-to-cell contact between cabozantinib pre-treated osteoblasts and untreated osteoclasts confirmed the indirect anti-resorptive effect of cabozantinib.We demonstrate that cabozantinib inhibits osteoclast functions "directly" and "indirectly" reducing the RANKL/osteoprotegerin ratio in osteoblasts.	cabozantinib	148-160	TNF superfamily member 11	Homo sapiens	265-270
28256196-4	2017	In this study, afatinib significantly suppressed receptor activator of nuclear factor kappaB (RANK) ligand (RANKL)-induced osteoclast formation in bone marrow macrophages (BMMs).	Afatinib	15-23	TNF superfamily member 11	Homo sapiens	108-113
28256196-7	2017	In addition, afatinib significantly inhibited RANKL-mediated Akt/protein kinase B and c-Jun N-terminal kinase phosphorylation.	Afatinib	13-21	TNF superfamily member 11	Homo sapiens	46-51
27762732-1	2017	BACKGROUND: Prostaglandin (PG)E2 accumulates in inflamed periodontal tissue and induces receptor activator of nuclear factor kappa-B ligand (RANKL)-RANK-osteoprotegerin (OPG) signaling associated with bone resorption.	Dinoprostone	12-32	TNF superfamily member 11	Homo sapiens	88-139
27762732-1	2017	BACKGROUND: Prostaglandin (PG)E2 accumulates in inflamed periodontal tissue and induces receptor activator of nuclear factor kappa-B ligand (RANKL)-RANK-osteoprotegerin (OPG) signaling associated with bone resorption.	Dinoprostone	12-32	TNF superfamily member 11	Homo sapiens	141-146
27762732-3	2017	METHODS: To mimic an inflamed condition, RANKL upregulation in human mandibular osteoblast-like cells (HMOBs) were stimulated with PGE2.	Dinoprostone	131-135	TNF superfamily member 11	Homo sapiens	41-46
27762732-7	2017	RESULTS: PGE2 significantly increased RANKL messenger RNA (mRNA) and protein in HMOBs in a dose-dependent manner, while OPG protein remained similar to baseline.	Dinoprostone	9-13	TNF superfamily member 11	Homo sapiens	38-43
27762732-9	2017	HMOBs treated with epithelial supernatant or recombinant IFN-gamma, concurrently with PGE2 stimulation, reduced RANKL, but not OPG, expression.	Dinoprostone	86-90	TNF superfamily member 11	Homo sapiens	112-117
27762732-11	2017	When cocultured with THP-1, RANKL released by PGE2-stimulated HMOBs is adequate to drive THP-1 differentiation as osteoclastogenic gene expression and bone resorption pit are increased.	Dinoprostone	46-50	TNF superfamily member 11	Homo sapiens	28-33
28088947-0	2017	Heme oxygenase-1 (HO-1)/carbon monoxide (CO) axis suppresses RANKL-induced osteoclastic differentiation by inhibiting redox-sensitive NF-kappaB activation.	Carbon Monoxide	24-39	TNF superfamily member 11	Homo sapiens	61-66
28088947-0	2017	Heme oxygenase-1 (HO-1)/carbon monoxide (CO) axis suppresses RANKL-induced osteoclastic differentiation by inhibiting redox-sensitive NF-kappaB activation.	Carbon Monoxide	41-43	TNF superfamily member 11	Homo sapiens	61-66
28088947-3	2017	Treatment of RAW264.7 cells with CORM-2 (a CO donor) and bilirubin, but not with iron, decreased RANKL-induced osteoclastogenesis, with CORM-2 having a more potent anti-osteogenic effect.	Bilirubin	57-66	TNF superfamily member 11	Homo sapiens	97-102
28088947-6	2017	CORM-2 reduced RANKL-induced NFATc1 expression by inhibiting IKK-dependent NF-kappaB activation and reactive oxygen species production.	Reactive Oxygen Species	100-123	TNF superfamily member 11	Homo sapiens	15-20
28203164-3	2017	Since receptor activator of nuclear factor kappa-B ligand (RANKL) is expressed in cancers of apocrine origin, leading to immunosuppression at the tumor site, we hypothesized that targeting RANKL with denosumab might be useful for the treatment of PCAC.	pcac	247-251	TNF superfamily member 11	Homo sapiens	6-57
28035539-7	2017	RESULTS: Compared with the model group, brucine led to a dose-dependent decrease on migration of MDA-MB-231 cells, inhibited RANKL-induced osteoclastogenesis and bone resorption of RAW264.7 cells (P&lt;0.01).	brucine	40-47	TNF superfamily member 11	Homo sapiens	125-130
27913299-0	2017	The inhibitory effect of beta-lapachone on RANKL-induced osteoclastogenesis.	beta-lapachone	25-39	TNF superfamily member 11	Homo sapiens	43-48
27913299-7	2017	beta-L treatment of RANKL-induced osteoclastogenesis significantly increased the cellular NAD+/NADH ratio and resulted in the activation of 5" AMP-activated protein kinase (AMPK), a negative regulator of osteoclast differentiation.	beta-lapachone	0-6	TNF superfamily member 11	Homo sapiens	20-25
27913299-7	2017	beta-L treatment of RANKL-induced osteoclastogenesis significantly increased the cellular NAD+/NADH ratio and resulted in the activation of 5" AMP-activated protein kinase (AMPK), a negative regulator of osteoclast differentiation.	NAD	90-94	TNF superfamily member 11	Homo sapiens	20-25
27913299-7	2017	beta-L treatment of RANKL-induced osteoclastogenesis significantly increased the cellular NAD+/NADH ratio and resulted in the activation of 5" AMP-activated protein kinase (AMPK), a negative regulator of osteoclast differentiation.	NAD	95-99	TNF superfamily member 11	Homo sapiens	20-25
27913299-10	2017	Taken together, the results demonstrated that beta-L inhibits RANKL-induced osteoclastogenesis and could be considered a potent inhibitor of RANKL-mediated bone diseases, such as postmenopausal osteoporosis, rheumatoid arthritis, and periodontitis.	beta-lapachone	46-52	TNF superfamily member 11	Homo sapiens	62-67
27913299-10	2017	Taken together, the results demonstrated that beta-L inhibits RANKL-induced osteoclastogenesis and could be considered a potent inhibitor of RANKL-mediated bone diseases, such as postmenopausal osteoporosis, rheumatoid arthritis, and periodontitis.	beta-lapachone	46-52	TNF superfamily member 11	Homo sapiens	141-146
27743302-0	2017	Effect of lifestyle interventions with or without metformin therapy on serum levels of osteoprotegerin and receptor activator of nuclear factor kappa B ligand in patients with prediabetes.	Metformin	50-59	TNF superfamily member 11	Homo sapiens	107-158
28203164-3	2017	Since receptor activator of nuclear factor kappa-B ligand (RANKL) is expressed in cancers of apocrine origin, leading to immunosuppression at the tumor site, we hypothesized that targeting RANKL with denosumab might be useful for the treatment of PCAC.	pcac	247-251	TNF superfamily member 11	Homo sapiens	59-64
28203164-3	2017	Since receptor activator of nuclear factor kappa-B ligand (RANKL) is expressed in cancers of apocrine origin, leading to immunosuppression at the tumor site, we hypothesized that targeting RANKL with denosumab might be useful for the treatment of PCAC.	pcac	247-251	TNF superfamily member 11	Homo sapiens	189-194
28509316-0	2017	Effects of 17beta-estradioland raloxifene on endothelial OPG and RANKL secretion.	Raloxifene Hydrochloride	31-41	TNF superfamily member 11	Homo sapiens	65-70
29050490-4	2017	After beta-GP treatment, beta-GP promoted clear mineralized nodule changes, and miR-26a and OPG expression were significantly decreased and CTGF, RANKL and ALP expression were increased in VSMCs.	beta-glycerophosphoric acid	6-13	TNF superfamily member 11	Homo sapiens	146-151
29081815-0	2017	Effects of Brucine on the OPG/RANKL/RANK Signaling Pathway in MDA-MB-231 and MC3T3-E1 Cell Coculture System.	brucine	11-18	TNF superfamily member 11	Homo sapiens	30-35
28231743-4	2017	Here we found that water extract of Glycyrrhizae radix (GR) inhibits receptor activator of nuclear factor-[Formula: see text]B ligand (RANKL)-induced osteoclast differentiation in a dose-dependent manner without causing cytotoxicity.	Water	19-24	TNF superfamily member 11	Homo sapiens	135-140
27384064-0	2017	Ellagic acid inhibits RANKL-induced osteoclast differentiation by suppressing the p38 MAP kinase pathway.	Ellagic Acid	0-12	TNF superfamily member 11	Homo sapiens	22-27
28589137-5	2017	Furthermore, we found that miR-16-5p expression considerably decreased with the progression of receptor activator of nuclear factor-kappaB ligand- (RANKL-) induced osteoclastogenesis.	mir-16-5p	27-36	TNF superfamily member 11	Homo sapiens	95-146
28589137-5	2017	Furthermore, we found that miR-16-5p expression considerably decreased with the progression of receptor activator of nuclear factor-kappaB ligand- (RANKL-) induced osteoclastogenesis.	mir-16-5p	27-36	TNF superfamily member 11	Homo sapiens	148-153
28589137-6	2017	Functionally, miR-16-5p mimics significantly reduced RANKL-induced osteoclast formation.	mir-16-5p	14-23	TNF superfamily member 11	Homo sapiens	53-58
27738322-10	2016	Antagonizing miR-218-5p reduced the expression of PTHrP and Rankl, inhibited osteoclast differentiation in vitro and in vivo, and prevented the development of osteolytic lesions in a preclinical metastasis model.	mir-218-5p	13-23	TNF superfamily member 11	Homo sapiens	60-65
30699493-7	2017	We present a case of a metastatic breast cancer patient who spontaneously developed ONJ following the use of Denosumab, a monoclonal RANKL antibody.	ONJ	84-87	TNF superfamily member 11	Homo sapiens	133-138
27779672-9	2016	It was found that the reduced expression of MIC-1 in the RPMI-8226 cells inhibited the osteoclastic differentiation of PBMNCs and decreased the expression levels of RANKL and phosphorylated Erk1/2.	rpmi	57-61	TNF superfamily member 11	Homo sapiens	165-170
28367895-0	2017	Effect of bisphosphonate as an adjunct treatment for chronic periodontitis on gingival crevicuar fluid levels of nuclear factor-kappaB ligand (RANKL) and osteoprotegerin in postmenopausal osteoporosis.	Diphosphonates	10-24	TNF superfamily member 11	Homo sapiens	143-148
28070039-0	2016	[Effects of laser solid forming of porous titanium on proliferation of osteoblast and RANKL/OPG expression].	Titanium	42-50	TNF superfamily member 11	Homo sapiens	86-91
27929439-7	2016	Apoptotic osteocytes release ATP, which induces the receptor activator of nuclear factor kappa-B ligand (Rankl) expression and osteoclastogenesis, from pannexin 1 channels.	Adenosine Triphosphate	29-32	TNF superfamily member 11	Homo sapiens	52-103
27929439-7	2016	Apoptotic osteocytes release ATP, which induces the receptor activator of nuclear factor kappa-B ligand (Rankl) expression and osteoclastogenesis, from pannexin 1 channels.	Adenosine Triphosphate	29-32	TNF superfamily member 11	Homo sapiens	105-110
27779672-0	2016	Knockdown of macrophage inhibitory cytokine-1 in RPMI-8226 human multiple myeloma cells inhibits osteoclastic differentiation through inhibiting the RANKL-Erk1/2 signaling pathway.	rpmi-8226	49-58	TNF superfamily member 11	Homo sapiens	149-154
27995121-10	2016	The expressions of OPG, RANKL, and M-CSF have decreased via the alendronate.	Alendronate	64-75	TNF superfamily member 11	Homo sapiens	24-29
27881164-8	2016	Sixty mg anti-RANKL antibody, which was subcutaneously injected to treat the osteoporosis every six months after replacement of 5 mg hydrocortisone and 30 mug oral desmopressin, rapidly decreased the levels of her liver enzymes (ALT and gammaGTP were 133 to 72 U/L and 284 to 99 U/L at 16 months after the beginning of the treatment, respectively).	Hydrocortisone	133-147	TNF superfamily member 11	Homo sapiens	14-19
27339288-0	2016	Acute effects of dietary fatty acids on osteclastogenesis via RANKL/RANK/OPG system.	dietary fatty acids	17-36	TNF superfamily member 11	Homo sapiens	62-67
27697839-4	2016	Presumably, HS could regulate the function of OPG and affect how it inhibits RANKL.	Heparitin Sulfate	12-14	TNF superfamily member 11	Homo sapiens	77-82
27697839-11	2016	Using a HS binding-deficient OPG mutant, we further show that in an osteoblast/bone marrow macrophage co-culture system, immobilization of OPG by HS at the osteoblast cell surface substantially lowers the inhibitory threshold of OPG toward RANKL.	Heparitin Sulfate	146-148	TNF superfamily member 11	Homo sapiens	240-245
27697839-12	2016	These discoveries strongly suggest that HS plays an active role in regulating OPG-RANKL interaction and osteoclastogenesis.	Heparitin Sulfate	40-42	TNF superfamily member 11	Homo sapiens	82-87
27576059-3	2016	In our study, we studied the effects of daidzein, raloxifene and E2 on expression of the osteoblast-produced bone regulatory factors OPG, RANKL and IL-6 in human osteoblastic MG-63 cells.	daidzein	40-48	TNF superfamily member 11	Homo sapiens	138-143
27576059-4	2016	Results suggest that treatment with daidzein, raloxifene and E2 increased the levels of OPG and decreased those of RANKL and IL-6.	daidzein	36-44	TNF superfamily member 11	Homo sapiens	115-120
27576059-4	2016	Results suggest that treatment with daidzein, raloxifene and E2 increased the levels of OPG and decreased those of RANKL and IL-6.	Raloxifene Hydrochloride	46-56	TNF superfamily member 11	Homo sapiens	115-120
27745802-3	2016	Consistently, in vitro experiments with TNF-alpha-stimulated primary F508del-CFTR osteoblasts demonstrated that correction of p.Phe508del-CFTR markedly decreased RANKL protein production, a major factor of bone resorption.	f508del	69-76	TNF superfamily member 11	Homo sapiens	162-167
27736957-10	2016	Moreover, TAS-115 inhibited Feline McDonough Sarcoma oncogene (FMS) kinase, as well as M-CSF and receptor activator of NF-kappaB ligand (RANKL)-induced osteoclast differentiation.	4-(2-fluoro-4-((((2-phenylacetyl)amino)thioxomethyl)amino)phenoxy)-7-methoxy-N-methyl-6-quinolinecarboxamide	10-17	TNF superfamily member 11	Homo sapiens	137-142
27894399-0	2016	Effect of iguratimod and methotrexate on RANKL and OPG expression in serum and IL-1beta-induced fibroblast-like synoviocytes from patients with rheumatoid arthritis.	Methotrexate	25-37	TNF superfamily member 11	Homo sapiens	41-46
27894399-3	2016	The objective of this study is to explore the effects of iguratimod, a small-molecule disease-modifying antirheumatic drug (DMARD), alone or in combination with methotrexate (MTX), on RANKL and OPG expression in RA.	Methotrexate	175-178	TNF superfamily member 11	Homo sapiens	184-189
27894399-8	2016	Our results suggest that iguratimod and MTX, especially in combination, efficaciously protected against bone erosion by suppressing the production of RANKL.	Methotrexate	40-43	TNF superfamily member 11	Homo sapiens	150-155
27515196-5	2016	Increased levels of ROS induce expression of receptor activator of nuclear factor kappa B (NF-kappaB) ligand (RANKL).	Reactive Oxygen Species	20-23	TNF superfamily member 11	Homo sapiens	110-115
30641006-0	2016	[Efficacy of Hebi Formula Combined Methotrexate on Early Rheumatoid Arthritis Patients with Dis- harmony of Gan and Pi Syndrome and Its Effects on Serum MMP-3 and RANK/RANKL/OPG Expressions].	Methotrexate	35-47	TNF superfamily member 11	Homo sapiens	168-173
30641006-24	2016	Conclusion HF com- bined MTX could improve symptoms of early RA patients with DGPS, and regulate bone destruction in- duced by RANK/RANKL/OPG systems.	Methotrexate	25-28	TNF superfamily member 11	Homo sapiens	132-137
30641012-14	2016	Curcumol down-regulated the expression of osteogenic differentiation related gene RANKL, and up-regulated the expression of OPG.	curcumol	0-8	TNF superfamily member 11	Homo sapiens	82-87
30641012-16	2016	Curcumol up-regulated the expression of OPG as well as down-regulated the expression of RANKL.	curcumol	0-8	TNF superfamily member 11	Homo sapiens	88-93
28228794-1	2016	BACKGROUND: We report on the clinical and biochemical outcomes in a 20-year-old male suffering from active craniofacial monostotic fibrous dysplasia (MFD) of the left mandible treated with the RANK-L inhibitor, denosumab, following unsatisfactory responses to prior long-term bisphosphonates therapy.	Diphosphonates	276-291	TNF superfamily member 11	Homo sapiens	193-199
26202855-0	2016	Methotrexate inhibits osteoclastogenesis by decreasing RANKL-induced calcium influx into osteoclast progenitors.	Methotrexate	0-12	TNF superfamily member 11	Homo sapiens	55-60
26202855-0	2016	Methotrexate inhibits osteoclastogenesis by decreasing RANKL-induced calcium influx into osteoclast progenitors.	Calcium	69-76	TNF superfamily member 11	Homo sapiens	55-60
26202855-6	2016	Here, we report that osteoclast formation and expression of osteoclastic genes such as NFATc1 and DC-STAMP, which are induced by the cytokine RANKL, are significantly inhibited by MTX.	Methotrexate	180-183	TNF superfamily member 11	Homo sapiens	142-147
26202855-7	2016	We found that RANKL-dependent calcium (Ca) influx into osteoclast progenitors was significantly inhibited by MTX.	Calcium	30-37	TNF superfamily member 11	Homo sapiens	14-19
26202855-7	2016	We found that RANKL-dependent calcium (Ca) influx into osteoclast progenitors was significantly inhibited by MTX.	Methotrexate	109-112	TNF superfamily member 11	Homo sapiens	14-19
27154288-8	2016	In contrast, the expression ratio of RANKL/OPG was reduced at 1h and significantly increased at 12h.	Hydrogen	62-64	TNF superfamily member 11	Homo sapiens	37-42
27154288-10	2016	Importantly, the canonical Wnt pathway inhibitor DKK1 blocked the osteogenesis effect and rescued the ratio of RANKL/OPG in PDLSCs under force treatment for 1h.	Hydrogen	157-159	TNF superfamily member 11	Homo sapiens	111-116
26754483-0	2016	Eriodictyol Inhibits RANKL-Induced Osteoclast Formation and Function Via Inhibition of NFATc1 Activity.	eriodictyol	0-11	TNF superfamily member 11	Homo sapiens	21-26
26754483-4	2016	This flavanone potently suppressed RANKL-induced osteoclastogenesis and bone resorption in a dose-dependent manner without detectable cytotoxicity, suppressing RANKL-induced NF-kappaB, MAPK, and Ca(2+) signaling pathways.	flavanone	5-14	TNF superfamily member 11	Homo sapiens	35-40
26754483-4	2016	This flavanone potently suppressed RANKL-induced osteoclastogenesis and bone resorption in a dose-dependent manner without detectable cytotoxicity, suppressing RANKL-induced NF-kappaB, MAPK, and Ca(2+) signaling pathways.	flavanone	5-14	TNF superfamily member 11	Homo sapiens	160-165
27279422-7	2016	We observed two pathways for receptor activator of NF-kappaB ligand (RANKL) induction by keratocystic odontogenic tumor fluid: the cyclooxygenase-2 (COX-2)/prostaglandin E2 (PGE2) pathway through interleukin-1alpha (IL-1alpha) signaling and non-COX-2/PGE2 pathway through TGF-beta receptor signaling.	Dinoprostone	174-178	TNF superfamily member 11	Homo sapiens	29-67
27582133-7	2016	Moreover, high levels of glucose induced a major decrease in the RANKL/OPG ratio when comparing the OP and the T2DM groups to the OA group.	Glucose	25-32	TNF superfamily member 11	Homo sapiens	65-70
27061090-7	2016	Results also demonstrated that the ratio of osteoprotegerin (Opg)/receptor activator of nuclear factor kappa B ligand (Rankl) expression was up-regulated following treatment with icariin.	icariin	179-186	TNF superfamily member 11	Homo sapiens	66-117
27061090-7	2016	Results also demonstrated that the ratio of osteoprotegerin (Opg)/receptor activator of nuclear factor kappa B ligand (Rankl) expression was up-regulated following treatment with icariin.	icariin	179-186	TNF superfamily member 11	Homo sapiens	119-124
27279422-7	2016	We observed two pathways for receptor activator of NF-kappaB ligand (RANKL) induction by keratocystic odontogenic tumor fluid: the cyclooxygenase-2 (COX-2)/prostaglandin E2 (PGE2) pathway through interleukin-1alpha (IL-1alpha) signaling and non-COX-2/PGE2 pathway through TGF-beta receptor signaling.	Dinoprostone	156-172	TNF superfamily member 11	Homo sapiens	29-67
27279422-7	2016	We observed two pathways for receptor activator of NF-kappaB ligand (RANKL) induction by keratocystic odontogenic tumor fluid: the cyclooxygenase-2 (COX-2)/prostaglandin E2 (PGE2) pathway through interleukin-1alpha (IL-1alpha) signaling and non-COX-2/PGE2 pathway through TGF-beta receptor signaling.	Dinoprostone	156-172	TNF superfamily member 11	Homo sapiens	69-74
27526327-0	2016	Ceylonamides A-F, Nitrogenous Spongian Diterpenes That Inhibit RANKL-Induced Osteoclastogenesis, from the Marine Sponge Spongia ceylonensis.	ceylonamides a-f	0-16	TNF superfamily member 11	Homo sapiens	63-68
27526327-0	2016	Ceylonamides A-F, Nitrogenous Spongian Diterpenes That Inhibit RANKL-Induced Osteoclastogenesis, from the Marine Sponge Spongia ceylonensis.	Diterpenes	39-49	TNF superfamily member 11	Homo sapiens	63-68
26573914-2	2016	Receptor activator for NF-kappaB ligand (RANKL or TNFSF11), a tumor necrosis factor (TNF) superfamily member, is the master cytokine required for osteoclastogenesis with essential co-stimulatory signals mediated by immunoreceptor tyrosine-based activation motif (ITAM)-signaling adaptors, DNAX-associated protein 12 kDa size (DAP12) and FcepsilonRI gamma chain (FcRgamma).	Tyrosine	230-238	TNF superfamily member 11	Homo sapiens	41-46
26573914-2	2016	Receptor activator for NF-kappaB ligand (RANKL or TNFSF11), a tumor necrosis factor (TNF) superfamily member, is the master cytokine required for osteoclastogenesis with essential co-stimulatory signals mediated by immunoreceptor tyrosine-based activation motif (ITAM)-signaling adaptors, DNAX-associated protein 12 kDa size (DAP12) and FcepsilonRI gamma chain (FcRgamma).	Tyrosine	230-238	TNF superfamily member 11	Homo sapiens	50-57
27279422-7	2016	We observed two pathways for receptor activator of NF-kappaB ligand (RANKL) induction by keratocystic odontogenic tumor fluid: the cyclooxygenase-2 (COX-2)/prostaglandin E2 (PGE2) pathway through interleukin-1alpha (IL-1alpha) signaling and non-COX-2/PGE2 pathway through TGF-beta receptor signaling.	Dinoprostone	174-178	TNF superfamily member 11	Homo sapiens	69-74
27279422-7	2016	We observed two pathways for receptor activator of NF-kappaB ligand (RANKL) induction by keratocystic odontogenic tumor fluid: the cyclooxygenase-2 (COX-2)/prostaglandin E2 (PGE2) pathway through interleukin-1alpha (IL-1alpha) signaling and non-COX-2/PGE2 pathway through TGF-beta receptor signaling.	Dinoprostone	251-255	TNF superfamily member 11	Homo sapiens	29-67
27279422-7	2016	We observed two pathways for receptor activator of NF-kappaB ligand (RANKL) induction by keratocystic odontogenic tumor fluid: the cyclooxygenase-2 (COX-2)/prostaglandin E2 (PGE2) pathway through interleukin-1alpha (IL-1alpha) signaling and non-COX-2/PGE2 pathway through TGF-beta receptor signaling.	Dinoprostone	251-255	TNF superfamily member 11	Homo sapiens	69-74
27447722-0	2016	Methylsulfonylmethane Inhibits RANKL-Induced Osteoclastogenesis in BMMs by Suppressing NF-kappaB and STAT3 Activities.	dimethyl sulfone	0-21	TNF superfamily member 11	Homo sapiens	31-36
26795736-3	2016	The target molecules of ROS in RANKL signaling remain unclear; however, several reports support the theory that NF-kappaB signaling could be the crucial downstream signaling molecule of RANKL-mediated ROS signaling.	Reactive Oxygen Species	24-27	TNF superfamily member 11	Homo sapiens	31-36
26795736-3	2016	The target molecules of ROS in RANKL signaling remain unclear; however, several reports support the theory that NF-kappaB signaling could be the crucial downstream signaling molecule of RANKL-mediated ROS signaling.	Reactive Oxygen Species	24-27	TNF superfamily member 11	Homo sapiens	186-191
26795736-3	2016	The target molecules of ROS in RANKL signaling remain unclear; however, several reports support the theory that NF-kappaB signaling could be the crucial downstream signaling molecule of RANKL-mediated ROS signaling.	Reactive Oxygen Species	201-204	TNF superfamily member 11	Homo sapiens	31-36
26795736-3	2016	The target molecules of ROS in RANKL signaling remain unclear; however, several reports support the theory that NF-kappaB signaling could be the crucial downstream signaling molecule of RANKL-mediated ROS signaling.	Reactive Oxygen Species	201-204	TNF superfamily member 11	Homo sapiens	186-191
27459539-0	2016	MicroRNA-145 Mediates Steroid-Induced Necrosis of the Femoral Head by Targeting the OPG/RANK/RANKL Signaling Pathway.	Steroids	22-29	TNF superfamily member 11	Homo sapiens	93-98
27356092-1	2016	A new inhibitor, acredinone C (1), of receptor activator of nuclear factor-kappaB ligand (RANKL)-induced osteoclast differentiation was isolated from the culture broth of the fungus Acremonium sp.	acredinone C	17-29	TNF superfamily member 11	Homo sapiens	38-88
27356092-1	2016	A new inhibitor, acredinone C (1), of receptor activator of nuclear factor-kappaB ligand (RANKL)-induced osteoclast differentiation was isolated from the culture broth of the fungus Acremonium sp.	acredinone C	17-29	TNF superfamily member 11	Homo sapiens	90-95
27356092-3	2016	The structure of acredinone C (1), which incorporates benzophenone and xanthone moieties, was established by the analyses of combined spectroscopic data including 1D and 2D NMR and MS. All of the acredinones studied efficiently inhibited the RANKL-induced formation of TRAP(+)-MNCs in a dose-dependent manner without any cytotoxicity up to 10 muM.	acredinone c (1)	17-33	TNF superfamily member 11	Homo sapiens	242-247
26432443-9	2016	CONCLUSION: GECs producing RANKL are able to support osteoclastogenesis in an in vitro co-culture system using GECs and BMMs, in a process promoted by forskolin.	Colforsin	151-160	TNF superfamily member 11	Homo sapiens	27-32
27322743-4	2016	Coupled with the findings that tumor necrosis factor superfamily member 11 (TNFSF11; also known as RANKL) is a key paracrine effector of progesterone signaling and that RANKL and its receptor TNFRSF11A (also known as RANK) contribute to mammary tumorigenesis, we investigated a role for this pathway in the pre-neoplastic phase of BRCA1-mutation carriers.	Progesterone	137-149	TNF superfamily member 11	Homo sapiens	31-74
27322743-4	2016	Coupled with the findings that tumor necrosis factor superfamily member 11 (TNFSF11; also known as RANKL) is a key paracrine effector of progesterone signaling and that RANKL and its receptor TNFRSF11A (also known as RANK) contribute to mammary tumorigenesis, we investigated a role for this pathway in the pre-neoplastic phase of BRCA1-mutation carriers.	Progesterone	137-149	TNF superfamily member 11	Homo sapiens	76-83
27322743-4	2016	Coupled with the findings that tumor necrosis factor superfamily member 11 (TNFSF11; also known as RANKL) is a key paracrine effector of progesterone signaling and that RANKL and its receptor TNFRSF11A (also known as RANK) contribute to mammary tumorigenesis, we investigated a role for this pathway in the pre-neoplastic phase of BRCA1-mutation carriers.	Progesterone	137-149	TNF superfamily member 11	Homo sapiens	99-104
27322743-7	2016	Inhibition of RANKL signaling by treatment with denosumab in three-dimensional breast organoids derived from pre-neoplastic BRCA1(mut/+) tissue attenuated progesterone-induced proliferation.	Progesterone	155-167	TNF superfamily member 11	Homo sapiens	14-19
27089213-0	2016	Design, synthesis and SARs of novel salicylanilides as potent inhibitors of RANKL-induced osteoclastogenesis and bone resorption.	Salicylanilides	36-51	TNF superfamily member 11	Homo sapiens	76-81
27411457-10	2016	In contrast, serum RANKL inversely associated with LS and FN T-score (r = -0.62, P &lt; 0.001 and r = -0.48, P &lt; 0.001) but directly correlated with betaCL (r = 0.48, P &lt; 0.001).	betacl	152-158	TNF superfamily member 11	Homo sapiens	19-24
27089213-2	2016	Herein, we synthesized a series of modified salicylanilides and their corresponding 3-phenyl-2H-benzo[e][1,3]oxazine-2,4(3H)-dione and 10-phenyldibenzo[b,f][1,4]oxazepin-11(10H)-one derivatives, and investigated the effects of such compounds on RANKL-induced osteoclast formation.	Salicylanilides	44-59	TNF superfamily member 11	Homo sapiens	245-250
27089213-3	2016	Among them, a salicylanilide derivative (A04) and its 3-phenyl-2H-benzo[e][1,3]oxazine-2,4(3H)-dione derivative (B04) markedly suppressed RANKL-induced osteoclast differentiation and showed no significant cytotoxic effects at doses higher than that required to inhibit osteoclast formation.	salicylanilide	14-28	TNF superfamily member 11	Homo sapiens	138-143
27089213-3	2016	Among them, a salicylanilide derivative (A04) and its 3-phenyl-2H-benzo[e][1,3]oxazine-2,4(3H)-dione derivative (B04) markedly suppressed RANKL-induced osteoclast differentiation and showed no significant cytotoxic effects at doses higher than that required to inhibit osteoclast formation.	5-[2-(Trifluoromethoxy)phenyl]-2-Furoic Acid	41-44	TNF superfamily member 11	Homo sapiens	138-143
27089213-3	2016	Among them, a salicylanilide derivative (A04) and its 3-phenyl-2H-benzo[e][1,3]oxazine-2,4(3H)-dione derivative (B04) markedly suppressed RANKL-induced osteoclast differentiation and showed no significant cytotoxic effects at doses higher than that required to inhibit osteoclast formation.	3-phenyl-1,3-benzoxazine-2,4-dione	54-100	TNF superfamily member 11	Homo sapiens	138-143
27089213-3	2016	Among them, a salicylanilide derivative (A04) and its 3-phenyl-2H-benzo[e][1,3]oxazine-2,4(3H)-dione derivative (B04) markedly suppressed RANKL-induced osteoclast differentiation and showed no significant cytotoxic effects at doses higher than that required to inhibit osteoclast formation.	D-Phenylalanyl-N-[(1-Methylpyridinium-2-Yl)methyl]-L-Prolinamide	113-116	TNF superfamily member 11	Homo sapiens	138-143
27170515-5	2016	We investigated the effects of carvacrol on osteoclast formation induced by RANKL and LPS.	carvacrol	31-40	TNF superfamily member 11	Homo sapiens	76-81
27170515-6	2016	Carvacrol suppressed RANKL-induced formation of tartrate resistant acid phosphatase (TRAP)-positive multinucleated cells in RAW264.7 macrophages and human CD14(+) monocytes.	carvacrol	0-9	TNF superfamily member 11	Homo sapiens	21-26
27170515-8	2016	Investigation of the underlying molecular mechanisms revealed that carvacrol downregulated RANKL-induced NF-kappaB activation in a dose-dependent manner.	carvacrol	67-76	TNF superfamily member 11	Homo sapiens	91-96
27336899-0	2016	OPG and RANKL polymorphisms are associated with alcohol-induced osteonecrosis of the femoral head in the north area of China population in men.	Alcohols	48-55	TNF superfamily member 11	Homo sapiens	8-13
26856585-14	2016	CONCLUSIONS: Our study demonstrated the key role of DKK1, RANKL, and TNF-alpha in regulating bone cell activity of subjects with OI untreated and treated with bisphosphonates.	Diphosphonates	159-174	TNF superfamily member 11	Homo sapiens	58-63
27061293-3	2016	In our study, we wanted to examine whether changes in OPG and receptor activator of the nuclear factor-kappaB ligand (RANKL) levels during an 8-week abstinence period in alcohol-dependent patients treated in an alcohol rehabilitation clinic would occur and whether alcohol-related variables, smoking, status, or physical activity prior to the study served as an influence on BMD and on OPG/RANKL levels.	Alcohols	170-177	TNF superfamily member 11	Homo sapiens	118-123
27313530-11	2016	Moreover, molecular analysis demonstrated that rhEndostatin attenuated RANKL-induced NF-kappaB signaling by inhibiting the phosphorylation of IkappaBalpha and NF-kappaB p65 nuclear translocation.	rhendostatin	47-59	TNF superfamily member 11	Homo sapiens	71-76
27313530-12	2016	Furthermore, rhEndostatin significantly inhibited the activation of RANKL-dependent mitogen-activated protein kinases, such as ERK1/2, JNK, and p38.	rhendostatin	13-25	TNF superfamily member 11	Homo sapiens	68-73
26271967-10	2016	Finally, the UV-irradiated 7-DHC and VitE coating decreased the level of RANKL mRNA in HGFs.	7-dehydrocholesterol	27-32	TNF superfamily member 11	Homo sapiens	73-78
27336899-4	2016	The purpose of this article was to explore the association between OPG and RANKL gene variants and alcohol-induced ONFH.	Alcohols	99-106	TNF superfamily member 11	Homo sapiens	75-80
27336899-10	2016	We concluded that OPG and RANKL polymorphisms were associated with the occurrence of alcohol-induced ONFH.	Alcohols	85-92	TNF superfamily member 11	Homo sapiens	26-31
26962001-5	2016	Mechanistically, upon RANKL activation, HDAC2 activated Akt; Akt directly phosphorylates and abrogates Forkhead box protein O1 (FoxO1), which is a negative regulator during osteoclastogenesis through reducing reactive oxygen species.	Reactive Oxygen Species	209-232	TNF superfamily member 11	Homo sapiens	22-27
27664484-5	2016	Surprisingly, 17beta-estradiol (E2) treatment led to remarkably reduced RANKL compared with that in E2 untreated cells.	Estradiol	14-30	TNF superfamily member 11	Homo sapiens	72-77
27113904-0	2016	MiR-142-3p is a RANKL-dependent inducer of cell death in osteoclasts.	mir-142-3p	0-10	TNF superfamily member 11	Homo sapiens	16-21
26983669-10	2016	Sinomenine inhibited invasion by suppressing CXCR4 and STAT3 phosphorylation then downregulating the expression of MMP-2, MMP-9, RANKL, VEGF downstream.	sinomenine	0-10	TNF superfamily member 11	Homo sapiens	129-134
26923188-2	2016	Our previous work on the structure of the RANK-RANKL complex revealed that Loop3 of RANK, specifically the non-canonical disulfide bond at the tip, performs a crucial role in specific recognition of RANKL.	Disulfides	121-130	TNF superfamily member 11	Homo sapiens	47-52
26923188-2	2016	Our previous work on the structure of the RANK-RANKL complex revealed that Loop3 of RANK, specifically the non-canonical disulfide bond at the tip, performs a crucial role in specific recognition of RANKL.	Disulfides	121-130	TNF superfamily member 11	Homo sapiens	199-204
26923188-5	2016	The kinetic analysis and osteoclast differentiation assay showed that in addition to the sharp turn induced by the disulfide bond, two consecutive arginine residues were also important for binding to RANKL and inhibiting osteoclastogenesis.	Disulfides	115-124	TNF superfamily member 11	Homo sapiens	200-205
26923188-5	2016	The kinetic analysis and osteoclast differentiation assay showed that in addition to the sharp turn induced by the disulfide bond, two consecutive arginine residues were also important for binding to RANKL and inhibiting osteoclastogenesis.	Arginine	147-155	TNF superfamily member 11	Homo sapiens	200-205
26923188-6	2016	Docking and molecular dynamics simulations proposed the binding mode of the peptide to the RANKL trimer, showing that the arginine residues provide electrostatic interactions with RANKL and contribute to stabilizing the complex.	Arginine	122-130	TNF superfamily member 11	Homo sapiens	91-96
26923188-6	2016	Docking and molecular dynamics simulations proposed the binding mode of the peptide to the RANKL trimer, showing that the arginine residues provide electrostatic interactions with RANKL and contribute to stabilizing the complex.	Arginine	122-130	TNF superfamily member 11	Homo sapiens	180-185
27077737-2	2016	However, the functional role of lactate dehydrogenase (LDH), a tetrameric enzyme consisting of an A and/or B subunit that catalyzes interconversion of pyruvate to lactate, in RANKL-induced osteoclast differentiation is not known.	Pyruvic Acid	151-159	TNF superfamily member 11	Homo sapiens	175-180
26947453-8	2016	Interestingly, ISL inhibited the RANKL-stimulated NF-kappaB expression and nuclear translocation, whereas the NF-kappaB inhibitor Bay 11-7082 markedly suppressed the RANKL-induced autophagic activation.	3-(4-methylphenylsulfonyl)-2-propenenitrile	130-141	TNF superfamily member 11	Homo sapiens	166-171
27077737-2	2016	However, the functional role of lactate dehydrogenase (LDH), a tetrameric enzyme consisting of an A and/or B subunit that catalyzes interconversion of pyruvate to lactate, in RANKL-induced osteoclast differentiation is not known.	Lactic Acid	32-39	TNF superfamily member 11	Homo sapiens	175-180
27054952-0	2016	Hyaluronan Inhibits Tlr-4-Dependent RANKL Expression in Human Rheumatoid Arthritis Synovial Fibroblasts.	Hyaluronic Acid	0-10	TNF superfamily member 11	Homo sapiens	36-41
27068678-5	2016	In addition, 1alpha,25-(OH)2D3-stimulation elevated the expression of osteoclast-related genes, as well as RANKL mRNA levels and RANKL/OPG ratios in control hDFCs.	25-(oh)2d3	20-30	TNF superfamily member 11	Homo sapiens	107-112
27068678-5	2016	In addition, 1alpha,25-(OH)2D3-stimulation elevated the expression of osteoclast-related genes, as well as RANKL mRNA levels and RANKL/OPG ratios in control hDFCs.	25-(oh)2d3	20-30	TNF superfamily member 11	Homo sapiens	129-134
27068678-6	2016	Conversely, RUNX2 mutation abolished this 1alpha,25-(OH)2D3-induced RANKL gene activation and osteoclast formation in CCD hDFCs.	25-(oh)2d3	49-59	TNF superfamily member 11	Homo sapiens	68-73
27068678-8	2016	Furthermore, this abnormality was not rescued by 1alpha,25-(OH)2D3 application because 1alpha,25-(OH)2D3-induced RANKL activation in hDFCs is mediated principally via the RUNX2-dependent pathway.	25-(oh)2d3	94-104	TNF superfamily member 11	Homo sapiens	113-118
26851123-1	2016	Bone marrow macrophages (BMMs), in the presence of cyclooxygenase-2 (Cox2) produced PGE2, secrete an inhibitory factor in response to Rankl that blocks PTH-stimulated osteoblastic differentiation.	Dinoprostone	84-88	TNF superfamily member 11	Homo sapiens	134-139
25545964-0	2016	Dual Effect of Cyanidin on RANKL-Induced Differentiation and Fusion of Osteoclasts.	cyanidin	15-23	TNF superfamily member 11	Homo sapiens	27-32
26280807-4	2016	Activation of GPR120 by its ligand GW9508 suppressed receptor activator of NF- kappaB ligand (RANKL)-induced osteoclast differentiation and the expression of nuclear factor of activated T cells c1 (NFATc1), a key modulator of osteoclastogenesis.	GW9508	35-41	TNF superfamily member 11	Homo sapiens	94-99
26615413-10	2016	The data demonstrate transcriptional regulation of the components of cellular iron transporters during OC development and suggests that iron homeostasis may contribute to fine-tuning of the RANKL-induced OC development.	Iron	78-82	TNF superfamily member 11	Homo sapiens	190-195
26921922-5	2016	The regulatory function of RANKL is one of the key factors in progesterone-induced proliferation of the breast.	Progesterone	62-74	TNF superfamily member 11	Homo sapiens	27-32
25545964-5	2016	We investigated the effect of cyanidin on RANKL-induced osteoclasts differentiation and cell fusion.	cyanidin	30-38	TNF superfamily member 11	Homo sapiens	42-47
25545964-6	2016	The results showed that cyanidin had a dual effect on RANKL-induced osteoclastogenesis.	cyanidin	24-32	TNF superfamily member 11	Homo sapiens	54-59
26734994-8	2016	Furthermore, the combination of medroxyprogesterone acetate (MPA) and RANKL could in turn attenuate the effect of RANKL alone.	Medroxyprogesterone Acetate	32-59	TNF superfamily member 11	Homo sapiens	114-119
26792726-0	2016	Niclosamide suppresses RANKL-induced osteoclastogenesis and prevents LPS-induced bone loss.	Niclosamide	0-11	TNF superfamily member 11	Homo sapiens	23-28
26792726-5	2016	Our in vitro study showed that receptor activator of nuclear factor-kappaB ligand (RANKL)-induced osteoclast differentiation was inhibited by niclosamide, due to inhibition of serine-threonine protein kinase (Akt) phosphorylation, inhibitor of nuclear factor-kappaB (IkappaB), and STAT3 serine(727).	Niclosamide	142-153	TNF superfamily member 11	Homo sapiens	31-81
26792726-5	2016	Our in vitro study showed that receptor activator of nuclear factor-kappaB ligand (RANKL)-induced osteoclast differentiation was inhibited by niclosamide, due to inhibition of serine-threonine protein kinase (Akt) phosphorylation, inhibitor of nuclear factor-kappaB (IkappaB), and STAT3 serine(727).	Niclosamide	142-153	TNF superfamily member 11	Homo sapiens	83-88
26792726-5	2016	Our in vitro study showed that receptor activator of nuclear factor-kappaB ligand (RANKL)-induced osteoclast differentiation was inhibited by niclosamide, due to inhibition of serine-threonine protein kinase (Akt) phosphorylation, inhibitor of nuclear factor-kappaB (IkappaB), and STAT3 serine(727).	Serine	176-182	TNF superfamily member 11	Homo sapiens	31-81
26792726-5	2016	Our in vitro study showed that receptor activator of nuclear factor-kappaB ligand (RANKL)-induced osteoclast differentiation was inhibited by niclosamide, due to inhibition of serine-threonine protein kinase (Akt) phosphorylation, inhibitor of nuclear factor-kappaB (IkappaB), and STAT3 serine(727).	Serine	176-182	TNF superfamily member 11	Homo sapiens	83-88
26498169-1	2016	The tumor necrosis factor-related cytokine receptor activator of nuclear factor kappa B ligand (RANKL) has been proposed as predictor of incident type 2 diabetes mellitus, and experimental blockade of RANKL resulted in a marked improvement of glucose tolerance.	Glucose	243-250	TNF superfamily member 11	Homo sapiens	96-101
26498169-1	2016	The tumor necrosis factor-related cytokine receptor activator of nuclear factor kappa B ligand (RANKL) has been proposed as predictor of incident type 2 diabetes mellitus, and experimental blockade of RANKL resulted in a marked improvement of glucose tolerance.	Glucose	243-250	TNF superfamily member 11	Homo sapiens	201-206
26506085-0	2016	Atorvastatin Reduces Circulating Osteoprogenitor Cells and T-Cell RANKL Expression in Osteoporotic Women: Implications for the Bone-Vascular Axis.	Atorvastatin	0-12	TNF superfamily member 11	Homo sapiens	66-71
26506085-12	2016	In vitro studies showed that Atorvastatin reduced RANKL expression in activated human T-lymphoblastoid cells (Jurkat cell line).	Atorvastatin	29-41	TNF superfamily member 11	Homo sapiens	50-55
26506085-13	2016	CONCLUSIONS: Three-month Atorvastatin treatment leads to a reduction in circulating osteoprogenitor cells and RANKL expression in T cells, as well as increase in OPG serum levels.	Atorvastatin	25-37	TNF superfamily member 11	Homo sapiens	110-115
27266195-0	2016	[Effect of MT01/PEN complexes on the expression of osteoprotegerin and receptor activator of nuclear factor kappaB ligand in human osteoblast-like cell line MG63].	tempol	11-15	TNF superfamily member 11	Homo sapiens	71-121
27266195-0	2016	[Effect of MT01/PEN complexes on the expression of osteoprotegerin and receptor activator of nuclear factor kappaB ligand in human osteoblast-like cell line MG63].	Polyethyleneimine	16-19	TNF superfamily member 11	Homo sapiens	71-121
27266195-1	2016	OBJECTIVE: This study aims to synthesize MTO1 (a kind of oligodeoxynucleotides) and N-isopropylacrylamide-modified polyethylenimines (PEN) complexes (MT01/PEN) as well as to investigate the effect of the complexes on the expression of osteoprotegerin (OPG) and the receptor activator of nuclear factor kappaB ligand (RANKL) in the human osteoblast-like cell line MG63.	N-isopropylacrylamide	84-105	TNF superfamily member 11	Homo sapiens	265-315
26740180-3	2016	In this study, we investigated the effect of salicortin on RANKL-induced osteoclasts formation, bone resorption, and activation of osteoclast-related signaling pathways.	salicortin	45-55	TNF superfamily member 11	Homo sapiens	59-64
27266195-1	2016	OBJECTIVE: This study aims to synthesize MTO1 (a kind of oligodeoxynucleotides) and N-isopropylacrylamide-modified polyethylenimines (PEN) complexes (MT01/PEN) as well as to investigate the effect of the complexes on the expression of osteoprotegerin (OPG) and the receptor activator of nuclear factor kappaB ligand (RANKL) in the human osteoblast-like cell line MG63.	N-isopropylacrylamide	84-105	TNF superfamily member 11	Homo sapiens	317-322
27266195-1	2016	OBJECTIVE: This study aims to synthesize MTO1 (a kind of oligodeoxynucleotides) and N-isopropylacrylamide-modified polyethylenimines (PEN) complexes (MT01/PEN) as well as to investigate the effect of the complexes on the expression of osteoprotegerin (OPG) and the receptor activator of nuclear factor kappaB ligand (RANKL) in the human osteoblast-like cell line MG63.	Polyethyleneimine	115-132	TNF superfamily member 11	Homo sapiens	265-315
27266195-1	2016	OBJECTIVE: This study aims to synthesize MTO1 (a kind of oligodeoxynucleotides) and N-isopropylacrylamide-modified polyethylenimines (PEN) complexes (MT01/PEN) as well as to investigate the effect of the complexes on the expression of osteoprotegerin (OPG) and the receptor activator of nuclear factor kappaB ligand (RANKL) in the human osteoblast-like cell line MG63.	Polyethyleneimine	115-132	TNF superfamily member 11	Homo sapiens	317-322
26573960-10	2016	Free serotonin led to an increase in the expression of RUNX2 in breast cancer cells (MDA-MB-231), which directly inhibited osteoblast differentiation and stimulated osteoclast differentiation by the PTHrP/RANKL pathway, which caused bone destruction and formed osteolytic bone lesions.	Serotonin	5-14	TNF superfamily member 11	Homo sapiens	205-210
26740180-4	2016	Salicortin suppressed RANKL-induced osteoclastogenesis in bone marrow macrophage cultures in a dose-dependent manner, and inhibited osteoclastic bone resorption activity without any cytotoxicity.	salicortin	0-10	TNF superfamily member 11	Homo sapiens	22-27
26740180-5	2016	Salicortin inhibited RANKL-induced c-Jun N-terminal kinase and NF-kappaB activation, concomitant with retarded IkappaBalpha phosphorylation and inhibition of p65 nuclear translocation, leading to impaired transcription of nuclear factor of activated T cells c1 (NFATc1) and expression of osteoclastic-specific genes.	salicortin	0-10	TNF superfamily member 11	Homo sapiens	21-26
26884284-1	2016	INTRODUCTION: The aim of this study was to evaluate quantitative changes in OPG and RANKL proteins after treatment with strontium ranelate (SR) and ibandronate in patients with postmenopausal osteoporosis.	strontium ranelate	120-138	TNF superfamily member 11	Homo sapiens	84-89
27074164-0	2016	Effects of IL-10 and glucose on expression of OPG and RANKL in human periodontal ligament fibroblasts.	Glucose	21-28	TNF superfamily member 11	Homo sapiens	54-59
27074164-5	2016	Glucose stimulation had the opposite concentration-dependent effect to that of IL-10 on OPG and RANKL expression.	Glucose	0-7	TNF superfamily member 11	Homo sapiens	96-101
27074164-6	2016	IL-10 upregulated OPG expression and downregulated RANKL expression, whereas high glucose upregulated RANKL and downregulated OPG in HDPLFs.	Glucose	82-89	TNF superfamily member 11	Homo sapiens	102-107
26789270-7	2016	Tbeta4 activation with a Tbeta4 peptide attenuated the H2O2-induced production of NO and PGE2 and up-regulated iNOS, COX-2, and osteoclastogenic cytokines (TNF-alpha, IL-1beta, IL-6, IL-8, and IL-17) as well as reversed the effect on RANKL and OPG in PDLCs.	Hydrogen Peroxide	55-59	TNF superfamily member 11	Homo sapiens	234-239
26884284-1	2016	INTRODUCTION: The aim of this study was to evaluate quantitative changes in OPG and RANKL proteins after treatment with strontium ranelate (SR) and ibandronate in patients with postmenopausal osteoporosis.	strontium ranelate	140-142	TNF superfamily member 11	Homo sapiens	84-89
26884284-1	2016	INTRODUCTION: The aim of this study was to evaluate quantitative changes in OPG and RANKL proteins after treatment with strontium ranelate (SR) and ibandronate in patients with postmenopausal osteoporosis.	Ibandronic Acid	148-159	TNF superfamily member 11	Homo sapiens	84-89
26635910-0	2016	Higher Urinary Levels of 8-Hydroxy-2"-deoxyguanosine Are Associated with a Worse RANKL/OPG Ratio in Postmenopausal Women with Osteopenia.	8-ohdg	25-52	TNF superfamily member 11	Homo sapiens	81-86
26982319-2	2016	The aim of this study was to examine the effects of prematurity on OPG and RANKL concentrations at birth and to investigate in particular whether antenatal corticosteroid (ACS) exposure affects serum OPG and RANKL levels in premature neonates.	Aminocaproic Acid	172-175	TNF superfamily member 11	Homo sapiens	208-213
25813008-8	2016	Of the multiple genes tested, statistically significant associations were observed for M-CSF1 (p = 0.028), RANKL (p = 0.035), RUNX1 (p = 0.032), and RUNX2 (p = 0.047) that were increased in "Type II MC," while OSCAR (p = 0.042) was increased in "Type I MC" group compared to "No MC."	Methylcholanthrene	199-201	TNF superfamily member 11	Homo sapiens	107-112
26376946-7	2016	RESULTS: Endothelin-1 stimulated the production of MMP1, MMP8, and RANKL in a dose- and time-dependent manner; blocking EDNRA function with the antagonist TBC3214 inhibited the response, although EDNRA activation had no effects on osteoprotegerin production.	TBC 3214	155-162	TNF superfamily member 11	Homo sapiens	67-72
26635910-4	2016	In the attempt to address this issue, we sought to determine if OxS, as assessed by 8-hydroxy-2-deoxyguanosine (8-OHdG), may influence the level of receptor activator of nuclear factor-kappab ligand (RANKL)/osteoprotegerin (OPG) ratio (a central regulator of bone metabolism) in a sample (n = 124), including postmenopausal women with osteoporosis, osteopenia and normal bone mass density (BMD).	8-ohdg	84-110	TNF superfamily member 11	Homo sapiens	148-198
26635910-4	2016	In the attempt to address this issue, we sought to determine if OxS, as assessed by 8-hydroxy-2-deoxyguanosine (8-OHdG), may influence the level of receptor activator of nuclear factor-kappab ligand (RANKL)/osteoprotegerin (OPG) ratio (a central regulator of bone metabolism) in a sample (n = 124), including postmenopausal women with osteoporosis, osteopenia and normal bone mass density (BMD).	8-ohdg	84-110	TNF superfamily member 11	Homo sapiens	200-205
26635910-4	2016	In the attempt to address this issue, we sought to determine if OxS, as assessed by 8-hydroxy-2-deoxyguanosine (8-OHdG), may influence the level of receptor activator of nuclear factor-kappab ligand (RANKL)/osteoprotegerin (OPG) ratio (a central regulator of bone metabolism) in a sample (n = 124), including postmenopausal women with osteoporosis, osteopenia and normal bone mass density (BMD).	8-ohdg	112-118	TNF superfamily member 11	Homo sapiens	148-198
26798359-10	2016	Further, an indirect effect of Si on osteoclastogenesis may also occur, through a downregulation of M-CSF and RANKL expression by osteoblasts.	Silicon	31-33	TNF superfamily member 11	Homo sapiens	110-115
26426211-1	2016	OBJECTIVE: The aim of the study was to explore the association between OPG, RANKL, and RANK gene variations and the bone mineral density (BMD) response to alendronate therapy in postmenopausal Chinese women with osteoporosis or osteopenia.	Alendronate	155-166	TNF superfamily member 11	Homo sapiens	76-81
26556352-0	2015	Natural Germacrane Sesquiterpenes Inhibit Osteoclast Formation, Bone Resorption, RANKL-Induced NF-kappaB Activation, and IkappaBalpha Degradation.	Sesquiterpenes, Germacrane	8-18	TNF superfamily member 11	Homo sapiens	81-86
27095621-0	2015	Effect of Bisphosphonates on the Levels of Rankl and Opg in Gingival Crevicular Fluid of Patients With Periodontal Disease and Post-menopausal Osteoporosis.	Diphosphonates	10-25	TNF superfamily member 11	Homo sapiens	43-48
27095621-1	2015	The Receptor activator of nuclear factor-kappa B ligand (RANKL)/RANK/Osteoprotegerine (OPG) system has been proposed as essential for osteoclast biology and identified as key part in regulating the physiology and pathology of the skeletal system.	osteoprotegerine	69-85	TNF superfamily member 11	Homo sapiens	4-55
27095621-1	2015	The Receptor activator of nuclear factor-kappa B ligand (RANKL)/RANK/Osteoprotegerine (OPG) system has been proposed as essential for osteoclast biology and identified as key part in regulating the physiology and pathology of the skeletal system.	osteoprotegerine	69-85	TNF superfamily member 11	Homo sapiens	57-62
27095621-1	2015	The Receptor activator of nuclear factor-kappa B ligand (RANKL)/RANK/Osteoprotegerine (OPG) system has been proposed as essential for osteoclast biology and identified as key part in regulating the physiology and pathology of the skeletal system.	SCHEMBL12347590	87-90	TNF superfamily member 11	Homo sapiens	4-55
27095621-1	2015	The Receptor activator of nuclear factor-kappa B ligand (RANKL)/RANK/Osteoprotegerine (OPG) system has been proposed as essential for osteoclast biology and identified as key part in regulating the physiology and pathology of the skeletal system.	SCHEMBL12347590	87-90	TNF superfamily member 11	Homo sapiens	57-62
27095621-7	2015	The aim of this study was to evaluate the levels of RANKL, OPG and their relationship in gingival crevicular fluid (GCF) in patients with periodontal disease and postmenopausal osteoporosis/ osteopenia in relation to consumption of bisphosphonates.	Diphosphonates	232-247	TNF superfamily member 11	Homo sapiens	52-57
25769316-0	2015	The 1,2,3-triazole derivative KP-A021 suppresses osteoclast differentiation and function by inhibiting RANKL-mediated MEK-ERK signaling pathway.	Triazoles	4-18	TNF superfamily member 11	Homo sapiens	103-108
25769316-3	2015	KP-A021 and its triazole derivatives, at a concentration that does not cause a cytotoxic response in bone marrow macrophages (BMMs), significantly inhibited osteoclast differentiation induced by receptor activator of nuclear factor-kappaB ligand (RANKL) and macrophage colony-stimulating factor (M-CSF) as assessed by tartrate-resistant acid phosphatase (TRAP) staining.	Triazoles	16-24	TNF superfamily member 11	Homo sapiens	195-245
25769316-6	2015	Analysis of the signaling pathway for KP-A021 indicated that this triazole compound inhibited the RANKL-induced activation of extracellular signal-regulated kinase (ERK) and its upstream signaling molecule, mitogen-activated protein kinase kinase1/2 (MEK1/2).	Triazoles	66-74	TNF superfamily member 11	Homo sapiens	98-103
26734591-0	2015	Isoliquiritigenin Inhibits Metastatic Breast Cancer Cell-induced Receptor Activator of Nuclear Factor Kappa-B Ligand/Osteoprotegerin Ratio in Human Osteoblastic Cells.	isoliquiritigenin	0-17	TNF superfamily member 11	Homo sapiens	65-116
26614482-7	2015	We demonstrated that microinjury to osteocyte networks being treated with bisphosphonates modulates receptor activator of nuclear factor kappa-B ligand and osteoprotegerin activity, and subsequently osteoclastogenesis.	Diphosphonates	74-89	TNF superfamily member 11	Homo sapiens	100-151
26580592-0	2015	Berberine Sulfate Attenuates Osteoclast Differentiation through RANKL Induced NF-kappaB and NFAT Pathways.	BERBERINE SULFATE	0-17	TNF superfamily member 11	Homo sapiens	64-69
26580592-7	2015	Luciferase reporter gene assay and Western blot analysis further revealed that berberine sulfate inhibits receptor for activation of nuclear factor ligand (RANKL)-induced NF-kappaB and NFAT activity.	BERBERINE SULFATE	79-96	TNF superfamily member 11	Homo sapiens	156-161
26690415-0	2015	Calycosin Suppresses RANKL-Mediated Osteoclastogenesis through Inhibition of MAPKs and NF-kappaB.	7,3'-dihydroxy-4'-methoxyisoflavone	0-9	TNF superfamily member 11	Homo sapiens	21-26
26690415-2	2015	In this study, we examined the effects of calycosin on osteoclastogenesis induced by RANKL.	7,3'-dihydroxy-4'-methoxyisoflavone	42-51	TNF superfamily member 11	Homo sapiens	85-90
26690415-3	2015	The results showed that calycosin significantly inhibited RANKL-induced osteoclast formation from primary bone marrow macrophages (BMMs).	7,3'-dihydroxy-4'-methoxyisoflavone	24-33	TNF superfamily member 11	Homo sapiens	58-63
26608858-3	2015	Recently, anti-RANKL monoclonal antibodies have been shown to inhibit bone erosion and bone loss in combination with methotrexate in RA.	Methotrexate	117-129	TNF superfamily member 11	Homo sapiens	15-20
26556352-0	2015	Natural Germacrane Sesquiterpenes Inhibit Osteoclast Formation, Bone Resorption, RANKL-Induced NF-kappaB Activation, and IkappaBalpha Degradation.	Sesquiterpenes	19-33	TNF superfamily member 11	Homo sapiens	81-86
26556352-5	2015	Mechanistic studies by Luciferase reporter gene assay and Western blot analysis showed that germacrane sesquiterpene compound A inhibits RANKL-induced activation of NF-kappaB and IkappaBalpha degradation.	Sesquiterpenes, Germacrane	92-116	TNF superfamily member 11	Homo sapiens	137-142
26446504-0	2015	Effect of compressive loading and incubation with clodronate on the RANKL/OPG system of human osteoblasts.	Clodronic Acid	50-60	TNF superfamily member 11	Homo sapiens	68-73
26133738-9	2015	In the parallel experiments, we demonstrated that TG2 inhibition reduced RANKL expression in both HPDL cells from CP patients and monocytes differentiated to macrophages by tetradecanoyl phorbol acetate treatment.	Tetradecanoylphorbol Acetate	173-202	TNF superfamily member 11	Homo sapiens	73-78
26627060-6	2015	Piperine inhibited tartrate-resistant acid phosphatase-positive multinucleated osteoclast formation in murine RAW264.7 macrophages and human CD14+ monocytes induced by RANKL and breast cancer cells.	piperine	0-8	TNF superfamily member 11	Homo sapiens	168-173
26264596-2	2015	Denosumab, a fully human antibody that targets the receptor activator of nuclear factor-kappaB (RANK) ligand (RANKL), is indicated for prevention of SREs in patients with solid tumors and has demonstrated superiority in breast and prostate cancer, and in other solid tumors, in reducing the risk of first SRE by 17% versus zoledronic acid.	Zoledronic Acid	323-338	TNF superfamily member 11	Homo sapiens	110-115
26420479-8	2015	The expression of RANKL induced by IL-29 could be completely blocked by the inhibitors of mitogen-activated protein kinase (MAPK) signal pathway, including PD98059 (ERK inhibitor), SB203580 (p38 inhibitor) and SP600125 (JNK inhibitor).	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	156-163	TNF superfamily member 11	Homo sapiens	18-23
26420479-8	2015	The expression of RANKL induced by IL-29 could be completely blocked by the inhibitors of mitogen-activated protein kinase (MAPK) signal pathway, including PD98059 (ERK inhibitor), SB203580 (p38 inhibitor) and SP600125 (JNK inhibitor).	SB 203580	181-189	TNF superfamily member 11	Homo sapiens	18-23
26420479-8	2015	The expression of RANKL induced by IL-29 could be completely blocked by the inhibitors of mitogen-activated protein kinase (MAPK) signal pathway, including PD98059 (ERK inhibitor), SB203580 (p38 inhibitor) and SP600125 (JNK inhibitor).	pyrazolanthrone	210-218	TNF superfamily member 11	Homo sapiens	18-23
26446504-11	2015	CONCLUSION: This study demonstrates that clodronate decreases the compression-induced RANKL/OPG ratio expressed by human osteoblasts.	Clodronic Acid	41-51	TNF superfamily member 11	Homo sapiens	86-91
25837853-8	2015	In the analyzed group of patients (all patients receiving MTX regardless of responder non responder status) after 6 months of therapy, a statistically significant increase in the ratio of OPG/RANKL was found (0.0118 +- 0.0102 vs. 0.0141 +- 0.0118; p = 0.02).	Methotrexate	58-61	TNF superfamily member 11	Homo sapiens	192-197
26337218-1	2015	Denosumab, a monoclonal antibody against the receptor activator for nuclear factor-kappa B ligand (RANKL), is a recently approved antiresorptive drug that suppresses osteoclast formation by targeting preosteclasts, in contrast to the traditional antiresorptive bisphosphonates that target mature osteoclasts.	Diphosphonates	261-276	TNF superfamily member 11	Homo sapiens	45-97
26337218-1	2015	Denosumab, a monoclonal antibody against the receptor activator for nuclear factor-kappa B ligand (RANKL), is a recently approved antiresorptive drug that suppresses osteoclast formation by targeting preosteclasts, in contrast to the traditional antiresorptive bisphosphonates that target mature osteoclasts.	Diphosphonates	261-276	TNF superfamily member 11	Homo sapiens	99-104
25837853-14	2015	Treatment with MTX affects the value of the ratio of OPG/RANKL and concentration of Dkk-1.	Methotrexate	15-18	TNF superfamily member 11	Homo sapiens	57-62
26300429-6	2015	The ability of curcumin and its conjugate to suppress the receptor activator of nuclear factor kappa B ligand-induced osteoclastogenesis was assessed by tartrate-resistant acid phosphatase (TRAP) staining and activity as well as real-time polymerase chain reaction.	Curcumin	15-23	TNF superfamily member 11	Homo sapiens	58-109
26366858-6	2015	To address whether ER stress was involved in the expression of RANKL, the effects of ER stress blockers (including 4-PBA and TUDCA) on the expression of RANKL in TiPs-treated fibroblasts were examined by real-time PCR, western blot and ELISA.	4-phenylbutyric acid	117-120	TNF superfamily member 11	Homo sapiens	153-158
26267519-0	2015	The inhibitory effect of vitamin K on RANKL-induced osteoclast differentiation and bone resorption.	Vitamin K	25-34	TNF superfamily member 11	Homo sapiens	38-43
26267519-1	2015	To further understand the correlation between vitamin K and bone metabolism, the effects of vitamins K1, menaquinone-4 (MK-4), and menaquinone-7 (MK-7) on RANKL-induced osteoclast differentiation and bone resorption were comparatively investigated.	vitamin MK 7	131-144	TNF superfamily member 11	Homo sapiens	155-160
26267519-2	2015	Vitamin K2 groups (MK-4 and MK-7) were found to significantly inhibit RANKL-medicated osteoclast cell formation of bone marrow macrophages (BMMs) in a dose-dependent manner, without any evidence of cytotoxicity.	Vitamin K 2	0-10	TNF superfamily member 11	Homo sapiens	70-75
26267519-2	2015	Vitamin K2 groups (MK-4 and MK-7) were found to significantly inhibit RANKL-medicated osteoclast cell formation of bone marrow macrophages (BMMs) in a dose-dependent manner, without any evidence of cytotoxicity.	menatetrenone	19-23	TNF superfamily member 11	Homo sapiens	70-75
26267519-2	2015	Vitamin K2 groups (MK-4 and MK-7) were found to significantly inhibit RANKL-medicated osteoclast cell formation of bone marrow macrophages (BMMs) in a dose-dependent manner, without any evidence of cytotoxicity.	vitamin MK 7	28-32	TNF superfamily member 11	Homo sapiens	70-75
26442864-0	2015	NRROS Negatively Regulates Osteoclast Differentiation by Inhibiting RANKL-Mediated NF-N:B and Reactive Oxygen Species Pathways.	Reactive Oxygen Species	94-117	TNF superfamily member 11	Homo sapiens	68-73
26442864-6	2015	Additionally, NRROS attenuates RANKL-induced NF-N:B activation, as well as degradation of the NOX1 and NOX2 proteins, which are required for ROS generation.	Reactive Oxygen Species	16-19	TNF superfamily member 11	Homo sapiens	31-36
26337028-0	2015	Serum RANKL levels associate with anti- citrullinated protein antibodies in early untreated rheumatoid arthritis and are modulated following methotrexate.	Methotrexate	141-153	TNF superfamily member 11	Homo sapiens	6-11
26337028-5	2015	Serum RANKL (total RANKL), ACPA (anti-CCP2) and ACPA specificities (anti-citrullinated (cit)-vimentin, anti-cit-enolase and anti-cit-fibrinogen) were determined by enzyme-linked immunosorbent assay (ELISA).	cit	60-63	TNF superfamily member 11	Homo sapiens	6-11
26337028-13	2015	CONCLUSIONS: RANKL was elevated in ACPA-positive and in anti-cit-vimentin-positive patients with early untreated RA and associated with bone erosions.	cit	61-64	TNF superfamily member 11	Homo sapiens	13-18
26337028-12	2015	Significant reductions in both serum RANKL and ACPA levels were observed after 3 months of MTX treatment (p &lt;0.05).	Methotrexate	91-94	TNF superfamily member 11	Homo sapiens	37-42
26229438-9	2015	BSNXD-derived serum suppressed receptor activation of nuclear factor kappaB ligand (RANKL)-activated osteoclastogenesis in a dose-dependent manner; this effect could be reversed by estrogen receptor alpha antagonist methyl-piperidino-pyrazole.	Methyl-piperidino-pyrazole	216-242	TNF superfamily member 11	Homo sapiens	31-82
26383566-1	2015	PURPOSE: To investigate the influence of Pg-LPS stimulated monocyte (RAW264.7) culture supernatant on the OPG/RANKL expression of osteoblastic cells (MC3T3-E1).	pg-lps	41-47	TNF superfamily member 11	Homo sapiens	110-115
26383566-2	2015	METHODS: The culture supernatant of monocytes stimulated with Pg-LPS was applied to osteoblasts MC3T3-E1 with different diluted concentrations (10%, 20%, 30%, 40% and 50%) simultaneously for 24h, then RT-PCR was used to detect the expression changes of OPG/RANKL mRNA.	pg-lps	62-68	TNF superfamily member 11	Homo sapiens	257-262
26081760-0	2015	Novel inhibitors of RANKL-induced osteoclastogenesis: Design, synthesis, and biological evaluation of 6-(2,4-difluorophenyl)-3-phenyl-2H-benzo[e][1,3]oxazine-2,4(3H)-diones.	6-(2,4-difluorophenyl)-3-phenyl-2h-benzo[e][1,3]oxazine-2,4(3h)-diones	102-172	TNF superfamily member 11	Homo sapiens	20-25
26081760-4	2015	In addition, our biological results indicated that 3d and 3h could suppress RANKL-induced osteoclastogenesis-related marker genes, such as NFATc1, c-fos, TRAP, and cathepsin K.	Tritium	58-60	TNF superfamily member 11	Homo sapiens	76-81
26229438-9	2015	BSNXD-derived serum suppressed receptor activation of nuclear factor kappaB ligand (RANKL)-activated osteoclastogenesis in a dose-dependent manner; this effect could be reversed by estrogen receptor alpha antagonist methyl-piperidino-pyrazole.	Methyl-piperidino-pyrazole	216-242	TNF superfamily member 11	Homo sapiens	84-89
26229438-10	2015	The serum suppressed RANKL-induced NF-kappaB transcription and inhibited the accumulation of nuclear factor of activated T-cells, cytoplasmic 1 in osteoclast precursor cells; the inhibitory effect was abolished by methyl-piperidino-pyrazole but not the estrogen receptor beta antagonist or androgen receptor antagonist.	Methyl-piperidino-pyrazole	214-240	TNF superfamily member 11	Homo sapiens	21-26
26005025-0	2015	Discovery of 5-(2",4"-difluorophenyl)-salicylanilides as new inhibitors of receptor activator of NF-kappaB ligand (RANKL)-induced osteoclastogenesis.	5-(2",4"-difluorophenyl)-salicylanilides	13-53	TNF superfamily member 11	Homo sapiens	75-113
25979341-0	2015	The Proteasome Inhibitor Carfilzomib Suppresses Parathyroid Hormone-induced Osteoclastogenesis through a RANKL-mediated Signaling Pathway.	carfilzomib	25-36	TNF superfamily member 11	Homo sapiens	105-110
26154488-6	2015	At the molecular level, cafestol markedly decreased RANKL-induced phosphorylation of extracellular signal-regulated kinase (Erk) and inhibitor of nuclear factor kappa B alpha (IkappaBalpha).	cafestol	24-32	TNF superfamily member 11	Homo sapiens	52-57
26351562-10	2015	CONCLUSION: Our results suggest that miR-125b acts as a tumor suppressor through suppression of the PTH1R/RANKL signaling pathway.	mir-125b	37-45	TNF superfamily member 11	Homo sapiens	106-111
26005025-0	2015	Discovery of 5-(2",4"-difluorophenyl)-salicylanilides as new inhibitors of receptor activator of NF-kappaB ligand (RANKL)-induced osteoclastogenesis.	5-(2",4"-difluorophenyl)-salicylanilides	13-53	TNF superfamily member 11	Homo sapiens	115-120
26005025-1	2015	To improve the inhibitory potency of lead compound NDMC101 on RANKL-induced osteoclastogenesis, a series of new 5-(2",4"-difluorophenyl)-salicylanilide derivatives were synthesized and evaluated for osteoclast inhibition by using TRAP-staining assay.	N-(4-chloro-2-fluorophenyl)-2-hydroxybenzamide	51-58	TNF superfamily member 11	Homo sapiens	62-67
25859665-8	2015	15d-PGJ2 blocked RANKL-induced osteoclastogenesis and inhibited the formation of resorption pits by decreasing the activities of cathepsin K and matrix metalloproteinases, which are secreted by mature osteoclasts.	15-deoxy-delta(12,14)-prostaglandin J2	0-8	TNF superfamily member 11	Homo sapiens	17-22
25887803-3	2015	In the present study, we first confirmed the inhibitory effect of esculetin on receptor activator of nuclear factor-kappaB ligand (RANKL)-induced osteoclast formation.	esculetin	66-75	TNF superfamily member 11	Homo sapiens	131-136
25887803-8	2015	Taken together, our results indicate for the first time that esculetin inhibits RANKL-mediated osteoclastogenesis via direct suppression of c-Fos and NFATc1 expression and exerts an inhibitory effect on actin ring formation during osteoclastogenesis.	esculetin	61-70	TNF superfamily member 11	Homo sapiens	80-85
25721666-5	2015	Treatment of the cells with 22 mM glucose, 100 mug/mL either AGE2 or AGE3 significantly increased the expression of sclerostin protein and mRNA; however, both AGEs, but not glucose, significantly decreased the expression of RANKL protein and mRNA.	Glucose	34-41	TNF superfamily member 11	Homo sapiens	224-229
25806956-0	2015	Correction: olmesartan decreased levels of IL-1beta and TNF-alpha, down-regulated MMP-2, MMP-9, COX-2, RANK/RANKL and up-regulated SOCs-1 in an intestinal mucositis model.	olmesartan	12-22	TNF superfamily member 11	Homo sapiens	108-113
25780422-8	2015	Furthermore, the lithium ions appeared to alter osteoclastogenesis by regulating the OPG/RANKL ratio.	Lithium	17-24	TNF superfamily member 11	Homo sapiens	89-94
25887296-0	2015	(5R)-5-Hydroxytriptolide (LLDT-8) inhibits osteoclastogenesis via RANKL/RANK/OPG signaling pathway.	5alpha-Hydroxytriptolide	0-24	TNF superfamily member 11	Homo sapiens	66-71
25887296-0	2015	(5R)-5-Hydroxytriptolide (LLDT-8) inhibits osteoclastogenesis via RANKL/RANK/OPG signaling pathway.	5alpha-Hydroxytriptolide	26-32	TNF superfamily member 11	Homo sapiens	66-71
25887296-1	2015	BACKGROUND: The aim of this study was to investigate the regulative activity of (5R)-5-hydroxytriptolide (LLDT-8) on receptor activator of nuclear factor kappa-B ligand (RANKL)/receptor activator of nuclear factor kappa-B (RANK)/Osteoprotegerin (OPG) system in rheumatoid arthritis (RA) and its anti-osteoclastogenesis mechanism.	5alpha-Hydroxytriptolide	80-104	TNF superfamily member 11	Homo sapiens	170-175
25887296-1	2015	BACKGROUND: The aim of this study was to investigate the regulative activity of (5R)-5-hydroxytriptolide (LLDT-8) on receptor activator of nuclear factor kappa-B ligand (RANKL)/receptor activator of nuclear factor kappa-B (RANK)/Osteoprotegerin (OPG) system in rheumatoid arthritis (RA) and its anti-osteoclastogenesis mechanism.	5alpha-Hydroxytriptolide	106-112	TNF superfamily member 11	Homo sapiens	170-175
25887296-8	2015	In addition, LLDT-8 decreased the number of TRAP-positive cells derived from RAW264.7 in the presence of RANKL and M-CSF.	5alpha-Hydroxytriptolide	13-19	TNF superfamily member 11	Homo sapiens	105-110
25887296-9	2015	Furthermore, LLDT-8 also inhibited the expression of p-IkappaB, a key regulator of RANKL signaling pathway.	5alpha-Hydroxytriptolide	13-19	TNF superfamily member 11	Homo sapiens	83-88
25887296-10	2015	CONCLUSIONS: LLDT-8 exerts its anti-osteoclastogenesis effect in RA probably through regulating RANKL/RANK/OPG system and its downstream signaling pathway as well as cytokine productions.	5alpha-Hydroxytriptolide	13-19	TNF superfamily member 11	Homo sapiens	96-101
25466887-7	2015	EETs also prevented the production of reactive oxygen species (ROS) following RANKL stimulation.	Reactive Oxygen Species	38-61	TNF superfamily member 11	Homo sapiens	78-83
25668130-8	2015	These results suggested that, at least in part, RANKL expression by osteoblasts in an acidic environment was mediated by cAMP/PKA signaling resulting from GPR4 activation.	Cyclic AMP	121-125	TNF superfamily member 11	Homo sapiens	48-53
25466887-7	2015	EETs also prevented the production of reactive oxygen species (ROS) following RANKL stimulation.	Reactive Oxygen Species	63-66	TNF superfamily member 11	Homo sapiens	78-83
25872304-8	2015	Calcium hydroxide-treated primary pulp cells also exhibited significantly upregulated RANKL expression (P &lt; 0.01); by contrast, MTA-treated cells did not show any change in RANKL expression (P&gt;0.05).	Calcium Hydroxide	0-17	TNF superfamily member 11	Homo sapiens	86-91
25817340-1	2015	Receptor activator of NF&amp;mdash;&amp;#954;B ligand (RANKL), a TNF&amp;mdash;related protein, is a key factor regulating bone metabolism.	Adenosine Monophosphate	25-28	TNF superfamily member 11	Homo sapiens	55-60
25817340-1	2015	Receptor activator of NF&amp;mdash;&amp;#954;B ligand (RANKL), a TNF&amp;mdash;related protein, is a key factor regulating bone metabolism.	Adenosine Monophosphate	36-39	TNF superfamily member 11	Homo sapiens	55-60
25817340-1	2015	Receptor activator of NF&amp;mdash;&amp;#954;B ligand (RANKL), a TNF&amp;mdash;related protein, is a key factor regulating bone metabolism.	Adenosine Monophosphate	36-39	TNF superfamily member 11	Homo sapiens	55-60
25817340-5	2015	MTT assay showed that RANKL inhibited hFOB 1.19 cells growth in a dose&amp;mdash;dependent and time&amp;mdash;dependent manner.	monooxyethylene trimethylolpropane tristearate	0-3	TNF superfamily member 11	Homo sapiens	22-27
25817340-5	2015	MTT assay showed that RANKL inhibited hFOB 1.19 cells growth in a dose&amp;mdash;dependent and time&amp;mdash;dependent manner.	Adenosine Monophosphate	71-74	TNF superfamily member 11	Homo sapiens	22-27
25817340-5	2015	MTT assay showed that RANKL inhibited hFOB 1.19 cells growth in a dose&amp;mdash;dependent and time&amp;mdash;dependent manner.	Adenosine Monophosphate	100-103	TNF superfamily member 11	Homo sapiens	22-27
25820558-0	2015	RANK/RANKL/OPG signaling pathways in necrotic jaw bone from bisphosphonate-treated subjects.	Diphosphonates	60-74	TNF superfamily member 11	Homo sapiens	5-10
25820558-3	2015	The aim of the present study was to investigate the role of RANK/RANKL/OPG signaling pathway and, in parallel, to evaluate angiogenic and matrix mineralization processes in jaw bone necrotic samples obtained from bisphosphonate-treated subjects with established ONJ.	Diphosphonates	213-227	TNF superfamily member 11	Homo sapiens	65-70
25667102-0	2015	Quetiapine inhibits osteoclastogenesis and prevents human breast cancer-induced bone loss through suppression of the RANKL-mediated MAPK and NF-kappaB signaling pathways.	Quetiapine Fumarate	0-10	TNF superfamily member 11	Homo sapiens	117-122
25667102-4	2015	In this study, we detected whether quetiapine (QUE), a commonly used atypical antipsychotic drug, can inhibit RANKL-induced osteoclast differentiation in vitro and prevent human breast cancer-induced bone loss in vivo.	Quetiapine Fumarate	35-45	TNF superfamily member 11	Homo sapiens	110-115
25667102-4	2015	In this study, we detected whether quetiapine (QUE), a commonly used atypical antipsychotic drug, can inhibit RANKL-induced osteoclast differentiation in vitro and prevent human breast cancer-induced bone loss in vivo.	Quetiapine Fumarate	47-50	TNF superfamily member 11	Homo sapiens	110-115
25667102-10	2015	We demonstrate, for the first time, the novel suppressive effects of QUE on RANKL-induced osteoclast differentiation in vitro and human breast cancer-induced bone loss in vivo, suggesting that QUE may be a potential therapeutic drug for osteolysis treatment.	Quetiapine Fumarate	69-72	TNF superfamily member 11	Homo sapiens	76-81
25667102-10	2015	We demonstrate, for the first time, the novel suppressive effects of QUE on RANKL-induced osteoclast differentiation in vitro and human breast cancer-induced bone loss in vivo, suggesting that QUE may be a potential therapeutic drug for osteolysis treatment.	Quetiapine Fumarate	193-196	TNF superfamily member 11	Homo sapiens	76-81
25595364-10	2015	Pregnenolone sulfate (PS) and 4alpha-phorbol 12, 13-didecanoate (4alpha-PDD), which are agonists of TRPM3 and TRPV4, augmented Ca(2+) influx and RANKL mRNA expression.	pregnenolone sulfate	0-20	TNF superfamily member 11	Homo sapiens	145-150
25595364-10	2015	Pregnenolone sulfate (PS) and 4alpha-phorbol 12, 13-didecanoate (4alpha-PDD), which are agonists of TRPM3 and TRPV4, augmented Ca(2+) influx and RANKL mRNA expression.	pregnenolone sulfate	22-24	TNF superfamily member 11	Homo sapiens	145-150
25595364-10	2015	Pregnenolone sulfate (PS) and 4alpha-phorbol 12, 13-didecanoate (4alpha-PDD), which are agonists of TRPM3 and TRPV4, augmented Ca(2+) influx and RANKL mRNA expression.	phorbol-12,13-didecanoate	30-63	TNF superfamily member 11	Homo sapiens	145-150
25483570-8	2015	Moreover, medroxyprogesterone acetate (MPA)-mediated progesterone receptor B (PRB) was found to significantly inhibit the EC cell behavior induced by RANKL in vitro.	Medroxyprogesterone Acetate	10-37	TNF superfamily member 11	Homo sapiens	150-155
25211367-8	2015	Inhibition of MEK1/2 by U0126 resulted in decreased RANKL expression suggesting that stimulation through MEK1/2 was a prerequisite.	U 0126	24-29	TNF superfamily member 11	Homo sapiens	52-57
25352342-3	2015	The present study demonstrated that high glucose inhibited receptor activator of nuclear factor-kappaB ligand (RANKL)-induced osteoclastogenesis.	Glucose	41-48	TNF superfamily member 11	Homo sapiens	111-116
25892999-5	2015	Saikosaponins A and D inhibited the formation of resorptive pits by reducing the secreted levels of matrix metalloproteinase- (MMP-) 2, MMP-9, and cathepsin K in RANKL-induced osteoclasts.	saikosaponin D	0-15	TNF superfamily member 11	Homo sapiens	162-167
26273599-4	2015	We confirmed this effect by a decrease of the mRNA and protein RANKL and mRNA RANKL/OPG in RASFs exposed in vitro to T-614 or MTX.	T 614	117-122	TNF superfamily member 11	Homo sapiens	63-68
26273599-4	2015	We confirmed this effect by a decrease of the mRNA and protein RANKL and mRNA RANKL/OPG in RASFs exposed in vitro to T-614 or MTX.	T 614	117-122	TNF superfamily member 11	Homo sapiens	78-83
26273599-4	2015	We confirmed this effect by a decrease of the mRNA and protein RANKL and mRNA RANKL/OPG in RASFs exposed in vitro to T-614 or MTX.	Methotrexate	126-129	TNF superfamily member 11	Homo sapiens	63-68
26273599-4	2015	We confirmed this effect by a decrease of the mRNA and protein RANKL and mRNA RANKL/OPG in RASFs exposed in vitro to T-614 or MTX.	Methotrexate	126-129	TNF superfamily member 11	Homo sapiens	78-83
25412610-4	2015	Receptor activator for nuclear factor-kappaB (NF-kappaB) ligand (RANKL) plays an important role in progesterone-induced mammary carcinogenesis.	Progesterone	99-111	TNF superfamily member 11	Homo sapiens	65-70
26579531-6	2015	It is also evident that bortezomib either inhibits osteoclast differentiation induced by the receptor activator of nuclear factor kappa B (NF-kappaB) ligand (RANKL) or stimulates the osteoblast differentiation.	Bortezomib	24-34	TNF superfamily member 11	Homo sapiens	158-163
25892999-5	2015	Saikosaponins A and D inhibited the formation of resorptive pits by reducing the secreted levels of matrix metalloproteinase- (MMP-) 2, MMP-9, and cathepsin K in RANKL-induced osteoclasts.	Deuterium	20-21	TNF superfamily member 11	Homo sapiens	162-167
25150534-4	2014	RESULTS: High concentrations of glucose increased the production of pro-inflammatory cytokines interleukin-1 beta (IL-1beta), tumour necrosis factor alpha (TNF-alpha), Interleukin-6 (IL-6) at both mRNA and protein levels, and receptor activator of NF-kB ligand (RANKL) at mRNA levels in hPDL cells.	Glucose	32-39	TNF superfamily member 11	Homo sapiens	226-260
24557630-8	2015	The induction of RANKL was observed when IL-17 was added in combination with 1,25-dihydroxyvitamin D3 and prostaglandin E2, well-known inducers of RANKL, although the exact mechanism of this synergistic effect remains unclear.	Calcitriol	77-101	TNF superfamily member 11	Homo sapiens	17-22
24557630-8	2015	The induction of RANKL was observed when IL-17 was added in combination with 1,25-dihydroxyvitamin D3 and prostaglandin E2, well-known inducers of RANKL, although the exact mechanism of this synergistic effect remains unclear.	Calcitriol	77-101	TNF superfamily member 11	Homo sapiens	147-152
24557630-8	2015	The induction of RANKL was observed when IL-17 was added in combination with 1,25-dihydroxyvitamin D3 and prostaglandin E2, well-known inducers of RANKL, although the exact mechanism of this synergistic effect remains unclear.	Dinoprostone	106-122	TNF superfamily member 11	Homo sapiens	17-22
24557630-8	2015	The induction of RANKL was observed when IL-17 was added in combination with 1,25-dihydroxyvitamin D3 and prostaglandin E2, well-known inducers of RANKL, although the exact mechanism of this synergistic effect remains unclear.	Dinoprostone	106-122	TNF superfamily member 11	Homo sapiens	147-152
25577216-6	2015	Cells grown on PTFE-coated Ti surface exhibited delayed surface attachment and decreased proliferation after 48 h. However, after 168 h of culture cells grown on PTFE-coated surface exhibited higher viability/proliferation, higher expression levels of ALP and OC, and higher OPG/RANKL ratio compared to uncoated surface.	ptfe	15-19	TNF superfamily member 11	Homo sapiens	279-284
25577216-6	2015	Cells grown on PTFE-coated Ti surface exhibited delayed surface attachment and decreased proliferation after 48 h. However, after 168 h of culture cells grown on PTFE-coated surface exhibited higher viability/proliferation, higher expression levels of ALP and OC, and higher OPG/RANKL ratio compared to uncoated surface.	ptfe	162-166	TNF superfamily member 11	Homo sapiens	279-284
25420230-4	2014	We prepared beta-cyclodextrin (CD) conjugated GNPs (CGNPs), which can form inclusion complexes with curcumin (CUR-CGNPs), and used these to investigate their inhibitory effects on receptor activator of nuclear factor-kappab ligand (RANKL)-induced osteoclastogenesis in bone marrow-derived macrophages (BMMs).	betadex	12-29	TNF superfamily member 11	Homo sapiens	180-230
25420230-4	2014	We prepared beta-cyclodextrin (CD) conjugated GNPs (CGNPs), which can form inclusion complexes with curcumin (CUR-CGNPs), and used these to investigate their inhibitory effects on receptor activator of nuclear factor-kappab ligand (RANKL)-induced osteoclastogenesis in bone marrow-derived macrophages (BMMs).	betadex	12-29	TNF superfamily member 11	Homo sapiens	232-237
25420230-4	2014	We prepared beta-cyclodextrin (CD) conjugated GNPs (CGNPs), which can form inclusion complexes with curcumin (CUR-CGNPs), and used these to investigate their inhibitory effects on receptor activator of nuclear factor-kappab ligand (RANKL)-induced osteoclastogenesis in bone marrow-derived macrophages (BMMs).	betadex	31-33	TNF superfamily member 11	Homo sapiens	180-230
25420230-4	2014	We prepared beta-cyclodextrin (CD) conjugated GNPs (CGNPs), which can form inclusion complexes with curcumin (CUR-CGNPs), and used these to investigate their inhibitory effects on receptor activator of nuclear factor-kappab ligand (RANKL)-induced osteoclastogenesis in bone marrow-derived macrophages (BMMs).	betadex	31-33	TNF superfamily member 11	Homo sapiens	232-237
25720990-3	2015	RANKL and RANK are under the tight control of the female sex hormones estradiol and progesterone.	Estradiol	70-79	TNF superfamily member 11	Homo sapiens	0-5
25720990-3	2015	RANKL and RANK are under the tight control of the female sex hormones estradiol and progesterone.	Progesterone	84-96	TNF superfamily member 11	Homo sapiens	0-5
25403801-7	2015	In addition, the high levels of tumor necrosis factor-alpha, interleukin-1beta, and receptor activator of nuclear factor-kappa B ligand (RANKL) expression induced by LPS were inhibited after treatment with atRA.	Tretinoin	206-210	TNF superfamily member 11	Homo sapiens	84-135
25403801-7	2015	In addition, the high levels of tumor necrosis factor-alpha, interleukin-1beta, and receptor activator of nuclear factor-kappa B ligand (RANKL) expression induced by LPS were inhibited after treatment with atRA.	Tretinoin	206-210	TNF superfamily member 11	Homo sapiens	137-142
25442070-9	2015	CONCLUSIONS: We showed that ALN at very low concentrations is an effective inhibitor of RANKL-generated osteoclasts, without causing cytotoxic effects on their precursors or periapical cells.	Alendronate	28-31	TNF superfamily member 11	Homo sapiens	88-93
25531650-0	2014	Olmesartan decreased levels of IL-1beta and TNF-alpha, down-regulated MMP-2, MMP-9, COX-2, RANK/RANKL and up-regulated SOCs-1 in an intestinal mucositis model.	olmesartan	0-10	TNF superfamily member 11	Homo sapiens	96-101
25150534-4	2014	RESULTS: High concentrations of glucose increased the production of pro-inflammatory cytokines interleukin-1 beta (IL-1beta), tumour necrosis factor alpha (TNF-alpha), Interleukin-6 (IL-6) at both mRNA and protein levels, and receptor activator of NF-kB ligand (RANKL) at mRNA levels in hPDL cells.	Glucose	32-39	TNF superfamily member 11	Homo sapiens	262-267
25150534-5	2014	Insulin treatment alleviated the stimulatory effects of high glucose on pro-inflammatory cytokines and RANKL expression by hPDL cells.	Glucose	61-68	TNF superfamily member 11	Homo sapiens	103-108
25266469-0	2014	Influence of calcium hydroxide-loaded microcapsules on osteoprotegerin and receptor activator of nuclear factor kappa B ligand activity.	Calcium Hydroxide	13-30	TNF superfamily member 11	Homo sapiens	75-126
25270538-0	2014	Effects of icariin on the regulation of the OPG-RANKL-RANK system are mediated through the MAPK pathways in IL-1beta-stimulated human SW1353 chondrosarcoma cells.	icariin	11-18	TNF superfamily member 11	Homo sapiens	48-53
25270538-9	2014	In addition, treatment with icariin decreased the levels of RANK and RANKL.	icariin	28-35	TNF superfamily member 11	Homo sapiens	69-74
25266469-9	2014	The OPG/RANKL ratio in the microcapsules group was up-regulated at both the mRNA and protein levels compared with the negative control group and the pure Ca(OH)2 powder group.	Calcium Hydroxide	154-161	TNF superfamily member 11	Homo sapiens	8-13
25397676-0	2014	Formononetin attenuates osteoclastogenesis via suppressing the RANKL-induced activation of NF-kappaB, c-Fos, and nuclear factor of activated T-cells cytoplasmic 1 signaling pathway.	formononetin	0-12	TNF superfamily member 11	Homo sapiens	63-68
25551094-10	2014	OPG, RANKL, and M-CSF expression were all decreased by alendronate treatment.	Alendronate	55-66	TNF superfamily member 11	Homo sapiens	5-10
25397676-8	2014	SP600125, a specific inhibitor of JNK, reduced RANKL-induced expression of phospho-c-Jun, c-Fos, and NFATc1 and inhibited osteoclast formation.	pyrazolanthrone	0-8	TNF superfamily member 11	Homo sapiens	47-52
25584312-1	2014	UNLABELLED: Aim &amp; Objective: The receptor activator of NF-kappa B ligand (RANKL) and its decoy receptor, osteoprotegerin (OPG), are the important proteins implicated in osteoclastogenesis.	Adenosine Monophosphate	17-20	TNF superfamily member 11	Homo sapiens	37-76
25421321-2	2014	Treatment of bone marrow macrophages (BMMs) with receptor activator of nuclear factor kappaB ligand (RANKL) resulted in a differentiation of BMMs into osteoclasts as evidenced by generation of tartrate-resistant acid phosphatase (TRAP)-positive, multinucleated cells and formation of pits in calcium phosphate-coated plates.	calcium phosphate	292-309	TNF superfamily member 11	Homo sapiens	49-99
25421321-2	2014	Treatment of bone marrow macrophages (BMMs) with receptor activator of nuclear factor kappaB ligand (RANKL) resulted in a differentiation of BMMs into osteoclasts as evidenced by generation of tartrate-resistant acid phosphatase (TRAP)-positive, multinucleated cells and formation of pits in calcium phosphate-coated plates.	calcium phosphate	292-309	TNF superfamily member 11	Homo sapiens	101-106
25407893-0	2014	Exenatide can inhibit calcification of human VSMCs through the NF-kappaB/RANKL signaling pathway.	Exenatide	0-9	TNF superfamily member 11	Homo sapiens	73-78
25407893-11	2014	Exenatide decreased the expression of RANKL in a dose-dependent manner.	Exenatide	0-9	TNF superfamily member 11	Homo sapiens	38-43
25407893-12	2014	1,25 vitD3 (an activator of RANKL) upregulated, whereas BAY11-7082 (an inhibitor of NF-kappaB) downregulated RANKL, alkaline phosphatase (ALP), osteocalcin (OC), and core binding factor alpha1 (Runx2) protein levels and reduced mineralization in human CVSMCs.	3-(4-methylphenylsulfonyl)-2-propenenitrile	56-66	TNF superfamily member 11	Homo sapiens	109-114
25407893-15	2014	CONCLUSION: GLP-1RA exenatide can inhibit human VSMCs calcification through NF-kappaB/RANKL signaling.	Exenatide	20-29	TNF superfamily member 11	Homo sapiens	86-91
25173134-1	2014	Drug-induced osteonecrosis of the jaw (ONJ) is a detrimental intraoral lesion that often occurs after dental-related interventions in patients undergoing treatment with bisphosphonates or denosumab, the neutralizing human anti-receptor activator of NF-kappaB ligand (RANKL) antibody (Ab).	Diphosphonates	169-184	TNF superfamily member 11	Homo sapiens	222-265
25173134-1	2014	Drug-induced osteonecrosis of the jaw (ONJ) is a detrimental intraoral lesion that often occurs after dental-related interventions in patients undergoing treatment with bisphosphonates or denosumab, the neutralizing human anti-receptor activator of NF-kappaB ligand (RANKL) antibody (Ab).	Diphosphonates	169-184	TNF superfamily member 11	Homo sapiens	267-272
25375896-6	2014	ED71 was significantly less effective in inhibiting M-CSF and RANKL-stimulated osteoclastogenesis than was 1,25(OH)2D3 in vitro.	eldecalcitol	0-4	TNF superfamily member 11	Homo sapiens	62-67
25397470-10	2014	Reactive oxygen species (ROS) production is essential in RANKL-induced OC differentiation (2),3; effect of these proteins on ROS production was assessed using the fluorescent H2DCFH-DA.	Reactive Oxygen Species	0-23	TNF superfamily member 11	Homo sapiens	57-62
25397470-10	2014	Reactive oxygen species (ROS) production is essential in RANKL-induced OC differentiation (2),3; effect of these proteins on ROS production was assessed using the fluorescent H2DCFH-DA.	Reactive Oxygen Species	25-28	TNF superfamily member 11	Homo sapiens	57-62
25397470-10	2014	Reactive oxygen species (ROS) production is essential in RANKL-induced OC differentiation (2),3; effect of these proteins on ROS production was assessed using the fluorescent H2DCFH-DA.	Reactive Oxygen Species	125-128	TNF superfamily member 11	Homo sapiens	57-62
25397470-10	2014	Reactive oxygen species (ROS) production is essential in RANKL-induced OC differentiation (2),3; effect of these proteins on ROS production was assessed using the fluorescent H2DCFH-DA.	h2dcfh-da	175-184	TNF superfamily member 11	Homo sapiens	57-62
25216923-5	2014	In this study, we found that putrescine, spermidine or spermine inhibited the RANKL-mediated migration of preosteoclasts.	Putrescine	29-39	TNF superfamily member 11	Homo sapiens	78-83
25216923-5	2014	In this study, we found that putrescine, spermidine or spermine inhibited the RANKL-mediated migration of preosteoclasts.	Spermidine	41-51	TNF superfamily member 11	Homo sapiens	78-83
25216923-5	2014	In this study, we found that putrescine, spermidine or spermine inhibited the RANKL-mediated migration of preosteoclasts.	Spermine	55-63	TNF superfamily member 11	Homo sapiens	78-83
25216923-6	2014	Furthermore, the RANKL-mediated activation of the Src-PYK2 signaling axis and of transcription factors such as NF-kappaB and NFATc1 was prevented by each polyamine.	Polyamines	154-163	TNF superfamily member 11	Homo sapiens	17-22
25118085-8	2014	Consumption of supplemental Ca+Vit D increased circulating ionized Ca (group-by-time, P=0.022), maintained PTH (group-by-time, P=0.032), and increased the osteoprotegerin:RANKL ratio (group-by-time, P=0.006).	ca+vit d	28-36	TNF superfamily member 11	Homo sapiens	171-176
25138550-6	2014	In the present study, Western blot analysis showed that microRNA-17/20a markedly lowered the levels of RANKL protein and attenuated dexamethasone-induced RANKL expression in the osteoblasts.	Dexamethasone	132-145	TNF superfamily member 11	Homo sapiens	154-159
25584312-2	2014	This study aimed to identify &amp; quantify RANKL positive cells in gingival tissues in healthy &amp; diseased patients &amp; the study looks for immunohistochemical evidence of the expression of the protein in gingival tissue samples.	Adenosine Monophosphate	30-33	TNF superfamily member 11	Homo sapiens	44-49
25584312-2	2014	This study aimed to identify &amp; quantify RANKL positive cells in gingival tissues in healthy &amp; diseased patients &amp; the study looks for immunohistochemical evidence of the expression of the protein in gingival tissue samples.	Adenosine Monophosphate	97-100	TNF superfamily member 11	Homo sapiens	44-49
25584312-2	2014	This study aimed to identify &amp; quantify RANKL positive cells in gingival tissues in healthy &amp; diseased patients &amp; the study looks for immunohistochemical evidence of the expression of the protein in gingival tissue samples.	Adenosine Monophosphate	97-100	TNF superfamily member 11	Homo sapiens	44-49
25584312-9	2014	RESULTS: Immunohistochemical staining showed that RANKL-positive cells were significantly distributed in the inflammatory epithelium &amp; connective tissue zone of diseased &amp; non-diseased gingiva.	Adenosine Monophosphate	134-137	TNF superfamily member 11	Homo sapiens	50-55
25584312-9	2014	RESULTS: Immunohistochemical staining showed that RANKL-positive cells were significantly distributed in the inflammatory epithelium &amp; connective tissue zone of diseased &amp; non-diseased gingiva.	Adenosine Monophosphate	175-178	TNF superfamily member 11	Homo sapiens	50-55
25584312-11	2014	CONCLUSION: These findings imply that in this comparative study of gingival tissue for, RANKL positive cells, these cells were present in both healthy &amp; chronic periodontitis samples, but number of positive cells present is significantly increased in chronic periodontitis.	Adenosine Monophosphate	152-155	TNF superfamily member 11	Homo sapiens	88-93
24875904-3	2014	5-AzadC treatment of WL-2 cells led to demethylation and re-expression of RANKL.	Decitabine	0-7	TNF superfamily member 11	Homo sapiens	74-79
25034231-9	2014	GA abrogated the RANKL-induced differentiation of macrophages to osteoclasts in a dose- and time-dependent manner.	gambogic acid	0-2	TNF superfamily member 11	Homo sapiens	17-22
25274386-7	2014	Novel pharmaceutical therapy approaches with human monoclonal RANKL antibodies interfere in this osteodestructive process in an inhibitory manner and can represent alternative treatment options just as the osteosupportive therapy with bisphosphonates.	Diphosphonates	235-250	TNF superfamily member 11	Homo sapiens	62-67
25047443-0	2014	Triptolide, a diterpene, inhibits osteoclastogenesis, induced by RANKL signaling and human cancer cells.	triptolide	0-10	TNF superfamily member 11	Homo sapiens	65-70
25047443-0	2014	Triptolide, a diterpene, inhibits osteoclastogenesis, induced by RANKL signaling and human cancer cells.	Diterpenes	14-23	TNF superfamily member 11	Homo sapiens	65-70
25047443-4	2014	In the present study, we investigated the ability of triptolide, a diterpenoid isolated from Thunder of God Vine, to inhibit signaling by receptor activator of NF-kappaB (RANK) and its ligand (RANKL) and to modulate osteoclastogenesis induced by RANKL and human cancer cells.	triptolide	53-63	TNF superfamily member 11	Homo sapiens	193-198
25047443-4	2014	In the present study, we investigated the ability of triptolide, a diterpenoid isolated from Thunder of God Vine, to inhibit signaling by receptor activator of NF-kappaB (RANK) and its ligand (RANKL) and to modulate osteoclastogenesis induced by RANKL and human cancer cells.	triptolide	53-63	TNF superfamily member 11	Homo sapiens	246-251
25047443-5	2014	We found that triptolide suppressed RANKL-induced differentiation of precursor cells to osteoclasts, and also inhibited osteoclast formation induced by human breast tumor cells (MDA-MB-231), multiple myeloma cells (U266) and prostate tumor cells (PC-3).	triptolide	14-24	TNF superfamily member 11	Homo sapiens	36-41
25047443-6	2014	Triptolide inhibited RANKL-induced NF-kappaB activation in osteoclast precursor cells by inhibiting IkappaBalpha kinase activation, IkappaBalpha phosphorylation, and IkappaBalpha degradation.	triptolide	0-10	TNF superfamily member 11	Homo sapiens	21-26
25047443-7	2014	Our results suggest that triptolide effectively inhibits RANKL-induced NF-kappaB activation and RANKL- and tumor cell-induced osteoclastogenesis.	triptolide	25-35	TNF superfamily member 11	Homo sapiens	57-62
25047443-7	2014	Our results suggest that triptolide effectively inhibits RANKL-induced NF-kappaB activation and RANKL- and tumor cell-induced osteoclastogenesis.	triptolide	25-35	TNF superfamily member 11	Homo sapiens	96-101
25085325-14	2014	Alendronate had little effect on gene expression in HOB but in OSO increased osteopontin levels and decreased RANKL/OPG.	Alendronate	0-11	TNF superfamily member 11	Homo sapiens	110-115
25085325-15	2014	CONCLUSIONS: OSO cultures displayed properties of hypermineralization due to decreased osteopontin (OPN) and also had increased RANKL/OPG, which were normalized by alendronate.	Alendronate	164-175	TNF superfamily member 11	Homo sapiens	128-133
32261855-7	2014	The RANKL/RANK pathway, which enhances osteoclastogenesis, was inhibited by the SZS coatings, whereas the osteogenic differentiation of bone marrow mesenchymal stromal cells (BMSCs) was significantly enhanced by the SZS coatings/macrophages conditioned medium, probably via the activation of BMP2 pathway.	CHEMBL4749475	80-83	TNF superfamily member 11	Homo sapiens	4-9
32261855-7	2014	The RANKL/RANK pathway, which enhances osteoclastogenesis, was inhibited by the SZS coatings, whereas the osteogenic differentiation of bone marrow mesenchymal stromal cells (BMSCs) was significantly enhanced by the SZS coatings/macrophages conditioned medium, probably via the activation of BMP2 pathway.	CHEMBL4749475	216-219	TNF superfamily member 11	Homo sapiens	4-9
24998607-5	2014	The inhibition of human osteoclast differentiation was associated with a down-regulation in RANKL-dependent intracellular ROS levels in human pre-osteoclasts cells.	ros	122-125	TNF superfamily member 11	Homo sapiens	92-97
24998607-8	2014	Finally, we found that NaHS also downregulated the RANKL/OPG mRNA ratio in human mesenchymal stem cells, the key osteoclast-supporting cells.	sodium bisulfide	23-27	TNF superfamily member 11	Homo sapiens	51-56
23824148-5	2014	A significant dose-dependent decrease in TNF-alpha and RANKL production by cultured RA macrophages after 1,25(OH)2D3 treatment was found, whereas a significant reduction in normal cells was observed only at higher concentrations.	Calcitriol	105-116	TNF superfamily member 11	Homo sapiens	55-60
24842191-8	2014	Miconazole also inhibited RANKL-induced expression of the pro-inflammatory cytokines, COX-2 and iNOS.	Miconazole	0-10	TNF superfamily member 11	Homo sapiens	26-31
25007964-1	2014	The receptor activator of nuclear factor-kappaB ligand (RANKL) acts as a paracrine factor in progesterone-induced mammary epithelial proliferation and tumorigenesis.	Progesterone	93-105	TNF superfamily member 11	Homo sapiens	4-54
25007964-1	2014	The receptor activator of nuclear factor-kappaB ligand (RANKL) acts as a paracrine factor in progesterone-induced mammary epithelial proliferation and tumorigenesis.	Progesterone	93-105	TNF superfamily member 11	Homo sapiens	56-61
25007964-3	2014	Our aim was to examine whether RANKL expression in human normal and malignant breast is under the control of progesterone throughout the menstrual cycle.	Progesterone	109-121	TNF superfamily member 11	Homo sapiens	31-36
25007964-7	2014	Expression of RANKL, DIO2, and MYBPC1 was correlated with serum progesterone in CUB, and was significantly higher in luteal phase.	Progesterone	64-76	TNF superfamily member 11	Homo sapiens	14-19
25007964-9	2014	RANKL protein expression was also significantly increased in the luteal phase and highly correlated with serum progesterone levels in cancer samples, especially in hormone receptor positive tumors.	Progesterone	111-123	TNF superfamily member 11	Homo sapiens	0-5
25007964-11	2014	In normal breast and in breast cancer, RANKL mRNA and protein expression fluctuate with serum progesterone with highest levels in the luteal phase, suggesting that RANKL is a modulator of progesterone signaling in normal and malignant breast tissue and a potential biomarker of progesterone action and blockade.	Progesterone	94-106	TNF superfamily member 11	Homo sapiens	164-169
25007964-11	2014	In normal breast and in breast cancer, RANKL mRNA and protein expression fluctuate with serum progesterone with highest levels in the luteal phase, suggesting that RANKL is a modulator of progesterone signaling in normal and malignant breast tissue and a potential biomarker of progesterone action and blockade.	Progesterone	188-200	TNF superfamily member 11	Homo sapiens	39-44
25007964-11	2014	In normal breast and in breast cancer, RANKL mRNA and protein expression fluctuate with serum progesterone with highest levels in the luteal phase, suggesting that RANKL is a modulator of progesterone signaling in normal and malignant breast tissue and a potential biomarker of progesterone action and blockade.	Progesterone	188-200	TNF superfamily member 11	Homo sapiens	164-169
24842191-4	2014	Miconazole inhibited RANKL-induced osteoclast formation in a dose-dependent manner without cytotoxicity.	Miconazole	0-10	TNF superfamily member 11	Homo sapiens	21-26
24842191-6	2014	Miconazole suppressed RANKL-induced expression of c-Fos and NFATc1, two essential transcription factors for osteoclast differentiation.	Miconazole	0-10	TNF superfamily member 11	Homo sapiens	22-27
24102429-16	2014	Surprisingly, forskolin, a PKA activator, increased TNF-alpha-induced RANKL expression.	Colforsin	14-23	TNF superfamily member 11	Homo sapiens	70-75
24115533-7	2014	Receptor activator of nuclear factor kappa B ligand, an osteoclast inducer, was also upregulated, indicating that osteocytes would also participated in activation of osteoclasts, which played a major role in the degradation process of beta-TCP and new bone remodeling.	beta-tricalcium phosphate	235-243	TNF superfamily member 11	Homo sapiens	0-51
25032991-7	2014	Our in vitro data indicate that thiazolidinediones dose-dependently inhibit osteoclastogenesis from bone marrow macrophages, but the inhibitory effect is considerably reduced when bone marrow macrophages are pretreated with RANKL.	Thiazolidinediones	32-50	TNF superfamily member 11	Homo sapiens	224-229
25134536-0	2014	A medium-chain fatty acid, capric acid, inhibits RANKL-induced osteoclast differentiation via the suppression of NF-kappaB signaling and blocks cytoskeletal organization and survival in mature osteoclasts.	medium-chain fatty acid	2-25	TNF superfamily member 11	Homo sapiens	49-54
25134536-0	2014	A medium-chain fatty acid, capric acid, inhibits RANKL-induced osteoclast differentiation via the suppression of NF-kappaB signaling and blocks cytoskeletal organization and survival in mature osteoclasts.	decanoic acid	27-38	TNF superfamily member 11	Homo sapiens	49-54
25134536-3	2014	In this study, we investigated the impact of a medium-chain fatty acid, capric acid, on the osteoclast differentiation, function, and survival induced by receptor activator of NF-kappaB ligand (RANKL) and macrophage colony-stimulating factor (MCSF).	medium-chain fatty acid	47-70	TNF superfamily member 11	Homo sapiens	154-192
25134536-3	2014	In this study, we investigated the impact of a medium-chain fatty acid, capric acid, on the osteoclast differentiation, function, and survival induced by receptor activator of NF-kappaB ligand (RANKL) and macrophage colony-stimulating factor (MCSF).	medium-chain fatty acid	47-70	TNF superfamily member 11	Homo sapiens	194-199
25134536-3	2014	In this study, we investigated the impact of a medium-chain fatty acid, capric acid, on the osteoclast differentiation, function, and survival induced by receptor activator of NF-kappaB ligand (RANKL) and macrophage colony-stimulating factor (MCSF).	decanoic acid	72-83	TNF superfamily member 11	Homo sapiens	154-192
25134536-3	2014	In this study, we investigated the impact of a medium-chain fatty acid, capric acid, on the osteoclast differentiation, function, and survival induced by receptor activator of NF-kappaB ligand (RANKL) and macrophage colony-stimulating factor (MCSF).	decanoic acid	72-83	TNF superfamily member 11	Homo sapiens	194-199
25134536-4	2014	Capric acid inhibited RANKL-mediated osteoclastogenesis in bone marrow-derived macrophages and suppressed RANKL-induced IkappaBalpha phosphorylation, p65 nuclear translocation, and NF-kappaB transcriptional activity.	decanoic acid	0-11	TNF superfamily member 11	Homo sapiens	22-27
25134536-4	2014	Capric acid inhibited RANKL-mediated osteoclastogenesis in bone marrow-derived macrophages and suppressed RANKL-induced IkappaBalpha phosphorylation, p65 nuclear translocation, and NF-kappaB transcriptional activity.	decanoic acid	0-11	TNF superfamily member 11	Homo sapiens	106-111
25134536-5	2014	Capric acid further blocked the RANKL-stimulated activation of ERK without affecting JNK or p38.	decanoic acid	0-11	TNF superfamily member 11	Homo sapiens	32-37
25134536-6	2014	The induction of NFATc1 in response to RANKL was also attenuated by capric acid.	decanoic acid	68-79	TNF superfamily member 11	Homo sapiens	39-44
25134536-7	2014	In addition, capric acid abrogated M-CSF and RANKL-mediated cytoskeleton reorganization, which is crucial for the efficient bone resorption of osteoclasts.	decanoic acid	13-24	TNF superfamily member 11	Homo sapiens	45-50
25032991-11	2014	However, the ability of thiazolidinediones to inhibit the expression of NFATc1, c-Fos and the four osteoclast genes is notably weakened in RANKL-pretreated bone marrow macrophages.	Thiazolidinediones	24-42	TNF superfamily member 11	Homo sapiens	139-144
25032991-9	2014	Nonetheless, thiazolidinediones inhibit osteoclastogenesis by suppressing RANKL-induced expression of NFATc1 and c-Fos, two key transcriptional regulators of osteoclastogenesis, in bone marrow macrophages.	Thiazolidinediones	13-31	TNF superfamily member 11	Homo sapiens	74-79
25032991-10	2014	In addition, thiazolidinediones inhibit the RANKL-induced expression of osteoclast genes encoding matrix metalloproteinase 9, cathepsin K, tartrate-resistant acid phosphatase and carbonic anhydrase II in bone marrow macrophages.	Thiazolidinediones	13-31	TNF superfamily member 11	Homo sapiens	44-49
24742230-7	2014	Quantitative reverse transcription-polymerase chain reaction (RT-PCR) analysis indicated that dioscin could increase the ratio of osteoprotegerin (OPG)/receptor activator of NF-kappaB ligand (RANKL) and up-regulate the level of Lrp5 and beta-catenin.	dioscin	94-101	TNF superfamily member 11	Homo sapiens	192-197
24470120-7	2014	C3 gene expression in bone was increased in the high bone turnover states of ovariectomy (OVX) or a receptor activator of NF-kappaB ligand (RANKL) injection, and blocking the action of C3a with the daily administration of SB290157 resulted in the attenuation of bone formation elevated by OVX and the exacerbation of bone loss.	SB 290157	222-230	TNF superfamily member 11	Homo sapiens	100-138
24473535-5	2014	RESULTS: In the WOMAN Study, higher OPG was associated with higher CAC, and higher total RANKL was associated with lower CAC and triglycerides.	Triglycerides	129-142	TNF superfamily member 11	Homo sapiens	89-94
24473535-6	2014	In the HWS, higher total RANKL was also associated with lower CAC and triglycerides.	Triglycerides	70-83	TNF superfamily member 11	Homo sapiens	25-30
24473535-8	2014	CONCLUSIONS: The inverse association of total RANKL with CAC and triglycerides is a new finding and may have important implications given the increasing use of drugs that modify total RANKL and its receptor, receptor activator of nuclear kappa-B.	Triglycerides	65-78	TNF superfamily member 11	Homo sapiens	46-51
24473535-8	2014	CONCLUSIONS: The inverse association of total RANKL with CAC and triglycerides is a new finding and may have important implications given the increasing use of drugs that modify total RANKL and its receptor, receptor activator of nuclear kappa-B.	Triglycerides	65-78	TNF superfamily member 11	Homo sapiens	184-189
23934086-8	2014	Treatment with topical melatonin was associated with an improvement in the gingival index and pocket depth, a reduction in salivary concentrations of RANKL and increase in salivary concentrations of OPG, which indicates that melatonin has a favorable effect in slowing osteoclastogenesis, improving the quality of alveolar bone and preventing the progression of periodontal disease.	Melatonin	23-32	TNF superfamily member 11	Homo sapiens	150-155
23934086-8	2014	Treatment with topical melatonin was associated with an improvement in the gingival index and pocket depth, a reduction in salivary concentrations of RANKL and increase in salivary concentrations of OPG, which indicates that melatonin has a favorable effect in slowing osteoclastogenesis, improving the quality of alveolar bone and preventing the progression of periodontal disease.	Melatonin	225-234	TNF superfamily member 11	Homo sapiens	150-155
25147613-4	2014	The fluorescent compound 12 showed a more potent inhibitory activity on RANKL-induced osteoclastogenesis at 2 muM compared with that of QOA-8a.	qoa-8a	136-142	TNF superfamily member 11	Homo sapiens	72-77
24737168-2	2014	RANKL functions as a major paracrine effector of the mitogenic action of progesterone in mammary epithelium via its receptor RANK and has a role in expansion and regenerative potential of mammary stem cells.	Progesterone	73-85	TNF superfamily member 11	Homo sapiens	0-5
23104956-11	2014	CONCLUSIONS: Impact of heparin on endothelial cells and simultaneously on OPG/RANK/RANKL axis reinforces the presumption of the pathophysiological linkage between bone mineralization and endothelial dysfunction in end-stage renal disease.	Heparin	23-30	TNF superfamily member 11	Homo sapiens	83-88
23934086-0	2014	Effect of topical application of melatonin to the gingiva on salivary osteoprotegerin, RANKL and melatonin levels in patients with diabetes and periodontal disease.	Melatonin	33-42	TNF superfamily member 11	Homo sapiens	87-92
23934086-6	2014	After treatment with melatonin, there was a statistically significant decrease of the gingival index, pocket depth and salivary levels of RANKL, and a significant rise in salivary values of OPG.	Melatonin	21-30	TNF superfamily member 11	Homo sapiens	138-143
24854571-0	2014	Puerarin concurrently stimulates osteoprotegerin and inhibits receptor activator of NF-kappaB ligand (RANKL) and interleukin-6 production in human osteoblastic MG-63 cells.	puerarin	0-8	TNF superfamily member 11	Homo sapiens	102-107
24854571-6	2014	Here we show that puerarin concurrently stimulates osteoprotegerin (OPG) and inhibits receptor activator of nuclear factor-kappaB ligand (RANKL) and Interleukin-6 (IL-6) production by human osteoblastic MG-63 cells containing two estrogen receptor (ER) isotypes.	puerarin	18-26	TNF superfamily member 11	Homo sapiens	86-136
24854571-6	2014	Here we show that puerarin concurrently stimulates osteoprotegerin (OPG) and inhibits receptor activator of nuclear factor-kappaB ligand (RANKL) and Interleukin-6 (IL-6) production by human osteoblastic MG-63 cells containing two estrogen receptor (ER) isotypes.	puerarin	18-26	TNF superfamily member 11	Homo sapiens	138-143
24854571-8	2014	Using small interfering double-stranded RNAs technology, we further demonstrate that the effects of puerarin on OPG and RANKL expression are mediated by both ERalpha and ERbeta but those on IL-6 production primarily by ERalpha.	puerarin	100-108	TNF superfamily member 11	Homo sapiens	120-125
24934156-1	2014	Parathyroid hormone (PTH) and the sympathetic tone promote Rankl expression in osteoblasts and osteoclast differentiation by enhancing cyclic adenosine monophosphate production through an unidentified transcription factor for PTH and through ATF4 for the sympathetic tone.	Cyclic AMP	135-165	TNF superfamily member 11	Homo sapiens	59-64
24982847-7	2014	With the new generation bisphosphonate zoledronic acid (ZA) or denosumab (anti-RANKL activity), one can reduce the number of patients who experience SREs, decrease the annual incidence of SREs and delay the median time to first SRE.	Diphosphonates	24-38	TNF superfamily member 11	Homo sapiens	79-84
24982847-7	2014	With the new generation bisphosphonate zoledronic acid (ZA) or denosumab (anti-RANKL activity), one can reduce the number of patients who experience SREs, decrease the annual incidence of SREs and delay the median time to first SRE.	Zoledronic Acid	39-54	TNF superfamily member 11	Homo sapiens	79-84
24959146-3	2014	Reactive oxygen species (ROS) are emerging as intracellular redox signaling molecules involved in the regulation of bone metabolism, including receptor activator of nuclear factor-kappaB ligand-dependent osteoclast differentiation, but they also have cytotoxic effects that include lipoperoxidation and oxidative damage to proteins and DNA.	Reactive Oxygen Species	0-23	TNF superfamily member 11	Homo sapiens	143-193
24959146-3	2014	Reactive oxygen species (ROS) are emerging as intracellular redox signaling molecules involved in the regulation of bone metabolism, including receptor activator of nuclear factor-kappaB ligand-dependent osteoclast differentiation, but they also have cytotoxic effects that include lipoperoxidation and oxidative damage to proteins and DNA.	Reactive Oxygen Species	25-28	TNF superfamily member 11	Homo sapiens	143-193
24838929-7	2014	Meantime, cells transfected with siRNA significantly decreased the protein level of alkaline phosphatase (ALP) and nuclear factor kappa B ligand (RANKL) in cells under fluoride exposure.	Fluorides	168-176	TNF superfamily member 11	Homo sapiens	146-151
24838929-10	2014	This study proved that the mechanism underlying fluoride induced osteoblastic and osteoclastic differentiation possible was due to activation of ALP and RANKL mediated by PERK in OS732 cells.	Fluorides	48-56	TNF superfamily member 11	Homo sapiens	153-158
24443409-0	2014	Bisphosphonates inhibit osteosarcoma-mediated osteolysis via attenuation of tumor expression of MCP-1 and RANKL.	Diphosphonates	0-15	TNF superfamily member 11	Homo sapiens	106-111
24630975-3	2014	In this study, HDDQ dose-dependently inhibited the early stage of RANKL-mediated osteoclast differentiation in bone marrow macrophages (BMMs) without cytotoxicity.	9-hydroxy-6,7-dimethoxydalbergiquinol	15-19	TNF superfamily member 11	Homo sapiens	66-71
24357524-1	2014	In search of anti-bone resorbing agents for the potential treatment of osteoporosis, we synthesized a novel compound Tert-butyl 4-(3-[1H-indole-2-carboxamido]benzoyl)piperazine-1-carboxylate (OA10) and found that OA10 is capable of inhibiting RANKL-mediated osteoclast formation and osteoclastic bone resorption in a dose-dependent manner.	tert-butyl 4-(3-(1H-indole-2-carboxamido)benzoyl)piperazine-1-carboxylate	117-190	TNF superfamily member 11	Homo sapiens	243-248
24742230-8	2014	And by RNA interference analysis, we proved that the effect of dioscin increasing the ratio of OPG/RANKL was dependent on Lrp5 pathway.	dioscin	63-70	TNF superfamily member 11	Homo sapiens	99-104
24705502-0	2014	Placotylene A, an inhibitor of the receptor activator of nuclear factor-kappaB ligand-induced osteoclast differentiation, from a Korean sponge Placospongia sp.	14-iodotetradeca-13-en-3,5-diyn-1-ol	0-13	TNF superfamily member 11	Homo sapiens	35-85
24705502-3	2014	Placotylene A (1) displayed inhibitory activity against RANKL-induced osteoclast differentiation at 10 muM while placotylene B (2) did not show any significant activity up to 100 muM, respectively.	14-iodotetradeca-13-en-3,5-diyn-1-ol	0-13	TNF superfamily member 11	Homo sapiens	56-61
24705502-1	2014	A new inhibitor, placotylene A (1), of the receptor activator of nuclear factor-kappaB ligand (RANKL)-induced osteoclast differentiation, and a regioisomer of placotylene A, placotylene B (2), were isolated from a Korean marine sponge Placospongia sp.	14-iodotetradeca-13-en-3,5-diyn-1-ol	17-30	TNF superfamily member 11	Homo sapiens	43-93
24705502-1	2014	A new inhibitor, placotylene A (1), of the receptor activator of nuclear factor-kappaB ligand (RANKL)-induced osteoclast differentiation, and a regioisomer of placotylene A, placotylene B (2), were isolated from a Korean marine sponge Placospongia sp.	14-iodotetradeca-13-en-3,5-diyn-1-ol	17-30	TNF superfamily member 11	Homo sapiens	95-100
24518283-6	2014	The secretion of TNF-alpha (from RAW 264.7), OPG and RANKL protein (from ROS 17/2.8) was analyzed by ELISA.	ros	73-76	TNF superfamily member 11	Homo sapiens	53-58
24518283-7	2014	The OPG and RANKL mRNA from ROS 17/2.8 was detected by RT-PCR.	ros	28-31	TNF superfamily member 11	Homo sapiens	12-17
24518283-9	2014	The ratio of OPG/RANKL in the 8% SCPP group was significantly increased compared to that of all other test groups.	scpp	33-37	TNF superfamily member 11	Homo sapiens	17-22
24518283-11	2014	In general, this study showed that 8% SCPP particles can inhibit the expression of TNF-alpha and RANKL, promote the expression of OPG so that SCPP can inhibit bone resorption and promote bone formation, and then inhibit aseptic loosening.	scpp	38-42	TNF superfamily member 11	Homo sapiens	97-102
23624721-7	2014	Interestingly, LPA stimulated osteoclast stimulatory transmembrane protein (OC-STAMP) and P2X7 receptor mRNA expression during osteoclast fusion under a RANKL limiting condition.	lysophosphatidic acid	15-18	TNF superfamily member 11	Homo sapiens	153-158
24486161-4	2014	Sex hormones, in particular progesterone, induce RANKL expression resulting in proliferation of mammary epithelial cells.	Progesterone	28-40	TNF superfamily member 11	Homo sapiens	49-54
23832494-3	2014	Herein, we found that costunolide significantly inhibited RANKL-induced BMM differentiation into osteoclasts in a dose-dependent manner without affecting cytotoxicity.	costunolide	22-33	TNF superfamily member 11	Homo sapiens	58-63
23832494-7	2014	Taken together, our results suggest that costunolide inhibited RANKL-induced osteoclast differentiation by suppressing RANKL-mediated c-Fos transcriptional activity.	costunolide	41-52	TNF superfamily member 11	Homo sapiens	63-68
23832494-7	2014	Taken together, our results suggest that costunolide inhibited RANKL-induced osteoclast differentiation by suppressing RANKL-mediated c-Fos transcriptional activity.	costunolide	41-52	TNF superfamily member 11	Homo sapiens	119-124
24598408-8	2014	The expression of osteoclastogenesis-related genes (RANKL and MCSF) in bone-marrow-derived mesenchymal cells (BMSCs) with the involvement of macrophages was decreased, whereas OPG expression was enhanced on SMS coatings compared to HA coatings, indicating that SMS coatings also downregulated the osteoclastogenesis.	sms	207-210	TNF superfamily member 11	Homo sapiens	52-57
24598408-8	2014	The expression of osteoclastogenesis-related genes (RANKL and MCSF) in bone-marrow-derived mesenchymal cells (BMSCs) with the involvement of macrophages was decreased, whereas OPG expression was enhanced on SMS coatings compared to HA coatings, indicating that SMS coatings also downregulated the osteoclastogenesis.	sms	261-264	TNF superfamily member 11	Homo sapiens	52-57
24372640-5	2014	The signal transduction mechanisms underlying osteoblast and osteoclast differentiation and coupling with one another are discussed with a focus on how melatonin, through the regulation of RANKL and osteoprotegerin synthesis and release from osteoblasts, can induce osteoblastogenesis while inhibiting osteoclastogenesis.	Melatonin	152-161	TNF superfamily member 11	Homo sapiens	189-194
23115104-11	2014	Importantly, silibinin also decreased the expression of osteomimicry biomarkers (RANKL, Runx2, osteocalcin, and PTHrP) in cell culture (PC3 and C4-2B cells) and/or in PC3 tumors.	Silybin	13-22	TNF superfamily member 11	Homo sapiens	81-86
24496001-10	2014	RANKL inhibition also reduced skeletal tumor burden, presumably through the indirect mechanism of blocking tumor-induced osteoclastogenesis and resultant production of growth factors and calcium from the bone microenvironment.	Calcium	187-194	TNF superfamily member 11	Homo sapiens	0-5
24496001-11	2014	RANKL inhibition also provided an additive benefit to docetaxel treatment by augmenting the reduction of tumor burden.	Docetaxel	54-63	TNF superfamily member 11	Homo sapiens	0-5
24360989-3	2014	Exposing the BMCs to 3%, 5%, or 10% O2 in the presence of receptor activator of NF-kappaB ligand (RANKL) and macrophage colony-stimulating factor (M-CSF) generated tartrate-resistant acid phosphatase (TRAP)-positive multinuclear cells, consistent with OCs.	Oxygen	36-38	TNF superfamily member 11	Homo sapiens	58-96
24463094-6	2014	Betulinic acid blocked an increase in the receptor activator of nuclear factor-kappa B ligand (RANKL)/osteoprotegerin ratio by downregulating RANKL protein expression in PTHrP-treated human osteoblastic cells.	betulinic acid	0-14	TNF superfamily member 11	Homo sapiens	142-147
24463094-6	2014	Betulinic acid blocked an increase in the receptor activator of nuclear factor-kappa B ligand (RANKL)/osteoprotegerin ratio by downregulating RANKL protein expression in PTHrP-treated human osteoblastic cells.	betulinic acid	0-14	TNF superfamily member 11	Homo sapiens	42-93
24463094-6	2014	Betulinic acid blocked an increase in the receptor activator of nuclear factor-kappa B ligand (RANKL)/osteoprotegerin ratio by downregulating RANKL protein expression in PTHrP-treated human osteoblastic cells.	betulinic acid	0-14	TNF superfamily member 11	Homo sapiens	95-100
24360989-3	2014	Exposing the BMCs to 3%, 5%, or 10% O2 in the presence of receptor activator of NF-kappaB ligand (RANKL) and macrophage colony-stimulating factor (M-CSF) generated tartrate-resistant acid phosphatase (TRAP)-positive multinuclear cells, consistent with OCs.	Oxygen	36-38	TNF superfamily member 11	Homo sapiens	98-103
24605212-8	2014	Eldecalcitol administration suppressed RANKL expression in osteoblasts.	eldecalcitol	0-12	TNF superfamily member 11	Homo sapiens	39-44
24370195-6	2014	RESULTS: Both CS- and LPS-applications upregulated COX-2 and RANKL but downregulated OPG.	Cesium	14-16	TNF superfamily member 11	Homo sapiens	61-66
24370195-8	2014	NS398 (a specific inhibitor of COX-2) significantly inhibited CS-induced RANKL-upregulation but not LPS-induced RANKL upregulation, indicating a critical role of COX-2/PGE2 pathway in CS-induced osteoclastogenesis.	N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide	0-5	TNF superfamily member 11	Homo sapiens	73-78
24370195-8	2014	NS398 (a specific inhibitor of COX-2) significantly inhibited CS-induced RANKL-upregulation but not LPS-induced RANKL upregulation, indicating a critical role of COX-2/PGE2 pathway in CS-induced osteoclastogenesis.	Cesium	62-64	TNF superfamily member 11	Homo sapiens	73-78
24333429-3	2014	In this study, we for the first time demonstrated that dioscin suppressed RANKL-mediated osteoclast differentiation and bone resorption in vitro in a dose-dependent manner.	dioscin	55-62	TNF superfamily member 11	Homo sapiens	74-79
24481680-0	2014	Andrographolide prevents human breast cancer-induced osteoclastic bone loss via attenuated RANKL signaling.	andrographolide	0-15	TNF superfamily member 11	Homo sapiens	91-96
24333429-5	2014	Further molecular analysis revealed that dioscin abrogated AKT phosphorylation, which subsequently impaired RANKL-induced nuclear factor-kappaB (NF-kappaB) signaling pathway and inhibited NFATc1 transcriptional activity.	dioscin	41-48	TNF superfamily member 11	Homo sapiens	108-113
24333429-7	2014	Together our data demonstrate that dioscin suppressed RANKL-induced osteoclast formation and function through Akt signaling cascades.	dioscin	35-42	TNF superfamily member 11	Homo sapiens	54-59
24615483-0	2014	Raloxifene pharmacodynamics is influenced by genetic variants in the RANKL/RANK/OPG system and in the Wnt signaling pathway.	Raloxifene Hydrochloride	0-10	TNF superfamily member 11	Homo sapiens	69-74
25182258-10	2014	Positive correlation between OPG concentration and HCO3 -and BE levels has been observed, as well as negative correlation between RANKL/OPG ratio and HCO3 -and BE levels.	Bicarbonates	150-154	TNF superfamily member 11	Homo sapiens	130-135
25182258-10	2014	Positive correlation between OPG concentration and HCO3 -and BE levels has been observed, as well as negative correlation between RANKL/OPG ratio and HCO3 -and BE levels.	Beryllium	160-162	TNF superfamily member 11	Homo sapiens	130-135
24615483-3	2014	As the receptor activator of the nuclear factor kappaB (RANK) ligand (RANKL)/RANK/osteoprotegerin (OPG) system is essential for osteoclastogensis and Wnt signaling pathway for osteoblastogenesis, we decided to evaluate the raloxifene treatment in regard to selected polymorphisms in key genes of these two main bone regulatory pathways.	Raloxifene Hydrochloride	223-233	TNF superfamily member 11	Homo sapiens	70-75
24615483-9	2014	CONCLUSIONS: We have shown that, in postmenopausal osteoporotic women treated with raloxifene, the efficacy of raloxifene treatment might be influenced by +34901G&gt;A in TNFRSF11A gene and -1397_-1396insGGA in the SOST gene as well as -643C&gt;T in TNFSF11 gene and +34694C&gt;T in TNFRSF11A gene.	Raloxifene Hydrochloride	83-93	TNF superfamily member 11	Homo sapiens	250-257
25365870-3	2014	Strontium ranelate activates the Wnt signal pathway (with participation of calcium-sensitive receptor), increases the replication activity (by changing the function of RANKL/RANK/OPG system) thus suppressing the apoptosis of osteoblasts, and retards the resorptive function by accelerating the apoptosis of osteoclasts.	strontium ranelate	0-18	TNF superfamily member 11	Homo sapiens	168-173
24615483-9	2014	CONCLUSIONS: We have shown that, in postmenopausal osteoporotic women treated with raloxifene, the efficacy of raloxifene treatment might be influenced by +34901G&gt;A in TNFRSF11A gene and -1397_-1396insGGA in the SOST gene as well as -643C&gt;T in TNFSF11 gene and +34694C&gt;T in TNFRSF11A gene.	Raloxifene Hydrochloride	111-121	TNF superfamily member 11	Homo sapiens	250-257
24200305-10	2013	Importantly, the relative OPG/RANKL expression ratio was significantly increased upon induction by H2S, an effect that was enhanced by tension-force application.	Hydrogen Sulfide	99-102	TNF superfamily member 11	Homo sapiens	30-35
25345075-2	2014	RANKL in bone has also been shown to serve as a chemoattractant for cancer cells, thu explaining the tropism of certain cancers such as breast and prostate cancer to preferentially metastasize to bone.	thu	82-85	TNF superfamily member 11	Homo sapiens	0-5
24370273-8	2013	Prostate cancer factors increased basal calcium levels and calcium fluctuations, induced nuclear localization of nuclear factor of activated t-cells (NFAT)c1, and activated prolonged phosphorylation of ERK1/2 in RANKL-primed osteoclast precursors.	Calcium	40-47	TNF superfamily member 11	Homo sapiens	212-217
24337478-2	2013	that progesterone regulates RANKL in an ex vivo microstructure model of the human breast, but dispute the suppression of estradiol on progesterone-stimulated RANKL expression.	Progesterone	5-17	TNF superfamily member 11	Homo sapiens	28-33
24337478-2	2013	that progesterone regulates RANKL in an ex vivo microstructure model of the human breast, but dispute the suppression of estradiol on progesterone-stimulated RANKL expression.	Estradiol	121-130	TNF superfamily member 11	Homo sapiens	158-163
24337478-2	2013	that progesterone regulates RANKL in an ex vivo microstructure model of the human breast, but dispute the suppression of estradiol on progesterone-stimulated RANKL expression.	Progesterone	134-146	TNF superfamily member 11	Homo sapiens	158-163
24337478-3	2013	RANKL responds to progesterone in a three-dimensional organoid culture model under conditions mimicking luteal-phase hormone concentration, suggesting that the microstructure may not be crucial to demonstrate progesterone responsiveness.	Progesterone	18-30	TNF superfamily member 11	Homo sapiens	0-5
25747033-4	2014	Birefringent polyethylene wear particles were found behind the metal cup in macrophages containing pro-inflammatory tumor necrosis factor-alpha and interleukin-1beta, whereas fibroblast-like cells stained for osteoclastogenic receptor activator of nuclear factor kappa B ligand (RANKL).	Polyethylene	13-25	TNF superfamily member 11	Homo sapiens	279-284
24200305-11	2013	CONCLUSIONS: H2S could promote osteogenic differentiation by regulating the relative OPG/RANKL expression ratio of hPDLCs, which is enhanced by tension force.	Hydrogen Sulfide	13-16	TNF superfamily member 11	Homo sapiens	89-94
23716040-5	2013	Bone resorption is reduced by increased synthesis of osteoprogeterin (OPG), a decoy receptor that prevents receptor activator of NK-kappaB ligand (RANKL) in binding to its receptor.	osteoprogeterin	53-68	TNF superfamily member 11	Homo sapiens	107-145
23339033-0	2013	Involvement of geranylgeranylation of Rho and Rac GTPases in adipogenic and RANKL expression, which was inhibited by simvastatin.	Simvastatin	117-128	TNF superfamily member 11	Homo sapiens	76-81
23339033-2	2013	Statins also inhibit adipogenic differentiation and receptor activator of NFkappaB ligand (RANKL) expression, possibly through the mevalonic acid pathway, although the involvement of that pathway and effector proteins in these cellular events has not been fully clarified.	Mevalonic Acid	131-145	TNF superfamily member 11	Homo sapiens	52-89
23339033-2	2013	Statins also inhibit adipogenic differentiation and receptor activator of NFkappaB ligand (RANKL) expression, possibly through the mevalonic acid pathway, although the involvement of that pathway and effector proteins in these cellular events has not been fully clarified.	Mevalonic Acid	131-145	TNF superfamily member 11	Homo sapiens	91-96
23339033-3	2013	In the present study, we aimed to elucidate the mechanism of the effects of simvastatin on adipogenic differentiation and calcitriol-induced RANKL expression in bone marrow stromal ST2 cells.	Calcitriol	122-132	TNF superfamily member 11	Homo sapiens	141-146
23339033-5	2013	In addition, RANKL expression induced by calcitriol was abrogated by simvastatin in ST2 cells.	Calcitriol	41-51	TNF superfamily member 11	Homo sapiens	13-18
23339033-5	2013	In addition, RANKL expression induced by calcitriol was abrogated by simvastatin in ST2 cells.	Simvastatin	69-80	TNF superfamily member 11	Homo sapiens	13-18
23744843-0	2013	Analyses of RANK and RANKL in the post-GWAS context: functional evidence of vitamin D stimulation through a RANKL distal region.	Vitamin D	76-85	TNF superfamily member 11	Homo sapiens	108-113
23744843-9	2013	In conclusion, the GWA-associated SNP rs9594738 lies in a region involved in transcription regulation through which vitamin D could be regulating RANKL expression and bone mineral density.	Vitamin D	116-125	TNF superfamily member 11	Homo sapiens	146-151
23716040-5	2013	Bone resorption is reduced by increased synthesis of osteoprogeterin (OPG), a decoy receptor that prevents receptor activator of NK-kappaB ligand (RANKL) in binding to its receptor.	osteoprogeterin	53-68	TNF superfamily member 11	Homo sapiens	147-152
22901640-2	2013	A new alternative class of agents, receptor activator of nuclear factor kappa-B ligand (RANKL) inhibitors, are now available for use in these indications and have the potential to replace intravenous BPs.	Diphosphonates	200-203	TNF superfamily member 11	Homo sapiens	35-86
23716040-5	2013	Bone resorption is reduced by increased synthesis of osteoprogeterin (OPG), a decoy receptor that prevents receptor activator of NK-kappaB ligand (RANKL) in binding to its receptor.	SCHEMBL12347590	70-73	TNF superfamily member 11	Homo sapiens	107-145
22901640-2	2013	A new alternative class of agents, receptor activator of nuclear factor kappa-B ligand (RANKL) inhibitors, are now available for use in these indications and have the potential to replace intravenous BPs.	Diphosphonates	200-203	TNF superfamily member 11	Homo sapiens	88-93
23716040-5	2013	Bone resorption is reduced by increased synthesis of osteoprogeterin (OPG), a decoy receptor that prevents receptor activator of NK-kappaB ligand (RANKL) in binding to its receptor.	SCHEMBL12347590	70-73	TNF superfamily member 11	Homo sapiens	147-152
23716040-6	2013	Moreover, melatonin is believed to reduce the synthesis of RANKL preventing further bone resorption.	Melatonin	10-19	TNF superfamily member 11	Homo sapiens	59-64
24370033-1	2013	This study was aimed to investigate the effect of bortezomib combined with bisphosphonates on serum levels of DKK-1 and RANKL in multiple myeloma patients, and to evaluate its role in the therapy of osteolytic lesion.	Bortezomib	50-60	TNF superfamily member 11	Homo sapiens	120-125
23401151-5	2013	Moreover, treatment with licochalcone A and isoliquiritigenin as the active components, whose contents are increased by the roasting process, remarkably suppressed RANKL-induced osteoclast formation in BMMs, respectively.	licochalcone A	25-39	TNF superfamily member 11	Homo sapiens	164-169
23401151-5	2013	Moreover, treatment with licochalcone A and isoliquiritigenin as the active components, whose contents are increased by the roasting process, remarkably suppressed RANKL-induced osteoclast formation in BMMs, respectively.	isoliquiritigenin	44-61	TNF superfamily member 11	Homo sapiens	164-169
24370033-1	2013	This study was aimed to investigate the effect of bortezomib combined with bisphosphonates on serum levels of DKK-1 and RANKL in multiple myeloma patients, and to evaluate its role in the therapy of osteolytic lesion.	Diphosphonates	75-90	TNF superfamily member 11	Homo sapiens	120-125
24370033-7	2013	It is concluded that bortezomib combined with bisphosphonates obviously reduce the serum levels of DKK-1 and RANKL, thus has beneficial effect on osteolytic lesion.	Bortezomib	21-31	TNF superfamily member 11	Homo sapiens	109-114
24370033-7	2013	It is concluded that bortezomib combined with bisphosphonates obviously reduce the serum levels of DKK-1 and RANKL, thus has beneficial effect on osteolytic lesion.	Diphosphonates	46-61	TNF superfamily member 11	Homo sapiens	109-114
23529979-2	2013	In an attempt to exploit the capacity of Receptor Activator of Nuclear factor Kappa-B Ligand (RANKL) to stimulate osteoclast-like cells formation, this study explored different loading methods for RANKL in injectable calcium phosphate cement (CPC) and the effect on release and biological activity.	cpc	243-246	TNF superfamily member 11	Homo sapiens	197-202
23529979-0	2013	RANKL delivery from calcium phosphate containing PLGA microspheres.	calcium phosphate	20-37	TNF superfamily member 11	Homo sapiens	0-5
23529979-3	2013	RANKL was loaded via the liquid phase of CPC by adsorption onto or incorporation into poly(lactic-co-glycolic acid) (PLGA) microspheres with two different morphologies (i.e., hollow and dense), which were subsequently embedded in CPC.	cpc	41-44	TNF superfamily member 11	Homo sapiens	0-5
23529979-2	2013	In an attempt to exploit the capacity of Receptor Activator of Nuclear factor Kappa-B Ligand (RANKL) to stimulate osteoclast-like cells formation, this study explored different loading methods for RANKL in injectable calcium phosphate cement (CPC) and the effect on release and biological activity.	calcium phosphate	217-234	TNF superfamily member 11	Homo sapiens	94-99
23529979-2	2013	In an attempt to exploit the capacity of Receptor Activator of Nuclear factor Kappa-B Ligand (RANKL) to stimulate osteoclast-like cells formation, this study explored different loading methods for RANKL in injectable calcium phosphate cement (CPC) and the effect on release and biological activity.	calcium phosphate	217-234	TNF superfamily member 11	Homo sapiens	197-202
23529979-3	2013	RANKL was loaded via the liquid phase of CPC by adsorption onto or incorporation into poly(lactic-co-glycolic acid) (PLGA) microspheres with two different morphologies (i.e., hollow and dense), which were subsequently embedded in CPC.	Polylactic Acid-Polyglycolic Acid Copolymer	86-115	TNF superfamily member 11	Homo sapiens	0-5
24293011-4	2013	CX-4945 inhibited the RANKL-induced activation of TRAP and NFATc1 expression accompanied with suppression of Akt phosphorylation, but in contrast, it enhanced the BMP2-mediated ALP induction and MAPK ERK1/2 phosphorylation.	silmitasertib	0-7	TNF superfamily member 11	Homo sapiens	22-27
24074896-0	2013	Inhibitory effect of metformin on bone metastasis of cancer via OPG/RANKL/RANK system.	Metformin	21-30	TNF superfamily member 11	Homo sapiens	68-73
24074896-5	2013	In addition, metformin as a commonly used medicine for type 2 diabetes is a negative regulator of RANKL and inhibits the differentiation of osteoclasts.	Metformin	13-22	TNF superfamily member 11	Homo sapiens	98-103
24074896-6	2013	We present a hypothesis that metformin serves an inhibitory effect on bone metastasis of cancer via OPG/RANKL/RANK system.	Metformin	29-38	TNF superfamily member 11	Homo sapiens	104-109
24116222-6	2013	Further, chafuroside B at 1 microM also suppressed UVB-induced expression of receptor activator of nuclear factor kappaB ligand (RANKL) mRNA.	3,4,11-trihydroxy-2-(hydroxymethyl)-8-(4-hydroxyphenyl)-3,4,4a,11b-tetrahydro-2H,10H-pyrano(2',3'-4,5)furo(3,2-g)chromen-10-one	9-22	TNF superfamily member 11	Homo sapiens	77-127
24070606-3	2013	In human smooth muscle cells, Cu(2+)-oxidized LDL (CuLDL) 10-50 mug/ml increased reactive oxygen species (ROS) and RANKL level in a dose-dependent manner, whereas OPG level was not affected.	cupric ion	30-36	TNF superfamily member 11	Homo sapiens	115-120
24070606-5	2013	Vivit, an inhibitor of the transcription factor NFAT, reduced the CuLDL-induced increase in RANKL, whereas PKA and NFkappaB inhibitors were ineffective.	NFAT Inhibitor	0-5	TNF superfamily member 11	Homo sapiens	92-97
24070606-6	2013	LDL oxidized by myeloperoxidase (MPO-LDL), or other pro-oxidant conditions such as ultraviolet A (UVA) irradiation, incubation with H2O2 or with buthionine sulfoximine (BSO), an inhibitor of glutathione synthesis, also induced an oxidative stress and enhanced RANKL level.	Buthionine Sulfoximine	145-167	TNF superfamily member 11	Homo sapiens	260-265
24116222-6	2013	Further, chafuroside B at 1 microM also suppressed UVB-induced expression of receptor activator of nuclear factor kappaB ligand (RANKL) mRNA.	3,4,11-trihydroxy-2-(hydroxymethyl)-8-(4-hydroxyphenyl)-3,4,4a,11b-tetrahydro-2H,10H-pyrano(2',3'-4,5)furo(3,2-g)chromen-10-one	9-22	TNF superfamily member 11	Homo sapiens	129-134
24116222-7	2013	These results indicate that chafuroside B promotes repair of UVB-induced DNA damage and ameliorates the generation of IL-10, TNF-alpha, PGE2, and RANKL, all of which are UVB-induced immunosuppression related mediators.	3,4,11-trihydroxy-2-(hydroxymethyl)-8-(4-hydroxyphenyl)-3,4,4a,11b-tetrahydro-2H,10H-pyrano(2',3'-4,5)furo(3,2-g)chromen-10-one	28-41	TNF superfamily member 11	Homo sapiens	146-151
23588618-3	2013	Our aim was to find out whether triglyceride (TG) metabolism in bone tissue is associated with osteoblast and osteoclast differentiation by gene expression analysis of lipoprotein lipase (LPL), hormone sensitive lipase (HSL), fatty acid synthase (FASN), adiponectin, RUNX2, RANK, RANKL and OPG.	Triglycerides	32-44	TNF superfamily member 11	Homo sapiens	280-285
23631878-6	2013	Dopamine and dopamine D2-like receptor agonists, but not a D1-like receptor agonist, suppressed intracellular cAMP concentration as well as RANKL-meditated induction of c-Fos and NFATc1 mRNA expression in human osteoclast precursor cells.	Dopamine	0-8	TNF superfamily member 11	Homo sapiens	140-145
22923429-6	2013	Studies assessing mechanisms of estrogen action on bone in humans have identified effects of estrogen on RANKL expression by several different cell types in the bone microenvironment, a role for TNF-alpha and IL-1beta in mediating effects of estrogen deficiency on bone, and possible regulation of the Wnt inhibitor, sclerostin, by estrogen.	sclerostin	317-327	TNF superfamily member 11	Homo sapiens	105-110
24011086-11	2013	Moreover, dimethyl fumarate, a NF-kappaB inhibitor, inhibited RANKL-induced EMT, cell migration, and invasion, and upregulated the expressions of Snail, Twist, vimentin, and N-cadherin.	Dimethyl Fumarate	10-27	TNF superfamily member 11	Homo sapiens	62-67
24040204-6	2013	Consistent with this, RANKL mRNA was significantly elevated with 24 h calcium treatment, while OPG and TRAIL expression in human VSMCs was inhibited.	Calcium	70-77	TNF superfamily member 11	Homo sapiens	22-27
23888411-11	2013	Both parathyroidectomy and treatment with alendronate diminish bone resorption, and correct the OPG/RANKL ratio in favor of OPG, although the mechanisms of their actions are different.	Alendronate	42-53	TNF superfamily member 11	Homo sapiens	100-105
24048691-4	2013	Extracellular addition of UDP-sugars such as UDP-glucose, UDP-galactose, UDP-glucuronic acid, and UDP-N-acetyl glucosamine promoted RANKL-induced osteoclastogenesis, while P2Y14 downregulation by RNA interference inhibited osteoclast formation.	Uridine Diphosphate Sugars	26-36	TNF superfamily member 11	Homo sapiens	132-137
24048691-4	2013	Extracellular addition of UDP-sugars such as UDP-glucose, UDP-galactose, UDP-glucuronic acid, and UDP-N-acetyl glucosamine promoted RANKL-induced osteoclastogenesis, while P2Y14 downregulation by RNA interference inhibited osteoclast formation.	Uridine Diphosphate Glucose	45-56	TNF superfamily member 11	Homo sapiens	132-137
24048691-4	2013	Extracellular addition of UDP-sugars such as UDP-glucose, UDP-galactose, UDP-glucuronic acid, and UDP-N-acetyl glucosamine promoted RANKL-induced osteoclastogenesis, while P2Y14 downregulation by RNA interference inhibited osteoclast formation.	Uridine Diphosphate Galactose	58-71	TNF superfamily member 11	Homo sapiens	132-137
24048691-4	2013	Extracellular addition of UDP-sugars such as UDP-glucose, UDP-galactose, UDP-glucuronic acid, and UDP-N-acetyl glucosamine promoted RANKL-induced osteoclastogenesis, while P2Y14 downregulation by RNA interference inhibited osteoclast formation.	Uridine Diphosphate Glucuronic Acid	73-92	TNF superfamily member 11	Homo sapiens	132-137
24048691-4	2013	Extracellular addition of UDP-sugars such as UDP-glucose, UDP-galactose, UDP-glucuronic acid, and UDP-N-acetyl glucosamine promoted RANKL-induced osteoclastogenesis, while P2Y14 downregulation by RNA interference inhibited osteoclast formation.	Uridine Diphosphate N-Acetylglucosamine	98-122	TNF superfamily member 11	Homo sapiens	132-137
23691159-5	2013	We have identified cardamonin, a chalcone isolated from Alpinia katsumadai Hayata that can affect osteoclastogenesis through modulation of RANKL.	Chalcone	33-41	TNF superfamily member 11	Homo sapiens	139-144
23419777-5	2013	PTEN phosphorylation at threonine 366 (T366) decreased gradually during RANKL-induced osteoclastogenesis, whereas PTEN protein levels were unaffected.	Threonine	24-33	TNF superfamily member 11	Homo sapiens	72-77
23351153-1	2013	The receptor activator of the NF-kappaB ligand (RANKL)-osteoprotegerin (OPG) axis has been shown to play a role in the inflammatory process of atherogenesis and may be regulated by changes in levels of cholesterol.	Cholesterol	202-213	TNF superfamily member 11	Homo sapiens	48-53
23351153-6	2013	Multivariate models for HIV-1(+) subjects, but not in uninfected controls, demonstrated that perturbations in serum cholesterol levels were significantly associated (p&lt;0.05) with perturbations in serum levels of RANKL and OPG, and their ratio (RANKL/OPG).	Cholesterol	116-127	TNF superfamily member 11	Homo sapiens	215-220
23351153-6	2013	Multivariate models for HIV-1(+) subjects, but not in uninfected controls, demonstrated that perturbations in serum cholesterol levels were significantly associated (p&lt;0.05) with perturbations in serum levels of RANKL and OPG, and their ratio (RANKL/OPG).	Cholesterol	116-127	TNF superfamily member 11	Homo sapiens	247-252
23322328-9	2013	Mutation analysis showed homozygosity for a unique missense change (c.130T&gt;C, p.Cys44Arg) in TNFRSF11B that would compromise the cysteine-rich domain of OPG that binds receptor activator of NF-kappaB ligand (RANKL).	Cysteine	132-140	TNF superfamily member 11	Homo sapiens	171-209
23458362-0	2013	A novel role for receptor activator of nuclear factor (NF)-kappabeta ligand (RANKL) in atorvastatin-mediated mobilization of endothelial progenitor cells.	Atorvastatin	87-99	TNF superfamily member 11	Homo sapiens	77-82
23702841-0	2013	RANK/RANK-L/OPG in patients with bone metastases treated with anticancer agents and zoledronic acid: a prospective study.	Zoledronic Acid	84-99	TNF superfamily member 11	Homo sapiens	5-11
24018454-8	2013	Histamine increases bone resorption both by direct effects on osteoclast precursors and osteoclasts, and indirectly, by increasing the expression of RANKL in osteoblasts.	Histamine	0-9	TNF superfamily member 11	Homo sapiens	149-154
23945674-2	2013	We previously reported that DHA, not EPA, inhibited osteoclastogenesis induced by the receptor activator of nuclear factor-kappaB ligand (sRANKL) in vitro.	Docosahexaenoic Acids	28-31	TNF superfamily member 11	Homo sapiens	86-136
23922683-8	2013	Notably, osteogenic media and SB415286 reversed the receptor activator of NF-kappaB ligand (RANKL)/osteoprotegerin (OPG) expression ratio resulting in diminished osteoclastogenic capacity.	3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione	30-38	TNF superfamily member 11	Homo sapiens	52-90
23922683-8	2013	Notably, osteogenic media and SB415286 reversed the receptor activator of NF-kappaB ligand (RANKL)/osteoprotegerin (OPG) expression ratio resulting in diminished osteoclastogenic capacity.	3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione	30-38	TNF superfamily member 11	Homo sapiens	92-97
23411401-1	2013	OBJECTIVE: We previously demonstrated that the activation of transient receptor potential vanilloid 1 (TRPV1), a nociceptive ion channel receptor, by capsaicin led to the up-regulation of the osteoprotegerin (OPG)/receptor activator of nuclear factor kappa B ligand (RANKL) ratio in human periodontal ligament (HPDL) cells.	Capsaicin	150-159	TNF superfamily member 11	Homo sapiens	214-265
23411401-1	2013	OBJECTIVE: We previously demonstrated that the activation of transient receptor potential vanilloid 1 (TRPV1), a nociceptive ion channel receptor, by capsaicin led to the up-regulation of the osteoprotegerin (OPG)/receptor activator of nuclear factor kappa B ligand (RANKL) ratio in human periodontal ligament (HPDL) cells.	Capsaicin	150-159	TNF superfamily member 11	Homo sapiens	267-272
23691159-6	2013	We found that treatment of monocytes with cardamonin suppressed RANKL-induced NF-kappaB activation and this suppression correlated with inhibition of IkappaBalpha kinase and of phosphorylation and degradation of IkappaBalpha, an inhibitor of NF-kappaB.	cardamonin	42-52	TNF superfamily member 11	Homo sapiens	64-69
23104199-14	2013	CONCLUSIONS: An increase in the intake of omega-3 respect to omega-6 may provide protection against the loss of bone mass, since omega-6 favors the osteoclastic activity by diminishing the opg/rankl gene expression in osteoblasts and promotes MSC differentiation into adipocytes, thus diminishing the production of osteoblasts.	omega-6	129-136	TNF superfamily member 11	Homo sapiens	193-198
23271131-1	2013	1alpha,25-Dihydroxyvitamin D3 upregulates the expression of the receptor activator of nuclear factor kB ligand (RANKL), and downregulates osteoprotegerin (OPG) expression.	Calcitriol	0-29	TNF superfamily member 11	Homo sapiens	64-110
23271131-1	2013	1alpha,25-Dihydroxyvitamin D3 upregulates the expression of the receptor activator of nuclear factor kB ligand (RANKL), and downregulates osteoprotegerin (OPG) expression.	Calcitriol	0-29	TNF superfamily member 11	Homo sapiens	112-117
23543663-0	2013	Assessment of OPG/RANK/RANKL gene expression levels in peripheral blood mononuclear cells (PBMC) after treatment with strontium ranelate and ibandronate in patients with postmenopausal osteoporosis.	strontium ranelate	118-136	TNF superfamily member 11	Homo sapiens	23-28
23543663-0	2013	Assessment of OPG/RANK/RANKL gene expression levels in peripheral blood mononuclear cells (PBMC) after treatment with strontium ranelate and ibandronate in patients with postmenopausal osteoporosis.	Ibandronic Acid	141-152	TNF superfamily member 11	Homo sapiens	23-28
23543663-2	2013	AIM: The aim of the reported study was to assess gene expression levels of the OPG/RANK/RANKL system in peripheral blood mononuclear cells (PBMCs) after strontium ranelate (SR) and ibandronate administered to patients with postmenopausal osteoporosis.	strontium ranelate	153-171	TNF superfamily member 11	Homo sapiens	88-93
23543663-2	2013	AIM: The aim of the reported study was to assess gene expression levels of the OPG/RANK/RANKL system in peripheral blood mononuclear cells (PBMCs) after strontium ranelate (SR) and ibandronate administered to patients with postmenopausal osteoporosis.	Ibandronic Acid	181-192	TNF superfamily member 11	Homo sapiens	88-93
23457386-6	2013	Treatment with vitamin D3 increased the RANKL/OPG ratio and DKK-2 expression and reduced DKK-1 expression in each cell population, but did not affect beta-catenin levels.	Cholecalciferol	15-25	TNF superfamily member 11	Homo sapiens	40-45
23178378-0	2013	Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules.	Lenalidomide	23-35	TNF superfamily member 11	Homo sapiens	115-120
23616122-6	2013	In clinical specimens from healthy donors and intact breast tissue microstructures, hormone response was maintained and RANKL expression was under progesterone control, which increased RNA stability.	Progesterone	147-159	TNF superfamily member 11	Homo sapiens	120-125
23616122-7	2013	RANKL was sufficient to trigger cell proliferation and was required for progesterone-induced proliferation.	Progesterone	72-84	TNF superfamily member 11	Homo sapiens	0-5
23616122-8	2013	The findings were validated in vivo where RANKL protein expression in the breast epithelium correlated with serum progesterone levels and the protein was expressed in a subset of luminal cells that express PR.	Progesterone	114-126	TNF superfamily member 11	Homo sapiens	42-47
23178378-3	2013	We found that in vivo concentrations of both lenalidomide (LEN) and pomalidomide (POM) significantly blunted RANKL upregulation normalizing the RANKL/OPG ratio in human osteoprogenitor cells (PreOBs) when co-cultured with MM cells and also inhibited CCL3 production by MM cells.	pomalidomide	68-80	TNF superfamily member 11	Homo sapiens	109-114
23178378-3	2013	We found that in vivo concentrations of both lenalidomide (LEN) and pomalidomide (POM) significantly blunted RANKL upregulation normalizing the RANKL/OPG ratio in human osteoprogenitor cells (PreOBs) when co-cultured with MM cells and also inhibited CCL3 production by MM cells.	pomalidomide	68-80	TNF superfamily member 11	Homo sapiens	144-149
23178378-0	2013	Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules.	pomalidomide	40-52	TNF superfamily member 11	Homo sapiens	115-120
23178378-3	2013	We found that in vivo concentrations of both lenalidomide (LEN) and pomalidomide (POM) significantly blunted RANKL upregulation normalizing the RANKL/OPG ratio in human osteoprogenitor cells (PreOBs) when co-cultured with MM cells and also inhibited CCL3 production by MM cells.	Lenalidomide	45-57	TNF superfamily member 11	Homo sapiens	109-114
23178378-3	2013	We found that in vivo concentrations of both lenalidomide (LEN) and pomalidomide (POM) significantly blunted RANKL upregulation normalizing the RANKL/OPG ratio in human osteoprogenitor cells (PreOBs) when co-cultured with MM cells and also inhibited CCL3 production by MM cells.	Lenalidomide	45-57	TNF superfamily member 11	Homo sapiens	144-149
23443505-8	2013	Compared with mono-culture systems, stimulation with nicotine caused an increased secretion of IL-1beta in serum of human PDL cell-CD4(+) T cell co-culture, and the expression of RANKL in human PDL cells was further upregulated co-cultured with CD4(+) T cells, while no differences were observed in the expression of OPG between the co-culture and mono-culture systems.	Nicotine	53-61	TNF superfamily member 11	Homo sapiens	179-184
23443505-9	2013	Our data suggested that nicotine upregulated IL-1beta secretion, further upregulated RANKL expression in smoking-associated periodontitis, which may aid in the better understanding of the relationship between nicotine and alveolar bone resorption.	Nicotine	24-32	TNF superfamily member 11	Homo sapiens	85-90
23443505-9	2013	Our data suggested that nicotine upregulated IL-1beta secretion, further upregulated RANKL expression in smoking-associated periodontitis, which may aid in the better understanding of the relationship between nicotine and alveolar bone resorption.	Nicotine	209-217	TNF superfamily member 11	Homo sapiens	85-90
23436579-1	2013	Osteoclasts are multinucleated myeloid lineage cells formed in response to macrophage colony-stimulating factor (M-CSF) and receptor activator of NF-kappaB ligand (RANKL) by fusion of bone marrow-derived precursors that circulate in the blood and are attracted to sites of bone resorption in response to factors, such as sphingosine-1 phosphate signaling.	sphingosine 1-phosphate	321-344	TNF superfamily member 11	Homo sapiens	164-169
23275387-1	2013	OBJECTIVE: To study the effects of low-dose prednisolone on the osteoclast-regulating proteins osteoprotegerin (OPG) and RANK ligand (RANKL) and on markers of bone resorption, 1CTP generated by MMPs and CTX-1 generated by cathepsin K, in patients with early RA in relation to inflammation and joint destruction.	Prednisolone	44-56	TNF superfamily member 11	Homo sapiens	121-132
23165727-3	2013	sEphB4 treatment of cultured osteoblasts specifically inhibited EphB4 and ephrinB2 phosphorylation and reduced mRNA levels of late markers of osteoblast/osteocyte differentiation (osteocalcin, dentin matrix protein-1 [DMP-1], sclerostin, matrix-extracellular phosphoglycoprotein [MEPE]), while substantially increasing RANKL.	sephb4	0-6	TNF superfamily member 11	Homo sapiens	319-324
23458303-1	2013	A one-dimensional model for the transport of vitamin D(3) in an osteoblast cell is proposed, from its entry through the membrane to its activation of RANKL synthesis in the nucleus.	Vitamin D	45-54	TNF superfamily member 11	Homo sapiens	150-155
23458303-6	2013	To our knowledge, this is the first time, albeit using a simple model, a description of the complete passage of D(3) through the cell membrane, the cytoplasm, into the cell nucleus, and finally the production of RANKL with its passage to the exterior of the cell, has been modeled.	Cholecalciferol	112-116	TNF superfamily member 11	Homo sapiens	212-217
23275387-1	2013	OBJECTIVE: To study the effects of low-dose prednisolone on the osteoclast-regulating proteins osteoprotegerin (OPG) and RANK ligand (RANKL) and on markers of bone resorption, 1CTP generated by MMPs and CTX-1 generated by cathepsin K, in patients with early RA in relation to inflammation and joint destruction.	Prednisolone	44-56	TNF superfamily member 11	Homo sapiens	134-139
23275387-9	2013	CONCLUSION: Low-dose prednisolone may inhibit progression of joint destruction by interfering with MMP activity, seen as a marked decrease in 1CTP, as well as by impairing osteoclast activation, shown by a stable OPG/RANKL ratio.	Prednisolone	21-33	TNF superfamily member 11	Homo sapiens	217-222
23265887-1	2013	Triaylsulfonamides were identified as novel anti-inflammatory agents, acting by inhibition of RANKL and TNFalpha signaling.	triaylsulfonamides	0-18	TNF superfamily member 11	Homo sapiens	94-99
23600327-5	2013	The constitutive expression of RANKL and Ki-67 and the production of IL-6 and IL-8 were significantly inhibited by Dex treatment.	Dexamethasone	115-118	TNF superfamily member 11	Homo sapiens	31-36
23600327-6	2013	Further, Dex significantly suppressed the stimulatory effects of LPS on RANKL and Ki-67 expression and on IL-6 and IL-8 production.	Dexamethasone	9-12	TNF superfamily member 11	Homo sapiens	72-77
23220557-7	2013	The expression levels of 19 genes were statistically significantly correlated with the severity of AC degeneration and changes of SB structure; these included: ADAMTS1, ASPN, BMP6, BMPER, CCL2, CCL8, COL5A1, COL6A3, COL7A1, COL16A1, FRZB, GDF10, MMP3, OGN, OMD, POSTN, PTGES, TNFSF11 and WNT1.	Antimony	130-132	TNF superfamily member 11	Homo sapiens	276-283
23528950-8	2013	In this manner, bio-silica and bio-polyP cause an increased release of BMP-2, the key mediator activating the anabolic arm of the hydroxyapatite forming cells, and of RANKL.	Silicon Dioxide	20-26	TNF superfamily member 11	Homo sapiens	167-172
23201015-0	2013	UV photoactivation of 7-dehydrocholesterol on titanium implants enhances osteoblast differentiation and decreases Rankl gene expression.	7-dehydrocholesterol	22-42	TNF superfamily member 11	Homo sapiens	114-119
23201015-7	2013	Interestingly, Rankl gene expression was significantly reduced in osteoblasts cultured on 7-DHC-coated Ti surfaces when UV-irradiated for 15 and 30min to 33.56+-15.28% and 28.21+-4.40%, respectively, compared with the control.	7-dehydrocholesterol	90-95	TNF superfamily member 11	Homo sapiens	15-20
22487394-0	2013	Risedronate inhibits bone marrow mesenchymal stem cell adipogenesis and switches RANKL/OPG ratio to impair osteoclast differentiation.	Risedronic Acid	0-11	TNF superfamily member 11	Homo sapiens	81-86
22487394-9	2013	RESULTS: Risedronate not only dose-dependently inhibited the bone marrow adipogenesis from human mesenchymal stem cells but also suppressed receptor activator of nuclear factor-kappaB ligand, not osteoprotegerin, expression in differentiated adipocytes, as well as pro-osteoclastic inflammatory factors.	Risedronic Acid	9-20	TNF superfamily member 11	Homo sapiens	140-211
23735022-8	2013	Two theories try to explain this origin of low BMD: Micronutrients malabsorption (including calcium and vitamin D) determined by villous atrophy has been related to secondary hyperparathyroidism and incapacity to achieve the potential bone mass peak; chronic inflammation was also related with RANKL secretion, osteoclasts activation and increased bone resorption.	Calcium	92-99	TNF superfamily member 11	Homo sapiens	294-299
23735022-8	2013	Two theories try to explain this origin of low BMD: Micronutrients malabsorption (including calcium and vitamin D) determined by villous atrophy has been related to secondary hyperparathyroidism and incapacity to achieve the potential bone mass peak; chronic inflammation was also related with RANKL secretion, osteoclasts activation and increased bone resorption.	Vitamin D	104-113	TNF superfamily member 11	Homo sapiens	294-299
23440520-4	2013	RANKL (receptor activator of NF-kappaB ligand) stimulation did not affect the TRPM7 expression and TRPM7-mediated current was activated in HEK293, RAW264.7, and BMM cells by the regulation of Mg(2+).	Magnesium	192-194	TNF superfamily member 11	Homo sapiens	7-45
22773056-7	2013	RESULTS: RAF265 significantly impaired in vitro differentiation of PBMCs to OCs induced by receptor activator of NF-kB ligand (RANKL) and M-CSF (IC(50)   160 nM).	RAF265	9-15	TNF superfamily member 11	Homo sapiens	91-125
22773056-7	2013	RESULTS: RAF265 significantly impaired in vitro differentiation of PBMCs to OCs induced by receptor activator of NF-kB ligand (RANKL) and M-CSF (IC(50)   160 nM).	RAF265	9-15	TNF superfamily member 11	Homo sapiens	127-132
22587561-14	2013	Interestingly, capsaicin was able to increase the OPG/RANKL ratio, even in the presence of prostaglandin E2, a potent inducer of RANKL.	Capsaicin	15-24	TNF superfamily member 11	Homo sapiens	54-59
22587561-14	2013	Interestingly, capsaicin was able to increase the OPG/RANKL ratio, even in the presence of prostaglandin E2, a potent inducer of RANKL.	Capsaicin	15-24	TNF superfamily member 11	Homo sapiens	129-134
22587561-14	2013	Interestingly, capsaicin was able to increase the OPG/RANKL ratio, even in the presence of prostaglandin E2, a potent inducer of RANKL.	Dinoprostone	91-107	TNF superfamily member 11	Homo sapiens	129-134
23440520-5	2013	Knock-down of TRPM7 by siTRPM7 reduced intracellular Ca(2+) concentration ([Ca(2+)](i)) increases by 0 mM [Mg(2+)](e) in HEK293 cells and inhibited the generation of RANKL-induced Ca(2+) oscillations in RAW264.7 cells.	sitrpm7	23-30	TNF superfamily member 11	Homo sapiens	166-171
23714056-0	2013	[Effect of icariin on the expression of receptor activator nuclear factor-kappaB ligand and osteoprotegerin of human periodontal ligament cells].	icariin	11-18	TNF superfamily member 11	Homo sapiens	40-87
23714056-1	2013	OBJECTIVE: To investigate the effect of icariin on the expression of receptor activator nuclear factor-kappaB ligand (RANKL) and osteoprotegerin (OPG) of human periodontal ligament cells (hPDLC) inhibited by sonicated extracts of Porphyromonas gingivalis (Pg).	icariin	40-47	TNF superfamily member 11	Homo sapiens	69-116
23714056-1	2013	OBJECTIVE: To investigate the effect of icariin on the expression of receptor activator nuclear factor-kappaB ligand (RANKL) and osteoprotegerin (OPG) of human periodontal ligament cells (hPDLC) inhibited by sonicated extracts of Porphyromonas gingivalis (Pg).	icariin	40-47	TNF superfamily member 11	Homo sapiens	118-123
23714056-5	2013	Compared with control group, RANKL and OPG expression changed in groups stimulated with 0.001, 0.01, 0.1, 1 mg/L icariin.	icariin	113-120	TNF superfamily member 11	Homo sapiens	29-34
23714056-7	2013	CONCLUSIONS: The concentration of 0.1 mg/L icariin can inhibit hPDLC expression of RANKL in sonicated extracts of Pg and promote OPG expression.	icariin	43-50	TNF superfamily member 11	Homo sapiens	83-88
23261473-0	2013	Sanguinarine inhibits osteoclast formation and bone resorption via suppressing RANKL-induced activation of NF-kappaB and ERK signaling pathways.	sanguinarine	0-12	TNF superfamily member 11	Homo sapiens	79-84
23261473-5	2013	Further investigation revealed that sanguinarine attenuated RANKL-mediated IkappaBalpha phosphorylation and degradation, leading to the impairment of NF-kappaB signaling pathway during osteoclast differentiation.	sanguinarine	36-48	TNF superfamily member 11	Homo sapiens	60-65
23212591-3	2013	The widely-used bisphosphonates or the new therapeutic option, denosumab an inhibitor of the receptor activator of NF-kappaB ligand (RANKL), interrupt this vicious cycle, inhibit tumor growth, and in clinical practice prevent skeleton-related events.	Diphosphonates	16-31	TNF superfamily member 11	Homo sapiens	93-131
23261473-6	2013	In addition, sanguinarine also affected the ERK signaling pathway by inhibiting RANKL-induced ERK phosphorylation.	sanguinarine	13-25	TNF superfamily member 11	Homo sapiens	80-85
24295447-7	2013	RESULTS: MTX decreased synovial cellularity as well as RANK expression and the RANKL/OPG ratio.	Methotrexate	9-12	TNF superfamily member 11	Homo sapiens	79-84
24295447-8	2013	We confirmed this effect by a decrease of the mRNA and protein RANKL/OPG ratio in synovial-derived fibroblasts and osteoblasts-like tumoral cells exposed in vitro to methotrexate.	Methotrexate	166-178	TNF superfamily member 11	Homo sapiens	63-68
24295447-9	2013	Supernatants from MTX treated osteoblasts-like tumoral cells prevented pre-osteoclast formation in the absence of exogenous RANKL.	Methotrexate	18-21	TNF superfamily member 11	Homo sapiens	124-129
23546287-4	2013	CPC inhibited receptor activator of nuclear factor (NF)-kappaB ligand (RANKL)-induced osteoclast formation in a dose-dependent manner without causing cytotoxicity.	Cetylpyridinium	0-3	TNF superfamily member 11	Homo sapiens	71-76
23072920-3	2013	METHODS: As part of the Healthy Ageing across the Life Course (HALCyon) programme, men and women aged between 52 and 90+ years from six UK cohorts were genotyped for a polymorphism associated with serum calcium (rs1801725, CASR), two polymorphisms associated with bone mineral density (BMD) (rs2941740, ESR1 and rs9594759, RANKL) and one associated with osteoarthritis risk rs3815148 (COG5).	Calcium	203-210	TNF superfamily member 11	Homo sapiens	323-328
23869610-0	2013	Substance P enhanced titanium particles-induced RANKL expression in fibroblasts from periprosthetic membrane.	Titanium	21-29	TNF superfamily member 11	Homo sapiens	48-53
23869610-7	2013	Titanium particles or SP stimulated RANKL and COX-2 expression in fibroblasts, whereas NS-398 inhibited RANKL production, suggesting a COX-2-mediated event.	Titanium	0-8	TNF superfamily member 11	Homo sapiens	36-41
23869610-8	2013	Moreover, SP enhanced COX-2 and RANKL expression by titanium particles-stimulated fibroblasts.	Titanium	52-60	TNF superfamily member 11	Homo sapiens	32-37
23869610-9	2013	Thus, SP and titanium particles acted synergistically to increase RANKL expression.	Titanium	13-21	TNF superfamily member 11	Homo sapiens	66-71
23907946-0	2013	Effect of unfractionated heparin, enoxaparin and sulodexide on the relations between secretion and expression of OPG, RANKL and vWF in HUVEC.	glucuronyl glucosamine glycan sulfate	49-59	TNF superfamily member 11	Homo sapiens	118-123
23907946-7	2013	Already the lowest concentration of UFH caused 2.5-fold increase in OPG gene expression while higher UFH concentrations substantially increased RANKL mRNA level.	Heparin	101-104	TNF superfamily member 11	Homo sapiens	144-149
23907946-10	2013	Of the tested heparin formulas UFH seems to be the most potent in altering the OPG, RANKL and vWF axis.	Heparin	14-21	TNF superfamily member 11	Homo sapiens	84-89
23907946-10	2013	Of the tested heparin formulas UFH seems to be the most potent in altering the OPG, RANKL and vWF axis.	Heparin	31-34	TNF superfamily member 11	Homo sapiens	84-89
22546942-10	2013	SRP + PT group also showed a significant reduction in TNF-alpha and RANKL/OPG ratio at 8 weeks post-treatment compared with the SRP group (p &lt; 0.05).	Platinum	6-8	TNF superfamily member 11	Homo sapiens	68-73
22546942-10	2013	SRP + PT group also showed a significant reduction in TNF-alpha and RANKL/OPG ratio at 8 weeks post-treatment compared with the SRP group (p &lt; 0.05).	L-seryl-AMP	0-3	TNF superfamily member 11	Homo sapiens	68-73
24295447-10	2013	Furthermore, MTX blocked osteoclastogenesis from peripheral blood mononuclear cells despite the presence of macrophage colony stimulating factor and RANKL, which indicates that MTX directly inhibits osteoclastogenesis.	Methotrexate	177-180	TNF superfamily member 11	Homo sapiens	149-154
24295447-11	2013	CONCLUSIONS: The synovial membrane of early-untreated RA is characterized by a high RANKL/OPG ratio that can be reversed by methotrexate.	Methotrexate	124-136	TNF superfamily member 11	Homo sapiens	84-89
23546287-7	2013	CPC also inhibited RANKL-induced activation of extracellular signal-regulated kinase (ERK) and NF-kappaB and expression of cyclooxygenase (COX)-2.	Cetylpyridinium	0-3	TNF superfamily member 11	Homo sapiens	19-24
23710436-0	2013	1,25-dihydroxyvitamin D3 inhibits the RANKL pathway and impacts on the production of pathway-associated cytokines in early rheumatoid arthritis.	Calcitriol	0-24	TNF superfamily member 11	Homo sapiens	38-43
23710436-1	2013	OBJECTIVES: To study effects of 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) on RANKL signaling pathway and pathway-associated cytokines in patients with rheumatoid arthritis (RA).	Calcitriol	32-56	TNF superfamily member 11	Homo sapiens	74-79
23710436-1	2013	OBJECTIVES: To study effects of 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) on RANKL signaling pathway and pathway-associated cytokines in patients with rheumatoid arthritis (RA).	Calcitriol	58-69	TNF superfamily member 11	Homo sapiens	74-79
23710436-3	2013	RESULTS: After 72 hours of incubation of peripheral blood mononuclear cells (PBMCs) with 1,25(OH)2D3 in RA patients, the levels of RANKL, TNF- alpha , IL-17 and IL-6 significantly decreased compared to those of the control.	Calcitriol	89-100	TNF superfamily member 11	Homo sapiens	131-136
23710436-5	2013	CONCLUSIONS: The present study demonstrated that 1,25(OH)2D3 reduced the production of RANKL and the secretion of TNF- alpha , IL-17, and IL-6 in PBMCs of RA patients, which indicated that 1,25(OH)2D3 might be able to decrease damage of cartilage and bone in RA patients by regulating the expression of RANKL signaling pathway and pathway-associated cytokines.	(oh)2d3	53-60	TNF superfamily member 11	Homo sapiens	87-92
23710436-5	2013	CONCLUSIONS: The present study demonstrated that 1,25(OH)2D3 reduced the production of RANKL and the secretion of TNF- alpha , IL-17, and IL-6 in PBMCs of RA patients, which indicated that 1,25(OH)2D3 might be able to decrease damage of cartilage and bone in RA patients by regulating the expression of RANKL signaling pathway and pathway-associated cytokines.	(oh)2d3	53-60	TNF superfamily member 11	Homo sapiens	303-308
24348674-0	2013	Modulatory effect of 1,25-dihydroxyvitamin D 3 on IL1 beta -induced RANKL, OPG, TNF alpha , and IL-6 expression in human rheumatoid synoviocyte MH7A.	1,25-dihydroxyvitamin D	21-44	TNF superfamily member 11	Homo sapiens	68-73
24348674-2	2013	Considering that 1,25(OH)2D3 has been suggested as a potent inducer of RANKL expression, it should clarify whether vitamin D supplement could result in RANKL overexpression and thereby facilitate excessive osteoclastogenesis and bone resorption in RA.	Calcitriol	17-28	TNF superfamily member 11	Homo sapiens	71-76
24348674-2	2013	Considering that 1,25(OH)2D3 has been suggested as a potent inducer of RANKL expression, it should clarify whether vitamin D supplement could result in RANKL overexpression and thereby facilitate excessive osteoclastogenesis and bone resorption in RA.	Vitamin D	115-124	TNF superfamily member 11	Homo sapiens	71-76
24348674-2	2013	Considering that 1,25(OH)2D3 has been suggested as a potent inducer of RANKL expression, it should clarify whether vitamin D supplement could result in RANKL overexpression and thereby facilitate excessive osteoclastogenesis and bone resorption in RA.	Vitamin D	115-124	TNF superfamily member 11	Homo sapiens	152-157
24348674-3	2013	Here, we investigated modulatory effect of 1,25(OH)2D3 on the expression of RANKL and its decoy receptor osteoprotegerin (OPG) in an inflammatory condition of human rheumatoid synoviocyte MH7A.	Calcitriol	43-54	TNF superfamily member 11	Homo sapiens	76-81
24348674-4	2013	MH7A cells were stimulated with IL1 beta and then treated with different concentrations of 1,25(OH)2D3 for 48 h. A significantly elevated OPG/RANKL ratio and markedly decreased levels of IL-6 and TNF beta mRNA expression in cells and IL-6 protein in supernatants were observed in IL1 beta -induced MH7A in the presence of 1,25(OH)2D3 compared with those in the absence of it.	25(oh)2d3	93-102	TNF superfamily member 11	Homo sapiens	142-147
24348674-4	2013	MH7A cells were stimulated with IL1 beta and then treated with different concentrations of 1,25(OH)2D3 for 48 h. A significantly elevated OPG/RANKL ratio and markedly decreased levels of IL-6 and TNF beta mRNA expression in cells and IL-6 protein in supernatants were observed in IL1 beta -induced MH7A in the presence of 1,25(OH)2D3 compared with those in the absence of it.	mh7a	0-4	TNF superfamily member 11	Homo sapiens	142-147
24348674-4	2013	MH7A cells were stimulated with IL1 beta and then treated with different concentrations of 1,25(OH)2D3 for 48 h. A significantly elevated OPG/RANKL ratio and markedly decreased levels of IL-6 and TNF beta mRNA expression in cells and IL-6 protein in supernatants were observed in IL1 beta -induced MH7A in the presence of 1,25(OH)2D3 compared with those in the absence of it.	Calcitriol	91-102	TNF superfamily member 11	Homo sapiens	142-147
23538677-0	2013	Fisetin inhibits osteoclastogenesis through prevention of RANKL-induced ROS production by Nrf2-mediated up-regulation of phase II antioxidant enzymes.	fisetin	0-7	TNF superfamily member 11	Homo sapiens	58-63
23538677-0	2013	Fisetin inhibits osteoclastogenesis through prevention of RANKL-induced ROS production by Nrf2-mediated up-regulation of phase II antioxidant enzymes.	Reactive Oxygen Species	72-75	TNF superfamily member 11	Homo sapiens	58-63
23538677-6	2013	Fisetin up-regulated mRNA expression of phase II antioxidant enzymes including HO-1 and interfered with RANKL-mediated reactive oxygen species (ROS) production.	Reactive Oxygen Species	119-142	TNF superfamily member 11	Homo sapiens	104-109
23538677-6	2013	Fisetin up-regulated mRNA expression of phase II antioxidant enzymes including HO-1 and interfered with RANKL-mediated reactive oxygen species (ROS) production.	Reactive Oxygen Species	144-147	TNF superfamily member 11	Homo sapiens	104-109
23538677-9	2013	Therefore, fisetin inhibits OCL differentiation through blocking RANKL-mediated ROS production by Nrf2-mediated up-regulation of phase II antioxidant enzymes.	fisetin	11-18	TNF superfamily member 11	Homo sapiens	65-70
23538677-9	2013	Therefore, fisetin inhibits OCL differentiation through blocking RANKL-mediated ROS production by Nrf2-mediated up-regulation of phase II antioxidant enzymes.	Reactive Oxygen Species	80-83	TNF superfamily member 11	Homo sapiens	65-70
23212591-3	2013	The widely-used bisphosphonates or the new therapeutic option, denosumab an inhibitor of the receptor activator of NF-kappaB ligand (RANKL), interrupt this vicious cycle, inhibit tumor growth, and in clinical practice prevent skeleton-related events.	Diphosphonates	16-31	TNF superfamily member 11	Homo sapiens	133-138
22807029-5	2012	Ligand-occupied alphavbeta3 or RANKL promotes paxillin serine and tyrosine phosphorylation, the latter via cellular sarcoma (c-Src).	Tyrosine	66-74	TNF superfamily member 11	Homo sapiens	31-36
22867712-0	2012	Rheumatoid and pyrophosphate arthritis synovial fibroblasts induce osteoclastogenesis independently of RANKL, TNF and IL-6.	diphosphoric acid	15-28	TNF superfamily member 11	Homo sapiens	103-108
22795564-0	2012	Myricetin suppresses LPS-induced MMP expression in human gingival fibroblasts and inhibits osteoclastogenesis by downregulating NFATc1 in RANKL-induced RAW 264.7 cells.	myricetin	0-9	TNF superfamily member 11	Homo sapiens	138-143
22674155-0	2012	Histamine contributes to increased RANKL to osteoprotegerin ratio through altered nuclear receptor 4A activity in human chondrocytes.	Histamine	0-9	TNF superfamily member 11	Homo sapiens	35-40
22807029-8	2012	Most importantly, the abnormal phenotype of Pax(-/-) osteoclasts likely represents failed RANKL-mediated delivery of myosin IIA to the actin cytoskeleton via the paxillin LD4 domain but is independent of tyrosine phosphorylation.	pax	44-47	TNF superfamily member 11	Homo sapiens	90-95
22807029-8	2012	Most importantly, the abnormal phenotype of Pax(-/-) osteoclasts likely represents failed RANKL-mediated delivery of myosin IIA to the actin cytoskeleton via the paxillin LD4 domain but is independent of tyrosine phosphorylation.	Tyrosine	204-212	TNF superfamily member 11	Homo sapiens	90-95
23388484-13	2012	RANKL levels remain within normal range on standard steroid replacement.	Steroids	52-59	TNF superfamily member 11	Homo sapiens	0-5
22899318-0	2012	JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production.	tofacitinib	20-31	TNF superfamily member 11	Homo sapiens	95-100
22899318-7	2012	CONCLUSION: These results suggest that the JAK inhibitor tofacitinib suppresses osteoclast-mediated structural damage to arthritic joints, and this effect is secondary to decreased RANKL production.	tofacitinib	57-68	TNF superfamily member 11	Homo sapiens	181-186
22884709-2	2012	PGE(2) is a potent osteoclast-inducing factor that induces the receptor activator of nuclear factor-kappaB ligand (RANKL).	Prostaglandins E	0-3	TNF superfamily member 11	Homo sapiens	63-113
22981371-3	2012	Mevalonate deprivation induced by competitive inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase (e.g., statins) prevents the activation of GTPases, suppresses the expression of the receptor for activation of nuclear factor kappa B (NFkappaB) ligand (RANKL) and activation of NFkappaB and, consequently, inhibits osteoclast differentiation and induces osteoclast apoptosis.	Mevalonic Acid	0-10	TNF superfamily member 11	Homo sapiens	272-277
22981371-7	2012	The tocotrienols, vitamin E molecules with HMG CoA reductase-suppressive activity, induce mevalonate deprivation and concomitantly suppress the expression of RANKL and cyclooxygenase-2, the production of prostaglandin E2 and the activation of NFkappaB.	Tocotrienols	4-16	TNF superfamily member 11	Homo sapiens	158-163
22981371-7	2012	The tocotrienols, vitamin E molecules with HMG CoA reductase-suppressive activity, induce mevalonate deprivation and concomitantly suppress the expression of RANKL and cyclooxygenase-2, the production of prostaglandin E2 and the activation of NFkappaB.	Vitamin E	18-27	TNF superfamily member 11	Homo sapiens	158-163
22981371-7	2012	The tocotrienols, vitamin E molecules with HMG CoA reductase-suppressive activity, induce mevalonate deprivation and concomitantly suppress the expression of RANKL and cyclooxygenase-2, the production of prostaglandin E2 and the activation of NFkappaB.	Dinoprostone	204-220	TNF superfamily member 11	Homo sapiens	158-163
23388484-2	2012	The study was aimed to investigate the effect of steroid substitution on serum osteoprotegerin and receptor activator of nuclear factor kappa-beta ligand (RANKL) levels in relation to bone mineral density (BMD) in PAI.	Steroids	49-56	TNF superfamily member 11	Homo sapiens	99-153
23388484-2	2012	The study was aimed to investigate the effect of steroid substitution on serum osteoprotegerin and receptor activator of nuclear factor kappa-beta ligand (RANKL) levels in relation to bone mineral density (BMD) in PAI.	Steroids	49-56	TNF superfamily member 11	Homo sapiens	155-160
23388484-9	2012	RANKL correlated negatively with PAI duration (p=0.029) and positively with daily hydrocortisone dose (p=0.018).	Hydrocortisone	82-96	TNF superfamily member 11	Homo sapiens	0-5
22289672-7	2012	In addition, Zn augmented the inhibitory effect of phyto-oestrogens on the osteoblast-derived stimulus for osteoclast formation, significantly reducing the ratio of receptor activator of NF-kappaB ligand (RANKL)-to-osteoprotegerin mRNA expression in human osteoblast.	Zinc Sulfate	13-15	TNF superfamily member 11	Homo sapiens	165-203
22289672-7	2012	In addition, Zn augmented the inhibitory effect of phyto-oestrogens on the osteoblast-derived stimulus for osteoclast formation, significantly reducing the ratio of receptor activator of NF-kappaB ligand (RANKL)-to-osteoprotegerin mRNA expression in human osteoblast.	Zinc Sulfate	13-15	TNF superfamily member 11	Homo sapiens	205-210
23000100-6	2012	NecroX-7 significantly inhibited the NF-kappaB signaling pathway without affecting the activation of the mitogen-activated protein kinases (MAPKs) JNK, p38, and ERK in response to RANKL.	necrox-7	0-8	TNF superfamily member 11	Homo sapiens	180-185
22802109-6	2012	RESULTS: Combined administration of ETN/MTX significantly inhibited the proliferation of T lymphocytes, decreased serum IL-6, TNF-alpha, IL-1beta, RANKL and macrophage supernatant IL-17, LT-alpha, increased serum IFN-gamma and macrophage supernatant IL-10.	Methotrexate	40-43	TNF superfamily member 11	Homo sapiens	147-152
22820094-8	2012	Strontium-mediated activation of these pathways results in the modulation of key molecules such as RANKL and OPG that control bone resorption, and to the regulation of genes promoting osteoblastic cell replication, differentiation and survival.	Strontium	0-9	TNF superfamily member 11	Homo sapiens	99-104
22884709-2	2012	PGE(2) is a potent osteoclast-inducing factor that induces the receptor activator of nuclear factor-kappaB ligand (RANKL).	Prostaglandins E	0-3	TNF superfamily member 11	Homo sapiens	115-120
22884709-9	2012	RESULT: PGE(2) exposure increased significantly RANKL expression in HOBs compared with HPDLs.	Prostaglandins E	8-11	TNF superfamily member 11	Homo sapiens	48-53
22884709-12	2012	CONCLUSION: These results suggest that osteoblasts strongly influence the stimulation of osteoclastogenesis via RANKL, induced by PGE(2) in periodontal tissues, compared with PDLs.	Prostaglandins E	130-133	TNF superfamily member 11	Homo sapiens	112-117
22674155-10	2012	Histamine selectively signaled through H(1)  and H(2)  histamine receptors in chondrocytes to modulate RANKL and NR4A2 expression.	Histamine	0-9	TNF superfamily member 11	Homo sapiens	103-108
22674155-12	2012	Histamine modulated the expression of RANKL with modest effects on OPG levels, leading to increased RANKL:OPG mRNA and protein ratios.	Histamine	0-9	TNF superfamily member 11	Homo sapiens	38-43
22674155-12	2012	Histamine modulated the expression of RANKL with modest effects on OPG levels, leading to increased RANKL:OPG mRNA and protein ratios.	Histamine	0-9	TNF superfamily member 11	Homo sapiens	100-105
22674155-13	2012	Stable knockdown of NR4A1-3 expression resulted in reduced endogenous OPG levels and the loss of histamine-dependent regulation of RANKL expression.	Histamine	97-106	TNF superfamily member 11	Homo sapiens	131-136
22711317-3	2012	Estradiol and progesterone induce receptor activator of NF-kappa B ligand (RANKL) in estrogen receptor (ER)- and progesterone receptor (PgR)-positive luminal cells.	Estradiol	0-9	TNF superfamily member 11	Homo sapiens	34-73
22926264-11	2012	Upon treatment with OPG-Fc alone or in combination with tamoxifen, there was a complete absence of osteolytic lesions, demonstrating the ability of RANKL inhibition to prevent skeletal related morbidity in an ER+ model.	Tamoxifen	56-65	TNF superfamily member 11	Homo sapiens	148-153
22711317-3	2012	Estradiol and progesterone induce receptor activator of NF-kappa B ligand (RANKL) in estrogen receptor (ER)- and progesterone receptor (PgR)-positive luminal cells.	Estradiol	0-9	TNF superfamily member 11	Homo sapiens	75-80
22615001-6	2012	The SaOS-2 cells retain their capacity of differential gene expression of OPG and RANKL in favor of OPG after exposure to silicate.	Silicates	122-130	TNF superfamily member 11	Homo sapiens	82-87
22370427-3	2012	Bisphosphonates--and the recently approved anti-RANKL antibody, denosumab--have both demonstrated activity for the treatment of postmenopausal osteoporosis and cancer treatment-induced bone loss (CTIBL) in breast cancer patients, although neither has received widespread approval specifically for CTIBL.	ctibl	196-201	TNF superfamily member 11	Homo sapiens	48-53
23018352-6	2012	Plasma RANKL concentrations were associated with patients" age (p=0.0191), homocysteine levels (p&lt;0.00001), history of smoking (p=0.0185) and statins therapy (p=0.0004).	Homocysteine	75-87	TNF superfamily member 11	Homo sapiens	7-12
22791764-6	2012	The effects of dexamethasone on production of RANKL and OPG mRNA and protein by cultured normal human osteoblasts were evaluated by RT-PCR and ELISA, respectively.	Dexamethasone	15-28	TNF superfamily member 11	Homo sapiens	46-51
22791764-13	2012	Up-regulation of RANKL and OPG mRNA by IL-6 was suppressed by dexamethasone.	Dexamethasone	62-75	TNF superfamily member 11	Homo sapiens	17-22
23018352-7	2012	Diabetes, CAD, smoking status, statins therapy and homocysteine were identified as independent predictors of OPG concentrations (p=0.0157, p=0.0030, p=0.0249, p=0.0047 and p=0.0072, respectively), whereas smoking showed an independent effect for RANKL (p=0.0010).	Homocysteine	51-63	TNF superfamily member 11	Homo sapiens	246-251
22945589-0	2012	Experimental arthritis: JAK inhibition with tofacitinib curbs RANKL-induced joint damage.	tofacitinib	44-55	TNF superfamily member 11	Homo sapiens	62-67
22964327-0	2012	AMP-activated protein kinase acts as a negative regulator of high glucose-induced RANKL expression in human periodontal ligament cells.	Glucose	66-73	TNF superfamily member 11	Homo sapiens	82-87
23001207-11	2012	DHEAS suppression in girls with anorexia nervosa might have a harmful effect on their bone tissue, probably via a shift in the OPG/RANKL ratio toward a functional excess of sRANKL.	Dehydroepiandrosterone	0-5	TNF superfamily member 11	Homo sapiens	131-136
22627031-0	2012	RANKL in the osteolysis of AES total ankle replacement implants.	alanylglutamic acid	27-30	TNF superfamily member 11	Homo sapiens	0-5
22634178-0	2012	Effects of 17beta-estradiol on adiponectin regulation of the expression of osteoprotegerin and receptor activator of nuclear factor-kappaB ligand.	Estradiol	11-27	TNF superfamily member 11	Homo sapiens	95-145
22634178-3	2012	The present study was undertaken to investigate the effects of 17beta-estradiol (E2) on adiponectin-regulated OPG and RANKL expression in human osteoblast.	Estradiol	63-79	TNF superfamily member 11	Homo sapiens	118-123
22634178-11	2012	Furthermore, anisomycin or overexpression of p38 also reserved the effects of E2 on adiponectin-dependent p38 phosphorylation and OPG/RANKL expression.	Anisomycin	13-23	TNF superfamily member 11	Homo sapiens	134-139
22806876-8	2012	PBS-1086 also inhibits osteoclastogenesis through an inhibition of RANK ligand (RANKL)-induced NF-kappaB activation.	PBS-1086	0-8	TNF superfamily member 11	Homo sapiens	67-78
22806876-8	2012	PBS-1086 also inhibits osteoclastogenesis through an inhibition of RANK ligand (RANKL)-induced NF-kappaB activation.	PBS-1086	0-8	TNF superfamily member 11	Homo sapiens	80-85
22480456-3	2012	RESULTS: RANKL expression was higher after 5 days of exposure (p&lt;0.05), but thereafter reduced in those treated with the two lower doses of PGE(2) (p&lt;0.01).	Prostaglandins E	143-146	TNF superfamily member 11	Homo sapiens	9-14
22480456-4	2012	RANKL/OPG ratio reported in favour of OPG gene expression and alkaline phosphatase gene expression increased in osteoblasts exposed to the two lower doses of the eicosanoid after 15 days.	Eicosanoids	162-172	TNF superfamily member 11	Homo sapiens	0-5
22480456-7	2012	CONCLUSIONS: It is proposed that PGE(2)at a low dose switch osteoblast"s biology in favour of bone apposition by: first, inducing a significantly higher OPG gene expression overwhelming RANKL gene expression; second, reducing PGEs synthesis; and third, increasing ALP gene expression.	Dinoprostone	33-39	TNF superfamily member 11	Homo sapiens	186-191
22853997-1	2012	An HTS campaign led to the identification of 4-pyrroldino-2-(pyridin-2-yl)pyrimidine compound 1 as an RANKL-induced osteoclastogenesis inhibitor.	4-pyrroldino-2-(pyridin-2-yl)pyrimidine	45-84	TNF superfamily member 11	Homo sapiens	102-107
22964327-2	2012	This study investigated the direct effect of high glucose on the expression of receptor activator of nuclear factor-kappa B ligand (RANKL) in human PDL (hPDL) cells.	Glucose	50-57	TNF superfamily member 11	Homo sapiens	79-130
22964327-2	2012	This study investigated the direct effect of high glucose on the expression of receptor activator of nuclear factor-kappa B ligand (RANKL) in human PDL (hPDL) cells.	Glucose	50-57	TNF superfamily member 11	Homo sapiens	132-137
22964327-7	2012	RESULTS: High glucose levels caused an increase in RANKL mRNA and protein expression in hPDL cells.	Glucose	14-21	TNF superfamily member 11	Homo sapiens	51-56
22964327-9	2012	Suppression of AMPK by Compound C augmented RANKL expression, and AMPK activation by metformin significantly decreased RANKL expression in hPDL cells.	Metformin	85-94	TNF superfamily member 11	Homo sapiens	119-124
22964327-10	2012	Additionally, metformin down-regulated RANKL expression in hPDL cells exposed to high glucose via AMPK activation.	Metformin	14-23	TNF superfamily member 11	Homo sapiens	39-44
22964327-10	2012	Additionally, metformin down-regulated RANKL expression in hPDL cells exposed to high glucose via AMPK activation.	Glucose	86-93	TNF superfamily member 11	Homo sapiens	39-44
22964327-11	2012	CONCLUSION: High glucose-induced up-regulation of RANKL could be due to decreased AMPK activity, and AMPK activation may be involved in regulating of RANKL expression in hPDL cells.	Glucose	17-24	TNF superfamily member 11	Homo sapiens	50-55
22366413-3	2012	It has been demonstrated that bio-silica causes in vitro a differential effect on the expression of the genes OPG and RANKL, encoding two mediators that control the tuned interaction of the anabolic (osteoblasts) and catabolic (osteoclasts) pathways in human bone cells.	Silicon Dioxide	34-40	TNF superfamily member 11	Homo sapiens	118-123
22901757-0	2012	Atorvastatin inhibits osteoclastogenesis by decreasing the expression of RANKL in the synoviocytes of rheumatoid arthritis.	Atorvastatin	0-12	TNF superfamily member 11	Homo sapiens	73-78
22901757-2	2012	The authors undertook to determine the effect of atorvastatin on the expressions of osteoprotegerin (OPG) and receptor activator of nuclear factor kappaB ligand (RANKL) in RA fibroblast-like synoviocytes (FLSs), to identify the mechanisms responsible for these effects, and to determine whether the statin inhibits osteoclastogenesis.	Atorvastatin	49-61	TNF superfamily member 11	Homo sapiens	110-160
22901757-2	2012	The authors undertook to determine the effect of atorvastatin on the expressions of osteoprotegerin (OPG) and receptor activator of nuclear factor kappaB ligand (RANKL) in RA fibroblast-like synoviocytes (FLSs), to identify the mechanisms responsible for these effects, and to determine whether the statin inhibits osteoclastogenesis.	Atorvastatin	49-61	TNF superfamily member 11	Homo sapiens	162-167
22901757-7	2012	RESULTS: Atorvastatin inhibited the expression of RANKL in RA FLSs in a dose-dependent manner, and the suppression of RANKL was prevented by mevalonate.	Atorvastatin	9-21	TNF superfamily member 11	Homo sapiens	50-55
22901757-7	2012	RESULTS: Atorvastatin inhibited the expression of RANKL in RA FLSs in a dose-dependent manner, and the suppression of RANKL was prevented by mevalonate.	Mevalonic Acid	141-151	TNF superfamily member 11	Homo sapiens	118-123
23158430-2	2012	METHODS: In the presence of 50 ng/ml receptor activator of nuclear factor kappa-B ligand (RANKL), RAW264.7 was treated with ferric ammonium citrate (FAC).	ferric ammonium citrate	124-147	TNF superfamily member 11	Homo sapiens	37-88
23158430-2	2012	METHODS: In the presence of 50 ng/ml receptor activator of nuclear factor kappa-B ligand (RANKL), RAW264.7 was treated with ferric ammonium citrate (FAC).	ferric ammonium citrate	124-147	TNF superfamily member 11	Homo sapiens	90-95
22554886-6	2012	In vitro PE particles stimulated osteoclast resorption in the presence of 50 ng ml(-1) receptor activator NFkappaB (RANKL) and significantly elevated the expression of OSCAR, FcRgamma, TREM2 and DAP12 during osteoclast formation.	Polyethylene	9-11	TNF superfamily member 11	Homo sapiens	116-121
22562178-8	2012	Calcium and RANKL serum concentrations were also significantly decreased, while OPG was significantly increased, resulting in lower RANKL/OPG ratio.	Calcium	0-7	TNF superfamily member 11	Homo sapiens	132-137
22751853-11	2012	ECMN909 and UBS109 potently inhibited the receptor activator of NF-kappaB (RANK) ligand (RANKL)-increased preosteoclastic NF-kappaB-luciferase activity, in which NF-kappaB signaling plays a pivotal role in osteoclastogenesis.	UBS109	12-18	TNF superfamily member 11	Homo sapiens	89-94
22525805-4	2012	PtNP inhibited OC formation by impairing the receptor activator of nuclear factor-kappaB ligand (RANKL) signaling.	ptnp	0-4	TNF superfamily member 11	Homo sapiens	45-95
22525805-4	2012	PtNP inhibited OC formation by impairing the receptor activator of nuclear factor-kappaB ligand (RANKL) signaling.	ptnp	0-4	TNF superfamily member 11	Homo sapiens	97-102
22525805-6	2012	PtNP lowered RANKL-induced long lasting reactive oxygen species as well as intracellular concentrations of Ca(2+) oscillation.	ptnp	0-4	TNF superfamily member 11	Homo sapiens	13-18
22525805-6	2012	PtNP lowered RANKL-induced long lasting reactive oxygen species as well as intracellular concentrations of Ca(2+) oscillation.	Reactive Oxygen Species	40-63	TNF superfamily member 11	Homo sapiens	13-18
22709525-13	2012	Co-cultures demonstrated that PGE2-stimulated human chondrocytes, which produce RANKL, also induce osteoclasts differentiation from PBMCs.	Dinoprostone	30-34	TNF superfamily member 11	Homo sapiens	80-85
22664871-3	2012	In this article, we report the 2.7-A crystal structure of human RANKL trimer in complex with the N-terminal fragment of human OPG containing four cysteine-rich TNFR homologous domains (OPG-CRD).	Cysteine	146-154	TNF superfamily member 11	Homo sapiens	64-69
22664871-4	2012	The structure shows that RANKL trimer uses three equivalent grooves between two neighboring monomers to interact with three OPG-CRD monomers symmetrically.	2-butenal	128-131	TNF superfamily member 11	Homo sapiens	25-30
22556124-0	2012	Selective regulation of osteoblastic OPG and RANKL by dehydroepiandrosterone through activation of the estrogen receptor beta-mediated MAPK signaling pathway.	Dehydroepiandrosterone	54-76	TNF superfamily member 11	Homo sapiens	45-50
22025323-0	2012	Cobalt and chromium ions reduce human osteoblast-like cell activity in vitro, reduce the OPG to RANKL ratio, and induce oxidative stress.	Cobalt	0-6	TNF superfamily member 11	Homo sapiens	96-101
22556124-9	2012	DHEA seems to act selectively on osteoblasts via the dominant ER beta receptor, which mediates amplified cell viability through the MAPK signaling pathway involving pERK1/2 and upregulates the production of OPG rather than RANKL.	Dehydroepiandrosterone	0-4	TNF superfamily member 11	Homo sapiens	223-228
22646286-11	2012	On the other hand, sesamin was able to up-regulate OPG and down-regulate RANKL gene expression.	sesamin	19-26	TNF superfamily member 11	Homo sapiens	73-78
22646286-15	2012	CONCLUSIONS: The data suggest that sesamin has the ability to trigger osteoblast differentiation by activation of the p38 and ERK MAPK signaling pathway and possibly indirectly regulate osteoclast development via the expression of OPG and RANKL in osteoblasts.	sesamin	35-42	TNF superfamily member 11	Homo sapiens	239-244
22461633-13	2012	These results suggest that caldecrin inhibits RANKL-stimulated calcium signaling activation and cytoskeletal organization by suppression of the c-Src Syk pathway, which may in turn reduce the bone resorptive activity of mature osteoclasts.	Calcium	63-70	TNF superfamily member 11	Homo sapiens	46-51
22399266-10	2012	RANKL expression of AOBs was increased at all tested simvastatin concentrations and that in PDLs was increased by higher simvastatin concentrations (10-100 nM).	Simvastatin	53-64	TNF superfamily member 11	Homo sapiens	0-5
22646286-6	2012	Gene expression of COL1, ALP, BMP-2, Runx2, OC, RANKL and OPG were detected after 24 h of sesamin treatment.	sesamin	90-97	TNF superfamily member 11	Homo sapiens	48-53
22174188-9	2012	To study a possible role for snx10 in osteoclast differentiation and function we silenced snx10 expression and found that snx10 silencing inhibited RANKL-induced osteoclast formation and osteoclast resorption on hydroxyapatite.	Durapatite	212-226	TNF superfamily member 11	Homo sapiens	148-153
22025323-0	2012	Cobalt and chromium ions reduce human osteoblast-like cell activity in vitro, reduce the OPG to RANKL ratio, and induce oxidative stress.	Chromium	11-19	TNF superfamily member 11	Homo sapiens	96-101
22025323-2	2012	The effects of cobalt and chromium ions on cell number, activity, expression of osteoprotegerin (OPG) and receptor activator of nuclear factor kappa B ligand (RANKL) and oxidative stress on human osteoblast-like cells were addressed.	Chromium	26-34	TNF superfamily member 11	Homo sapiens	106-157
22025323-8	2012	The strongest reduction (11 +- 1%) was seen at 100 microg/L after 96 h. The OPG/RANKL ratio was reduced after 72 h with almost all Co(2+) and Cr(3+) concentrations.	Cobalt(2+)	131-137	TNF superfamily member 11	Homo sapiens	80-85
22025323-10	2012	In conclusion, cobalt and chromium ions reduce human osteoblast activity, reduce OPG/RANKL ratio and lead to oxidative stress.	Cobalt	15-21	TNF superfamily member 11	Homo sapiens	85-90
22025323-10	2012	In conclusion, cobalt and chromium ions reduce human osteoblast activity, reduce OPG/RANKL ratio and lead to oxidative stress.	Chromium	26-34	TNF superfamily member 11	Homo sapiens	85-90
22326262-0	2012	Sphingosine 1-phosphate (S1P)/S1P receptor 1 signaling regulates receptor activator of NF-kappaB ligand (RANKL) expression in rheumatoid arthritis.	sphingosine 1-phosphate	0-23	TNF superfamily member 11	Homo sapiens	65-103
22326262-0	2012	Sphingosine 1-phosphate (S1P)/S1P receptor 1 signaling regulates receptor activator of NF-kappaB ligand (RANKL) expression in rheumatoid arthritis.	sphingosine 1-phosphate	0-23	TNF superfamily member 11	Homo sapiens	105-110
22250082-5	2012	Doxycycline and minocycline inhibited the receptor activator of NF-kappaB ligand (RANKL)-induced osteoclastogenesis of BMMs, but they had no effects on cell growth and phagocytic activity.	Doxycycline	0-11	TNF superfamily member 11	Homo sapiens	42-80
22388612-6	2012	Regarding bone metabolism, 25-hydroxyvitamin D was positively related to osteoprotegerin, but negatively to the RANKL.	25-hydroxyvitamin D	27-46	TNF superfamily member 11	Homo sapiens	112-117
22388612-7	2012	The latter could be the result of parathyroid hormone suppression by 25-hydroxyvitamin D, since 25-hydroxyvitamin D negatively correlated with parathyroid hormone, which in turn was positively related to RANKL.	25-hydroxyvitamin D	69-88	TNF superfamily member 11	Homo sapiens	204-209
22388612-7	2012	The latter could be the result of parathyroid hormone suppression by 25-hydroxyvitamin D, since 25-hydroxyvitamin D negatively correlated with parathyroid hormone, which in turn was positively related to RANKL.	25-hydroxyvitamin D	96-115	TNF superfamily member 11	Homo sapiens	204-209
22202439-3	2012	We first observed that Ga treatment inhibited the expression of Rankl-induced early differentiation marker genes, while the same treatment performed subsequently did not modify the expression of late differentiation marker genes.	Gallium	23-25	TNF superfamily member 11	Homo sapiens	64-69
22449704-2	2012	Recently, reactive oxygen species (ROS) and antioxidant enzymes were shown to be closely associated with RANKL-mediated osteoclast differentiation.	Reactive Oxygen Species	10-33	TNF superfamily member 11	Homo sapiens	105-110
22449704-2	2012	Recently, reactive oxygen species (ROS) and antioxidant enzymes were shown to be closely associated with RANKL-mediated osteoclast differentiation.	Reactive Oxygen Species	35-38	TNF superfamily member 11	Homo sapiens	105-110
22250082-5	2012	Doxycycline and minocycline inhibited the receptor activator of NF-kappaB ligand (RANKL)-induced osteoclastogenesis of BMMs, but they had no effects on cell growth and phagocytic activity.	Doxycycline	0-11	TNF superfamily member 11	Homo sapiens	82-87
22250082-5	2012	Doxycycline and minocycline inhibited the receptor activator of NF-kappaB ligand (RANKL)-induced osteoclastogenesis of BMMs, but they had no effects on cell growth and phagocytic activity.	Minocycline	16-27	TNF superfamily member 11	Homo sapiens	42-80
22250082-5	2012	Doxycycline and minocycline inhibited the receptor activator of NF-kappaB ligand (RANKL)-induced osteoclastogenesis of BMMs, but they had no effects on cell growth and phagocytic activity.	Minocycline	16-27	TNF superfamily member 11	Homo sapiens	82-87
22250082-7	2012	Surprisingly, doxycycline and minocycline induced the expression of DC markers, CD11c and CD86, in BMMs in the presence of RANKL.	Doxycycline	14-25	TNF superfamily member 11	Homo sapiens	123-128
22250082-7	2012	Surprisingly, doxycycline and minocycline induced the expression of DC markers, CD11c and CD86, in BMMs in the presence of RANKL.	Minocycline	30-41	TNF superfamily member 11	Homo sapiens	123-128
20938793-0	2012	Influence of bisphosphonates on the osteoblast RANKL and OPG gene expression in vitro.	Diphosphonates	13-28	TNF superfamily member 11	Homo sapiens	47-52
20938793-8	2012	The non-nitrogen-containing bisphosphonate clodronate, however, effected OPG and RANKL gene expression much less, even at higher concentrations of 5 x 10(-3) M. The above-mentioned data suggest an enhanced RANKL/OPG gene expression after stimulation by bisphosphonates.	Clodronic Acid	43-53	TNF superfamily member 11	Homo sapiens	81-86
20938793-3	2012	The objective of this study was to evaluate the effect of bisphosphonates on the gene expression of receptor activator of NF-kappaB ligand (RANKL) and osteoprotegerin (OPG) in vitro.	Diphosphonates	58-73	TNF superfamily member 11	Homo sapiens	100-138
20938793-8	2012	The non-nitrogen-containing bisphosphonate clodronate, however, effected OPG and RANKL gene expression much less, even at higher concentrations of 5 x 10(-3) M. The above-mentioned data suggest an enhanced RANKL/OPG gene expression after stimulation by bisphosphonates.	Clodronic Acid	43-53	TNF superfamily member 11	Homo sapiens	206-211
20938793-8	2012	The non-nitrogen-containing bisphosphonate clodronate, however, effected OPG and RANKL gene expression much less, even at higher concentrations of 5 x 10(-3) M. The above-mentioned data suggest an enhanced RANKL/OPG gene expression after stimulation by bisphosphonates.	Diphosphonates	253-268	TNF superfamily member 11	Homo sapiens	206-211
20938793-3	2012	The objective of this study was to evaluate the effect of bisphosphonates on the gene expression of receptor activator of NF-kappaB ligand (RANKL) and osteoprotegerin (OPG) in vitro.	Diphosphonates	58-73	TNF superfamily member 11	Homo sapiens	140-145
20938793-7	2012	The results showed a moderate enhancement of OPG gene expression whereas RANKL gene expression was strongly increased by nitrogen-containing bisphosphonates reaching a maximum after 14 days at high concentrations of 5 x 10(-5) M. Lower concentrations did not enhance the RANKL and OPG expression considerably.	Nitrogen	121-129	TNF superfamily member 11	Homo sapiens	73-78
20938793-7	2012	The results showed a moderate enhancement of OPG gene expression whereas RANKL gene expression was strongly increased by nitrogen-containing bisphosphonates reaching a maximum after 14 days at high concentrations of 5 x 10(-5) M. Lower concentrations did not enhance the RANKL and OPG expression considerably.	Nitrogen	121-129	TNF superfamily member 11	Homo sapiens	271-276
20938793-7	2012	The results showed a moderate enhancement of OPG gene expression whereas RANKL gene expression was strongly increased by nitrogen-containing bisphosphonates reaching a maximum after 14 days at high concentrations of 5 x 10(-5) M. Lower concentrations did not enhance the RANKL and OPG expression considerably.	Diphosphonates	141-156	TNF superfamily member 11	Homo sapiens	73-78
20938793-8	2012	The non-nitrogen-containing bisphosphonate clodronate, however, effected OPG and RANKL gene expression much less, even at higher concentrations of 5 x 10(-3) M. The above-mentioned data suggest an enhanced RANKL/OPG gene expression after stimulation by bisphosphonates.	Nitrogen	8-16	TNF superfamily member 11	Homo sapiens	81-86
20938793-8	2012	The non-nitrogen-containing bisphosphonate clodronate, however, effected OPG and RANKL gene expression much less, even at higher concentrations of 5 x 10(-3) M. The above-mentioned data suggest an enhanced RANKL/OPG gene expression after stimulation by bisphosphonates.	Nitrogen	8-16	TNF superfamily member 11	Homo sapiens	206-211
20938793-8	2012	The non-nitrogen-containing bisphosphonate clodronate, however, effected OPG and RANKL gene expression much less, even at higher concentrations of 5 x 10(-3) M. The above-mentioned data suggest an enhanced RANKL/OPG gene expression after stimulation by bisphosphonates.	Diphosphonates	28-42	TNF superfamily member 11	Homo sapiens	81-86
20938793-8	2012	The non-nitrogen-containing bisphosphonate clodronate, however, effected OPG and RANKL gene expression much less, even at higher concentrations of 5 x 10(-3) M. The above-mentioned data suggest an enhanced RANKL/OPG gene expression after stimulation by bisphosphonates.	Diphosphonates	28-42	TNF superfamily member 11	Homo sapiens	206-211
22090419-3	2012	We investigated the potential of vitamin K3 analogue plumbagin (derived from Chitrak, an Ayurvedic medicinal plant) to modulate RANKL signaling, osteoclastogenesis, and breast cancer-induced osteolysis.	Vitamin K 3	33-43	TNF superfamily member 11	Homo sapiens	128-133
22086137-9	2012	Our results show that high glucose concentrations (12 mM and particularly 24 mM) alter the biomineralization process in osteoblastic cells and provoke the following: i) a rise in mineralization, ii) an increase in the mRNA expression of RANKL and a decrease of OPG, iii) an increase in the mRNA expression of osteocalcin, bone sialoprotein and the transcription factor Runx2, iv) a diminished quality of the mineral, and v) an increase in the expression of IL1beta, IL6, IL8, MCP-1 and IL10 mRNAs.	Glucose	27-34	TNF superfamily member 11	Homo sapiens	237-242
22101248-0	2012	Proteasome inhibitor bortezomib (PS-341) enhances RANKL-induced MDA-MB-231             breast cancer cell migration.	Bortezomib	21-31	TNF superfamily member 11	Homo sapiens	50-55
22101248-0	2012	Proteasome inhibitor bortezomib (PS-341) enhances RANKL-induced MDA-MB-231             breast cancer cell migration.	Bortezomib	33-39	TNF superfamily member 11	Homo sapiens	50-55
22101248-4	2012	In the present study, we explored the effect of the proteasome inhibitor bortezomib (PS-341) on RANKL-induced MDA-MB-231 breast cancer cell migration.	Bortezomib	73-83	TNF superfamily member 11	Homo sapiens	96-101
22101248-4	2012	In the present study, we explored the effect of the proteasome inhibitor bortezomib (PS-341) on RANKL-induced MDA-MB-231 breast cancer cell migration.	Bortezomib	85-91	TNF superfamily member 11	Homo sapiens	96-101
22101248-5	2012	Transwell migration assay showed that RANKL-induced MDA-MB-231 cell migration was significantly blocked by the decoy receptor osteoprotegerin (OPG), and was also inhibited by the PI3-K inhibitor LY294002.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	195-203	TNF superfamily member 11	Homo sapiens	38-43
22101248-7	2012	PS-341 significantly enhanced RANKL-induced MDA-MB-231 cell migration.	Bortezomib	0-6	TNF superfamily member 11	Homo sapiens	30-35
22740919-6	2012	The sRANKL-induced migration was blocked with RANKL inhibitor osteoprotegerin (OPG), MEK inhibitor PD98059, PI3K inhibitor LY294002 and Src inhibitor PP2.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	99-106	TNF superfamily member 11	Homo sapiens	5-10
22242921-4	2012	The studies revealed that an assembly including 3 denosumab antibody molecules bound to 2 RANKL trimers (3D2R) is the most stable complex in DPBS at 37  C. This differs from the 1:1 binding stoichiometry reported for RANKL and osteoprotegerin (OPG), a soluble homodimeric decoy receptor which binds RANKL with high affinity.	1,4-diphenylbutadiene	141-145	TNF superfamily member 11	Homo sapiens	90-95
22740919-6	2012	The sRANKL-induced migration was blocked with RANKL inhibitor osteoprotegerin (OPG), MEK inhibitor PD98059, PI3K inhibitor LY294002 and Src inhibitor PP2.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	123-131	TNF superfamily member 11	Homo sapiens	5-10
22361198-7	2012	The results indicated that GlcN increases the mineralization of mature osteoblasts and the expression of middle and late stage markers (osteopontin and osteocalcin, respectively) during osteoblastic differentiation, and reduces the expression of receptor activator of NF-kappaB ligand (RANKL), a differentiation and activation factor for osteoclasts.	Glucosamine	27-31	TNF superfamily member 11	Homo sapiens	246-284
22361198-7	2012	The results indicated that GlcN increases the mineralization of mature osteoblasts and the expression of middle and late stage markers (osteopontin and osteocalcin, respectively) during osteoblastic differentiation, and reduces the expression of receptor activator of NF-kappaB ligand (RANKL), a differentiation and activation factor for osteoclasts.	Glucosamine	27-31	TNF superfamily member 11	Homo sapiens	286-291
23008743-3	2012	In this study, fisetin dose-dependently inhibited the RANKL-induced osteoclast differentiation with downregulation of the activity or expression of p38, c-Fos, and NFATc1 signaling molecules.	fisetin	15-22	TNF superfamily member 11	Homo sapiens	54-59
26069623-0	2012	Influence of Tumor Necrosis Factor alpha, Parathyroid Hormone, and Vitamin D3 on Modulation of the RANKL2 Isoform: A Pilot Study.	Cholecalciferol	67-77	TNF superfamily member 11	Homo sapiens	99-105
26069623-3	2012	Here, we investigated through a mechanistic model, human 293 cells stably transfected with the RANKL2cDNA, the production and modulation of RANKL2 protein stability upon treatment with TNF-alpha, vitamin D3, and PTH.	Cholecalciferol	196-206	TNF superfamily member 11	Homo sapiens	140-146
22207352-5	2012	In addition, treatment with the DNA demethylating agent 5-azadeoxycitidine promoted a 170-fold induction of RANKL and a 20-fold induction of OPG mRNA expression in HEK-293 cells, which showed hypermethylation of the CpG islands and barely expressed RANKL and OPG transcripts at baseline.	5-azadeoxycitidine	56-74	TNF superfamily member 11	Homo sapiens	108-113
22207352-5	2012	In addition, treatment with the DNA demethylating agent 5-azadeoxycitidine promoted a 170-fold induction of RANKL and a 20-fold induction of OPG mRNA expression in HEK-293 cells, which showed hypermethylation of the CpG islands and barely expressed RANKL and OPG transcripts at baseline.	5-azadeoxycitidine	56-74	TNF superfamily member 11	Homo sapiens	249-254
23091492-10	2012	Both LPS and RANKL stimulated macrophages to form osteoclast-like TRAP positive cells, which resorbed calcium phosphate substrates.	calcium phosphate	102-119	TNF superfamily member 11	Homo sapiens	13-18
22927853-6	2012	That it has been observed melatonin, at pharmacological doses, decrease bone mass resorption by suppressing through down regulation of the RANK-L, as suggested by Penarrocha Diago et al.	Melatonin	26-35	TNF superfamily member 11	Homo sapiens	139-145
21726411-11	2011	Alteration in the OPG/RANKL pathway by glitazones may have implications for the understanding of both cardiovascular effects and bone side effects of the drug.	Thiazolidinediones	39-49	TNF superfamily member 11	Homo sapiens	22-27
22952578-13	2012	RPMI-8226/hRANKL/eGFP cells, but not RPMI-8226/eGFP cells, stimulated osteoclastic bone resorption (p&lt;0.05) in vitro.	rpmi	0-4	TNF superfamily member 11	Homo sapiens	10-16
22952578-14	2012	Sub-cutaneous injection of NOD/SCID mice with RPMI-8226/hRANKL/eGFP or RPMI-8226/eGFP cells resulted in tumour development in all mice.	rpmi	46-50	TNF superfamily member 11	Homo sapiens	56-62
22952578-15	2012	RPMI-8226/hRANKL/eGFP-bearing mice exhibited increased serum soluble hRANKL (p&lt;0.05) and a three-fold increase in osteoclast number (p&lt;0.05) compared to RPMI-8226/eGFP-bearing mice.	rpmi	0-4	TNF superfamily member 11	Homo sapiens	10-16
22952578-15	2012	RPMI-8226/hRANKL/eGFP-bearing mice exhibited increased serum soluble hRANKL (p&lt;0.05) and a three-fold increase in osteoclast number (p&lt;0.05) compared to RPMI-8226/eGFP-bearing mice.	rpmi	0-4	TNF superfamily member 11	Homo sapiens	69-75
22952578-15	2012	RPMI-8226/hRANKL/eGFP-bearing mice exhibited increased serum soluble hRANKL (p&lt;0.05) and a three-fold increase in osteoclast number (p&lt;0.05) compared to RPMI-8226/eGFP-bearing mice.	rpmi	159-163	TNF superfamily member 11	Homo sapiens	10-16
22919420-0	2012	Vitamin E as an Antiosteoporotic Agent via Receptor Activator of Nuclear Factor Kappa-B Ligand Signaling Disruption: Current Evidence and Other Potential Research Areas.	Vitamin E	0-9	TNF superfamily member 11	Homo sapiens	43-94
22919420-4	2012	A few in vitro studies showed that various forms of vitamin E can affect the receptor activator of nuclear factor kappa-B ligand (RANKL) signaling and their molecular targets, thus preventing the formation of osteoclasts in the early stage of osteoclastogenesis.	Vitamin E	52-61	TNF superfamily member 11	Homo sapiens	77-128
22919420-4	2012	A few in vitro studies showed that various forms of vitamin E can affect the receptor activator of nuclear factor kappa-B ligand (RANKL) signaling and their molecular targets, thus preventing the formation of osteoclasts in the early stage of osteoclastogenesis.	Vitamin E	52-61	TNF superfamily member 11	Homo sapiens	130-135
22919420-7	2012	Vitamin E may affect bone metabolism by disruption of free radical-mediated RANKL signaling, by its oestrogen-like effects, by its effects on the molecular mechanism of bone formation, by the anti-inflammatory effects of its long-chain metabolites on bone cells, and by the inhibition of 3-hydroxyl-3-methyglutaryl coenzyme A (HMG-CoA).	Vitamin E	0-9	TNF superfamily member 11	Homo sapiens	76-81
22919420-7	2012	Vitamin E may affect bone metabolism by disruption of free radical-mediated RANKL signaling, by its oestrogen-like effects, by its effects on the molecular mechanism of bone formation, by the anti-inflammatory effects of its long-chain metabolites on bone cells, and by the inhibition of 3-hydroxyl-3-methyglutaryl coenzyme A (HMG-CoA).	Free Radicals	54-66	TNF superfamily member 11	Homo sapiens	76-81
21925926-12	2012	In addition, CM derived from the LPA-stimulated OSCC induced receptor activator of nuclear factor (NF)-kappaB ligand (RANKL) expression in human osteoblasts and direct treatment with rIL-6 and/or sIL-6R or rIL-8 mimicked the effect of the CM derived from the LPA-stimulated OSCC for RANKL expression.	lysophosphatidic acid	33-36	TNF superfamily member 11	Homo sapiens	118-123
21925926-12	2012	In addition, CM derived from the LPA-stimulated OSCC induced receptor activator of nuclear factor (NF)-kappaB ligand (RANKL) expression in human osteoblasts and direct treatment with rIL-6 and/or sIL-6R or rIL-8 mimicked the effect of the CM derived from the LPA-stimulated OSCC for RANKL expression.	lysophosphatidic acid	33-36	TNF superfamily member 11	Homo sapiens	283-288
21925926-12	2012	In addition, CM derived from the LPA-stimulated OSCC induced receptor activator of nuclear factor (NF)-kappaB ligand (RANKL) expression in human osteoblasts and direct treatment with rIL-6 and/or sIL-6R or rIL-8 mimicked the effect of the CM derived from the LPA-stimulated OSCC for RANKL expression.	sil-6r	196-202	TNF superfamily member 11	Homo sapiens	118-123
21925926-12	2012	In addition, CM derived from the LPA-stimulated OSCC induced receptor activator of nuclear factor (NF)-kappaB ligand (RANKL) expression in human osteoblasts and direct treatment with rIL-6 and/or sIL-6R or rIL-8 mimicked the effect of the CM derived from the LPA-stimulated OSCC for RANKL expression.	ril-8	206-211	TNF superfamily member 11	Homo sapiens	118-123
21925926-12	2012	In addition, CM derived from the LPA-stimulated OSCC induced receptor activator of nuclear factor (NF)-kappaB ligand (RANKL) expression in human osteoblasts and direct treatment with rIL-6 and/or sIL-6R or rIL-8 mimicked the effect of the CM derived from the LPA-stimulated OSCC for RANKL expression.	lysophosphatidic acid	259-262	TNF superfamily member 11	Homo sapiens	118-123
21925926-14	2012	LPA-induced IL-6 and IL-8 exerted propound effects on RANKL expression in osteoblast and thereby promoted osteoclast formation from osteoclast precursors.	lysophosphatidic acid	0-3	TNF superfamily member 11	Homo sapiens	54-59
22761920-5	2012	After incubation with the 1alpha-hydroxylase substrate 25-hydroxyvitamin D(3), human gingival fibroblasts and periodontal ligament cells generated detectable 1alpha,25-dihydroxyvitamin D(3) that resulted in an up-regulation of CYP24A1 and RANKL mRNA.	25-hydroxyvitamin D	55-74	TNF superfamily member 11	Homo sapiens	239-244
22412975-4	2012	Interestingly, we found that formulated isoflavone and 3,3"-diindolylmethane (BR-DIM) were able to inhibit the differentiation of osteoclasts and osteoblasts through the inhibition of cell signal transduction in RANKL, osteoblastic, and PCa cell signaling.	Isoflavones	40-50	TNF superfamily member 11	Homo sapiens	212-217
22412975-4	2012	Interestingly, we found that formulated isoflavone and 3,3"-diindolylmethane (BR-DIM) were able to inhibit the differentiation of osteoclasts and osteoblasts through the inhibition of cell signal transduction in RANKL, osteoblastic, and PCa cell signaling.	3,3'-diindolylmethane	55-76	TNF superfamily member 11	Homo sapiens	212-217
22412975-4	2012	Interestingly, we found that formulated isoflavone and 3,3"-diindolylmethane (BR-DIM) were able to inhibit the differentiation of osteoclasts and osteoblasts through the inhibition of cell signal transduction in RANKL, osteoblastic, and PCa cell signaling.	br-dim	78-84	TNF superfamily member 11	Homo sapiens	212-217
22412975-5	2012	Moreover, we found that isoflavone and BR-DIM down-regulated the expression of miR-92a, which is known to be associated with RANKL signaling, EMT and cancer progression.	Isoflavones	24-34	TNF superfamily member 11	Homo sapiens	125-130
22412975-5	2012	Moreover, we found that isoflavone and BR-DIM down-regulated the expression of miR-92a, which is known to be associated with RANKL signaling, EMT and cancer progression.	Bromine	39-41	TNF superfamily member 11	Homo sapiens	125-130
22412975-5	2012	Moreover, we found that isoflavone and BR-DIM down-regulated the expression of miR-92a, which is known to be associated with RANKL signaling, EMT and cancer progression.	3,3'-diindolylmethane	42-45	TNF superfamily member 11	Homo sapiens	125-130
21837749-7	2011	Furthermore, bilirubin down-regulated RUNX2 (runt-related transcription factor 2) gene expression, a basic osteogenic factor involved in osteoblast differentiation, and serum from jaundiced patients significantly up-regulated the RANKL/OPG (receptor activator of nuclear factor-kappaB ligand/osteoprotegerin) gene expression ratio, a system closely involved in osteoblast-induced osteoclastogenesis.	Bilirubin	13-22	TNF superfamily member 11	Homo sapiens	230-235
21964949-1	2011	We sought to determine the influence of single-nucleotide polymorphisms (SNPs) in RANKL, RANK, and OPG on volumetric bone mineral density (vBMD) and bone geometry at the radius in men.	single-nucleotide	40-57	TNF superfamily member 11	Homo sapiens	82-87
21605080-9	2011	In conclusion, the present study indicated that GdCl3 inhibited PC3 cell migration mediated by the inactivation of both ERK and p38 MAPK pathways via PTx-sensitive G proteins, and also suppressed PC3 cell-induced osteoclast differentiation via regulating the mRNA expression of OPG and RANKL.	gadolinium chloride	48-53	TNF superfamily member 11	Homo sapiens	286-291
21703936-6	2011	Treatment with zoledronic acid reduces NTX, TRACP-5b, RANKL, and OPG levels.	Zoledronic Acid	15-30	TNF superfamily member 11	Homo sapiens	54-59
22040825-6	2011	These results suggest that daily administration of eldecalcitol increase BMD by suppressing RANKL expression in bone.	eldecalcitol	51-63	TNF superfamily member 11	Homo sapiens	92-97
21170936-0	2011	Butein, a tetrahydroxychalcone, suppresses cancer-induced osteoclastogenesis through inhibition of receptor activator of nuclear factor-kappaB ligand signaling.	butein	0-6	TNF superfamily member 11	Homo sapiens	99-149
21170936-3	2011	We therefore investigated whether butein, a tetrahydroxychalcone, could inhibit RANKL signaling and suppress osteoclastogenesis induced by RANKL or tumor cells.	butein	34-40	TNF superfamily member 11	Homo sapiens	80-85
21170936-3	2011	We therefore investigated whether butein, a tetrahydroxychalcone, could inhibit RANKL signaling and suppress osteoclastogenesis induced by RANKL or tumor cells.	butein	34-40	TNF superfamily member 11	Homo sapiens	139-144
21170936-5	2011	The chalcone also suppressed the expression of RANKL by the tumor cells.	Chalcone	4-12	TNF superfamily member 11	Homo sapiens	47-52
21170936-6	2011	We further found that butein suppressed RANKL-induced NF-kappaB activation and that this suppression correlated with the inhibition of IkappaBalpha kinase and suppression of phosphorylation and degradation of IkappaBalpha, an inhibitor of NF-kappaB.	butein	22-28	TNF superfamily member 11	Homo sapiens	40-45
21170936-8	2011	Collectively, our results indicate that butein suppresses the osteoclastogenesis induced by tumor cells and by RANKL, by suppression of the NF-kappaB activation pathway.	butein	40-46	TNF superfamily member 11	Homo sapiens	111-116
21688034-5	2011	Erlotinib treatment suppressed osteoclast activation to the basal level through suppressing receptor activator of NF-kappaB ligand (RANKL) expression in osteoblast/stromal cell at the bone metastatic sites, which leads to inhibition of osteolytic bone destruction caused by NCI-H292 cells.	Erlotinib Hydrochloride	0-9	TNF superfamily member 11	Homo sapiens	132-137
22100799-1	2011	BACKGROUND: It has been suggested that increased testosterone secretion in postmenopausal obese women might have some protective effect on bone tissue; the association might be significantly influenced by the RANKL/RANK/OPG system.	Testosterone	49-61	TNF superfamily member 11	Homo sapiens	209-214
21688034-8	2011	Furthermore, erlotinib also inhibited osteoblast/stromal cell proliferation in vitro and the development of osteoclasts induced by RANKL in vitro.	Erlotinib Hydrochloride	13-22	TNF superfamily member 11	Homo sapiens	131-136
21773989-6	2011	Constitutive expression of ERE-BP increased the sensitivity of cells toward 1,25-dihydroxyvitamin D(3) stimulation of RANKL expression.	Calcitriol	76-102	TNF superfamily member 11	Homo sapiens	118-123
21620893-7	2011	The levels of RANKL and PLD1 but not PLD2 were upregulated significantly by IL-15, and the RANKL level was significantly upregulated by PA in rheumatoid synovial fibroblasts.	Phosphatidic Acids	136-138	TNF superfamily member 11	Homo sapiens	91-96
21620893-8	2011	Blocking PA production with 1-butanol and siRNA against PLD1 significantly inhibited the IL-15-stimulated expression of RANKL and PLD1.	Phosphatidic Acids	9-11	TNF superfamily member 11	Homo sapiens	120-125
21620893-8	2011	Blocking PA production with 1-butanol and siRNA against PLD1 significantly inhibited the IL-15-stimulated expression of RANKL and PLD1.	1-Butanol	28-37	TNF superfamily member 11	Homo sapiens	120-125
21799342-4	2011	Conditioned medium from control MCF7 cells elevated the RANKL/OPG mRNA ratio in MC3T3-E1 cells; this effect was suppressed by carbon ion irradiation of the MCF7 cells.	Carbon	126-132	TNF superfamily member 11	Homo sapiens	56-61
21784849-4	2011	Here, we report that the LXR ligand GW3965 is able to clearly and potently inhibit the formation of mature osteoclasts from receptor activator of nuclear factor kappaB ligand (RANKL)-stimulated human and murine osteoclast precursors.	GW 3965	36-42	TNF superfamily member 11	Homo sapiens	124-174
21784849-4	2011	Here, we report that the LXR ligand GW3965 is able to clearly and potently inhibit the formation of mature osteoclasts from receptor activator of nuclear factor kappaB ligand (RANKL)-stimulated human and murine osteoclast precursors.	GW 3965	36-42	TNF superfamily member 11	Homo sapiens	176-181
21700005-6	2011	The effect of strontium ranelate was evaluated on the expression (qPCR) of MMP-2, MMP-9, OPG, RANKL (total), RANKL-1, and RANKL-3, on the production of OPG (ELISA), membranous RANKL (flow cytometry), and MT1-MMP, ADAM17, and ADAM19 (Western blot).	strontium ranelate	14-32	TNF superfamily member 11	Homo sapiens	94-99
21700005-6	2011	The effect of strontium ranelate was evaluated on the expression (qPCR) of MMP-2, MMP-9, OPG, RANKL (total), RANKL-1, and RANKL-3, on the production of OPG (ELISA), membranous RANKL (flow cytometry), and MT1-MMP, ADAM17, and ADAM19 (Western blot).	strontium ranelate	14-32	TNF superfamily member 11	Homo sapiens	109-114
21700005-6	2011	The effect of strontium ranelate was evaluated on the expression (qPCR) of MMP-2, MMP-9, OPG, RANKL (total), RANKL-1, and RANKL-3, on the production of OPG (ELISA), membranous RANKL (flow cytometry), and MT1-MMP, ADAM17, and ADAM19 (Western blot).	strontium ranelate	14-32	TNF superfamily member 11	Homo sapiens	109-114
21700005-6	2011	The effect of strontium ranelate was evaluated on the expression (qPCR) of MMP-2, MMP-9, OPG, RANKL (total), RANKL-1, and RANKL-3, on the production of OPG (ELISA), membranous RANKL (flow cytometry), and MT1-MMP, ADAM17, and ADAM19 (Western blot).	strontium ranelate	14-32	TNF superfamily member 11	Homo sapiens	109-114
21700005-15	2011	This is reflected by the significant (p&lt;=0.02) reduction in the level of membranous RANKL by strontium ranelate at 2 mM.	strontium ranelate	96-114	TNF superfamily member 11	Homo sapiens	87-92
21332944-6	2011	The RANKL expression induced by 1,25-(OH)(2) vitamin D(3) was not affected by RIS in human MSC-derived osteoblasts.	1,25-(oh)(2)	32-44	TNF superfamily member 11	Homo sapiens	4-9
21332944-6	2011	The RANKL expression induced by 1,25-(OH)(2) vitamin D(3) was not affected by RIS in human MSC-derived osteoblasts.	Vitamin D	45-54	TNF superfamily member 11	Homo sapiens	4-9
21305609-4	2011	Blockade of Smad signaling by overexpression of Smad7 or c-Ski markedly suppressed RANKL-induced osteoclastogenesis, and retroviral induction of an activated mutant of Smad2 or Smad3 reversed the inhibitory effect of SB431542.	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	217-225	TNF superfamily member 11	Homo sapiens	83-88
21514407-0	2011	High extracellular calcium-induced NFATc3 regulates the expression of receptor activator of NF-kappaB ligand in osteoblasts.	Calcium	19-26	TNF superfamily member 11	Homo sapiens	70-108
21514407-3	2011	High extracellular calcium ([Ca(2+)](o)) increases intracellular calcium, enhances RANKL expression in osteoblasts/stromal cells, and induces osteoclastogenesis in a coculture of osteoblasts and hematopoietic bone marrow cells.	Calcium	19-26	TNF superfamily member 11	Homo sapiens	83-88
21514407-7	2011	Cyclosporin A and FK506, inhibitors of calcineurin phosphatase, blocked high [Ca(2+)](o)-induced expression of NFAT and RANKL.	Cyclosporine	0-13	TNF superfamily member 11	Homo sapiens	120-125
21514407-7	2011	Cyclosporin A and FK506, inhibitors of calcineurin phosphatase, blocked high [Ca(2+)](o)-induced expression of NFAT and RANKL.	Tacrolimus	18-23	TNF superfamily member 11	Homo sapiens	120-125
21814026-3	2011	Central RANKL injection to the rodents induces fever via PGE(2)/EP3R pathway.	Prostaglandins E	57-60	TNF superfamily member 11	Homo sapiens	8-13
21814031-4	2011	RANKL (receptor activator of nuclear factor-kappaB ligand) antibody (denosumab) is effective for prevention of CTIBL and it may prevent CTIBL-induced fracture.	ctibl	111-116	TNF superfamily member 11	Homo sapiens	0-5
21814031-4	2011	RANKL (receptor activator of nuclear factor-kappaB ligand) antibody (denosumab) is effective for prevention of CTIBL and it may prevent CTIBL-induced fracture.	ctibl	111-116	TNF superfamily member 11	Homo sapiens	7-57
21814031-4	2011	RANKL (receptor activator of nuclear factor-kappaB ligand) antibody (denosumab) is effective for prevention of CTIBL and it may prevent CTIBL-induced fracture.	ctibl	136-141	TNF superfamily member 11	Homo sapiens	0-5
21814031-4	2011	RANKL (receptor activator of nuclear factor-kappaB ligand) antibody (denosumab) is effective for prevention of CTIBL and it may prevent CTIBL-induced fracture.	ctibl	136-141	TNF superfamily member 11	Homo sapiens	7-57
21868322-0	2011	[Influence of surface modification of titanium on OPG/RANKL mRNA expression in MG-63 human osteoblast-like cells].	Titanium	38-46	TNF superfamily member 11	Homo sapiens	54-59
21868322-1	2011	OBJECTIVE: To investigate the influence of surface modification of titanium on OPG/RANKL mRNA expression in human osteoblast-like cells.	Titanium	67-75	TNF superfamily member 11	Homo sapiens	83-88
21550432-10	2011	Nilotinib treatment of osteoblastic cells increased expression and secretion of OPG and decreased expression of RANKL.	nilotinib	0-9	TNF superfamily member 11	Homo sapiens	112-117
21463327-10	2011	Only atorvastatin at the highest concentration (5x10(-6)  m) significantly increased the IL-1beta-stimulated RANKL/OPG ratio.	Atorvastatin	5-17	TNF superfamily member 11	Homo sapiens	109-114
21613210-3	2011	In this study, we investigated the effects of N-methylpyrrolidone (NMP) on the regulation of RANKL-induced osteoclastogenesis.	N-methylpyrrolidone	46-65	TNF superfamily member 11	Homo sapiens	93-98
21613210-3	2011	In this study, we investigated the effects of N-methylpyrrolidone (NMP) on the regulation of RANKL-induced osteoclastogenesis.	N-methylpyrrolidone	67-70	TNF superfamily member 11	Homo sapiens	93-98
21491082-8	2011	The area under the ROC curve (NEDP vs. BMP) was higher for OPG (82.5, 95% CI 74.5-90.6) than for RANK-L (69.2, 95% CI 59.0-79.40).	nedp	30-34	TNF superfamily member 11	Homo sapiens	97-103
21360285-6	2011	Alcohol-induced oxidative stress as the result of increased NADPH-oxidase activity in bone cells also results in enhanced RANKL-RANK signaling to increase osteoclastogenesis.	Alcohols	0-7	TNF superfamily member 11	Homo sapiens	122-127
21708014-6	2011	Expression of RANKL was measured by RT-PCR and western blot in cultured synoviocytes with or without CXCL10 and also measured in Jurkat/Hut 78 T cells and CD4+ T cells in the presence of CXCL10 or dexamethasone.	Dexamethasone	197-210	TNF superfamily member 11	Homo sapiens	14-19
21413932-4	2011	RANKL stimulates NFATc1 acetylation via HATs (histone acetyltransferases), such as p300 and PCAF [p300/CREB (cAMP-response-element-binding protein)-binding protein-associated factor], thereby stabilizing NFATc1 proteins.	Cyclic AMP	109-113	TNF superfamily member 11	Homo sapiens	0-5
21413932-6	2011	In addition, RANKL-mediated NFATc1 acetylation is increased by the HDAC (histone deacetylase) inhibitors sodium butyrate and scriptaid.	Butyric Acid	105-120	TNF superfamily member 11	Homo sapiens	13-18
21338601-7	2011	Moreover, TAE226 inhibited the receptor activator for nuclear factor kappa B Ligand (RANKL) gene expression induced by parathyroid hormone-related protein (PTHrP) in bone stromal ST2 cells and blood free calcium concentration induced by PTHrP administration in vivo.	TAE226	10-16	TNF superfamily member 11	Homo sapiens	31-83
21611964-3	2011	The osteoclast differentiation factor receptor activator of NF-kappaB ligand (RANKL) increased the expression of adenylate cyclase 3 (AC3), accompanied by a rise in the intracellular cAMP level in osteoclasts.	Cyclic AMP	183-187	TNF superfamily member 11	Homo sapiens	78-83
21611964-7	2011	Knockdown or catalytic inhibition of CaMKs elevated intracellular cAMP levels in RANKL-treated osteoclast precursors and suppressed the activation of NFATc1.	Cyclic AMP	66-70	TNF superfamily member 11	Homo sapiens	81-86
21338601-7	2011	Moreover, TAE226 inhibited the receptor activator for nuclear factor kappa B Ligand (RANKL) gene expression induced by parathyroid hormone-related protein (PTHrP) in bone stromal ST2 cells and blood free calcium concentration induced by PTHrP administration in vivo.	TAE226	10-16	TNF superfamily member 11	Homo sapiens	85-90
21576410-10	2011	The EtOAc fraction most strongly inhibited the receptor activator for nuclear factor-kappaB ligand (RANKL)-induced osteoclastogenesis, followed by the n-BuOH, n-hexane and H(2)O fractions.	Butanols	151-157	TNF superfamily member 11	Homo sapiens	100-105
21576410-10	2011	The EtOAc fraction most strongly inhibited the receptor activator for nuclear factor-kappaB ligand (RANKL)-induced osteoclastogenesis, followed by the n-BuOH, n-hexane and H(2)O fractions.	Water	172-177	TNF superfamily member 11	Homo sapiens	100-105
21812275-0	2011	[Inhibitory acting mechanism of psoralen-osthole on bone metastasis of breast cancer--an expatiation viewing from OPG/RANKL/RANK system].	psoralen-osthole	32-48	TNF superfamily member 11	Homo sapiens	118-123
21349995-10	2011	In contrast to 17-AAG, PF-04928473 abrogates RANKL-induced osteoclast differentiation by affecting NF-kappaB activation and Src phosphorylation.	pyrazofurin	23-25	TNF superfamily member 11	Homo sapiens	45-50
21705982-4	2011	Chronic anemia, iron toxicity and endocrine complications, via a complex mechanism, lead to alterations in the RANK/RANKL/OPG system in favor of increased osteoclastic activity and enhanced osteoblastic dysfunction.	Iron	16-20	TNF superfamily member 11	Homo sapiens	116-121
21327765-0	2011	Reduced osteoclastogenesis and RANKL expression in marrow from women taking alendronate.	Alendronate	76-87	TNF superfamily member 11	Homo sapiens	31-36
21327765-5	2011	RANKL expression in +AL BMCs was 57% of that in controls (P = 0.001), and OPG expression in +AL BMCs was greater than in controls (153%, P = 0.01).	al bmcs	21-28	TNF superfamily member 11	Homo sapiens	0-5
21327765-5	2011	RANKL expression in +AL BMCs was 57% of that in controls (P = 0.001), and OPG expression in +AL BMCs was greater than in controls (153%, P = 0.01).	Alendronate	21-23	TNF superfamily member 11	Homo sapiens	0-5
21327765-5	2011	RANKL expression in +AL BMCs was 57% of that in controls (P = 0.001), and OPG expression in +AL BMCs was greater than in controls (153%, P = 0.01).	bmcs	24-28	TNF superfamily member 11	Homo sapiens	0-5
21327765-6	2011	The mean RANKL/OPG ratio in BMCs was 0.65 +- 0.35 for +AL specimens and 1.28 +- 0.53 for controls (P = 0.031).	bmcs	28-32	TNF superfamily member 11	Homo sapiens	9-14
21327765-6	2011	The mean RANKL/OPG ratio in BMCs was 0.65 +- 0.35 for +AL specimens and 1.28 +- 0.53 for controls (P = 0.031).	Alendronate	55-57	TNF superfamily member 11	Homo sapiens	9-14
21327765-7	2011	In addition, we assessed the direct effect of AL on expression of RANKL and OPG in marrow stromal cells isolated from nine control women.	Alendronate	46-48	TNF superfamily member 11	Homo sapiens	66-71
21327765-8	2011	Treatment with AL downregulated RANKL expression and upregulated OPG expression, with an average 50% decrease in RANKL/OPG ratio at 10(-7) M (P = 0.004).	Alendronate	15-17	TNF superfamily member 11	Homo sapiens	32-37
21327765-8	2011	Treatment with AL downregulated RANKL expression and upregulated OPG expression, with an average 50% decrease in RANKL/OPG ratio at 10(-7) M (P = 0.004).	Alendronate	15-17	TNF superfamily member 11	Homo sapiens	113-118
21239502-0	2011	Resveratrol-mediated SIRT-1 interactions with p300 modulate receptor activator of NF-kappaB ligand (RANKL) activation of NF-kappaB signaling and inhibit osteoclastogenesis in bone-derived cells.	Resveratrol	0-11	TNF superfamily member 11	Homo sapiens	60-98
21239502-0	2011	Resveratrol-mediated SIRT-1 interactions with p300 modulate receptor activator of NF-kappaB ligand (RANKL) activation of NF-kappaB signaling and inhibit osteoclastogenesis in bone-derived cells.	Resveratrol	0-11	TNF superfamily member 11	Homo sapiens	100-105
21239502-5	2011	In this study, we investigated the effects of resveratrol on RANKL during bone morphogenesis in high density bone cultures in vitro.	Resveratrol	46-57	TNF superfamily member 11	Homo sapiens	61-66
21239502-7	2011	Treatment with RANKL induced formation of tartrate-resistant acid phosphatase-positive multinucleated cells that exhibited morphological features of osteoclasts.	tartaric acid	42-50	TNF superfamily member 11	Homo sapiens	15-20
21239502-10	2011	Resveratrol inhibited RANKL-induced acetylation and nuclear translocation of NF-kappaB in a time- and concentration-dependent manner.	Resveratrol	0-11	TNF superfamily member 11	Homo sapiens	22-27
21239502-11	2011	In addition, activation of Sirt-1 (a histone deacetylase) by resveratrol induced Sirt-1-p300 association in bone-derived and preosteoblastic cells, leading to deacetylation of RANKL-induced NF-kappaB, inhibition of NF-kappaB transcriptional activation, and osteoclastogenesis.	Resveratrol	61-72	TNF superfamily member 11	Homo sapiens	176-181
21569702-6	2011	CONCLUSION: Bortezomib lowers levels of serum DKK-1 and RANKL in responders, thus leads to normalization of abnormal bone remodeling through the increase of bone formation and reduction of bone resorption.	Bortezomib	12-22	TNF superfamily member 11	Homo sapiens	56-61
21352805-0	2011	alpha-Tocotrienol inhibits osteoclastic bone resorption by suppressing RANKL expression and signaling and bone resorbing activity.	tocotrienol, alpha	0-17	TNF superfamily member 11	Homo sapiens	71-76
21352805-6	2011	In addition, alpha-TT but not alpha-TP inhibited RANKL-induced osteoclast differentiation from precursors by suppression of c-Fos expression, possibly through inhibiting ERK and NF-kappaB activation.	tocotrienol, alpha	13-21	TNF superfamily member 11	Homo sapiens	49-54
20886653-0	2011	Pamidronate, farnesyl transferase, and geranylgeranyl transferase-I inhibitors affects cell proliferation, apoptosis, and OPG/RANKL mRNA expression in stromal cells of giant cell tumor of bone.	Pamidronate	0-11	TNF superfamily member 11	Homo sapiens	126-131
21518496-4	2011	As compared with osteoblasts treated by supernatant of cultured MM cells alone, the mRNA levels of ALP, OC and OPG in osteoblasts treated by brucine combined with supernatant of cultured MM cells were enhanced (p &lt; 0.05), while the RANKL mRNA level was lowered (p &lt; 0.05), moreover the enhanced and lowered degree also was large (p &lt; 0.05).	brucine	141-148	TNF superfamily member 11	Homo sapiens	235-240
21399573-0	2011	A-type cranberry proanthocyanidins inhibit the RANKL-dependent differentiation and function of human osteoclasts.	Proanthocyanidins	17-34	TNF superfamily member 11	Homo sapiens	47-52
21399573-6	2011	More specifically, AC-PACs at 50 microg/mL caused a 95% inhibition of RANKL-dependent osteoclast differentiation.	ac-pacs	19-26	TNF superfamily member 11	Homo sapiens	70-75
21328467-6	2011	Pretreatment of A549 cells with the MAPK kinase (MEK) inhibitor PD98059 or U0126 inhibited RANKL-mediated migration and ICAM-1 expression.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	64-71	TNF superfamily member 11	Homo sapiens	91-96
21328467-6	2011	Pretreatment of A549 cells with the MAPK kinase (MEK) inhibitor PD98059 or U0126 inhibited RANKL-mediated migration and ICAM-1 expression.	U 0126	75-80	TNF superfamily member 11	Homo sapiens	91-96
21345313-4	2011	In this study, we observed that LTi cells expressed TLR2 and TLR4 mRNA as well as TLR2 protein and upregulated OX40L, CD30L, and TRANCE expression after stimulation with the TLR2 ligand zymosan or TLR4 ligand LPS.	Zymosan	186-193	TNF superfamily member 11	Homo sapiens	129-135
21383509-0	2011	Human bone marrow adipocytes support dexamethasone-induced osteoclast differentiation and function through RANKL expression.	Dexamethasone	37-50	TNF superfamily member 11	Homo sapiens	107-112
21383509-3	2011	RANKL expression and the RANKL/osteoprotegerin (OPG) mRNA ratio in marrow adipocytes increased following dexamethasone treatment.	Dexamethasone	105-118	TNF superfamily member 11	Homo sapiens	0-5
21383509-3	2011	RANKL expression and the RANKL/osteoprotegerin (OPG) mRNA ratio in marrow adipocytes increased following dexamethasone treatment.	Dexamethasone	105-118	TNF superfamily member 11	Homo sapiens	25-30
20659908-0	2011	Effects of unfractioned heparin and low-molecular-weight heparin on osteoprotegerin and RANKL plasma levels in haemodialysis patients.	Heparin	24-31	TNF superfamily member 11	Homo sapiens	88-93
20701670-16	2011	CONCLUSION: The action of alendronate and pamidronate on human gingival fibroblasts, through altering the production of RANKL and OPG, appears to contribute to a microenvironment favoring the inhibition of bone resorption and ONJ.	Alendronate	26-37	TNF superfamily member 11	Homo sapiens	120-125
20701670-16	2011	CONCLUSION: The action of alendronate and pamidronate on human gingival fibroblasts, through altering the production of RANKL and OPG, appears to contribute to a microenvironment favoring the inhibition of bone resorption and ONJ.	Pamidronate	42-53	TNF superfamily member 11	Homo sapiens	120-125
20659908-0	2011	Effects of unfractioned heparin and low-molecular-weight heparin on osteoprotegerin and RANKL plasma levels in haemodialysis patients.	Heparin	57-64	TNF superfamily member 11	Homo sapiens	88-93
21050847-12	2011	In the osteoporotic group, the RANKL/osteoprotegerin mRNA ratio was significantly increased after treatment with alendronate (112%) and after treatment with raloxifene (60%).	Raloxifene Hydrochloride	157-167	TNF superfamily member 11	Homo sapiens	31-36
21050847-13	2011	These results indicate a direct action of alendronate and raloxifene on hOB cultures from osteoporotic patients, and the cited drugs are able to modulate the osteoprotegerin/RANKL system.	Alendronate	42-53	TNF superfamily member 11	Homo sapiens	174-179
21050847-0	2011	Alendronate and raloxifene affect the osteoprotegerin/RANKL system in human osteoblast primary cultures from patients with osteoporosis and osteoarthritis.	Alendronate	0-11	TNF superfamily member 11	Homo sapiens	54-59
21050847-13	2011	These results indicate a direct action of alendronate and raloxifene on hOB cultures from osteoporotic patients, and the cited drugs are able to modulate the osteoprotegerin/RANKL system.	Raloxifene Hydrochloride	58-68	TNF superfamily member 11	Homo sapiens	174-179
21050847-0	2011	Alendronate and raloxifene affect the osteoprotegerin/RANKL system in human osteoblast primary cultures from patients with osteoporosis and osteoarthritis.	Raloxifene Hydrochloride	16-26	TNF superfamily member 11	Homo sapiens	54-59
22136246-3	2011	In a recent issue of Arthritis Research &amp; Therapy Lee and colleagues proposed that bone destruction in chronic gouty arthritis is at least in part dependent on expression by T cells of receptor activator of NF-kappaB ligand (RANKL).	Adenosine Monophosphate	41-44	TNF superfamily member 11	Homo sapiens	189-227
21050847-10	2011	Both raloxifene (34%) and estradiol (37%) increased osteoprotegerin mRNA expression, and alendronate (118%) and raloxifene (61%) increased the mRNA expression of RANKL.	Alendronate	89-100	TNF superfamily member 11	Homo sapiens	162-167
21050847-10	2011	Both raloxifene (34%) and estradiol (37%) increased osteoprotegerin mRNA expression, and alendronate (118%) and raloxifene (61%) increased the mRNA expression of RANKL.	Raloxifene Hydrochloride	112-122	TNF superfamily member 11	Homo sapiens	162-167
21050847-12	2011	In the osteoporotic group, the RANKL/osteoprotegerin mRNA ratio was significantly increased after treatment with alendronate (112%) and after treatment with raloxifene (60%).	Alendronate	113-124	TNF superfamily member 11	Homo sapiens	31-36
22136246-3	2011	In a recent issue of Arthritis Research &amp; Therapy Lee and colleagues proposed that bone destruction in chronic gouty arthritis is at least in part dependent on expression by T cells of receptor activator of NF-kappaB ligand (RANKL).	Adenosine Monophosphate	41-44	TNF superfamily member 11	Homo sapiens	229-234
24578893-3	2011	PGE2 represents a key factor in the modulation of bone metabolism and bone metastatic disease in prostate cancer interacting with bone regulatory signals including the RANK/RANKL/OPG system and Wnt pathways.	Dinoprostone	0-4	TNF superfamily member 11	Homo sapiens	173-178
24578893-4	2011	A high concentration of PGE2 exerts a prevalent stimulatory effect on osteoclastogenesis via OPG/RANK/RANKL axis activation and a inhibitory effect on osteoblastogenesis trough inhibition of Wnt pathway.	Dinoprostone	24-28	TNF superfamily member 11	Homo sapiens	102-107
21196156-6	2011	The immunoreceptor tyrosine-based activation motif (ITAM)-mediated signal was discovered as a co-stimulatory signal in RANKL-induced osteoclastogenesis.	Tyrosine	19-27	TNF superfamily member 11	Homo sapiens	119-124
21845073-7	2011	Angiotensin II along with factors such as LDL, HDL, NO and homocysteine that are commonly altered both in hypertension and osteoporosis, can down-regulate the expression of Cbfa1 but up-regulate RANKL expression via the cAMP signaling pathway.	Homocysteine	59-71	TNF superfamily member 11	Homo sapiens	195-200
21072493-8	2011	Vitamin K2 further antagonized receptor activator of NF-kappaB (RANK) ligand (RANKL)-induced NF-kappaB activation in osteoclast precursors.	Vitamin K 2	0-10	TNF superfamily member 11	Homo sapiens	78-83
21845073-0	2011	Reciprocal roles of angiotensin II and Angiotensin II Receptors Blockade (ARB) in regulating Cbfa1/RANKL via cAMP signaling pathway: possible mechanism for hypertension-related osteoporosis and antagonistic effect of ARB on hypertension-related osteoporosis.	Cyclic AMP	109-113	TNF superfamily member 11	Homo sapiens	99-104
21845073-8	2011	We thus hypothesized that, by altering the ratio of Cbfa1/RANKL expression via the cAMP-dependent pathway, angiotensin II differently regulates osteoblast and osteoclast differentiation leading to enhanced bone resorption and reduced bone formation.	Cyclic AMP	83-87	TNF superfamily member 11	Homo sapiens	58-63
20683903-7	2011	Mechanistic studies revealed that mangiferin inhibits RANKL-induced activation of NF-kappaB, concomitant with the inhibition of IkappaB-alpha degradation, and p65 nuclear translocation.	mangiferin	34-44	TNF superfamily member 11	Homo sapiens	54-59
21845073-0	2011	Reciprocal roles of angiotensin II and Angiotensin II Receptors Blockade (ARB) in regulating Cbfa1/RANKL via cAMP signaling pathway: possible mechanism for hypertension-related osteoporosis and antagonistic effect of ARB on hypertension-related osteoporosis.	beta-L-Arabinose	74-77	TNF superfamily member 11	Homo sapiens	99-104
21845073-6	2011	Cbfa1 and RANKL, the important factors for maintaining bone homeostasis and key mediators in controlling osteoblast and osteoclast differentiation, are both regulated by cAMP-dependent signaling.	Cyclic AMP	170-174	TNF superfamily member 11	Homo sapiens	10-15
21114291-1	2010	A novel benzopyran-fused molecular framework 7ai was discovered as a specific inhibitor of RANKL-induced osteoclastogenesis using a cell-based TRAP activity assay from drug-like small-molecule libraries constructed by diversity-oriented synthesis.	Benzopyrans	8-18	TNF superfamily member 11	Homo sapiens	91-96
21087090-4	2010	Recently, our group reported that the RANKL/RANK signaling pathway has an essential role in the central regulation of body temperature via the prostaglandin axis.	Prostaglandins	143-156	TNF superfamily member 11	Homo sapiens	38-43
21159177-9	2010	CONCLUSIONS: These results suggest that iloprost has anti-inflammatory and immunomodulating effects, reducing TNF alpha production by T cells and the number of T regulatory cells and increasing IL-2 and RANKL.	Iloprost	40-48	TNF superfamily member 11	Homo sapiens	203-208
21119343-7	2010	At present, the potential relationship between RANKL/OPG and the content of calcium within the intima of the coronary arteries (CAC score, assessed by computed tomography) needs to be explored in large clinical studies.	Calcium	76-83	TNF superfamily member 11	Homo sapiens	47-52
20850430-0	2010	The novel isoflavone derivatives inhibit RANKL-induced osteoclast formation.	Isoflavones	10-20	TNF superfamily member 11	Homo sapiens	41-46
20667748-0	2010	BAPTA-AM, an intracellular calcium chelator, inhibits RANKL-induced bone marrow macrophages differentiation through MEK/ERK, p38 MAPK and Akt, but not JNK pathways.	1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester	0-8	TNF superfamily member 11	Homo sapiens	54-59
20667748-0	2010	BAPTA-AM, an intracellular calcium chelator, inhibits RANKL-induced bone marrow macrophages differentiation through MEK/ERK, p38 MAPK and Akt, but not JNK pathways.	Calcium	27-34	TNF superfamily member 11	Homo sapiens	54-59
20667748-3	2010	BAPTA-AM inhibited osteoclastogenesis and osteoclast survival of BMMs by RANKL induction.	1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester	0-8	TNF superfamily member 11	Homo sapiens	73-78
20667748-5	2010	This response was sustained for 30 min and returned to the control level at 1h after RANKL-inducing, and the increased response of [Ca(2+)](i) was completely abolished and sustained to at least 8h by BAPTA-AM.	1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester	200-208	TNF superfamily member 11	Homo sapiens	85-90
20667748-6	2010	Although immunoblotting data revealed that RANKL could activate the phosphorylation of ERK1/2, SAPK/JNK, Akt and p38 MAPK, the expression of ERK1/2, Akt and p38 MAPK phosphorylation was inhibited by BAPTA-AM dose-dependently.	1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester	199-207	TNF superfamily member 11	Homo sapiens	43-48
20667748-7	2010	These results revealed that BAPTA-AM inhibit osteoclastogenic ability of BMMs via suppressing the increase of [Ca(2+)](i) which lead to inhibit RANKL-induced the phosphorylation of ERK, Akt and p38 MAPK, but not JNK.	1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester	28-36	TNF superfamily member 11	Homo sapiens	144-149
20850430-5	2010	However, RANKL-induced p38 and JNK but not ERK phosphorylation was attenuated by isoflavone derivatives.	Isoflavones	81-91	TNF superfamily member 11	Homo sapiens	9-14
20850430-6	2010	Furthermore, RANKL-mediated increase of p65 phosphorylation at Ser536, NF-kappaB-specific DNA-protein complex formation and kappaB-luciferase activity was inhibited by isoflavone derivatives.	Isoflavones	168-178	TNF superfamily member 11	Homo sapiens	13-18
20850430-8	2010	Our data suggest that the novel isoflavone derivatives inhibit osteoclastogenesis from bone marrow stromal cells and macrophage cells via attenuation of RANKL-induced p38, JNK and NF-kappaB activation.	Isoflavones	32-42	TNF superfamily member 11	Homo sapiens	153-158
20803525-8	2010	Inhibition of SIRT1 by sirtinol or SIRT1 siRNA blocked the HMGB1-stimulated expression of RANKL and cytokines.	sirtinol	23-31	TNF superfamily member 11	Homo sapiens	90-95
20705636-4	2010	It highlights the evidence suggesting that monosodium urate crystal deposition is associated with the presence of underlying osteoarthritis and the important role of osteoclasts and the receptor for activation of nuclear factor kappa B (RANK) and RANK ligand (RANK-RANKL) pathway in the pathogenesis of gouty erosions.	Uric Acid	43-59	TNF superfamily member 11	Homo sapiens	265-270
21059944-4	2010	The disulfide bond (C125-C127) at the tip of Loop3 is important for determining the unique topology of Loop3, and docking E126 close to RANKL, which was supported by the inability of C127A or E126A mutants of RANK to bind to RANKL.	Disulfides	4-13	TNF superfamily member 11	Homo sapiens	136-141
21059944-4	2010	The disulfide bond (C125-C127) at the tip of Loop3 is important for determining the unique topology of Loop3, and docking E126 close to RANKL, which was supported by the inability of C127A or E126A mutants of RANK to bind to RANKL.	Disulfides	4-13	TNF superfamily member 11	Homo sapiens	225-230
20949013-0	2010	Retinoic acid increases proliferation of human osteoclast progenitors and inhibits RANKL-stimulated osteoclast differentiation by suppressing RANK.	Tretinoin	0-13	TNF superfamily member 11	Homo sapiens	83-88
20717572-1	2010	A series of Fourier transform infrared spectra (FTIR) of the hydrogen bonded complexes (CH(2))(2)O-HF and -DF have been recorded in the 50-750 cm(-1) range up to 0.1 cm(-1) resolution in a static cell maintained at near room temperature.	Hydrogen	61-69	TNF superfamily member 11	Homo sapiens	97-109
20949013-7	2010	In contrast, RA inhibited differentiation of the receptor activator of nuclear factor kappaB ligand (RANKL)-induced osteoclastogenesis of human and murine osteoclast progenitors via retinoic acid receptors (RARs).	Tretinoin	13-15	TNF superfamily member 11	Homo sapiens	49-99
20949013-7	2010	In contrast, RA inhibited differentiation of the receptor activator of nuclear factor kappaB ligand (RANKL)-induced osteoclastogenesis of human and murine osteoclast progenitors via retinoic acid receptors (RARs).	Tretinoin	13-15	TNF superfamily member 11	Homo sapiens	101-106
20826545-12	2010	Thus, embelin, an inhibitor of RANKL-induced NF-kappaB activation has great potential as a therapeutic agent for osteoporosis and cancer-linked bone loss.	embelin	6-13	TNF superfamily member 11	Homo sapiens	31-36
20504098-6	2010	Estradiol induces growth factors" activation, receptor activator of nuclear factor kappa B ligand (RANKL) production inhibition and is mainly referred to antiresorptive activity.	Estradiol	0-9	TNF superfamily member 11	Homo sapiens	46-97
20663885-9	2010	Oxidized phospholipids also slightly induced RANKL expression in T lymphocytes, another potential source of RANKL in the vasculature.	Phospholipids	9-22	TNF superfamily member 11	Homo sapiens	45-50
20663885-9	2010	Oxidized phospholipids also slightly induced RANKL expression in T lymphocytes, another potential source of RANKL in the vasculature.	Phospholipids	9-22	TNF superfamily member 11	Homo sapiens	108-113
19949772-10	2010	CONCLUSIONS: We suggest that alendronate mainly acts on mature bone resorbing osteoclasts in the short term, whereas, its long-term administration diminishes their formation by reducing their precursors and serum RANKL.	Alendronate	29-40	TNF superfamily member 11	Homo sapiens	213-218
20614110-11	2010	RT-PCR showed that H2O2 stimulated the expression of M-CSF and RANKL and increased the RANKL/OPG ratio.	Hydrogen Peroxide	19-23	TNF superfamily member 11	Homo sapiens	63-68
20614110-11	2010	RT-PCR showed that H2O2 stimulated the expression of M-CSF and RANKL and increased the RANKL/OPG ratio.	Hydrogen Peroxide	19-23	TNF superfamily member 11	Homo sapiens	87-92
20504098-6	2010	Estradiol induces growth factors" activation, receptor activator of nuclear factor kappa B ligand (RANKL) production inhibition and is mainly referred to antiresorptive activity.	Estradiol	0-9	TNF superfamily member 11	Homo sapiens	99-104
20506523-5	2010	Pretreatment of JJ012 cells with MAPK kinase (MEK) inhibitors, PD98059 or U0126, inhibited the RANKL-induced migration and integrin expression.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	63-70	TNF superfamily member 11	Homo sapiens	95-100
20506157-0	2010	The increased expression of receptor activator of nuclear-kappaB ligand (RANKL) of multiple myeloma bone marrow stromal cells is inhibited by the bisphosphonate ibandronate.	Diphosphonates	146-160	TNF superfamily member 11	Homo sapiens	73-78
20300790-6	2010	However, RANKL-dependent transcription of tartrate-resistant acid phosphatase (TRAP) was reduced in the presence of DMOG.	dimethyloxallyl glycine	116-120	TNF superfamily member 11	Homo sapiens	9-14
20506523-5	2010	Pretreatment of JJ012 cells with MAPK kinase (MEK) inhibitors, PD98059 or U0126, inhibited the RANKL-induced migration and integrin expression.	U 0126	74-79	TNF superfamily member 11	Homo sapiens	95-100
20506157-0	2010	The increased expression of receptor activator of nuclear-kappaB ligand (RANKL) of multiple myeloma bone marrow stromal cells is inhibited by the bisphosphonate ibandronate.	Ibandronic Acid	161-172	TNF superfamily member 11	Homo sapiens	73-78
20506157-2	2010	In this work we analyzed RANKL expression in human bone marrow mesenchymal stromal cells and the effect of the bisphosphonate ibandronate on RANKL expression after IL-1beta activation of ERK pathway.	Diphosphonates	111-125	TNF superfamily member 11	Homo sapiens	141-146
20506157-2	2010	In this work we analyzed RANKL expression in human bone marrow mesenchymal stromal cells and the effect of the bisphosphonate ibandronate on RANKL expression after IL-1beta activation of ERK pathway.	Ibandronic Acid	126-137	TNF superfamily member 11	Homo sapiens	141-146
20506157-9	2010	Finally, the bisphosphonate ibandronate, that hindered activation of the MEK/ERK pathway significantly inhibited both basal and IL-1beta dependent RANKL expression by cells.	Diphosphonates	13-27	TNF superfamily member 11	Homo sapiens	147-152
20506157-9	2010	Finally, the bisphosphonate ibandronate, that hindered activation of the MEK/ERK pathway significantly inhibited both basal and IL-1beta dependent RANKL expression by cells.	Ibandronic Acid	28-39	TNF superfamily member 11	Homo sapiens	147-152
20506157-10	2010	Results indicate that RANKL expression involves the MEK/ERK pathway in multiple myeloma mesenchymal stromal cells, and that early obstruction of this path, such as that achieved with ibandronate, significantly deters RANKL protein expression.	Ibandronic Acid	183-194	TNF superfamily member 11	Homo sapiens	22-27
20530522-5	2010	There were no differences between groups in SLEDAI, CD146( AnnV+) cells, or receptor activator for nuclear factor kB ligand (RANKL)/osteoprotegerin, although RANKL was higher after treatment with Prasterone (mean difference -29.5 units; p = 0.097).	Dehydroepiandrosterone	196-206	TNF superfamily member 11	Homo sapiens	158-163
20506157-10	2010	Results indicate that RANKL expression involves the MEK/ERK pathway in multiple myeloma mesenchymal stromal cells, and that early obstruction of this path, such as that achieved with ibandronate, significantly deters RANKL protein expression.	Ibandronic Acid	183-194	TNF superfamily member 11	Homo sapiens	217-222
22767690-2	2010	The mechanisms of action include a pulsative influence on the RANKL/OPG system resulting in osteoblast activation and increased bone formation by teriparatide.	Teriparatide	146-158	TNF superfamily member 11	Homo sapiens	62-67
20595654-6	2010	RANKL also induced bone-related gene mRNA expression and calcium deposition (Alizarin red staining) followed by the osteogenic differentiation of HASMCs.	Calcium	57-64	TNF superfamily member 11	Homo sapiens	0-5
20595654-6	2010	RANKL also induced bone-related gene mRNA expression and calcium deposition (Alizarin red staining) followed by the osteogenic differentiation of HASMCs.	alizarin	77-89	TNF superfamily member 11	Homo sapiens	0-5
20565769-8	2010	RESULTS: Dasatinib significantly increased the activity of ALP and the level of calcium deposition in MSC cultured with DAG after, respectively, 7 and 14 days; it upregulated the expression of BSP and OPN genes independently of DAG; and it markedly downregulated the expression of RANKL gene and protein (decrease in RANKL/OPG ratio), the key factor that stimulates osteoclast differentiation and activity.	Dasatinib	9-18	TNF superfamily member 11	Homo sapiens	281-286
20682990-8	2010	TbetaRI-I treatment reduced the expression of TNF-alpha, RANKL and connective tissue growth factor (CTGF/CCN2), all of which were up-regulated by TGF-beta in HSC-2 cells.	tbetari-i	0-9	TNF superfamily member 11	Homo sapiens	57-62
20565769-8	2010	RESULTS: Dasatinib significantly increased the activity of ALP and the level of calcium deposition in MSC cultured with DAG after, respectively, 7 and 14 days; it upregulated the expression of BSP and OPN genes independently of DAG; and it markedly downregulated the expression of RANKL gene and protein (decrease in RANKL/OPG ratio), the key factor that stimulates osteoclast differentiation and activity.	Dasatinib	9-18	TNF superfamily member 11	Homo sapiens	317-322
20565769-9	2010	CONCLUSIONS: Our results suggest a dual role for dasatinib in both (i) stimulating osteoblast differentiation leading to a direct increase in bone formation, and (ii) downregulating RANKL synthesis by osteoblasts leading to an indirect inhibition of osteoclastogenesis.	Dasatinib	49-58	TNF superfamily member 11	Homo sapiens	182-187
19701599-10	2010	The results indicate that in women deficient in sex steroids, the OPG/RANKL system may play an important counter regulatory role in order to avoid bone loss and maintain BMD.	Steroids	52-60	TNF superfamily member 11	Homo sapiens	70-75
20346376-12	2010	Simvastatin also activated ERK pathways and inactivated Src phosphorylation in human osteoclasts differentiated by M-CSF and RANKL treatments.	Simvastatin	0-11	TNF superfamily member 11	Homo sapiens	125-130
20337886-1	2010	BACKGROUND AND OBJECTIVE: Our previous study showed that human periodontal ligament cells responded to mechanical stress by increasing adenosine triphosphate (ATP) release, accompanied by the increased expression of RANKL and osteopontin.	Adenosine Triphosphate	159-162	TNF superfamily member 11	Homo sapiens	216-221
20337886-3	2010	In this study, we further investigated the effect of extracellular ATP on the expression of RANKL and the mechanism involved.	Adenosine Triphosphate	67-70	TNF superfamily member 11	Homo sapiens	92-97
20337886-8	2010	RESULTS: Adenosine triphosphate induced the expression of RANKL.	Adenosine Triphosphate	9-31	TNF superfamily member 11	Homo sapiens	58-63
20337886-9	2010	Indomethacin, an inhibitor of COX, could abolish the induction of RANKL expression, suggesting a COX-dependent mechanism.	Indomethacin	0-12	TNF superfamily member 11	Homo sapiens	66-71
20337886-10	2010	A cAMP-dependent protein kinase inhibitor, H89, and a nuclear factor kappaB (NF kappaB) inhibitor, pyrrolidine dithiocarbamate, inhibited RANKL expression, prostaglandin E(2) production and NF kappaB translocation.	Cyclic AMP	2-6	TNF superfamily member 11	Homo sapiens	138-143
20337886-10	2010	A cAMP-dependent protein kinase inhibitor, H89, and a nuclear factor kappaB (NF kappaB) inhibitor, pyrrolidine dithiocarbamate, inhibited RANKL expression, prostaglandin E(2) production and NF kappaB translocation.	N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide	43-46	TNF superfamily member 11	Homo sapiens	138-143
20337886-10	2010	A cAMP-dependent protein kinase inhibitor, H89, and a nuclear factor kappaB (NF kappaB) inhibitor, pyrrolidine dithiocarbamate, inhibited RANKL expression, prostaglandin E(2) production and NF kappaB translocation.	pyrrolidine dithiocarbamic acid	99-126	TNF superfamily member 11	Homo sapiens	138-143
20337886-12	2010	CONCLUSION: Extracellular ATP stimulates RANKL expression in human periodontal ligament cells through a pathway dependent on the P2Y(1) receptor, cAMP-dependent protein kinase, NF kappaB and COX.	Adenosine Triphosphate	26-29	TNF superfamily member 11	Homo sapiens	41-46
20337886-13	2010	Our results suggest that, among the molecules responsible for the effect of mechanical stress, ATP participates in bone resorption or bone homeostasis by mediating its signal through the P2Y(1) receptor and the NF kappaB-COX-RANKL axis in periodontal tissue.	Adenosine Triphosphate	95-98	TNF superfamily member 11	Homo sapiens	225-230
20484016-9	2010	Receptor activator of NF-kappaB ligand (RANKL)-induced osteoclastogenesis and signaling were inhibited by saracatinib in both macrophages and PC-3 cells.	saracatinib	106-117	TNF superfamily member 11	Homo sapiens	40-45
20337886-0	2010	Adenosine triphosphate stimulates RANKL expression through P2Y1 receptor-cyclo-oxygenase-dependent pathway in human periodontal ligament cells.	Adenosine Triphosphate	0-22	TNF superfamily member 11	Homo sapiens	34-39
20631890-0	2010	Hyperosmotic Stimulus Down-regulates 1alpha, 25-dihydroxyvitamin D(3)-induced Osteoclastogenesis by Suppressing the RANKL Expression in a Co-culture System.	25-dihydroxyvitamin d(3)	45-69	TNF superfamily member 11	Homo sapiens	116-121
20976089-6	2010	Sex steroids act probably by increasing the expression of RANKL by osteoblastic cells and alterations in the RANK/RANKL/OPG system in favor of osteoclasts.	Steroids	4-12	TNF superfamily member 11	Homo sapiens	58-63
20976089-6	2010	Sex steroids act probably by increasing the expression of RANKL by osteoblastic cells and alterations in the RANK/RANKL/OPG system in favor of osteoclasts.	Steroids	4-12	TNF superfamily member 11	Homo sapiens	114-119
19836866-2	2010	Recently anti-RANKL agents (receptor activator of nuclear factor-kappaB ligand) such as denosumab (Prolia, Amgen Inc., California, USA) that have a similar mode of action to bisphosphonates have been introduced to treat such diseases.	Diphosphonates	174-189	TNF superfamily member 11	Homo sapiens	14-19
20157786-10	2010	Moreover, direct contact with RPMI8226 and U266 cells induces apoptosis of BMSCs which is mediated by an overproduction of RANKL.	rpmi8226	30-38	TNF superfamily member 11	Homo sapiens	123-128
20225238-0	2010	Effect of IL-1beta, PGE(2), and TGF-beta1 on the expression of OPG and RANKL in normal and osteoporotic primary human osteoblasts.	Prostaglandins E	20-23	TNF superfamily member 11	Homo sapiens	71-76
20050743-8	2010	PEMF induced a fivefold increase in RANKL mRNA expression at t = 0.	pemf	0-4	TNF superfamily member 11	Homo sapiens	36-41
19874203-5	2010	EPA (50 microM for 24 hours) inhibited RANKL-induced differentiation and decreased activation of NF-kappaB induced by 0.2 microg/mL of TNF-alpha for 30 minutes or by modeled weightlessness for 24 hours (p &lt; .05).	Eicosapentaenoic Acid	0-3	TNF superfamily member 11	Homo sapiens	39-44
20445416-0	2010	Iron chelation therapy in Upper Egyptian transfusion-dependent pediatric homozygous beta-thalassemia major: impact on serum L-carnitine/free fatty acids, osteoprotegerin/the soluble receptor activator of nuclear factor-kappabeta ligand systems, and bone mineral density.	Iron	0-4	TNF superfamily member 11	Homo sapiens	182-235
19836866-2	2010	Recently anti-RANKL agents (receptor activator of nuclear factor-kappaB ligand) such as denosumab (Prolia, Amgen Inc., California, USA) that have a similar mode of action to bisphosphonates have been introduced to treat such diseases.	Diphosphonates	174-189	TNF superfamily member 11	Homo sapiens	28-78
20960270-0	2010	The effect of the alendronate on OPG/RANKL system in differentiated primary human osteoblasts.	Alendronate	18-29	TNF superfamily member 11	Homo sapiens	37-42
20960270-2	2010	The effect of alendronate on osteoclasts is produced, at least in part, by the receptor activator of nuclear factor kappaB ligand (RANKL) and the osteoprotegerin (OPG) synthesized by the osteoblasts.	Alendronate	14-25	TNF superfamily member 11	Homo sapiens	79-129
20960270-2	2010	The effect of alendronate on osteoclasts is produced, at least in part, by the receptor activator of nuclear factor kappaB ligand (RANKL) and the osteoprotegerin (OPG) synthesized by the osteoblasts.	Alendronate	14-25	TNF superfamily member 11	Homo sapiens	131-136
20960270-6	2010	Unexpectedly, alendronate at 10-7 and 10-5 M concentrations increased the RANKL expression with the presence of vitamin D in differentiated hOB, and this induction of RANKL mRNA levels by alendronate was dose-dependent.	Alendronate	14-25	TNF superfamily member 11	Homo sapiens	74-79
20960270-6	2010	Unexpectedly, alendronate at 10-7 and 10-5 M concentrations increased the RANKL expression with the presence of vitamin D in differentiated hOB, and this induction of RANKL mRNA levels by alendronate was dose-dependent.	Alendronate	14-25	TNF superfamily member 11	Homo sapiens	167-172
20960270-6	2010	Unexpectedly, alendronate at 10-7 and 10-5 M concentrations increased the RANKL expression with the presence of vitamin D in differentiated hOB, and this induction of RANKL mRNA levels by alendronate was dose-dependent.	Vitamin D	112-121	TNF superfamily member 11	Homo sapiens	74-79
20960270-6	2010	Unexpectedly, alendronate at 10-7 and 10-5 M concentrations increased the RANKL expression with the presence of vitamin D in differentiated hOB, and this induction of RANKL mRNA levels by alendronate was dose-dependent.	Alendronate	188-199	TNF superfamily member 11	Homo sapiens	74-79
20960270-6	2010	Unexpectedly, alendronate at 10-7 and 10-5 M concentrations increased the RANKL expression with the presence of vitamin D in differentiated hOB, and this induction of RANKL mRNA levels by alendronate was dose-dependent.	Alendronate	188-199	TNF superfamily member 11	Homo sapiens	167-172
20960270-8	2010	Thus, we conclude that alendronate does not affect the ALP activity and OPG gene expression in differentiated hOB, but may increase RANKL gene expression induced by vitamin D.	Alendronate	23-34	TNF superfamily member 11	Homo sapiens	132-137
20960270-8	2010	Thus, we conclude that alendronate does not affect the ALP activity and OPG gene expression in differentiated hOB, but may increase RANKL gene expression induced by vitamin D.	Vitamin D	165-174	TNF superfamily member 11	Homo sapiens	132-137
20518272-5	2010	By contrast, at optimal concentration (C2), fosamprenavir induced a significant increase in OPG associated with a RANKL decrease whereas tipranavir down-regulated both OPG and RANKL (at C2 and C3) and darunavir increased RANKL only at C3 concentration.	fosamprenavir	44-57	TNF superfamily member 11	Homo sapiens	114-119
20518272-7	2010	Instead, cell cultures treated by the highest concentrations of tipranavir or darunavir showed a change in cell survival or an increase in RANKL, with a negative effect on the OPG/RANKL balance.	Darunavir	78-87	TNF superfamily member 11	Homo sapiens	139-144
20112374-0	2010	Nonsteroidal antiinflammatory drugs and prostaglandin E(2) modulate the synthesis of osteoprotegerin and RANKL in the cartilage of patients with severe knee osteoarthritis.	Dinoprostone	40-58	TNF superfamily member 11	Homo sapiens	105-110
20518272-7	2010	Instead, cell cultures treated by the highest concentrations of tipranavir or darunavir showed a change in cell survival or an increase in RANKL, with a negative effect on the OPG/RANKL balance.	Darunavir	78-87	TNF superfamily member 11	Homo sapiens	180-185
20153723-4	2010	Ly49Q is selectively induced by receptor activator of nuclear factor-kappaB (NF-kappaB) ligand (RANKL) stimulation in bone marrow-derived monocyte/macrophage precursor cells (BMMs) among the Ly49 family of NK receptors.	ly49q	0-5	TNF superfamily member 11	Homo sapiens	96-101
20153723-5	2010	The knockdown of Ly49Q resulted in a significant reduction in the RANKL-induced formation of tartrate-resistance acid phosphatase (TRAP)-positive multinucleated cells, accompanied by a decreased expression of osteoclast-specific genes such as Nfatc1, Tm7sf4, Oscar, Ctsk, and Acp5.	ly49q	17-22	TNF superfamily member 11	Homo sapiens	66-71
19810098-9	2010	Titanium influences phenotype and function of T-lymphocytes, resulting in activation of a CD69+ and CCR4+ T-lymphocyte population and secretion of RANK-L.	Titanium	0-8	TNF superfamily member 11	Homo sapiens	147-153
19796718-6	2010	Most importantly, the induction of Cxcl5, Cxcl12 and Tnfsf11 in osteoblasts by PC-3-conditioned medium was abrogated by the Stat3/5 inhibitor piceatannol, whereas the selective blockade of Stat1 and Erk activation had no effect.	3,3',4,5'-tetrahydroxystilbene	142-153	TNF superfamily member 11	Homo sapiens	53-60
20963568-0	2010	The effect of the alendronate on OPG/RANKL system in differentiated primary human osteoblasts.	Alendronate	18-29	TNF superfamily member 11	Homo sapiens	37-42
20963568-2	2010	The effect of alendronate on osteoclasts is produced, at least in part, by the receptor activator of nuclear factor kappaB ligand (RANKL) and the osteoprotegerin (OPG) synthesized by the osteoblasts.	Alendronate	14-25	TNF superfamily member 11	Homo sapiens	79-129
19900598-0	2010	Inhibition of osteoclast differentiation and bone resorption by rotenone, through down-regulation of RANKL-induced c-Fos and NFATc1 expression.	Rotenone	64-72	TNF superfamily member 11	Homo sapiens	101-106
19900598-3	2010	The effect of rotenone in RANKL-induced osteoclast differentiation was examined in this study.	Rotenone	14-22	TNF superfamily member 11	Homo sapiens	26-31
19900598-4	2010	Rotenone inhibited RANKL-mediated osteoclast differentiation in bone marrow macrophages (BMMs) in a dose-dependent manner without any evidence of cytotoxicity.	Rotenone	0-8	TNF superfamily member 11	Homo sapiens	19-24
19900598-5	2010	The mRNA expression of c-Fos, NFATc1, TRAP, and OSCAR in RANKL-treated BMMs was inhibited by rotenone treatment.	Rotenone	93-101	TNF superfamily member 11	Homo sapiens	57-62
19900598-6	2010	Rotenone strongly inhibited p38 and ERK phosphorylation and I-kappaB degradation in RANKL-stimulated BMMs, and did not inhibit JNK phosphorylation.	Rotenone	0-8	TNF superfamily member 11	Homo sapiens	84-89
19900598-7	2010	Further, RANKL-induced c-Fos and NFATc1 protein expression was suppressed by rotenone.	Rotenone	77-85	TNF superfamily member 11	Homo sapiens	9-14
19709134-6	2010	Leptin, body fat, weight standard deviation score (SDS), and body mass index (BMI) SDS were all significantly higher (each p&lt;0.001) in valproate-treated children than in the non-valproate group, as were calcium (p=0.027) and RANKL (p=0.007) concentrations.	Valproic Acid	138-147	TNF superfamily member 11	Homo sapiens	228-233
20963568-2	2010	The effect of alendronate on osteoclasts is produced, at least in part, by the receptor activator of nuclear factor kappaB ligand (RANKL) and the osteoprotegerin (OPG) synthesized by the osteoblasts.	Alendronate	14-25	TNF superfamily member 11	Homo sapiens	131-136
20963568-6	2010	Unexpectedly, alendronate at 10(-7) and 10(-5) M concentrations increased the RANKL expression with the presence of vitamin D in differentiated hOB and this induction of RANKL mRNA levels by alendronate was dose-dependent.	Alendronate	14-25	TNF superfamily member 11	Homo sapiens	78-83
20963568-6	2010	Unexpectedly, alendronate at 10(-7) and 10(-5) M concentrations increased the RANKL expression with the presence of vitamin D in differentiated hOB and this induction of RANKL mRNA levels by alendronate was dose-dependent.	Alendronate	14-25	TNF superfamily member 11	Homo sapiens	170-175
20963568-6	2010	Unexpectedly, alendronate at 10(-7) and 10(-5) M concentrations increased the RANKL expression with the presence of vitamin D in differentiated hOB and this induction of RANKL mRNA levels by alendronate was dose-dependent.	Vitamin D	116-125	TNF superfamily member 11	Homo sapiens	78-83
20963568-6	2010	Unexpectedly, alendronate at 10(-7) and 10(-5) M concentrations increased the RANKL expression with the presence of vitamin D in differentiated hOB and this induction of RANKL mRNA levels by alendronate was dose-dependent.	Alendronate	191-202	TNF superfamily member 11	Homo sapiens	170-175
20963568-8	2010	Thus, we conclude that alendronate does not affect the ALP activity and OPG gene expression in differentiated hOB, but may increase RANKL gene expression induced by vitamin D.	Alendronate	23-34	TNF superfamily member 11	Homo sapiens	132-137
20963568-8	2010	Thus, we conclude that alendronate does not affect the ALP activity and OPG gene expression in differentiated hOB, but may increase RANKL gene expression induced by vitamin D.	Vitamin D	165-174	TNF superfamily member 11	Homo sapiens	132-137
20112374-7	2010	RESULTS: In patients with OA, celecoxib decreased RANKL synthesis in the cartilage, thereby increasing the OPG:RANKL ratio.	Celecoxib	30-39	TNF superfamily member 11	Homo sapiens	50-55
20112374-7	2010	RESULTS: In patients with OA, celecoxib decreased RANKL synthesis in the cartilage, thereby increasing the OPG:RANKL ratio.	Celecoxib	30-39	TNF superfamily member 11	Homo sapiens	111-116
20112374-8	2010	In human OA chondrocytes in culture, PGE(2) elicited a dose- and time-dependent increase in the synthesis of RANKL, the extent of which was greater than that of OPG.	Dinoprostone	37-43	TNF superfamily member 11	Homo sapiens	109-114
20112374-9	2010	Confocal microscopy revealed that PGE(2) induced RANKL transport to the cell membrane.	Prostaglandins E	34-37	TNF superfamily member 11	Homo sapiens	49-54
20112374-10	2010	Only EP2/EP4 agonists reproduced the effects of PGE(2) on OPG and RANKL induction.	Dinoprostone	48-54	TNF superfamily member 11	Homo sapiens	66-71
20047521-6	2010	These results indicated that Leukotriene B4 is capable of inducing osteoclast differentiation by a RANKL-dependent mechanism.	Leukotriene B4	29-43	TNF superfamily member 11	Homo sapiens	99-104
19900478-7	2010	The expression of RANKL mRNA and protein was blocked completely by inhibitors of NF-kappaB (parthenolide) or of the JAK II-STAT3 pathway (AG490), showing that the RANKL expression pathway is mediated by NF-kappaB and STAT3.	parthenolide	92-104	TNF superfamily member 11	Homo sapiens	18-23
19900478-7	2010	The expression of RANKL mRNA and protein was blocked completely by inhibitors of NF-kappaB (parthenolide) or of the JAK II-STAT3 pathway (AG490), showing that the RANKL expression pathway is mediated by NF-kappaB and STAT3.	parthenolide	92-104	TNF superfamily member 11	Homo sapiens	163-168
21071867-3	2010	The nanoparticles also reduced the production of reactive oxygen species (ROS) in response to RANKL and upregulated RANKL-induced glutathione peroxidase-1 (Gpx-1), suggesting a role as an antioxidant in the BMM.	Reactive Oxygen Species	49-72	TNF superfamily member 11	Homo sapiens	94-99
21071867-3	2010	The nanoparticles also reduced the production of reactive oxygen species (ROS) in response to RANKL and upregulated RANKL-induced glutathione peroxidase-1 (Gpx-1), suggesting a role as an antioxidant in the BMM.	Reactive Oxygen Species	74-77	TNF superfamily member 11	Homo sapiens	94-99
20055894-7	2010	Vitamin D stimulated CYP24A, BGLAP and TNFSF11 expression in hOB and these effects were modified by nontoxic LCA concentrations.	Vitamin D	0-9	TNF superfamily member 11	Homo sapiens	39-46
20055894-8	2010	LCA significantly decreased vitamin D stimulation of CYP24A, BGLAP and TNFSF11 gene expression at 72%, 79% and 56% (respectively).	Lithocholic Acid	0-3	TNF superfamily member 11	Homo sapiens	71-78
20055894-8	2010	LCA significantly decreased vitamin D stimulation of CYP24A, BGLAP and TNFSF11 gene expression at 72%, 79% and 56% (respectively).	Vitamin D	28-37	TNF superfamily member 11	Homo sapiens	71-78
20055894-11	2010	CONCLUSIONS: Lithocholic acid decreases the stimulatory effect of vitamin D on CYP24A, BGLAP and TNFSF11 expression in hOB.	Lithocholic Acid	13-29	TNF superfamily member 11	Homo sapiens	97-104
20055894-11	2010	CONCLUSIONS: Lithocholic acid decreases the stimulatory effect of vitamin D on CYP24A, BGLAP and TNFSF11 expression in hOB.	Vitamin D	66-75	TNF superfamily member 11	Homo sapiens	97-104
19574937-8	2010	The main outcome measures are the changes in OPG and total RANKL serum levels after alendronate treatment.	Alendronate	84-95	TNF superfamily member 11	Homo sapiens	59-64
19911374-5	2010	It was observed that the conditioned medium from dexamethasone osteogenic-induced bone marrow cell cultures displayed the highest osteoclastogenic potential, with similar behaviour to that observed in the presence of both M-CSF and RANKL.	Dexamethasone	49-62	TNF superfamily member 11	Homo sapiens	232-237
19574937-3	2010	The effects of bisphosphonate treatment in OPG-RANKL system have not been fully elucidated.	Diphosphonates	15-29	TNF superfamily member 11	Homo sapiens	47-52
19602125-4	2009	MATERIAL AND METHODS: Differences in the expression of interleukin-1, interleukin-8 and RANKL mRNAs, in response to exposure to various concentrations of nicotine (0, 0.125, 0.25, 0.5 and 1 mm) were evaluated in U2OS cells using the reverse transcription-polymerase chain reaction.In addition, the levels of interleukin-1, interleukin-8 and RANKL proteins were determined using enzyme-linked immunosorbent assays.	Nicotine	154-162	TNF superfamily member 11	Homo sapiens	88-93
19725047-5	2009	OxLDL also prevented the RANKL-induced phosphorylation of ERK, p38 and JNK kinases, together with the RANKL-induced DNA binding activities of NFkappaB and NFAT transcription factors.	oxldl	0-5	TNF superfamily member 11	Homo sapiens	25-30
19725047-5	2009	OxLDL also prevented the RANKL-induced phosphorylation of ERK, p38 and JNK kinases, together with the RANKL-induced DNA binding activities of NFkappaB and NFAT transcription factors.	oxldl	0-5	TNF superfamily member 11	Homo sapiens	102-107
19725047-6	2009	Concomitantly, OxLDL enhanced RANKL-induced generation of reactive oxygen species in a dose-dependent manner.	oxldl	15-20	TNF superfamily member 11	Homo sapiens	30-35
19725047-6	2009	Concomitantly, OxLDL enhanced RANKL-induced generation of reactive oxygen species in a dose-dependent manner.	Reactive Oxygen Species	58-81	TNF superfamily member 11	Homo sapiens	30-35
19725047-7	2009	The antioxidant glutathione (GSH) prevented whereas the prooxidant compound buthionine-sulfoximine (BSO) enhanced the effect of OxLDL on RANKL-induced oxidative stress and RANKL-induced differentiation.	Glutathione	16-27	TNF superfamily member 11	Homo sapiens	137-142
19725047-7	2009	The antioxidant glutathione (GSH) prevented whereas the prooxidant compound buthionine-sulfoximine (BSO) enhanced the effect of OxLDL on RANKL-induced oxidative stress and RANKL-induced differentiation.	Glutathione	29-32	TNF superfamily member 11	Homo sapiens	137-142
19725047-7	2009	The antioxidant glutathione (GSH) prevented whereas the prooxidant compound buthionine-sulfoximine (BSO) enhanced the effect of OxLDL on RANKL-induced oxidative stress and RANKL-induced differentiation.	Buthionine Sulfoximine	76-98	TNF superfamily member 11	Homo sapiens	137-142
19725047-7	2009	The antioxidant glutathione (GSH) prevented whereas the prooxidant compound buthionine-sulfoximine (BSO) enhanced the effect of OxLDL on RANKL-induced oxidative stress and RANKL-induced differentiation.	Buthionine Sulfoximine	76-98	TNF superfamily member 11	Homo sapiens	172-177
19725047-7	2009	The antioxidant glutathione (GSH) prevented whereas the prooxidant compound buthionine-sulfoximine (BSO) enhanced the effect of OxLDL on RANKL-induced oxidative stress and RANKL-induced differentiation.	Buthionine Sulfoximine	100-103	TNF superfamily member 11	Homo sapiens	137-142
19725047-7	2009	The antioxidant glutathione (GSH) prevented whereas the prooxidant compound buthionine-sulfoximine (BSO) enhanced the effect of OxLDL on RANKL-induced oxidative stress and RANKL-induced differentiation.	oxldl	128-133	TNF superfamily member 11	Homo sapiens	137-142
19725047-7	2009	The antioxidant glutathione (GSH) prevented whereas the prooxidant compound buthionine-sulfoximine (BSO) enhanced the effect of OxLDL on RANKL-induced oxidative stress and RANKL-induced differentiation.	oxldl	128-133	TNF superfamily member 11	Homo sapiens	172-177
19725047-8	2009	Finally, OxLDL also prevented RANKL-induced TRAP activity and RANKL-induced bone resorbing activity of human peripheral blood mononuclear cells.	oxldl	9-14	TNF superfamily member 11	Homo sapiens	30-35
19725047-8	2009	Finally, OxLDL also prevented RANKL-induced TRAP activity and RANKL-induced bone resorbing activity of human peripheral blood mononuclear cells.	oxldl	9-14	TNF superfamily member 11	Homo sapiens	62-67
19725047-9	2009	These results demonstrate that OxLDL, by generation of an intracellular oxidative stress, prevents the differentiation of osteoclasts by inhibition of RANKL signaling pathway.	oxldl	31-36	TNF superfamily member 11	Homo sapiens	151-156
19602125-6	2009	RESULTS: Nicotine was found to increase the expression of interleukin-1, interleukin-8 and RANKL mRNA and protein in U2OS cells (p &lt; 0.05).	Nicotine	9-17	TNF superfamily member 11	Homo sapiens	91-96
19748486-9	2009	In conclusion, OPG exerts direct osteoanabolic effects on HOC metabolism via RANKL in addition to its well described role as decoy receptor for RANKL.	(2S)-2-HYDROXYOCTANOIC ACID	58-61	TNF superfamily member 11	Homo sapiens	77-82
19762475-10	2009	OPG and membranous RANKL levels were significantly enhanced by IL-1beta, TNF-alpha and PGE(2), whereas membranous RANK was significantly increased only with IL-1beta.	Prostaglandins E	87-90	TNF superfamily member 11	Homo sapiens	19-24
19766111-0	2009	Trichostatin A inhibits osteoclastogenesis and bone resorption by suppressing the induction of c-Fos by RANKL.	trichostatin A	0-14	TNF superfamily member 11	Homo sapiens	104-109
19766111-4	2009	In this study, we analyzed the effects of TSA on osteoclast differentiation induced by the differentiation factor RANKL (receptor activator of NF-kappaB ligand).	trichostatin A	42-45	TNF superfamily member 11	Homo sapiens	114-119
19766111-4	2009	In this study, we analyzed the effects of TSA on osteoclast differentiation induced by the differentiation factor RANKL (receptor activator of NF-kappaB ligand).	trichostatin A	42-45	TNF superfamily member 11	Homo sapiens	121-159
19766111-6	2009	Furthermore, TSA suppressed RANKL-induced osteoclast formation from primary bone marrow-derived macrophages.	trichostatin A	13-16	TNF superfamily member 11	Homo sapiens	28-33
19766111-11	2009	Taken together, our findings suggest a novel action of TSA: inhibiting RANKL-induced osteoclast formation by suppressing the induction of the osteoclastogenic transcription factor c-Fos.	trichostatin A	55-58	TNF superfamily member 11	Homo sapiens	71-76
19876787-1	2009	Osteoclasts are multinucleated cells that form in response to M-CSF and RANKL (receptor activator for NF kappaB ligand) from osteoclast precursors (OCPs), which are generated in the bone marrow.	ocps	148-152	TNF superfamily member 11	Homo sapiens	72-77
19231130-6	2009	Moreover, the ionic products of Ca(2)SiO(4) coating differentially regulated osteoclastogenic gene expression by up-regulated OPG and down-regulated RANKL.	calcium silicate	32-43	TNF superfamily member 11	Homo sapiens	149-154
19698700-1	2009	Recognition of oligodeoxynucleotides containing CpG motifs (CpG-ODNs) by toll-like receptor 9 (TLR9) inhibits RANKL-induced osteoclastogenesis from precursors.	Oligodeoxyribonucleotides	15-36	TNF superfamily member 11	Homo sapiens	110-115
19699688-6	2009	The effect, which is also observed with 8-iso-Prostaglandin E2, an inflammatory isoprostane produced by lipid peroxidation, is mediated via the NFkappaB pathway, and involves increased RANKL mRNA expression.	8-isoprostaglandin E2	40-62	TNF superfamily member 11	Homo sapiens	185-190
19699688-6	2009	The effect, which is also observed with 8-iso-Prostaglandin E2, an inflammatory isoprostane produced by lipid peroxidation, is mediated via the NFkappaB pathway, and involves increased RANKL mRNA expression.	Isoprostanes	80-91	TNF superfamily member 11	Homo sapiens	185-190
19876787-1	2009	Osteoclasts are multinucleated cells that form in response to M-CSF and RANKL (receptor activator for NF kappaB ligand) from osteoclast precursors (OCPs), which are generated in the bone marrow.	ocps	148-152	TNF superfamily member 11	Homo sapiens	79-118
19632246-6	2009	KEY FINDINGS: Genistein and daidzein, at nM range, increased both the PTHrP/PTH1R system and the OPG/RANKL protein ratio, while genistein and, to a lesser extent, daidzein, at &gt;microM doses, inhibited cell viability in PCa cells.	Genistein	14-23	TNF superfamily member 11	Homo sapiens	101-106
19632246-6	2009	KEY FINDINGS: Genistein and daidzein, at nM range, increased both the PTHrP/PTH1R system and the OPG/RANKL protein ratio, while genistein and, to a lesser extent, daidzein, at &gt;microM doses, inhibited cell viability in PCa cells.	daidzein	28-36	TNF superfamily member 11	Homo sapiens	101-106
19546479-10	2009	Activation of neutrophil membrane-bound RANKL was linked to tyrosine phosphorylation of Src-homology domain-containing cytosolic phosphatase 1 with concomitant down-regulation of cytokine production.	Tyrosine	60-68	TNF superfamily member 11	Homo sapiens	40-45
19167063-7	2009	These findings suggest that 17beta-estradiol may temper the inhibitory effects of myeloma cells on osteoblasts and improve RANKL/OPG balance, providing a new agent for treatment of bone disease in myeloma.	Estradiol	28-44	TNF superfamily member 11	Homo sapiens	123-128
19894327-6	2009	MK4 could stimulate genes of RANKL and collagen type 1.	menatetrenone	0-3	TNF superfamily member 11	Homo sapiens	29-34
19494233-2	2009	Our prior work showed that synovial-like fibroblasts respond to titanium particles by producing receptor activator of NF-kappaB ligand (RANKL), a critical activator of osteoclastogenesis.	Titanium	64-72	TNF superfamily member 11	Homo sapiens	96-134
19494233-2	2009	Our prior work showed that synovial-like fibroblasts respond to titanium particles by producing receptor activator of NF-kappaB ligand (RANKL), a critical activator of osteoclastogenesis.	Titanium	64-72	TNF superfamily member 11	Homo sapiens	136-141
19334040-10	2009	Fenoterol nearly doubled RANKL mRNA and this was inhibited by propranolol.	Fenoterol	0-9	TNF superfamily member 11	Homo sapiens	25-30
19590040-5	2009	Prednisolone pellets were implanted into human RANKL knock-in (huRANKL-KI) mice, which unlike wild-type mice are responsive to denosumab.	Prednisolone	0-12	TNF superfamily member 11	Homo sapiens	47-52
19563530-9	2009	Knocking down CaSR suppressed strontium ranelate-induced stimulation of OPG mRNA, reduction of RANKL mRNA, and increase in replication, indicating the involvement of CaSR in these responses.	strontium ranelate	30-48	TNF superfamily member 11	Homo sapiens	95-100
19558335-5	2009	Current therapies used to prevent or treat metabolic bone diseases are thought to act, at least in part, through modification of the RANKL/OPG dipole.	dipole	143-149	TNF superfamily member 11	Homo sapiens	133-138
19500694-0	2009	In vitro effects of erythromycin on RANKL and nuclear factor-kappa B by human TNF-alpha stimulated Jurkat cells.	Erythromycin	20-32	TNF superfamily member 11	Homo sapiens	36-41
19500694-2	2009	The present study aimed to examine the effects of erythromycin (EM) on the activation of RANKL, correlation with NF-kappaB expression, proliferation and apoptosis of human Jurkat T cells.	Erythromycin	50-62	TNF superfamily member 11	Homo sapiens	89-94
19349075-6	2009	NHBC responded to PE particles by increasing the mRNA expression of several genes associated with osteoclast formation and activity (RANKL, IL-8 and M-CSF) and decreased the expression of the osteoclast antagonist, OPG.	Polyethylene	18-20	TNF superfamily member 11	Homo sapiens	133-138
19563530-6	2009	As strontium ranelate has been proposed as an agonist of the calcium-sensing receptor (CaSR), the involvement of CaSR in the effects of strontium ranelate on OPG and RANKL expression, and cell replication was examined using siRNA.	strontium ranelate	136-154	TNF superfamily member 11	Homo sapiens	166-171
19656028-0	2009	Effects of nicotine on antioxidant defense enzymes and RANKL expression in human periodontal ligament cells.	Nicotine	11-19	TNF superfamily member 11	Homo sapiens	55-60
19656028-4	2009	RESULTS: Nicotine treatment concomitantly downregulated the expression of OPG and osteoblastic differentiation markers, such as alkaline phosphatase, osteocalcin, and osteopontin, and upregulated the expression of RANKL.	Nicotine	9-17	TNF superfamily member 11	Homo sapiens	214-219
19656028-7	2009	CONCLUSIONS: Nicotine upregulated RANKL and antioxidant defense enzymes.	Nicotine	13-21	TNF superfamily member 11	Homo sapiens	34-39
19464673-0	2009	Osteogenic induction and 1,25-dihydroxyvitamin D3 oppositely regulate the proliferation and expression of RANKL and the vitamin D receptor of human periodontal ligament cells.	Calcitriol	25-49	TNF superfamily member 11	Homo sapiens	106-111
19334040-10	2009	Fenoterol nearly doubled RANKL mRNA and this was inhibited by propranolol.	Propranolol	62-73	TNF superfamily member 11	Homo sapiens	25-30
19648688-1	2009	OBJECTIVE: To observe the influence of technetium 99Tc methylenediphosphonate (99Tc-MDP) on osteoclastogenesis induced by receptor activator of NF-kappaB ligand (RANKL) and macrophage-colony stimulating factor (M-CSF) in peripheral blood mononuclear cells in patients with rheumatoid arthritis, and to study the mechanism of 99Tc-MDP in osteoclast differentiation.	technetium 99tc methylenediphosphonate	39-77	TNF superfamily member 11	Homo sapiens	122-160
19278793-6	2009	It is well established that increasing cyclic 3",5"-adenosine monophosphate (cAMP) can regulate the expression of key genes involved in bone metabolism, including Cbfa1, PPARgamma, RANKL and OPG.	cyclic 3",5"-adenosine monophosphate	39-75	TNF superfamily member 11	Homo sapiens	181-186
19278793-6	2009	It is well established that increasing cyclic 3",5"-adenosine monophosphate (cAMP) can regulate the expression of key genes involved in bone metabolism, including Cbfa1, PPARgamma, RANKL and OPG.	Cyclic AMP	77-81	TNF superfamily member 11	Homo sapiens	181-186
19648688-1	2009	OBJECTIVE: To observe the influence of technetium 99Tc methylenediphosphonate (99Tc-MDP) on osteoclastogenesis induced by receptor activator of NF-kappaB ligand (RANKL) and macrophage-colony stimulating factor (M-CSF) in peripheral blood mononuclear cells in patients with rheumatoid arthritis, and to study the mechanism of 99Tc-MDP in osteoclast differentiation.	technetium 99tc methylenediphosphonate	39-77	TNF superfamily member 11	Homo sapiens	162-167
19648688-1	2009	OBJECTIVE: To observe the influence of technetium 99Tc methylenediphosphonate (99Tc-MDP) on osteoclastogenesis induced by receptor activator of NF-kappaB ligand (RANKL) and macrophage-colony stimulating factor (M-CSF) in peripheral blood mononuclear cells in patients with rheumatoid arthritis, and to study the mechanism of 99Tc-MDP in osteoclast differentiation.	99mTc-Methylene diphosphonate	79-87	TNF superfamily member 11	Homo sapiens	122-160
19648688-1	2009	OBJECTIVE: To observe the influence of technetium 99Tc methylenediphosphonate (99Tc-MDP) on osteoclastogenesis induced by receptor activator of NF-kappaB ligand (RANKL) and macrophage-colony stimulating factor (M-CSF) in peripheral blood mononuclear cells in patients with rheumatoid arthritis, and to study the mechanism of 99Tc-MDP in osteoclast differentiation.	99mTc-Methylene diphosphonate	79-87	TNF superfamily member 11	Homo sapiens	162-167
19648688-1	2009	OBJECTIVE: To observe the influence of technetium 99Tc methylenediphosphonate (99Tc-MDP) on osteoclastogenesis induced by receptor activator of NF-kappaB ligand (RANKL) and macrophage-colony stimulating factor (M-CSF) in peripheral blood mononuclear cells in patients with rheumatoid arthritis, and to study the mechanism of 99Tc-MDP in osteoclast differentiation.	99mTc-Methylene diphosphonate	325-333	TNF superfamily member 11	Homo sapiens	162-167
19324007-6	2009	Dexamethasone significantly induced RANKL and OPG expression.	Dexamethasone	0-13	TNF superfamily member 11	Homo sapiens	36-41
19243669-8	2009	It appears that polyphenols may act on cellular signalling such as mitogen-activated protein kinase (MAPK), bone morphogenetic protein (BMP), oestrogen receptor and osteoprotegerin/receptor activator of NF-kappaB ligand (OPG/RANKL) and thus may affect osteoblast functions.	Polyphenols	16-27	TNF superfamily member 11	Homo sapiens	225-230
19324007-7	2009	The RANKL/OPG ratio was increased by dexamethasone and was significant at 10(-7) M dexamethasone.	Dexamethasone	37-50	TNF superfamily member 11	Homo sapiens	4-9
19324007-7	2009	The RANKL/OPG ratio was increased by dexamethasone and was significant at 10(-7) M dexamethasone.	Dexamethasone	83-96	TNF superfamily member 11	Homo sapiens	4-9
19325147-12	2009	Furthermore, in an in vivo model, the increase in vascular calcium content was parallel to an increase in RANKL and BMP4 expression, which was localized in calcified areas.	Calcium	59-66	TNF superfamily member 11	Homo sapiens	106-111
19404943-5	2009	RESULTS: The 4-week prednisolone treatment induced loss of vertebral and femoral volumetric bone mineral density in the hRANKL-knockin mice.	Prednisolone	20-32	TNF superfamily member 11	Homo sapiens	120-126
19206164-6	2009	mRNA levels of receptor activator of nuclear factor-kappaB ligand (RANKL) were increased in both populations when they were cultured with dexamethasone and vitamin D(3).	Dexamethasone	138-151	TNF superfamily member 11	Homo sapiens	15-65
19357551-6	2009	As opposed to other current gauges of hypoxia, ODF is a local and sensitive measure of both the extent and severity of corneal oxygen deprivation.	Oxygen	127-133	TNF superfamily member 11	Homo sapiens	47-50
19360288-13	2009	An increased expression of RANKL in stromal tissue surrounding bone metastases, RANK in osteoclasts and VEGF may serve as future targeted therapies possibly in conjunction with bisphosphonates.	Diphosphonates	177-192	TNF superfamily member 11	Homo sapiens	27-32
19331827-3	2009	Osteoclast differentiation was suppressed 14 days after addition of RANKL even when estradiol was withdrawn after 18 h. In CD14+ cells apoptosis was rare and was not augmented by RANKL or by 17-beta-estradiol.	Estradiol	84-93	TNF superfamily member 11	Homo sapiens	68-73
19331827-9	2009	Reduction of NF-kappaB nuclear localization occurred within 30 min of RANKL stimulation, and estradiol inhibited the phosphorylation of IkappaB in response to RANKL.	Estradiol	93-102	TNF superfamily member 11	Homo sapiens	159-164
19206164-6	2009	mRNA levels of receptor activator of nuclear factor-kappaB ligand (RANKL) were increased in both populations when they were cultured with dexamethasone and vitamin D(3).	Dexamethasone	138-151	TNF superfamily member 11	Homo sapiens	67-72
19206164-6	2009	mRNA levels of receptor activator of nuclear factor-kappaB ligand (RANKL) were increased in both populations when they were cultured with dexamethasone and vitamin D(3).	Vitamin D	156-165	TNF superfamily member 11	Homo sapiens	15-65
19206164-6	2009	mRNA levels of receptor activator of nuclear factor-kappaB ligand (RANKL) were increased in both populations when they were cultured with dexamethasone and vitamin D(3).	Vitamin D	156-165	TNF superfamily member 11	Homo sapiens	67-72
19154802-7	2009	Our results demonstrate that oral EM reduces the inflammation of periprosthetic tissues, as manifested by the reduction of the numbers of infiltrating cells, CD68+ macrophages, RANKL+ cells, and TRAP+ cells.	Estramustine	34-36	TNF superfamily member 11	Homo sapiens	177-182
19131500-1	2009	1alpha,25-dihydroxyvitamin D(3) upregulates tumour necrosis factor superfamily member 11 (TNFSF11) that codes for the receptor activator of nuclear factor kappaB ligand (RANKL), and downregulates osteoprotegerin (OPG) expression.	Calcitriol	0-30	TNF superfamily member 11	Homo sapiens	44-88
18705650-3	2009	MATERIAL AND METHODS: Naringenin was tested in a human osteoclastogenesis model using primary osteoclast precursor cells activated by receptor activator of nuclear factor-kappaB ligand (RANKL) and macrophage colony-stimulating factor (M-CSF) for 6 days.	naringenin	22-32	TNF superfamily member 11	Homo sapiens	134-184
18705650-3	2009	MATERIAL AND METHODS: Naringenin was tested in a human osteoclastogenesis model using primary osteoclast precursor cells activated by receptor activator of nuclear factor-kappaB ligand (RANKL) and macrophage colony-stimulating factor (M-CSF) for 6 days.	naringenin	22-32	TNF superfamily member 11	Homo sapiens	186-191
19370270-0	2009	Formaldehyde cross-linking of proteins to osteoclast differentiation factor promoter for the identification of biofunctional proteins.	Formaldehyde	0-12	TNF superfamily member 11	Homo sapiens	42-75
19370270-5	2009	Interaction between NFYs and the ODF promoter was detected by polymerase chain reaction.	nfys	20-24	TNF superfamily member 11	Homo sapiens	33-36
19131500-1	2009	1alpha,25-dihydroxyvitamin D(3) upregulates tumour necrosis factor superfamily member 11 (TNFSF11) that codes for the receptor activator of nuclear factor kappaB ligand (RANKL), and downregulates osteoprotegerin (OPG) expression.	Calcitriol	0-30	TNF superfamily member 11	Homo sapiens	90-97
19131500-1	2009	1alpha,25-dihydroxyvitamin D(3) upregulates tumour necrosis factor superfamily member 11 (TNFSF11) that codes for the receptor activator of nuclear factor kappaB ligand (RANKL), and downregulates osteoprotegerin (OPG) expression.	Calcitriol	0-30	TNF superfamily member 11	Homo sapiens	118-168
19131500-1	2009	1alpha,25-dihydroxyvitamin D(3) upregulates tumour necrosis factor superfamily member 11 (TNFSF11) that codes for the receptor activator of nuclear factor kappaB ligand (RANKL), and downregulates osteoprotegerin (OPG) expression.	Calcitriol	0-30	TNF superfamily member 11	Homo sapiens	170-175
19190327-0	2009	Zerumbone abolishes RANKL-induced NF-kappaB activation, inhibits osteoclastogenesis, and suppresses human breast cancer-induced bone loss in athymic nude mice.	zerumbone	0-9	TNF superfamily member 11	Homo sapiens	20-25
19190327-3	2009	In the present report, the potential of zerumbone, a sesquiterpene derived from subtropical ginger, to modulate osteoclastogenesis induced by RANKL and breast cancer was examined.	zerumbone	40-49	TNF superfamily member 11	Homo sapiens	142-147
19190327-5	2009	Zerumbone also suppressed RANKL-induced differentiation of these cells to osteoclasts.	zerumbone	0-9	TNF superfamily member 11	Homo sapiens	26-31
19190327-9	2009	These results indicate that zerumbone is an effective blocker of RANKL-induced NF-kappaB activation and of osteoclastogenesis induced by RANKL and tumor cells, suggesting its potential as a therapeutic agent for osteoporosis and cancer-associated bone loss.	zerumbone	28-37	TNF superfamily member 11	Homo sapiens	65-70
19190327-9	2009	These results indicate that zerumbone is an effective blocker of RANKL-induced NF-kappaB activation and of osteoclastogenesis induced by RANKL and tumor cells, suggesting its potential as a therapeutic agent for osteoporosis and cancer-associated bone loss.	zerumbone	28-37	TNF superfamily member 11	Homo sapiens	137-142
19449178-4	2009	CTS-induced osteoprotegerin (OPG) synthesis in osteoblasts increased at the third passage and decreased at the fifth passage, whereas CTS-induced receptor activator of nuclear factor-kappaB ligand (RANKL) mRNA expression decreased in osteoblasts at the third passage and increased at the fifth passage.	castanospermine	134-137	TNF superfamily member 11	Homo sapiens	146-196
19046964-6	2009	In agreement with this we found that HCT1026 inhibited RANKL-induced activation of the nuclear factor kappa B (NFkappaB) and extracellular signal-regulated kinase (ERK) pathways in both osteoclast and macrophage cultures, whereas its parent compound flurbiprofen did not.	Flurbiprofen	250-262	TNF superfamily member 11	Homo sapiens	55-60
19590968-3	2009	However, the regulation and functional significance of RANKL at the TB-interface in tumor-induced osteolysis remains unclear.	Terbium	68-70	TNF superfamily member 11	Homo sapiens	55-60
19590968-5	2009	Using a novel mammary tumor model, we identified that RANKL expression was upregulated at the TB-interface as compared to the tumor alone area.	Terbium	94-96	TNF superfamily member 11	Homo sapiens	54-59
19590968-7	2009	The ratio of RANKL to osteoprotegrin (OPG), a decoy receptor for RANKL, at the TB-interface was also increased.	Terbium	79-81	TNF superfamily member 11	Homo sapiens	13-18
19590968-7	2009	The ratio of RANKL to osteoprotegrin (OPG), a decoy receptor for RANKL, at the TB-interface was also increased.	Terbium	79-81	TNF superfamily member 11	Homo sapiens	65-70
19590968-8	2009	Targeting RANKL expression with antisense oligonucleotides (RANKL-ASO), significantly abrogated tumor-induced osteolysis, decreased RANKL expression and the RANKL:OPG ratio at the TB-interface.	Oligonucleotides	42-58	TNF superfamily member 11	Homo sapiens	10-15
19590968-8	2009	Targeting RANKL expression with antisense oligonucleotides (RANKL-ASO), significantly abrogated tumor-induced osteolysis, decreased RANKL expression and the RANKL:OPG ratio at the TB-interface.	Oligonucleotides	42-58	TNF superfamily member 11	Homo sapiens	60-65
19590968-8	2009	Targeting RANKL expression with antisense oligonucleotides (RANKL-ASO), significantly abrogated tumor-induced osteolysis, decreased RANKL expression and the RANKL:OPG ratio at the TB-interface.	Oligonucleotides	42-58	TNF superfamily member 11	Homo sapiens	60-65
19590968-8	2009	Targeting RANKL expression with antisense oligonucleotides (RANKL-ASO), significantly abrogated tumor-induced osteolysis, decreased RANKL expression and the RANKL:OPG ratio at the TB-interface.	Oligonucleotides	42-58	TNF superfamily member 11	Homo sapiens	60-65
19590968-8	2009	Targeting RANKL expression with antisense oligonucleotides (RANKL-ASO), significantly abrogated tumor-induced osteolysis, decreased RANKL expression and the RANKL:OPG ratio at the TB-interface.	Terbium	180-182	TNF superfamily member 11	Homo sapiens	10-15
19590968-8	2009	Targeting RANKL expression with antisense oligonucleotides (RANKL-ASO), significantly abrogated tumor-induced osteolysis, decreased RANKL expression and the RANKL:OPG ratio at the TB-interface.	Terbium	180-182	TNF superfamily member 11	Homo sapiens	60-65
19590968-8	2009	Targeting RANKL expression with antisense oligonucleotides (RANKL-ASO), significantly abrogated tumor-induced osteolysis, decreased RANKL expression and the RANKL:OPG ratio at the TB-interface.	Terbium	180-182	TNF superfamily member 11	Homo sapiens	60-65
19590968-8	2009	Targeting RANKL expression with antisense oligonucleotides (RANKL-ASO), significantly abrogated tumor-induced osteolysis, decreased RANKL expression and the RANKL:OPG ratio at the TB-interface.	Terbium	180-182	TNF superfamily member 11	Homo sapiens	60-65
19590968-9	2009	Together, these results demonstrate that upregulation of RANKL expression and sRANKL generation at the TB-interface potentiates tumor-induced osteolysis.	Terbium	103-105	TNF superfamily member 11	Homo sapiens	57-62
19059194-4	2009	Noradrenaline and the selective beta2-adrenoceptor agonists isoprenaline and salmeterol stimulated osteoclast formation and bone resorption in BM osteoblast co-cultures and increased expression of RANK-L by osteoblasts.	Norepinephrine	0-13	TNF superfamily member 11	Homo sapiens	197-203
19059194-4	2009	Noradrenaline and the selective beta2-adrenoceptor agonists isoprenaline and salmeterol stimulated osteoclast formation and bone resorption in BM osteoblast co-cultures and increased expression of RANK-L by osteoblasts.	Isoproterenol	60-72	TNF superfamily member 11	Homo sapiens	197-203
19059194-4	2009	Noradrenaline and the selective beta2-adrenoceptor agonists isoprenaline and salmeterol stimulated osteoclast formation and bone resorption in BM osteoblast co-cultures and increased expression of RANK-L by osteoblasts.	Salmeterol Xinafoate	77-87	TNF superfamily member 11	Homo sapiens	197-203
19059209-0	2009	A novel PPARgamma agonist, KR62776, suppresses RANKL-induced osteoclast differentiation and activity by inhibiting MAP kinase pathways.	KR 62776	27-34	TNF superfamily member 11	Homo sapiens	47-52
19059209-5	2009	An analysis of a signaling pathway showed that KR62776 inhibited the receptor activator of nuclear factor-kappaB ligand (RANKL)-induced activation of p38 mitogen-activated protein kinase (p38MAPK), extracellular regulated kinase (ERK), c-Jun N-terminal kinase (JNK) and nuclear factor-kappaB (NF-kappaB).	KR 62776	47-54	TNF superfamily member 11	Homo sapiens	69-119
19059209-5	2009	An analysis of a signaling pathway showed that KR62776 inhibited the receptor activator of nuclear factor-kappaB ligand (RANKL)-induced activation of p38 mitogen-activated protein kinase (p38MAPK), extracellular regulated kinase (ERK), c-Jun N-terminal kinase (JNK) and nuclear factor-kappaB (NF-kappaB).	KR 62776	47-54	TNF superfamily member 11	Homo sapiens	121-126
19059209-6	2009	Together, these results demonstrate that KR62776 negatively affects osteoclast differentiation and activity by inhibiting the RANKL-induced activation of MAP kinases and NF-kappaB.	KR 62776	41-48	TNF superfamily member 11	Homo sapiens	126-131
19095956-4	2009	In addition, the HIV PI ritonavir abrogated the interferon-gamma-mediated degradation of the RANKL nuclear adapter protein TRAF6, a physiological block to RANKL activity.	Ritonavir	24-33	TNF superfamily member 11	Homo sapiens	93-98
19095956-4	2009	In addition, the HIV PI ritonavir abrogated the interferon-gamma-mediated degradation of the RANKL nuclear adapter protein TRAF6, a physiological block to RANKL activity.	Ritonavir	24-33	TNF superfamily member 11	Homo sapiens	155-160
19301089-3	2009	The objective of this study was to determine the effects of risedronate treatment on the level of serum cytokines including receptor activator of nuclear factor-kappaB ligand (RANKL) and osteoprotegerin among postmenopausal women with osteoporosis.	Risedronic Acid	60-71	TNF superfamily member 11	Homo sapiens	124-174
19301089-3	2009	The objective of this study was to determine the effects of risedronate treatment on the level of serum cytokines including receptor activator of nuclear factor-kappaB ligand (RANKL) and osteoprotegerin among postmenopausal women with osteoporosis.	Risedronic Acid	60-71	TNF superfamily member 11	Homo sapiens	176-181
19301089-11	2009	In group 1 (risedronate plus calcium/vitamin D-treated patients), serum levels of RANKL and IL-1beta significantly decreased and the level of osteoprotegerin significantly increased after three and 6 months, but no significant difference was found in TNF-alpha level.	Risedronic Acid	12-23	TNF superfamily member 11	Homo sapiens	82-87
19301089-11	2009	In group 1 (risedronate plus calcium/vitamin D-treated patients), serum levels of RANKL and IL-1beta significantly decreased and the level of osteoprotegerin significantly increased after three and 6 months, but no significant difference was found in TNF-alpha level.	Calcium	29-36	TNF superfamily member 11	Homo sapiens	82-87
19301089-11	2009	In group 1 (risedronate plus calcium/vitamin D-treated patients), serum levels of RANKL and IL-1beta significantly decreased and the level of osteoprotegerin significantly increased after three and 6 months, but no significant difference was found in TNF-alpha level.	Vitamin D	37-46	TNF superfamily member 11	Homo sapiens	82-87
19301089-14	2009	In conclusion risedronate could improve osteoporosis by increasing osteoprotegerin and reducing RANKL and IL-1beta.	Risedronic Acid	14-25	TNF superfamily member 11	Homo sapiens	96-101
19449178-4	2009	CTS-induced osteoprotegerin (OPG) synthesis in osteoblasts increased at the third passage and decreased at the fifth passage, whereas CTS-induced receptor activator of nuclear factor-kappaB ligand (RANKL) mRNA expression decreased in osteoblasts at the third passage and increased at the fifth passage.	castanospermine	134-137	TNF superfamily member 11	Homo sapiens	198-203
19134349-0	2008	[Effects of calcitriol on the expression of vitamin D receptor, RANKL and osteoprotegerin in human periodontal ligament cells].	Calcitriol	12-22	TNF superfamily member 11	Homo sapiens	64-69
18932123-3	2008	The effect of 17- beta-estradiol and 1,25dihydroxyvitamin D3 on the OPG/RANKL system is not known during the different states of cellular maturation.	Estradiol	14-32	TNF superfamily member 11	Homo sapiens	72-77
18932123-3	2008	The effect of 17- beta-estradiol and 1,25dihydroxyvitamin D3 on the OPG/RANKL system is not known during the different states of cellular maturation.	Calcitriol	37-60	TNF superfamily member 11	Homo sapiens	72-77
18719352-0	2008	Curcumin inhibits osteoclastogenesis by decreasing receptor activator of nuclear factor-kappaB ligand (RANKL) in bone marrow stromal cells.	Curcumin	0-8	TNF superfamily member 11	Homo sapiens	51-101
18719352-0	2008	Curcumin inhibits osteoclastogenesis by decreasing receptor activator of nuclear factor-kappaB ligand (RANKL) in bone marrow stromal cells.	Curcumin	0-8	TNF superfamily member 11	Homo sapiens	103-108
18719352-5	2008	Exposure to curcumin led to dose-dependent suppression of osteoclastogenesis in the coculture system, and to reduced expression of RANKL in IL-1alpha-stimulated BMSCs.	Curcumin	12-20	TNF superfamily member 11	Homo sapiens	131-136
20204061-4	2009	Therefore, we examined the effect of IL-1beta and/or celecoxib on the expression of macrophage colony-stimulating factor (M-CSF), receptor activator of NF-kappaB ligand (RANKL), and osteoprotegerin (OPG) in human chondrocytes, and the indirect effect of IL-1beta on osteoclast-like cell formation using RAW264.7 cells.	Celecoxib	53-62	TNF superfamily member 11	Homo sapiens	130-168
19134349-1	2008	OBJECTIVE: To study the effects of 1, 25-dihydroxyvitamin D(3) (VD(3)) on the expression of vitamin D receptor (VDR), receptor activator of nuclear factor-kappa B ligand (RANKL) and osteoprotegerin (OPG) in human periodontal ligament cells (hPDLC) populations and to analyze the potential mechanisms.	1,25-dihydroxyvitamin D	35-59	TNF superfamily member 11	Homo sapiens	118-169
18719352-6	2008	Addition of RANKL abolished the inhibition of osteoclastogenesis by curcumin, whereas the addition of prostaglandin E2(PGE2) did not.	Curcumin	68-76	TNF superfamily member 11	Homo sapiens	12-17
19134349-1	2008	OBJECTIVE: To study the effects of 1, 25-dihydroxyvitamin D(3) (VD(3)) on the expression of vitamin D receptor (VDR), receptor activator of nuclear factor-kappa B ligand (RANKL) and osteoprotegerin (OPG) in human periodontal ligament cells (hPDLC) populations and to analyze the potential mechanisms.	1,25-dihydroxyvitamin D	35-59	TNF superfamily member 11	Homo sapiens	171-176
18597628-0	2008	Vitamin D depletion induces RANKL-mediated osteoclastogenesis and bone loss in a rodent model.	Vitamin D	0-9	TNF superfamily member 11	Homo sapiens	28-33
18761403-7	2008	The presence of trehalose was shown to stabilize the bioactivity of RANKL adsorbed to brushite cement.	Trehalose	16-25	TNF superfamily member 11	Homo sapiens	68-73
18761403-7	2008	The presence of trehalose was shown to stabilize the bioactivity of RANKL adsorbed to brushite cement.	calcium phosphate, dibasic, dihydrate	86-94	TNF superfamily member 11	Homo sapiens	68-73
18688862-5	2008	The effect of simvastatin on RANKL signaling and consequent osteoclastogenesis was investigated.	Simvastatin	14-25	TNF superfamily member 11	Homo sapiens	29-34
18394701-4	2008	A 3 h pulse with 25 nM bortezomib followed by a 3-day culture in its absence markedly inhibited osteoclast activity as evaluated through bone resorption, TRAcP release, and RANKL-induced NF-kappaB translocation into nuclei, an event dependent on proteasomes and critical for osteoclast function.	Bortezomib	23-33	TNF superfamily member 11	Homo sapiens	173-178
18688862-6	2008	RANKL induced NF-kappaB activation, whereas pretreatment with simvastatin completely suppressed such activation and correlated with suppression of RANKL-induced activation of IkappaBalpha kinase, IkappaBalpha phosphorylation and IkappaBalpha degradation.	Simvastatin	62-73	TNF superfamily member 11	Homo sapiens	147-152
18688862-10	2008	Together, our results indicate that simvastatin inhibits the RANKL-induced NF-kappaB activation pathway that leads to suppression of osteoclastogenesis induced by RANKL and by tumor cells, thereby suggesting its therapeutic potential in osteoporosis and in cancer-related bone loss.	Simvastatin	36-47	TNF superfamily member 11	Homo sapiens	61-66
18688862-10	2008	Together, our results indicate that simvastatin inhibits the RANKL-induced NF-kappaB activation pathway that leads to suppression of osteoclastogenesis induced by RANKL and by tumor cells, thereby suggesting its therapeutic potential in osteoporosis and in cancer-related bone loss.	Simvastatin	36-47	TNF superfamily member 11	Homo sapiens	163-168
17990294-11	2008	Interestingly, treatment with Wnt3a markedly reduced the forskolin-induced expression of receptor activator of NF-kappaB ligand (RANKL), a target gene of PTH/cAMP/PKA.	Colforsin	57-66	TNF superfamily member 11	Homo sapiens	89-127
18810375-5	2008	The ratio of osteoclast stimulating RANKL and its soluble decoy receptor OPG is modulated by sex hormones, vitamin D, parathyroid hormone, local growth factors and mechanical loading.	Vitamin D	107-116	TNF superfamily member 11	Homo sapiens	36-41
19337163-9	2008	Sex steroids probably act by increasing the expression of RANKL by osteoblastic cells, and alterations in the RANK/RANKL/OPG system in favour of osteoclasts are characteristic in TM, where the ratio of sRANKL/OPG is increased.	Steroids	4-12	TNF superfamily member 11	Homo sapiens	58-63
18792431-0	2008	Re: RANKL inhibition is an effective adjuvant for docetaxel in a prostate cancer bone metastasis model.	Docetaxel	50-59	TNF superfamily member 11	Homo sapiens	4-9
18771377-6	2008	RESULTS: Estradiol caused an increase in OPG expression and decreased RANKL expression in hPDL cells.	Estradiol	9-18	TNF superfamily member 11	Homo sapiens	70-75
18600791-7	2008	Inhibition of the Na(+)/H(+) exchanger family by amiloride suppressed RANKL-induced osteoclast fusion and bone resorption.	Amiloride	49-58	TNF superfamily member 11	Homo sapiens	70-75
18661071-3	2008	alpha-MEM which contains RANKL and M-CSF was used as the culture medium.	alpha minimal essential medium	0-9	TNF superfamily member 11	Homo sapiens	25-30
18443424-5	2008	Based on structural and biochemical information about RANKL and the OPG peptides, we suggest that complex formation between the peptide and RANKL is mediated by both hydrophobic and hydrogen bonding interactions.	Hydrogen	182-190	TNF superfamily member 11	Homo sapiens	54-59
18443424-5	2008	Based on structural and biochemical information about RANKL and the OPG peptides, we suggest that complex formation between the peptide and RANKL is mediated by both hydrophobic and hydrogen bonding interactions.	Hydrogen	182-190	TNF superfamily member 11	Homo sapiens	140-145
18596740-9	2008	Importantly, in serum from MM patients treated with lenalidomide, the essential bone-remodeling factor RANKL, as well as the RANKL/OPG ratio, were significantly reduced, whereas osteoprotegerin (OPG) was increased.	Lenalidomide	52-64	TNF superfamily member 11	Homo sapiens	103-108
18596740-9	2008	Importantly, in serum from MM patients treated with lenalidomide, the essential bone-remodeling factor RANKL, as well as the RANKL/OPG ratio, were significantly reduced, whereas osteoprotegerin (OPG) was increased.	Lenalidomide	52-64	TNF superfamily member 11	Homo sapiens	125-130
18301383-8	2008	When osteoprotegerin/IgG1 Fc chimera was added to high-density MOMC cultures, osteoclast formation was completely inhibited by neutralizing the endogenous RANKL.	N(4)-Methoxy-5-methylcytosine	63-67	TNF superfamily member 11	Homo sapiens	155-160
18938273-6	2008	Pamidronate promoted higher RANKL gene expression and osteoclast recruitment by mandible BMSCs.	Pamidronate	0-11	TNF superfamily member 11	Homo sapiens	28-33
18754324-3	2008	CDT induces receptor activator of NF-kappaB ligand (RANKL) expression in periodontal fibroblasts, the key bone-resorbing cytokine.	1,5,9-cyclododecatriene	0-3	TNF superfamily member 11	Homo sapiens	52-57
18754324-5	2008	The aim of this study was to investigate the effects of purified CDT on the expression of RANKL and its decoy receptor osteoprotegerin (OPG), in the Jurkat T-cell line.	1,5,9-cyclododecatriene	65-68	TNF superfamily member 11	Homo sapiens	90-95
18754324-9	2008	In conclusion, CDT enhances RANKL expression in T-cells, denoting that these cells are a potential target for the toxin and strengthening the potential link between this virulence factor and mechanisms associated with localized bone resorption.	1,5,9-cyclododecatriene	15-18	TNF superfamily member 11	Homo sapiens	28-33
18555623-4	2008	Several hormones such as parathyroid hormone, calcitriol and prostaglandins stimulate RANK Ligand expression by osteoblasts.	Calcitriol	46-56	TNF superfamily member 11	Homo sapiens	86-97
18555623-4	2008	Several hormones such as parathyroid hormone, calcitriol and prostaglandins stimulate RANK Ligand expression by osteoblasts.	Prostaglandins	61-75	TNF superfamily member 11	Homo sapiens	86-97
17990294-11	2008	Interestingly, treatment with Wnt3a markedly reduced the forskolin-induced expression of receptor activator of NF-kappaB ligand (RANKL), a target gene of PTH/cAMP/PKA.	Colforsin	57-66	TNF superfamily member 11	Homo sapiens	129-134
18252198-6	2008	In conclusion, 17beta-estradiol suppressed OPG production by human breast cancer cell lines in a dose-dependent and specific manner, indicating that the RANKL/OPG cytokine system is an estrogen-responsive target in breast cancer.	Estradiol	15-31	TNF superfamily member 11	Homo sapiens	153-158
18560259-11	2008	In conclusion, our results support the hypothesis that raloxifene may inhibit osteoclast activity, at least partly modulating the OPG-RANKL system.	Raloxifene Hydrochloride	55-65	TNF superfamily member 11	Homo sapiens	134-139
18202151-0	2008	An enhancer 20 kilobases upstream of the human receptor activator of nuclear factor-kappaB ligand gene mediates dominant activation by 1,25-dihydroxyvitamin D3.	Calcitriol	135-159	TNF superfamily member 11	Homo sapiens	47-97
18560259-3	2008	The aim of this study was to determine the effects of raloxifene treatment on serum concentrations of OPG, receptor RANKL and its relationship with biochemical markers of bone turnover and bone mineral density (BMD) in previously untreated women with post-menopausal osteoporosis.	Raloxifene Hydrochloride	54-64	TNF superfamily member 11	Homo sapiens	116-121
18560259-8	2008	There was a significant decrease of RANKL levels and OPG/RANKL ratio after 1 yr of raloxifene treatment.	Raloxifene Hydrochloride	83-93	TNF superfamily member 11	Homo sapiens	36-41
18560259-8	2008	There was a significant decrease of RANKL levels and OPG/RANKL ratio after 1 yr of raloxifene treatment.	Raloxifene Hydrochloride	83-93	TNF superfamily member 11	Homo sapiens	57-62
18379028-3	2008	An antagonist of EP4, a receptor subtype for PGE(2), suppressed RANKL expression in osteoblast and following osteoclast formation that was induced by B16, suggesting cancer induced bone resorption mediate PGE(2) production in host osteoblast is a key role of cancer metastasis to bone.	Prostaglandins E	45-48	TNF superfamily member 11	Homo sapiens	64-69
17894387-0	2008	High extracellular inorganic phosphate concentration inhibits RANK-RANKL signaling in osteoclast-like cells.	Phosphates	19-38	TNF superfamily member 11	Homo sapiens	67-72
18275008-1	2008	Risedronate and teriparatide have opposite actions on the osteoblast-osteoclast dipole and are expected to influence the RANK/RANKL/osteoprotegerin (OPG) system.	Risedronic Acid	0-11	TNF superfamily member 11	Homo sapiens	126-131
18275008-1	2008	Risedronate and teriparatide have opposite actions on the osteoblast-osteoclast dipole and are expected to influence the RANK/RANKL/osteoprotegerin (OPG) system.	Teriparatide	16-28	TNF superfamily member 11	Homo sapiens	126-131
18275008-2	2008	We aimed to evaluate changes in serum OPG and RANKL after risedronate or teriparatide administration in postmenopausal osteoporotic women.	Risedronic Acid	58-69	TNF superfamily member 11	Homo sapiens	46-51
18275008-2	2008	We aimed to evaluate changes in serum OPG and RANKL after risedronate or teriparatide administration in postmenopausal osteoporotic women.	Teriparatide	73-85	TNF superfamily member 11	Homo sapiens	46-51
18399769-10	2008	CONCLUSIONS: The low serum TSH observed in thyroidectomized patients on l-thyroxine therapy is associated with an increase of bone turnover in postmenopausal women and men that is associated with an increase of OPG and a decrease of serum RANKL levels.	Thyroxine	72-83	TNF superfamily member 11	Homo sapiens	239-244
18399769-11	2008	The acute TSH administration results in an increase of PINP, an index of osteoblastic activity, associated with an increase of serum RANKL.	Thyrotropin	10-13	TNF superfamily member 11	Homo sapiens	133-138
18299476-0	2008	Acute changes in serum osteoprotegerin and receptor activator for nuclear factor-kappaB ligand levels in women with established osteoporosis treated with teriparatide.	Teriparatide	154-166	TNF superfamily member 11	Homo sapiens	43-94
18299476-2	2008	The aim of this prospective study was to evaluate the acute effect (up to 1 month) of teriparatide (TPTD; human recombinant PTH 1-34) on serum levels of osteoprotegerin (OPG) and receptor activator for nuclear factor-kappaB ligand (RANKL) in women with established osteoporosis.	Teriparatide	86-98	TNF superfamily member 11	Homo sapiens	179-230
18299476-2	2008	The aim of this prospective study was to evaluate the acute effect (up to 1 month) of teriparatide (TPTD; human recombinant PTH 1-34) on serum levels of osteoprotegerin (OPG) and receptor activator for nuclear factor-kappaB ligand (RANKL) in women with established osteoporosis.	Teriparatide	86-98	TNF superfamily member 11	Homo sapiens	232-237
18299476-9	2008	CONCLUSIONS: TPTD therapy in women with postmenopausal osteoporosis results in acute increase in serum RANKL levels but does not affect serum OPG.	Teriparatide	13-17	TNF superfamily member 11	Homo sapiens	103-108
17967134-2	2008	Risedronate is effective in reducing the number of osteoclast precursors, their formation, vitality, and activity and the level of RANKL and TNF-alpha in cultures.	Risedronic Acid	0-11	TNF superfamily member 11	Homo sapiens	131-136
17967134-9	2008	RESULTS: After 3 mo of risedronate, there was a significant reduction in the number and degree of differentiation of osteoclast precursors, osteoclast formation, vitality and activity, and in the level of RANKL and TNF in cultures and of TNF and osteoprotegerin (OPG) in serum, whereas in the group treated with calcium and vitamin D, there were no significant changes.	Risedronic Acid	23-34	TNF superfamily member 11	Homo sapiens	205-210
18083161-0	2008	Berberine inhibits RANKL-induced osteoclast formation and survival through suppressing the NF-kappaB and Akt pathways.	Berberine	0-9	TNF superfamily member 11	Homo sapiens	19-24
18565252-10	2008	Inhibition of endogenous PGE(2) levels by indomethacin markedly decreased the ratio of OPG/RANKL on the H OA.	Prostaglandins E	25-28	TNF superfamily member 11	Homo sapiens	91-96
18565252-10	2008	Inhibition of endogenous PGE(2) levels by indomethacin markedly decreased the ratio of OPG/RANKL on the H OA.	Indomethacin	42-54	TNF superfamily member 11	Homo sapiens	91-96
18565252-13	2008	Treatment of L OA osteoblasts with osteotropic factors revealed that the OPG/RANKL mRNA expression ratio was significantly reduced by vitamin D(3) and significantly increased by TNF-alpha, PTH and PGE(2), while IL-1Beta demonstrated no effect.	Vitamin D	134-143	TNF superfamily member 11	Homo sapiens	77-82
18565252-13	2008	Treatment of L OA osteoblasts with osteotropic factors revealed that the OPG/RANKL mRNA expression ratio was significantly reduced by vitamin D(3) and significantly increased by TNF-alpha, PTH and PGE(2), while IL-1Beta demonstrated no effect.	Prostaglandins E	197-200	TNF superfamily member 11	Homo sapiens	77-82
18260178-10	2008	CONCLUSION: Vit K2 alone or in combination with bisphosphonates for treatment of osteoporosis in patients with RA may inhibit osteoclast induction via decreases in levels of RANKL.	Vitamin K 2	12-18	TNF superfamily member 11	Homo sapiens	174-179
18260178-10	2008	CONCLUSION: Vit K2 alone or in combination with bisphosphonates for treatment of osteoporosis in patients with RA may inhibit osteoclast induction via decreases in levels of RANKL.	Diphosphonates	48-63	TNF superfamily member 11	Homo sapiens	174-179
18305398-1	2008	Rutin, a glycoside of flavonol, inhibits osteoclast formation induced by receptor activator of NF-kappaB ligand (RANKL) in bone marrow-derived macrophages.	Rutin	0-5	TNF superfamily member 11	Homo sapiens	73-111
18305398-1	2008	Rutin, a glycoside of flavonol, inhibits osteoclast formation induced by receptor activator of NF-kappaB ligand (RANKL) in bone marrow-derived macrophages.	Rutin	0-5	TNF superfamily member 11	Homo sapiens	113-118
18305398-1	2008	Rutin, a glycoside of flavonol, inhibits osteoclast formation induced by receptor activator of NF-kappaB ligand (RANKL) in bone marrow-derived macrophages.	3-hydroxyflavone	22-30	TNF superfamily member 11	Homo sapiens	73-111
18305398-1	2008	Rutin, a glycoside of flavonol, inhibits osteoclast formation induced by receptor activator of NF-kappaB ligand (RANKL) in bone marrow-derived macrophages.	3-hydroxyflavone	22-30	TNF superfamily member 11	Homo sapiens	113-118
18305398-2	2008	It reduces reactive oxygen species produced by RANKL and its inhibitory effect results from reduced levels of TNF-alpha.	Reactive Oxygen Species	11-34	TNF superfamily member 11	Homo sapiens	47-52
18083161-3	2008	This study focused on the suppressive effects of berberine on receptor activator of nuclear factor kappaB (NF-kappaB) ligand (RANKL)-induced osteoclastogenesis and survival.	Berberine	49-58	TNF superfamily member 11	Homo sapiens	126-131
18083161-4	2008	Berberine inhibited RANKL-mediated osteoclast formation and survival while having no cytotoxic effects on bone marrow macrophages or osteoblastic cells.	Berberine	0-9	TNF superfamily member 11	Homo sapiens	20-25
18083161-5	2008	Berberine attenuated RANKL-induced activation of NF-kappaB through inhibiting phosphorylation at the activation loop of IkappaBalpha kinase beta, phosphorylation and degradation of IkappaBalpha, and NF-kappaB p65 nuclear translocation.	Berberine	0-9	TNF superfamily member 11	Homo sapiens	21-26
18083161-6	2008	RANKL-induced Akt phosphorylation was strongly inhibited by berberine; however, neither monocyte/macrophage-colony stimulating factor (M-CSF)-induced nor insulin-induced Akt activation was inhibited by the drug.	Berberine	60-69	TNF superfamily member 11	Homo sapiens	0-5
18083161-7	2008	Under M-CSF- and RANKL-deprived condition, berberine increased the active form of caspase-3 in osteoclasts.	Berberine	43-52	TNF superfamily member 11	Homo sapiens	17-22
17539726-8	2007	Interestingly, application of indomethacin could abolish the induction of RANKL but not that of OPN, suggesting the cyclooxygenase-independent mechanism for stress-induced OPN expression.	Indomethacin	30-42	TNF superfamily member 11	Homo sapiens	74-79
18209032-10	2008	Treatment with flagellin or RANKL stimulated STAT1 activation, and STAT1 deficiency or the JAK2 inhibitor AG490 dramatically prevented IFN-beta induction in response to flagellin or RANKL.	alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide	106-111	TNF superfamily member 11	Homo sapiens	182-187
17768586-0	2008	Estradiol rapidly inhibits osteoclastogenesis and RANKL expression in bone marrow cultures in postmenopausal women: a pilot study.	Estradiol	0-9	TNF superfamily member 11	Homo sapiens	50-55
18182105-10	2008	Also in the male group, RANKL mRNA levels were associated with a number of indices of bone structure (bone volume fraction relative to bone tissue volume, specific surface of bone relative to bone tissue volume, and trabecular thickness), bone remodelling (eroded surface and osteoid surface), and biochemical markers of bone turnover (serum alkaline phosphatase and osteocalcin, and urinary deoxypyridinoline).	deoxypyridinoline	392-409	TNF superfamily member 11	Homo sapiens	24-29
18463808-8	2008	Although RANKL production by the stroma supports osteoclast differentiation, this process is antagonized by osteoprotogerin (OPG) production, which acts as a soluble decoy receptor for RANKL (5, 6).	osteoprotogerin	108-123	TNF superfamily member 11	Homo sapiens	185-190
18463808-8	2008	Although RANKL production by the stroma supports osteoclast differentiation, this process is antagonized by osteoprotogerin (OPG) production, which acts as a soluble decoy receptor for RANKL (5, 6).	SCHEMBL12347590	125-128	TNF superfamily member 11	Homo sapiens	185-190
19112497-8	2008	Lysine-deficient TRAF6 also rescued RANKL-mediated NFkappaB and MAPK activation, and osteoclastogenesis in retrovirally-rescued TRAF6-deficient bone marrow macrophages.	Lysine	0-6	TNF superfamily member 11	Homo sapiens	36-41
17971207-4	2007	Dkk1 and -2 increased the expression of the osteoclast differentiation factors, receptor activator of NF-kappaB ligand (RANKL) and macrophage-colony stimulating factor (M-CSF), upon stimulation with Wnt3a/1,25-dihydroxyvitamine D3 and Wnt3a/BMP2, respectively.	1,25-dihydroxyvitamine d3	205-230	TNF superfamily member 11	Homo sapiens	80-118
17611556-8	2007	In myeloma patients, bortezomib reduces biochemical markers of bone resorption and normalizes the RANKL/osteoprotegerin ratio, while at the same time increases bone formation markers reducing levels of dickkopf-1 protein.	Bortezomib	21-31	TNF superfamily member 11	Homo sapiens	98-103
17559630-6	2007	CONCLUSION: These data suggest that heme oxygenase-1 induction plays a protective role in periodontal ligament cells against the cytotoxic and RANKL-inducing effects of H2O2, through multiple signaling pathways.	Hydrogen Peroxide	169-173	TNF superfamily member 11	Homo sapiens	143-148
17559635-1	2007	BACKGROUND AND OBJECTIVE: Interleukin-1beta-stimulated receptor activator of nuclear factor-kappaB ligand (RANKL) expression in human periodontal ligament cells is partially mediated by endogenous prostaglandin E2, whereas mitogen-activated protein kinases (MAPKs) are implicated in regulating various interleukin-1-responsive genes.	Dinoprostone	197-213	TNF superfamily member 11	Homo sapiens	107-112
17559635-9	2007	CONCLUSION: In human periodontal ligament cells, three types of MAPK inhibitor may abrogate RANKL expression and activity induced by interleukin-1beta, directly or indirectly through partial suppression of prostaglandin E2 synthesis.	Dinoprostone	206-222	TNF superfamily member 11	Homo sapiens	92-97
17666255-1	2007	OBJECTIVE: To investigate the effect of nasal mucosal inflammation on bone remodeling and the inhibitory effect of macrolide antibiotics on bone remodeling through the inhibition of receptor activator of nuclear factor-kappaB ligand (RANKL) and macrophage colony-stimulating factor (M-CSF).	macrolide antibiotics	115-136	TNF superfamily member 11	Homo sapiens	182-232
17666255-6	2007	Macrolide antibiotics reduced RANKL mRNA and M-CSF expression by nasal polyp fibroblasts in a dose-dependent manner, and inhibited osteoclastogenesis from PBMCs.	macrolide antibiotics	0-21	TNF superfamily member 11	Homo sapiens	30-35
17521508-3	2007	RANKL activates the tumor necrosis factor receptor-associated factor 6, c-Fos, and calcium signaling pathways, all of which are indispensable for the induction and activation of nuclear factor of activated T cells (NFAT) c1.	Calcium	83-90	TNF superfamily member 11	Homo sapiens	0-5
18271850-11	2008	Furthermore, testosterone"s association with sRANKL levels in male HD patients suggests that RANKL may mediate the effect of testosterone on bone metabolism in these patients.	Testosterone	13-25	TNF superfamily member 11	Homo sapiens	46-51
18271850-11	2008	Furthermore, testosterone"s association with sRANKL levels in male HD patients suggests that RANKL may mediate the effect of testosterone on bone metabolism in these patients.	Testosterone	125-137	TNF superfamily member 11	Homo sapiens	46-51
18290714-2	2007	Recent studies have identified novel genes such as TRPV5, TRPV6, and RANKL whose products are integral to the maintenance of extracellular calcium.	Calcium	139-146	TNF superfamily member 11	Homo sapiens	69-74
17664058-3	2007	METHODS: This study examined the expression of RANKL and OPG, collagen synthesis, and ALP activity in AsA-treated osteoblast-like cells (MG63) using reverse transcription-polymerase chain reaction and biochemical assays.	Ascorbic Acid	102-105	TNF superfamily member 11	Homo sapiens	47-52
17510321-6	2007	AZD6244 down-regulates the expression/secretion of osteoclast (OC)-activating factors from MM cells and inhibits in vitro differentiation of MM patient PBMCs to OCs induced by ligand for receptor activator of NF-kappaB (RANKL) and macrophage-colony stimulating factor (M-CSF).	AZD 6244	0-7	TNF superfamily member 11	Homo sapiens	220-225
17488193-10	2007	RESULTS: We found that RANKL and TLR9 ligand, oligodeoxynucleotides containing unmethylated CpG dinucleotides (CpG-ODN), induce sustained and transient extracellular signal-regulated kinase (ERK) phosphorylation, respectively.	Oligodeoxyribonucleotides	46-67	TNF superfamily member 11	Homo sapiens	23-28
17488193-10	2007	RESULTS: We found that RANKL and TLR9 ligand, oligodeoxynucleotides containing unmethylated CpG dinucleotides (CpG-ODN), induce sustained and transient extracellular signal-regulated kinase (ERK) phosphorylation, respectively.	cytidylyl-3'-5'-guanosine	92-109	TNF superfamily member 11	Homo sapiens	23-28
17488193-10	2007	RESULTS: We found that RANKL and TLR9 ligand, oligodeoxynucleotides containing unmethylated CpG dinucleotides (CpG-ODN), induce sustained and transient extracellular signal-regulated kinase (ERK) phosphorylation, respectively.	CPG-oligonucleotide	111-118	TNF superfamily member 11	Homo sapiens	23-28
17559630-0	2007	Defense mechanism of heme oxygenase-1 against cytotoxic and receptor activator of nuclear factor-kappaB ligand inducing effects of hydrogen peroxide in human periodontal ligament cells.	Hydrogen Peroxide	131-148	TNF superfamily member 11	Homo sapiens	60-110
17559630-4	2007	RESULTS: H2O2 produced a cytotoxic effect by reducing the cell viability and enhancing the expression of heme oxygenase-1 and RANKL mRNAs in a concentration- and time-dependent manner.	Hydrogen Peroxide	9-13	TNF superfamily member 11	Homo sapiens	126-131
17352647-12	2007	Furthermore, only cells incubated with calcitriol showed an increased RANKL/osteoprotegerin (OPG) expression.	Calcitriol	39-49	TNF superfamily member 11	Homo sapiens	70-75
17331472-6	2007	Sodium butyrate also decreased the ratio of RANKL/OPG gene expression by MSCs.	Butyric Acid	0-15	TNF superfamily member 11	Homo sapiens	44-49
17349971-5	2007	Beta1 Integrin-induced up-regulation of ICAM-1 and RANKL was inhibited by transfection with adenoviruses encoding C3 transferase or pretreated with Y-27632, specific Rho and Rho-kinase inhibitors.	Y 27632	148-155	TNF superfamily member 11	Homo sapiens	51-56
17502723-16	2007	Short-term data indicate that replacing stavudine and PI with tenofovir and efavirenz restores the RANKL/osteoprotegerin equilibrium, and may thus lead to a reduction in the bone resorption rate.	Stavudine	40-49	TNF superfamily member 11	Homo sapiens	99-104
17502723-16	2007	Short-term data indicate that replacing stavudine and PI with tenofovir and efavirenz restores the RANKL/osteoprotegerin equilibrium, and may thus lead to a reduction in the bone resorption rate.	Tenofovir	62-71	TNF superfamily member 11	Homo sapiens	99-104
17445547-2	2007	The aim of our study was to evaluate osteoprotegerin (OPG) and soluble receptor activator of nuclear factor kappaB ligand (RANK-L) in patients with DTC with suppressed endogenous thyrotropin due to L-T4 regimen.	dtc	148-151	TNF superfamily member 11	Homo sapiens	71-121
17445547-2	2007	The aim of our study was to evaluate osteoprotegerin (OPG) and soluble receptor activator of nuclear factor kappaB ligand (RANK-L) in patients with DTC with suppressed endogenous thyrotropin due to L-T4 regimen.	dtc	148-151	TNF superfamily member 11	Homo sapiens	123-129
17445547-2	2007	The aim of our study was to evaluate osteoprotegerin (OPG) and soluble receptor activator of nuclear factor kappaB ligand (RANK-L) in patients with DTC with suppressed endogenous thyrotropin due to L-T4 regimen.	Thyroxine	198-202	TNF superfamily member 11	Homo sapiens	123-129
17445547-11	2007	Overall, RANK-L levels were significantly higher (P = .03) in subjects with DTC than in controls.	dtc	76-79	TNF superfamily member 11	Homo sapiens	9-15
17445547-14	2007	Serum RANK-L correlated negatively with age in subjects with DTC (P = .05).	dtc	61-64	TNF superfamily member 11	Homo sapiens	6-12
17331472-8	2007	The MEK-specific inhibitor, PD98059 but not p38- or JNK-specific inhibitor and the transfection with dominant negative ERK expressing plasmids blocked the sodium butyrate-induced regulation of MSC differentiation and increase in the RANKL/OPG ratio.	Butyric Acid	155-170	TNF superfamily member 11	Homo sapiens	233-238
17331472-9	2007	Our results suggest that sodium butyrate modulates MSC differentiation and the RANKL/OPG ratio via activating ERK, and could be applied for in vivo bone growth using MSCs.	Butyric Acid	25-40	TNF superfamily member 11	Homo sapiens	79-84
17368333-13	2007	In conclusion, COX-2-mediated PGE(2) expression is required for LPS-induced inflammatory bone resorption and maintaining the baseline level of RANKL and OPG expression.	Prostaglandins E	30-33	TNF superfamily member 11	Homo sapiens	143-148
17371958-0	2007	15-deoxy-Delta12,14-prostaglandin J2 negatively regulates rankl gene expression in activated T lymphocytes: role of NF-kappaB and early growth response transcription factors.	14-prostaglandin j2	17-36	TNF superfamily member 11	Homo sapiens	58-63
17195907-2	2007	METHODS: We retrospectively examined the immunohistochemical expression of RANKL in formalin-fixed, paraffin-embedded resected specimens obtained from 96 patients with HCC with (n = 16) and without (n = 80) bone metastases.	Formaldehyde	84-92	TNF superfamily member 11	Homo sapiens	75-80
17222389-1	2007	Phosphodiesterase 4 (PDE4) inhibitors stimulate osteoclast formation by increasing the TRANCE/OPG mRNA ratio via cAMP-mediated pathways in a manner similar to parathyroid hormone (PTH) in osteoblasts.	Cyclic AMP	113-117	TNF superfamily member 11	Homo sapiens	87-93
17222389-6	2007	These data suggest that COX-2 mediates rolipram induced osteoclast formation by regulating the TRANCE/OPG mRNA ratio in osteoblasts.	Rolipram	39-47	TNF superfamily member 11	Homo sapiens	95-101
17371958-7	2007	We show that 15d-PGJ(2) inhibits rankl mRNA expression, protein, and rankl promoter activity by mechanisms mediated by its chemically reactive cyclopentenone moiety.	15d-pgj	13-20	TNF superfamily member 11	Homo sapiens	33-38
17371958-7	2007	We show that 15d-PGJ(2) inhibits rankl mRNA expression, protein, and rankl promoter activity by mechanisms mediated by its chemically reactive cyclopentenone moiety.	15d-pgj	13-20	TNF superfamily member 11	Homo sapiens	69-74
17371958-7	2007	We show that 15d-PGJ(2) inhibits rankl mRNA expression, protein, and rankl promoter activity by mechanisms mediated by its chemically reactive cyclopentenone moiety.	cyclopentenone	143-157	TNF superfamily member 11	Homo sapiens	33-38
17195907-2	2007	METHODS: We retrospectively examined the immunohistochemical expression of RANKL in formalin-fixed, paraffin-embedded resected specimens obtained from 96 patients with HCC with (n = 16) and without (n = 80) bone metastases.	Paraffin	100-108	TNF superfamily member 11	Homo sapiens	75-80
17328065-5	2007	RESULTS: PGE(2) formation and cyclooxygenase 2 (COX-2) protein expression were induced by IL-1beta and potentiated by kinins with affinity for the B1 or B2 receptors, resulting in PGE(2)-dependent enhancement of RANKL.	Prostaglandins E	9-12	TNF superfamily member 11	Homo sapiens	212-217
17328065-5	2007	RESULTS: PGE(2) formation and cyclooxygenase 2 (COX-2) protein expression were induced by IL-1beta and potentiated by kinins with affinity for the B1 or B2 receptors, resulting in PGE(2)-dependent enhancement of RANKL.	Dinoprostone	9-15	TNF superfamily member 11	Homo sapiens	212-217
17223545-4	2007	In the studies reported here, we utilized the above techniques to identify key enhancer regions that mediate the actions of vitamin D on the calcium ion channel gene TRPV6, the catabolic bone calcium-mobilizing factor gene RankL and the bone anabolic Wnt signaling pathway co-receptor gene LRP5.	Vitamin D	124-133	TNF superfamily member 11	Homo sapiens	223-228
17273786-5	2007	Low-pH media controlled by HEPES-buffered conditions to mimic metabolic acidosis led to synergistic activation of RANKL-stimulated signals, including mitogen-activated protein kinases and transcription factor NF-kappaB, resulting in enhanced osteoclastogenesis.	HEPES	27-32	TNF superfamily member 11	Homo sapiens	114-119
17197168-0	2007	Multiple enhancer regions located at significant distances upstream of the transcriptional start site mediate RANKL gene expression in response to 1,25-dihydroxyvitamin D3.	Calcitriol	147-171	TNF superfamily member 11	Homo sapiens	110-115
17095620-7	2007	SDX-308 decreased constitutive and RANKL-stimulated NF-kappaB activation and osteoclast formation in an osteoclast cellular model, RAW 264.7.	SDX	0-3	TNF superfamily member 11	Homo sapiens	35-40
16586042-1	2007	In the present study, we aimed to determine whether tacrolimus (FK506) and cyclosporine A act directly on human osteoclast precursors obtained from patients with rheumatoid arthritis (RA) and influence monocyte-osteoclast differentiation induced by receptor activator of NF-kappaB ligand (RANKL) in vitro, the stage at which differentiation was affected and the manner in which tacrolimus or cyclosporine A affected the osteoclast signaling pathway.	Tacrolimus	52-62	TNF superfamily member 11	Homo sapiens	249-287
17197168-1	2007	One of the primary regulators of receptor activator of NF-kappaB ligand (RANKL) is 1,25-dihydoxyvitamin D(3) (1,25(OH)(2)D(3)).	1,25-dihydoxyvitamin d	83-105	TNF superfamily member 11	Homo sapiens	33-71
17197168-1	2007	One of the primary regulators of receptor activator of NF-kappaB ligand (RANKL) is 1,25-dihydoxyvitamin D(3) (1,25(OH)(2)D(3)).	1,25-dihydoxyvitamin d	83-105	TNF superfamily member 11	Homo sapiens	73-78
17304327-1	2007	OBJECTIVE: To investigate the effect of 17-beta estradiol (E(2))on the expression of receptor activator of nuclear factor kappaB ligand(RANKL) and osteoprotegerin(OPG) in human periodontal ligament cells( hPDLCs) during their osteogenic differentiation.	Estradiol	40-57	TNF superfamily member 11	Homo sapiens	85-142
16979395-10	2007	In contrast, in patients classified as non-responders, OPG and RANKL levels after pamidronate infusion did not significantly differ with respect to pre-treatment values.	Pamidronate	82-93	TNF superfamily member 11	Homo sapiens	63-68
16979395-11	2007	Thus, the positive effect of amino bisphosphonates in the treatment of PDB may be due to either direct or indirect suppression of RANKL-induced bone resorption through decreased RANKL and increased OPG production.	amino bisphosphonates	29-50	TNF superfamily member 11	Homo sapiens	130-135
16979395-11	2007	Thus, the positive effect of amino bisphosphonates in the treatment of PDB may be due to either direct or indirect suppression of RANKL-induced bone resorption through decreased RANKL and increased OPG production.	amino bisphosphonates	29-50	TNF superfamily member 11	Homo sapiens	178-183
16586042-1	2007	In the present study, we aimed to determine whether tacrolimus (FK506) and cyclosporine A act directly on human osteoclast precursors obtained from patients with rheumatoid arthritis (RA) and influence monocyte-osteoclast differentiation induced by receptor activator of NF-kappaB ligand (RANKL) in vitro, the stage at which differentiation was affected and the manner in which tacrolimus or cyclosporine A affected the osteoclast signaling pathway.	Tacrolimus	52-62	TNF superfamily member 11	Homo sapiens	289-294
16586042-1	2007	In the present study, we aimed to determine whether tacrolimus (FK506) and cyclosporine A act directly on human osteoclast precursors obtained from patients with rheumatoid arthritis (RA) and influence monocyte-osteoclast differentiation induced by receptor activator of NF-kappaB ligand (RANKL) in vitro, the stage at which differentiation was affected and the manner in which tacrolimus or cyclosporine A affected the osteoclast signaling pathway.	Tacrolimus	64-69	TNF superfamily member 11	Homo sapiens	249-287
16586042-1	2007	In the present study, we aimed to determine whether tacrolimus (FK506) and cyclosporine A act directly on human osteoclast precursors obtained from patients with rheumatoid arthritis (RA) and influence monocyte-osteoclast differentiation induced by receptor activator of NF-kappaB ligand (RANKL) in vitro, the stage at which differentiation was affected and the manner in which tacrolimus or cyclosporine A affected the osteoclast signaling pathway.	Tacrolimus	64-69	TNF superfamily member 11	Homo sapiens	289-294
16586042-1	2007	In the present study, we aimed to determine whether tacrolimus (FK506) and cyclosporine A act directly on human osteoclast precursors obtained from patients with rheumatoid arthritis (RA) and influence monocyte-osteoclast differentiation induced by receptor activator of NF-kappaB ligand (RANKL) in vitro, the stage at which differentiation was affected and the manner in which tacrolimus or cyclosporine A affected the osteoclast signaling pathway.	Cyclosporine	75-89	TNF superfamily member 11	Homo sapiens	249-287
16586042-1	2007	In the present study, we aimed to determine whether tacrolimus (FK506) and cyclosporine A act directly on human osteoclast precursors obtained from patients with rheumatoid arthritis (RA) and influence monocyte-osteoclast differentiation induced by receptor activator of NF-kappaB ligand (RANKL) in vitro, the stage at which differentiation was affected and the manner in which tacrolimus or cyclosporine A affected the osteoclast signaling pathway.	Cyclosporine	75-89	TNF superfamily member 11	Homo sapiens	289-294
16909305-0	2007	Ribavirin enhances osteoclast formation through osteoblasts via up-regulation of TRANCE/RANKL.	Ribavirin	0-9	TNF superfamily member 11	Homo sapiens	81-87
16909305-0	2007	Ribavirin enhances osteoclast formation through osteoblasts via up-regulation of TRANCE/RANKL.	Ribavirin	0-9	TNF superfamily member 11	Homo sapiens	88-93
16909305-3	2007	Ribavirin enhances osteoclast formation through osteoblasts by up-regulation of TRANCE/RANKL gene expression, whereas it has no significant effect on either osteoblast differentiation or on bone formation.	Ribavirin	0-9	TNF superfamily member 11	Homo sapiens	80-86
16909305-3	2007	Ribavirin enhances osteoclast formation through osteoblasts by up-regulation of TRANCE/RANKL gene expression, whereas it has no significant effect on either osteoblast differentiation or on bone formation.	Ribavirin	0-9	TNF superfamily member 11	Homo sapiens	87-92
16787719-2	2007	Raloxifene (RAL) stimulates the production of OPG from osteoblasts, as demonstrated in vitro, carring out their antiresorption activity, at least in part, as means of the OPG/RANK/RANKL system.	Raloxifene Hydrochloride	0-10	TNF superfamily member 11	Homo sapiens	180-185
17892600-6	2007	DHMEQ significantly suppressed formation of osteoclasts in arthritic joints, and also suppressed expression of NFATc1 along the inner surfaces of bone lacunae and the eroded bone surface, while serum levels of soluble receptor activator of NF-kappaB ligand (RANKL), osteoprotegerin and macrophage colony-stimulating factor were not affected by the treatment.	dehydroxymethylepoxyquinomicin	0-5	TNF superfamily member 11	Homo sapiens	258-263
17892600-9	2007	Furthermore, in the presence of RANKL and macrophage colony-stimulating factor, differentiation and activation of human osteoclasts were also suppressed by DHMEQ, suggesting the possibility of future application of NF-kappaB inhibitors to rheumatoid arthritis therapy.	dehydroxymethylepoxyquinomicin	156-161	TNF superfamily member 11	Homo sapiens	32-37
17996099-7	2007	Under basal conditions, RANKL expression was significantly reduced by CS and by both drugs incubated together.	Chondroitin Sulfates	70-72	TNF superfamily member 11	Homo sapiens	24-29
17982276-3	2007	We report that glycolysis and oxidative phosphorylation characterized by glucose and oxygen consumption as well as lactate production were increased during receptor activator of nuclear factor-kappaB ligand (RANKL)-induced osteoclastogenesis from RAW264.7 and bone marrow-derived macrophage cells.	Glucose	73-80	TNF superfamily member 11	Homo sapiens	156-206
17996099-8	2007	Under vitamin D3, these drugs also showed a decrease in RANKL level, which, however, did not reach statistical significance.	Cholecalciferol	6-16	TNF superfamily member 11	Homo sapiens	56-61
17996099-9	2007	Importantly, under basal conditions, CS and both compounds combined significantly upregulated the expression ratio of OPG/RANKL.	Chondroitin Sulfates	37-39	TNF superfamily member 11	Homo sapiens	122-127
17996099-13	2007	Yet CS and both compounds together increase the expression ratio of OPG/RANKL, suggesting a positive effect on OA subchondral bone structural changes.	Chondroitin Sulfates	4-6	TNF superfamily member 11	Homo sapiens	72-77
17982276-3	2007	We report that glycolysis and oxidative phosphorylation characterized by glucose and oxygen consumption as well as lactate production were increased during receptor activator of nuclear factor-kappaB ligand (RANKL)-induced osteoclastogenesis from RAW264.7 and bone marrow-derived macrophage cells.	Glucose	73-80	TNF superfamily member 11	Homo sapiens	208-213
17982276-3	2007	We report that glycolysis and oxidative phosphorylation characterized by glucose and oxygen consumption as well as lactate production were increased during receptor activator of nuclear factor-kappaB ligand (RANKL)-induced osteoclastogenesis from RAW264.7 and bone marrow-derived macrophage cells.	Oxygen	85-91	TNF superfamily member 11	Homo sapiens	156-206
17982276-3	2007	We report that glycolysis and oxidative phosphorylation characterized by glucose and oxygen consumption as well as lactate production were increased during receptor activator of nuclear factor-kappaB ligand (RANKL)-induced osteoclastogenesis from RAW264.7 and bone marrow-derived macrophage cells.	Oxygen	85-91	TNF superfamily member 11	Homo sapiens	208-213
17982276-3	2007	We report that glycolysis and oxidative phosphorylation characterized by glucose and oxygen consumption as well as lactate production were increased during receptor activator of nuclear factor-kappaB ligand (RANKL)-induced osteoclastogenesis from RAW264.7 and bone marrow-derived macrophage cells.	Lactic Acid	115-122	TNF superfamily member 11	Homo sapiens	156-206
17982276-3	2007	We report that glycolysis and oxidative phosphorylation characterized by glucose and oxygen consumption as well as lactate production were increased during receptor activator of nuclear factor-kappaB ligand (RANKL)-induced osteoclastogenesis from RAW264.7 and bone marrow-derived macrophage cells.	Lactic Acid	115-122	TNF superfamily member 11	Homo sapiens	208-213
17982276-9	2007	Treatment of pyruvate synergistically increased osteoclastogenesis through the activation of RANKL-stimulated signals (ERK and JNK).	Pyruvic Acid	13-21	TNF superfamily member 11	Homo sapiens	93-98
17107351-5	2006	This is the first study showing that bortezomib reduces DKK-1 and RANKL serum levels, leading to the normalisation of bone remodelling in relapsed myeloma.	Bortezomib	37-47	TNF superfamily member 11	Homo sapiens	66-71
17278017-5	2007	Methotrexate (MTX), bucillamine (Buc) and salazosulphapyridine (SASP) inhibited osteoclastogenesis by acting on osteoclast precursor cells and interfering with receptor activator of NF-kappaB ligand (RANKL)-mediated induction of the nuclear factor of activated T cells (NFAT) c1.	Methotrexate	0-12	TNF superfamily member 11	Homo sapiens	160-198
17278017-5	2007	Methotrexate (MTX), bucillamine (Buc) and salazosulphapyridine (SASP) inhibited osteoclastogenesis by acting on osteoclast precursor cells and interfering with receptor activator of NF-kappaB ligand (RANKL)-mediated induction of the nuclear factor of activated T cells (NFAT) c1.	Methotrexate	0-12	TNF superfamily member 11	Homo sapiens	200-205
17278017-5	2007	Methotrexate (MTX), bucillamine (Buc) and salazosulphapyridine (SASP) inhibited osteoclastogenesis by acting on osteoclast precursor cells and interfering with receptor activator of NF-kappaB ligand (RANKL)-mediated induction of the nuclear factor of activated T cells (NFAT) c1.	bucillamine	20-31	TNF superfamily member 11	Homo sapiens	160-198
17278017-5	2007	Methotrexate (MTX), bucillamine (Buc) and salazosulphapyridine (SASP) inhibited osteoclastogenesis by acting on osteoclast precursor cells and interfering with receptor activator of NF-kappaB ligand (RANKL)-mediated induction of the nuclear factor of activated T cells (NFAT) c1.	bucillamine	20-31	TNF superfamily member 11	Homo sapiens	200-205
17278017-5	2007	Methotrexate (MTX), bucillamine (Buc) and salazosulphapyridine (SASP) inhibited osteoclastogenesis by acting on osteoclast precursor cells and interfering with receptor activator of NF-kappaB ligand (RANKL)-mediated induction of the nuclear factor of activated T cells (NFAT) c1.	bucillamine	33-36	TNF superfamily member 11	Homo sapiens	160-198
17278017-5	2007	Methotrexate (MTX), bucillamine (Buc) and salazosulphapyridine (SASP) inhibited osteoclastogenesis by acting on osteoclast precursor cells and interfering with receptor activator of NF-kappaB ligand (RANKL)-mediated induction of the nuclear factor of activated T cells (NFAT) c1.	Sulfasalazine	42-62	TNF superfamily member 11	Homo sapiens	160-198
17278017-5	2007	Methotrexate (MTX), bucillamine (Buc) and salazosulphapyridine (SASP) inhibited osteoclastogenesis by acting on osteoclast precursor cells and interfering with receptor activator of NF-kappaB ligand (RANKL)-mediated induction of the nuclear factor of activated T cells (NFAT) c1.	Sulfasalazine	42-62	TNF superfamily member 11	Homo sapiens	200-205
17278017-5	2007	Methotrexate (MTX), bucillamine (Buc) and salazosulphapyridine (SASP) inhibited osteoclastogenesis by acting on osteoclast precursor cells and interfering with receptor activator of NF-kappaB ligand (RANKL)-mediated induction of the nuclear factor of activated T cells (NFAT) c1.	Sulfasalazine	64-68	TNF superfamily member 11	Homo sapiens	160-198
17278017-5	2007	Methotrexate (MTX), bucillamine (Buc) and salazosulphapyridine (SASP) inhibited osteoclastogenesis by acting on osteoclast precursor cells and interfering with receptor activator of NF-kappaB ligand (RANKL)-mediated induction of the nuclear factor of activated T cells (NFAT) c1.	Sulfasalazine	64-68	TNF superfamily member 11	Homo sapiens	200-205
17053039-0	2007	Transcriptional control of receptor activator of nuclear factor-kappaB ligand by the protein kinase A activator forskolin and the transmembrane glycoprotein 130-activating cytokine, oncostatin M, is exerted through multiple distal enhancers.	Colforsin	112-121	TNF superfamily member 11	Homo sapiens	27-77
17053039-5	2007	Mapping studies pointed to two highly conserved cAMP response elements as well as an adjacent regulatory site that bound Runt transcription factor 2 and was able to influence both basal as well as hormone-inducible RankL activity.	Cyclic AMP	48-52	TNF superfamily member 11	Homo sapiens	215-220
17053039-8	2007	This study demonstrates that the activation of RankL gene expression by PKA- and gp130-inducers is mediated via common regulatory domains that also served to facilitate the activity of 1,25-(OH)2D3.	(oh)2d3	190-197	TNF superfamily member 11	Homo sapiens	47-52
17259742-0	2007	Osteoprotegerin and RANKL serum levels and their relationship with serum ghrelin in children with chronic renal failure and on dialysis.	Ghrelin	73-80	TNF superfamily member 11	Homo sapiens	20-25
17259742-13	2007	Therefore, ghrelin may be of importance in mediating the effects of the RANKL/OPG system in renal bone disease.	Ghrelin	11-18	TNF superfamily member 11	Homo sapiens	72-77
17124500-7	2006	In contrast, S1P addition to BMM/osteoblast cocultures greatly increased osteoclastogenesis by increasing RANKL in osteoblasts via cyclooxygenase-2 and PGE(2) regulation.	Prostaglandins E	152-155	TNF superfamily member 11	Homo sapiens	106-111
17052691-5	2006	Interestingly, overexpression of c-Fos restored RANKL-induced osteoclast differentiation from and NFATc1 expression in SB203580-treated precursor cells.	SB 203580	119-127	TNF superfamily member 11	Homo sapiens	48-53
17147500-3	2006	Here, we confirmed that the AZT-induced osteoclastogenesis is dependent on RANKL in that osteoclastogenesis is blocked by osteoprotegestin.	Zidovudine	28-31	TNF superfamily member 11	Homo sapiens	75-80
17214584-7	2006	PGE2 binding to EP4 stimulates osteoclastogenesis through enhancing RANKL expression.	Dinoprostone	0-4	TNF superfamily member 11	Homo sapiens	68-73
17147500-9	2006	Finally, AZT induced osteoclastogenesis of human osteoclast precursors in a RANKL-dependent manner.	Zidovudine	9-12	TNF superfamily member 11	Homo sapiens	76-81
17288976-7	2006	Therefore, anti-RANKL therapy most likely will be used in the context of MTX therapy.	Methotrexate	73-76	TNF superfamily member 11	Homo sapiens	16-21
16498455-5	2006	Transduction of TAK1-DN and MKK6-DN and treatment with the p38 inhibitor SB203580 attenuated NFATc1 induction by RANKL.	SB 203580	73-81	TNF superfamily member 11	Homo sapiens	113-118
16498455-6	2006	TAK1-DN, MKK6-DN, and SB203580, but not MKK3-DN, also suppressed RANKL stimulation of NF-kappaB transcription activity in a manner dependent on p65 phosphorylation on Ser-536.	SB 203580	22-30	TNF superfamily member 11	Homo sapiens	65-70
16498455-6	2006	TAK1-DN, MKK6-DN, and SB203580, but not MKK3-DN, also suppressed RANKL stimulation of NF-kappaB transcription activity in a manner dependent on p65 phosphorylation on Ser-536.	Serine	167-170	TNF superfamily member 11	Homo sapiens	65-70
16995820-12	2006	Furthermore, pretreatment of osteoblasts with the MAPK inhibitor SB203580 abolished adiponectin-regulated RANKL and OPG mRNA expression.	SB 203580	65-73	TNF superfamily member 11	Homo sapiens	106-111
16730419-0	2006	Association of TNFSF11 gene promoter polymorphisms with bone mineral density in postmenopausal women.	bone mineral	56-68	TNF superfamily member 11	Homo sapiens	15-22
16806459-4	2006	Immunohistochemical analysis of formalin fixed tissue sections demonstrated that RANK, RANKL and TNFalpha were strongly expressed by large multinucleated cells containing polyethylene wear debris in revision tissues.	Formaldehyde	32-40	TNF superfamily member 11	Homo sapiens	87-92
16806459-4	2006	Immunohistochemical analysis of formalin fixed tissue sections demonstrated that RANK, RANKL and TNFalpha were strongly expressed by large multinucleated cells containing polyethylene wear debris in revision tissues.	Polyethylene	171-183	TNF superfamily member 11	Homo sapiens	87-92
16806459-8	2006	This suggests that the interaction of TNFalpha and RANKL promotes osteoclast activity associated with polyethylene wear and therapies targeting TNF activity may be useful to treat peri-implant osteolysis.	Polyethylene	102-114	TNF superfamily member 11	Homo sapiens	51-56
17161616-9	2006	RANKL expression and RANKL/OPG ratio were increased by DEX.	Dexamethasone	55-58	TNF superfamily member 11	Homo sapiens	0-5
17161616-9	2006	RANKL expression and RANKL/OPG ratio were increased by DEX.	Dexamethasone	55-58	TNF superfamily member 11	Homo sapiens	21-26
16690366-7	2006	However in THX women the residual T cells produce higher levels of IL-7 and RANKL.	Thyroxine	11-14	TNF superfamily member 11	Homo sapiens	76-81
17032166-5	2006	Steady-state RANKL RNA levels were increased approximately 17-fold by IL-1beta treatment and subsequently reduced approximately 70%-90% when p38 MAPK was inhibited with SB203580.	SB 203580	169-177	TNF superfamily member 11	Homo sapiens	13-18
16690366-12	2006	The RANKL/OPG ratio and indices of bone metabolisms are also not affected by THX, although THX increases the levels of IL-7 and RANKL.	Thyroxine	91-94	TNF superfamily member 11	Homo sapiens	128-133
16951469-1	2006	Osteoprotegerine (OPG) acts as a decoy receptor for receptor activator of NF-kappaB (RANK) ligand (RANKL) to compete against RANK.	osteoprotegerine	0-16	TNF superfamily member 11	Homo sapiens	99-104
16951469-1	2006	Osteoprotegerine (OPG) acts as a decoy receptor for receptor activator of NF-kappaB (RANK) ligand (RANKL) to compete against RANK.	SCHEMBL12347590	18-21	TNF superfamily member 11	Homo sapiens	99-104
16914732-2	2006	In osteoblasts, RANKL expression is regulated by two major calcemic hormones, 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)] and parathyroid hormone (PTH), as well as by several inflammatory/osteoclastogenic cytokines; the molecular mechanisms for this regulation are unclear.	1,25-dihydroxyvitamin D	78-101	TNF superfamily member 11	Homo sapiens	16-21
16914732-8	2006	An evolutionarily conserved region within the human RANKL gene contained a similar vitamin D response element and exhibited an equivalent behavior.	Vitamin D	83-92	TNF superfamily member 11	Homo sapiens	52-57
16828054-0	2006	Characterization of osteoprotegerin binding to glycosaminoglycans by surface plasmon resonance: role in the interactions with receptor activator of nuclear factor kappaB ligand (RANKL) and RANK.	Glycosaminoglycans	47-65	TNF superfamily member 11	Homo sapiens	178-183
16893379-4	2006	The aim was to analyze the effects of a suppressive thyroid hormone therapy in males with DTC on the OPG/RANKL system and on bone metabolism.	dtc	90-93	TNF superfamily member 11	Homo sapiens	105-110
16828054-4	2006	Kinetic data demonstrated that OPG binds to heparin with a high-affinity (KD: 0.28 nM) and that the pre-incubation of OPG with heparin inhibits in a dose-dependent manner the OPG binding to the complex RANK-RANKL.	Heparin	44-51	TNF superfamily member 11	Homo sapiens	207-212
16828054-4	2006	Kinetic data demonstrated that OPG binds to heparin with a high-affinity (KD: 0.28 nM) and that the pre-incubation of OPG with heparin inhibits in a dose-dependent manner the OPG binding to the complex RANK-RANKL.	Heparin	127-134	TNF superfamily member 11	Homo sapiens	207-212
16828054-7	2006	The results demonstrated that sulfation is essential in the OPG-blocking function of GAGs since a totally desulfated heparin loses its capacity to bind and to block OPG binding to RANKL.	Heparin	117-124	TNF superfamily member 11	Homo sapiens	180-185
16828054-8	2006	Moreover, a decasaccharide is the minimal structure that totally inhibits the OPG binding to the complex RANK-RANKL.	decasaccharide	12-26	TNF superfamily member 11	Homo sapiens	110-115
16828054-10	2006	These data support an essential function of the related glycosaminoglycans heparin and heparan sulfate in the activity of the triad RANK-RANKL-OPG.	glycosaminoglycans heparin	56-82	TNF superfamily member 11	Homo sapiens	137-142
16828054-10	2006	These data support an essential function of the related glycosaminoglycans heparin and heparan sulfate in the activity of the triad RANK-RANKL-OPG.	Heparitin Sulfate	87-102	TNF superfamily member 11	Homo sapiens	137-142
16893379-11	2006	CONCLUSIONS: Suppressive thyroid hormone therapy in men with DTC increased bone degradation and induced significant changes in the OPG/RANKL system.	dtc	61-64	TNF superfamily member 11	Homo sapiens	135-140
16768824-5	2006	Genistein (at 1 microM) could stimulate the mRNA expression of receptor activator of NF-kappaB ligand (RANKL).	Genistein	0-9	TNF superfamily member 11	Homo sapiens	63-101
16861295-7	2006	Clodronate also strongly inhibited stress-induced gene expression for COX-2 and RANKL.	Clodronic Acid	0-10	TNF superfamily member 11	Homo sapiens	80-85
16861295-8	2006	These results suggest that the inhibitory effects of clodronate on tooth movement and osteoclasts may be due, at least in part, to the inhibition of COX-2-dependent PGE(2) production and RANKL expression in PDL cells.	Clodronic Acid	53-63	TNF superfamily member 11	Homo sapiens	187-192
16813535-15	2006	UBA mutations (K378X and P392L) significantly increased the number of OLCs formed in response to RANKL and also the number of nuclei of the OLCs.	UBP 310	0-3	TNF superfamily member 11	Homo sapiens	97-102
16732613-4	2006	We have also found that polymethyl methacrylate (PMMA) particles stimulate osteoclastogenesis, at least in part, by induction of RANKL, TNF, and by activation of NF-kappaB and MAP kinases.	Polymethyl Methacrylate	24-47	TNF superfamily member 11	Homo sapiens	129-134
16732613-4	2006	We have also found that polymethyl methacrylate (PMMA) particles stimulate osteoclastogenesis, at least in part, by induction of RANKL, TNF, and by activation of NF-kappaB and MAP kinases.	Polymethyl Methacrylate	49-53	TNF superfamily member 11	Homo sapiens	129-134
16768824-5	2006	Genistein (at 1 microM) could stimulate the mRNA expression of receptor activator of NF-kappaB ligand (RANKL).	Genistein	0-9	TNF superfamily member 11	Homo sapiens	103-108
16298558-14	2006	All of the dissociated glucocorticoids and deflazacort were poor stimulators of RANKL gene expression stimulating by only approximately 1-3-fold compared to 7-fold by prednisolone.	deflazacort	43-54	TNF superfamily member 11	Homo sapiens	80-85
16476762-2	2006	Oestrogens, androgens, corticosteroids, parathyroid hormone (PTH), vitamin D, and several cytokines exert their effects on bone modulating the OPG/RANKL system.	Vitamin D	67-76	TNF superfamily member 11	Homo sapiens	147-152
16646024-4	2006	We further investigated the effect of dexamethasone (DEX) on RANKL expression by lymphocytes from rheumatoid arthritis synovial fluids (RA SF), using flow cytometric analysis.	Dexamethasone	38-51	TNF superfamily member 11	Homo sapiens	61-66
16646024-4	2006	We further investigated the effect of dexamethasone (DEX) on RANKL expression by lymphocytes from rheumatoid arthritis synovial fluids (RA SF), using flow cytometric analysis.	Dexamethasone	53-56	TNF superfamily member 11	Homo sapiens	61-66
16646024-5	2006	Finally, we evaluated the in vitro effect of DEX on RANKL and OPG expression in osteoblast-like cells, by Western blotting.	Dexamethasone	45-48	TNF superfamily member 11	Homo sapiens	52-57
16646024-8	2006	DEX down-regulated RANKL expression on lymphocytes derived from RA SF.	Dexamethasone	0-3	TNF superfamily member 11	Homo sapiens	19-24
16646024-9	2006	Moreover, in vitro pretreatment of osteoblast-like cells with tumor necrosis factor favored an antiresorptive effect of DEX treatment through a similar down-regulation of RANKL expression.	Dexamethasone	120-123	TNF superfamily member 11	Homo sapiens	171-176
16490746-9	2006	Patients with pre-HD bicarbonate higher than 20 mEq/l had higher serum phosphate and, accordingly, higher phosphate removal; of interest, these individuals also have significant differences in RANKL/OPG.	Bicarbonates	21-32	TNF superfamily member 11	Homo sapiens	193-198
16513293-14	2006	Transduction with dnNFAT inhibited RANKL induction of the human beta3 integrin promoter.	dnnfat	18-24	TNF superfamily member 11	Homo sapiens	35-40
16298558-15	2006	These data demonstrate that deflazacort and the dissociated glucocorticoids are weak stimulators of the RANKL:OPG ratio compared to prednisolone.	deflazacort	28-39	TNF superfamily member 11	Homo sapiens	104-109
16771731-9	2006	Minodronate decreased expression of RANKL, PTHrP and MMP-2 in PC-3 cells.	YM 529	0-11	TNF superfamily member 11	Homo sapiens	36-41
16651437-0	2006	Antitumor and antimetastatic activities of docetaxel are enhanced by genistein through regulation of osteoprotegerin/receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/MMP-9 signaling in prostate cancer.	Docetaxel	43-52	TNF superfamily member 11	Homo sapiens	168-179
16651437-11	2006	These results suggest that the observed potentiation of antitumor activity of docetaxel by genistein in the SCID-human model of experimental bone metastasis could be mediated by regulation of OPG/RANK/RANKL/MMP-9 signaling, resulting in the inhibition of osteoclastic bone resorption and prostate cancer bone metastasis.	Docetaxel	78-87	TNF superfamily member 11	Homo sapiens	201-206
16651437-11	2006	These results suggest that the observed potentiation of antitumor activity of docetaxel by genistein in the SCID-human model of experimental bone metastasis could be mediated by regulation of OPG/RANK/RANKL/MMP-9 signaling, resulting in the inhibition of osteoclastic bone resorption and prostate cancer bone metastasis.	Genistein	91-100	TNF superfamily member 11	Homo sapiens	201-206
16632109-0	2006	Antioxidant alpha-lipoic acid inhibits osteoclast differentiation by reducing nuclear factor-kappaB DNA binding and prevents in vivo bone resorption induced by receptor activator of nuclear factor-kappaB ligand and tumor necrosis factor-alpha.	Thioctic Acid	12-29	TNF superfamily member 11	Homo sapiens	160-210
16632109-2	2006	As bone loss occurring in osteoporosis and inflammatory diseases is primarily due to increases in osteoclast number, reactive oxygen species (ROS) may be relevant to osteoclast differentiation, which requires receptor activator of nuclear factor-kappaB ligand (RANKL).	Reactive Oxygen Species	117-140	TNF superfamily member 11	Homo sapiens	209-259
16632109-2	2006	As bone loss occurring in osteoporosis and inflammatory diseases is primarily due to increases in osteoclast number, reactive oxygen species (ROS) may be relevant to osteoclast differentiation, which requires receptor activator of nuclear factor-kappaB ligand (RANKL).	Reactive Oxygen Species	117-140	TNF superfamily member 11	Homo sapiens	261-266
16632109-2	2006	As bone loss occurring in osteoporosis and inflammatory diseases is primarily due to increases in osteoclast number, reactive oxygen species (ROS) may be relevant to osteoclast differentiation, which requires receptor activator of nuclear factor-kappaB ligand (RANKL).	Reactive Oxygen Species	142-145	TNF superfamily member 11	Homo sapiens	209-259
16632109-2	2006	As bone loss occurring in osteoporosis and inflammatory diseases is primarily due to increases in osteoclast number, reactive oxygen species (ROS) may be relevant to osteoclast differentiation, which requires receptor activator of nuclear factor-kappaB ligand (RANKL).	Reactive Oxygen Species	142-145	TNF superfamily member 11	Homo sapiens	261-266
16632109-6	2006	alpha-LA abolished ROS elevation by RANKL or RANKL/TNF-alpha and inhibited NF-kappaB activation in osteoclast precursor cells.	Reactive Oxygen Species	19-22	TNF superfamily member 11	Homo sapiens	36-41
16632109-6	2006	alpha-LA abolished ROS elevation by RANKL or RANKL/TNF-alpha and inhibited NF-kappaB activation in osteoclast precursor cells.	Reactive Oxygen Species	19-22	TNF superfamily member 11	Homo sapiens	45-50
16567424-0	2006	Pepstatin A, an aspartic proteinase inhibitor, suppresses RANKL-induced osteoclast differentiation.	pepstatin	0-11	TNF superfamily member 11	Homo sapiens	58-63
16266722-9	2006	The conditioned medium containing M-CSF and PGE2 produced by nicotine and LPS-treated Saos-2 cells with soluble RANKL increased the TRAP staining of osteoclast precursors compared with that produced by nicotine treatment alone.	Dinoprostone	44-48	TNF superfamily member 11	Homo sapiens	112-117
16831910-6	2006	Most factors that induce OCL differentiation, such as PTHrP, IL-11, and prostaglandins, do so by inducing expression of RANKL on the surface of immature osteoblasts.	Prostaglandins	72-86	TNF superfamily member 11	Homo sapiens	120-125
16831922-0	2006	Interactive effect of interleukin-6 and prostaglandin E2 on osteoclastogenesis via the OPG/RANKL/RANK system.	Dinoprostone	40-56	TNF superfamily member 11	Homo sapiens	91-96
16831922-4	2006	We herein demonstrate that COX-2 and PGE2 stimulated osteoclastogenesis through inhibition of OPG secretion, stimulation of RANKL production by osteoblasts, and upregulation of RANK expression in osteoclasts.	Dinoprostone	37-41	TNF superfamily member 11	Homo sapiens	124-129
16831922-6	2006	These findings provide evidence of interactive effect of PGE2 and IL-6 signaling pathways in osteoclastogenesis via effect on the OPG/RANKL/RANK system.	Dinoprostone	57-61	TNF superfamily member 11	Homo sapiens	134-139
16567424-2	2006	In this study, we found that pepstatin A suppressed receptor activator of NF-kappaB ligand (RANKL)-induced osteoclast differentiation.	pepstatin	29-40	TNF superfamily member 11	Homo sapiens	92-97
16491292-0	2006	Deletion of aspartate 182 in OPG causes juvenile Paget"s disease by impairing both protein secretion and binding to RANKL.	Aspartic Acid	12-21	TNF superfamily member 11	Homo sapiens	116-121
16538029-2	2006	In the present study, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol (D-PDMP), a glucosylceramide synthase inhibitor, completely inhibited osteoclastogenesis induced by macrophage-colony stimulating factor (M-CSF) and receptor activator of NF-kappaB ligand (RANKL).	RV 538	22-78	TNF superfamily member 11	Homo sapiens	228-266
16538029-2	2006	In the present study, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol (D-PDMP), a glucosylceramide synthase inhibitor, completely inhibited osteoclastogenesis induced by macrophage-colony stimulating factor (M-CSF) and receptor activator of NF-kappaB ligand (RANKL).	RV 538	22-78	TNF superfamily member 11	Homo sapiens	268-273
16538029-2	2006	In the present study, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol (D-PDMP), a glucosylceramide synthase inhibitor, completely inhibited osteoclastogenesis induced by macrophage-colony stimulating factor (M-CSF) and receptor activator of NF-kappaB ligand (RANKL).	RV 538	80-86	TNF superfamily member 11	Homo sapiens	228-266
16538029-7	2006	Furthermore, receptor activator of nuclear factor kappaB (RANK) induced the recruitment of tumor necrosis factor (TNF)-associated factors 2 and 6 (TRAF2 and 6, respectively) to the cytoplasmic tail of RANKL with activated IkappaB kinase and IkappaB phosphorylation, while D-PDMP treatment inhibited RANKL and induced IkappaB phosphorylation, and that inhibition was recovered by LacCer.	Deuterium	272-273	TNF superfamily member 11	Homo sapiens	201-206
16538029-2	2006	In the present study, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol (D-PDMP), a glucosylceramide synthase inhibitor, completely inhibited osteoclastogenesis induced by macrophage-colony stimulating factor (M-CSF) and receptor activator of NF-kappaB ligand (RANKL).	RV 538	80-86	TNF superfamily member 11	Homo sapiens	268-273
16538029-5	2006	Following treatment with RANKL, ganglioside GM3 and GM1 were increased in the treated bone marrow cells, whereas other types were not detected using thin layer chromatography analysis.	G(M3) Ganglioside	32-47	TNF superfamily member 11	Homo sapiens	25-30
16538029-7	2006	Furthermore, receptor activator of nuclear factor kappaB (RANK) induced the recruitment of tumor necrosis factor (TNF)-associated factors 2 and 6 (TRAF2 and 6, respectively) to the cytoplasmic tail of RANKL with activated IkappaB kinase and IkappaB phosphorylation, while D-PDMP treatment inhibited RANKL and induced IkappaB phosphorylation, and that inhibition was recovered by LacCer.	RV 538	274-278	TNF superfamily member 11	Homo sapiens	201-206
16538029-5	2006	Following treatment with RANKL, ganglioside GM3 and GM1 were increased in the treated bone marrow cells, whereas other types were not detected using thin layer chromatography analysis.	G(M1) Ganglioside	52-55	TNF superfamily member 11	Homo sapiens	25-30
16549048-0	2006	Dehydroepiandrosterone inhibited the bone resorption through the upregulation of OPG/RANKL.	Dehydroepiandrosterone	0-22	TNF superfamily member 11	Homo sapiens	85-90
16549048-6	2006	DHEA could apparently increase the ratio of OPG/RANKL mRNA in OBs.	Dehydroepiandrosterone	0-4	TNF superfamily member 11	Homo sapiens	48-53
16549048-8	2006	We concluded, therefore, only in the presence of OBs, DHEA could inhibit the bone resorption of OCs, which may be mediated by OPG/RANKL of OBs.	Dehydroepiandrosterone	54-58	TNF superfamily member 11	Homo sapiens	130-135
16428513-0	2006	Guggulsterone inhibits osteoclastogenesis induced by receptor activator of nuclear factor-kappaB ligand and by tumor cells by suppressing nuclear factor-kappaB activation.	pregna-4,17-diene-3,16-dione	0-13	TNF superfamily member 11	Homo sapiens	53-103
16612568-7	2006	RESULTS: The levels of PGE2 and sRANKL increased in the presence of SP, though the increases were greater in the experimental groups in both a time- and concentration-dependent manner, and the increase of RANKL was partially mediated by PGE2.	Dinoprostone	237-241	TNF superfamily member 11	Homo sapiens	33-38
16428513-5	2006	We investigated whether guggulsterone could modulate RANKL signaling and osteoclastogenesis induced by RANKL or tumor cells.	pregna-4,17-diene-3,16-dione	24-37	TNF superfamily member 11	Homo sapiens	53-58
16428513-5	2006	We investigated whether guggulsterone could modulate RANKL signaling and osteoclastogenesis induced by RANKL or tumor cells.	pregna-4,17-diene-3,16-dione	24-37	TNF superfamily member 11	Homo sapiens	103-108
16428513-6	2006	We found that treatment of monocytes with guggulsterone suppressed RANKL-activated NF-kappaB activation (as indicated by gel-shift assay) and that this suppression correlated with inhibition of IkappaBalpha kinase and phosphorylation and degradation of IkappaBalpha, an inhibitor of NF-kappaB.	pregna-4,17-diene-3,16-dione	42-55	TNF superfamily member 11	Homo sapiens	67-72
16428513-10	2006	Collectively, our results indicate that guggulsterone suppresses RANKL and tumor cell-induced osteoclastogenesis by suppressing the activation of NF-kappaB.	pregna-4,17-diene-3,16-dione	40-53	TNF superfamily member 11	Homo sapiens	65-70
16109714-3	2005	Here we show that NFATc1 expression precedes that of OSCAR during TRANCE-mediated osteoclastogenesis and that inhibition of NFATc1 by cyclosporin A abolishes TRANCE-induced OSCAR expression and subsequent osteoclast differentiation.	Cyclosporine	134-147	TNF superfamily member 11	Homo sapiens	158-164
16005483-0	2005	Changes in RANKL/OPG/RANK gene expression in peripheral mononuclear cells following treatment with estrogen or raloxifene.	Raloxifene Hydrochloride	111-121	TNF superfamily member 11	Homo sapiens	11-16
16005483-16	2005	These results suggest that the expression of RANKL/OPG/RANK in PBMCs are responsive to the slowing in bone turnover/remodeling associated with treatment with estrogen or raloxifene.	Raloxifene Hydrochloride	170-180	TNF superfamily member 11	Homo sapiens	45-50
16404151-1	2005	We show that sulforaphane inhibits osteoclastogenesis in the presence of macrophage colony-stimulating factor (M-CSF) and receptor for activation of nuclear factor-kB ligand (RANKL) in osteoclast (OC) precursors.	sulforaphane	13-25	TNF superfamily member 11	Homo sapiens	122-173
16404151-1	2005	We show that sulforaphane inhibits osteoclastogenesis in the presence of macrophage colony-stimulating factor (M-CSF) and receptor for activation of nuclear factor-kB ligand (RANKL) in osteoclast (OC) precursors.	sulforaphane	13-25	TNF superfamily member 11	Homo sapiens	175-180
16152630-4	2005	Here, we evaluated the effect of atorvastatin on osteoblastic production of receptor activator of nuclear factor-kappaB ligand (RANKL) and osteoprotegerin (OPG), cytokines that are essential for osteoclast cell biology.	Atorvastatin	33-45	TNF superfamily member 11	Homo sapiens	76-126
16152630-4	2005	Here, we evaluated the effect of atorvastatin on osteoblastic production of receptor activator of nuclear factor-kappaB ligand (RANKL) and osteoprotegerin (OPG), cytokines that are essential for osteoclast cell biology.	Atorvastatin	33-45	TNF superfamily member 11	Homo sapiens	128-133
16150915-12	2005	The conditioned medium of CD14(+) cells pretreated with PGE(2) inhibited RANKL-induced osteoclast formation not only in human CD14(+) cell cultures, but also in mouse macrophage cultures.	Prostaglandins E	56-59	TNF superfamily member 11	Homo sapiens	73-78
16304637-5	2005	We also found that RANKL is not involved in AICD but participates in doxorubicin-induced apoptosis of leukemia T cell lines including Jurkat, CEM and HSB-2.	Doxorubicin	69-80	TNF superfamily member 11	Homo sapiens	19-24
16304637-6	2005	In this respect, Coll I protected leukemia T cell lines from doxorubicin-induced apoptosis by inhibiting doxorubicin-induced RANKL expression.	Doxorubicin	61-72	TNF superfamily member 11	Homo sapiens	125-130
16304637-6	2005	In this respect, Coll I protected leukemia T cell lines from doxorubicin-induced apoptosis by inhibiting doxorubicin-induced RANKL expression.	Doxorubicin	105-116	TNF superfamily member 11	Homo sapiens	125-130
16393773-0	2005	The inhibitory effect of bisphosphonates on glucocorticoid-induced RANKL expression in human cells.	Diphosphonates	25-40	TNF superfamily member 11	Homo sapiens	67-72
16393773-2	2005	However, little is known about the effect of bisphosphonates on glucocorticoid-induced RANKL expression in human cells.	Diphosphonates	45-60	TNF superfamily member 11	Homo sapiens	87-92
16393773-3	2005	Our study was intended to clarify effects of bisphosphonates on glucocorticoid-induced RANKL expression in human cells.	Diphosphonates	45-60	TNF superfamily member 11	Homo sapiens	87-92
16393773-7	2005	RESULTS: In Jurkat and MG-63 cells, dexamethasone induced expression of soluble RANKL (sRANKL) protein in supernatants and RANKL mRNA in cells.	Dexamethasone	36-49	TNF superfamily member 11	Homo sapiens	80-85
16393773-7	2005	RESULTS: In Jurkat and MG-63 cells, dexamethasone induced expression of soluble RANKL (sRANKL) protein in supernatants and RANKL mRNA in cells.	Dexamethasone	36-49	TNF superfamily member 11	Homo sapiens	88-93
16393773-11	2005	Bisphosphonates inhibited glucocorticoid-induced RANKL expression, suggesting that these effects might be a new therapeutic mechanism for bisphosphonates.	Diphosphonates	0-15	TNF superfamily member 11	Homo sapiens	49-54
16393773-11	2005	Bisphosphonates inhibited glucocorticoid-induced RANKL expression, suggesting that these effects might be a new therapeutic mechanism for bisphosphonates.	Diphosphonates	138-153	TNF superfamily member 11	Homo sapiens	49-54
16101188-2	2005	We hypothesized that bisphosphonate treatment and the subsequent fall in serum calcium might induce changes in the RANK/RANKL/OPG system, which plays a pivotal role in the regulation of bone resorption.	Diphosphonates	21-35	TNF superfamily member 11	Homo sapiens	120-125
16183790-6	2005	Furthermore, in the fibroblasts, rhIL-1alpha enhanced the expression of macrophage colony-stimulating factor (M-CSF) mRNA, and rhIL-1alpha-induced PGE2 increased the expression of nuclear factor kappaB ligand (RANKL) mRNA.	Dinoprostone	147-151	TNF superfamily member 11	Homo sapiens	210-215
16046394-3	2005	Immunoreceptors, including osteoclast-associated receptor (OSCAR) and triggering receptor expressed by myeloid cells (TREM)-2, constitute the co-stimulatory signals required for RANKL-mediated activation of calcium signaling, which leads to the activation of NFATc1.	Calcium	207-214	TNF superfamily member 11	Homo sapiens	178-183
16101188-2	2005	We hypothesized that bisphosphonate treatment and the subsequent fall in serum calcium might induce changes in the RANK/RANKL/OPG system, which plays a pivotal role in the regulation of bone resorption.	Calcium	79-86	TNF superfamily member 11	Homo sapiens	120-125
16164220-3	2005	Leflunomide has a direct inhibitory effect on RANKL-mediated osteoclast differentiation by inhibiting the induction of NFATc1, the master switch regulator for osteoclast differentiation.	Leflunomide	0-11	TNF superfamily member 11	Homo sapiens	46-51
16024207-3	2005	Furthermore, OCIF/OPG inhibited GCTSC-induced osteoclastogenesis, showing that the RANK-RANKL system is involved in GCTSC-induced osteoclastogenesis and that soluble form of ODF/RANKL induces osteoclasts from monocytes.	gctsc	32-37	TNF superfamily member 11	Homo sapiens	88-93
16024207-3	2005	Furthermore, OCIF/OPG inhibited GCTSC-induced osteoclastogenesis, showing that the RANK-RANKL system is involved in GCTSC-induced osteoclastogenesis and that soluble form of ODF/RANKL induces osteoclasts from monocytes.	gctsc	32-37	TNF superfamily member 11	Homo sapiens	174-177
16024207-9	2005	GCTSC express CaSR, and stimulation of GCTSC with either extracellular Ca(2+) or neomycin, agonist of CaSR, augmented the expression of RANKL.	Neomycin	81-89	TNF superfamily member 11	Homo sapiens	136-141
16085103-6	2005	Increased concentrations of ATP were detected in the culture medium of US-treated cells and both ATP and US stimulation caused increased receptor activator of nuclear factor-kappa B ligand (RANKL), decreased osteoprotegerin expression and increased cell proliferation by SaOS-2 cells.	Adenosine Triphosphate	28-31	TNF superfamily member 11	Homo sapiens	137-188
15817678-3	2005	A deficiency in TRAF6 or expression of a dominant-interfering mutant of TRAF6 blocks RANKL-mediated ROS production.	Reactive Oxygen Species	100-103	TNF superfamily member 11	Homo sapiens	85-90
15817678-4	2005	Application of N-acetylcysteine (NAC) or blocking the activity of Nox, a protein leading to the formation of ROS, with diphenylene iodonium (DPI) inhibits the responses of BMM cells to RANKL, including ROS production, activation of c-Jun N-terminal kinase (JNK), p38 mitogen-activated protein (MAP) kinase, and extracellular signal-regulated kinase (ERK), and osteoclast differentiation.	Acetylcysteine	15-31	TNF superfamily member 11	Homo sapiens	185-190
15817678-4	2005	Application of N-acetylcysteine (NAC) or blocking the activity of Nox, a protein leading to the formation of ROS, with diphenylene iodonium (DPI) inhibits the responses of BMM cells to RANKL, including ROS production, activation of c-Jun N-terminal kinase (JNK), p38 mitogen-activated protein (MAP) kinase, and extracellular signal-regulated kinase (ERK), and osteoclast differentiation.	Acetylcysteine	33-36	TNF superfamily member 11	Homo sapiens	185-190
15817678-4	2005	Application of N-acetylcysteine (NAC) or blocking the activity of Nox, a protein leading to the formation of ROS, with diphenylene iodonium (DPI) inhibits the responses of BMM cells to RANKL, including ROS production, activation of c-Jun N-terminal kinase (JNK), p38 mitogen-activated protein (MAP) kinase, and extracellular signal-regulated kinase (ERK), and osteoclast differentiation.	nicotine 1-N-oxide	66-69	TNF superfamily member 11	Homo sapiens	185-190
15817678-4	2005	Application of N-acetylcysteine (NAC) or blocking the activity of Nox, a protein leading to the formation of ROS, with diphenylene iodonium (DPI) inhibits the responses of BMM cells to RANKL, including ROS production, activation of c-Jun N-terminal kinase (JNK), p38 mitogen-activated protein (MAP) kinase, and extracellular signal-regulated kinase (ERK), and osteoclast differentiation.	Reactive Oxygen Species	109-112	TNF superfamily member 11	Homo sapiens	185-190
15817678-4	2005	Application of N-acetylcysteine (NAC) or blocking the activity of Nox, a protein leading to the formation of ROS, with diphenylene iodonium (DPI) inhibits the responses of BMM cells to RANKL, including ROS production, activation of c-Jun N-terminal kinase (JNK), p38 mitogen-activated protein (MAP) kinase, and extracellular signal-regulated kinase (ERK), and osteoclast differentiation.	diphenyleneiodonium	119-139	TNF superfamily member 11	Homo sapiens	185-190
15817678-4	2005	Application of N-acetylcysteine (NAC) or blocking the activity of Nox, a protein leading to the formation of ROS, with diphenylene iodonium (DPI) inhibits the responses of BMM cells to RANKL, including ROS production, activation of c-Jun N-terminal kinase (JNK), p38 mitogen-activated protein (MAP) kinase, and extracellular signal-regulated kinase (ERK), and osteoclast differentiation.	diphenyleneiodonium	141-144	TNF superfamily member 11	Homo sapiens	185-190
15817678-4	2005	Application of N-acetylcysteine (NAC) or blocking the activity of Nox, a protein leading to the formation of ROS, with diphenylene iodonium (DPI) inhibits the responses of BMM cells to RANKL, including ROS production, activation of c-Jun N-terminal kinase (JNK), p38 mitogen-activated protein (MAP) kinase, and extracellular signal-regulated kinase (ERK), and osteoclast differentiation.	Reactive Oxygen Species	202-205	TNF superfamily member 11	Homo sapiens	185-190
15817678-5	2005	Moreover, both RANKL-mediated ROS production and osteoclast differentiation were completely blocked in precursors depleted of Nox1 activity by RNA interference or by expressing a dominant-negative mutant of Rac1.	Reactive Oxygen Species	30-33	TNF superfamily member 11	Homo sapiens	15-20
16085103-6	2005	Increased concentrations of ATP were detected in the culture medium of US-treated cells and both ATP and US stimulation caused increased receptor activator of nuclear factor-kappa B ligand (RANKL), decreased osteoprotegerin expression and increased cell proliferation by SaOS-2 cells.	Adenosine Triphosphate	97-100	TNF superfamily member 11	Homo sapiens	137-188
16085103-6	2005	Increased concentrations of ATP were detected in the culture medium of US-treated cells and both ATP and US stimulation caused increased receptor activator of nuclear factor-kappa B ligand (RANKL), decreased osteoprotegerin expression and increased cell proliferation by SaOS-2 cells.	Adenosine Triphosphate	97-100	TNF superfamily member 11	Homo sapiens	190-195
16085103-7	2005	These findings indicate that US causes ATP release by osteoblasts in vitro and that this may contribute to accelerated fracture healing by enhancing osteoblast proliferation and increasing RANKL expression and decreasing osteoprotegerin expression by osteoblasts to promote osteoclastogenesis.	Adenosine Triphosphate	39-42	TNF superfamily member 11	Homo sapiens	189-194
15817678-0	2005	A crucial role for reactive oxygen species in RANKL-induced osteoclast differentiation.	Reactive Oxygen Species	19-42	TNF superfamily member 11	Homo sapiens	46-51
15817678-2	2005	Here, we show RANKL stimulation of BMM cells transiently increased the intracellular level of reactive oxygen species (ROS) through a signaling cascade involving TNF (tumor necrosis factor) receptor-associated factor (TRAF) 6, Rac1, and NADPH (nicotinamide adenine dinucleotide phosphate) oxidase (Nox) 1.	Reactive Oxygen Species	94-117	TNF superfamily member 11	Homo sapiens	14-19
15817678-2	2005	Here, we show RANKL stimulation of BMM cells transiently increased the intracellular level of reactive oxygen species (ROS) through a signaling cascade involving TNF (tumor necrosis factor) receptor-associated factor (TRAF) 6, Rac1, and NADPH (nicotinamide adenine dinucleotide phosphate) oxidase (Nox) 1.	Reactive Oxygen Species	119-122	TNF superfamily member 11	Homo sapiens	14-19
16085103-6	2005	Increased concentrations of ATP were detected in the culture medium of US-treated cells and both ATP and US stimulation caused increased receptor activator of nuclear factor-kappa B ligand (RANKL), decreased osteoprotegerin expression and increased cell proliferation by SaOS-2 cells.	Adenosine Triphosphate	28-31	TNF superfamily member 11	Homo sapiens	190-195
15573398-7	2005	1,25D and DEX induced the greatest ratio of RANKL:OPG mRNA, predictive of supporting osteoclast formation.	Dexamethasone	10-13	TNF superfamily member 11	Homo sapiens	44-49
16191370-2	2005	METHODS: RANKL and OPG were detected by immunohistochemistry (SP) in 24 paraffin-embedded and 2 frozen specimens of central giant cell lesion of jaw.	TFF2 protein, human	62-64	TNF superfamily member 11	Homo sapiens	9-14
16191370-2	2005	METHODS: RANKL and OPG were detected by immunohistochemistry (SP) in 24 paraffin-embedded and 2 frozen specimens of central giant cell lesion of jaw.	Paraffin	72-80	TNF superfamily member 11	Homo sapiens	9-14
15936724-3	2005	In this study, we examined the effects of the proteasome inhibitors MG-132 and MG-262 on RANKL-induced osteoclast differentiation and function.	Magnesium	68-70	TNF superfamily member 11	Homo sapiens	89-94
15936724-3	2005	In this study, we examined the effects of the proteasome inhibitors MG-132 and MG-262 on RANKL-induced osteoclast differentiation and function.	Magnesium	79-81	TNF superfamily member 11	Homo sapiens	89-94
15972689-7	2005	It also led to the production of reactive oxygen species via PKC- and PI3K-dependent activation of NADPH oxidase in the endothelial cells, and antioxidants suppressed the responses to TRANCE.	Reactive Oxygen Species	33-56	TNF superfamily member 11	Homo sapiens	184-190
15947117-7	2005	Treatment of HDS cells with gefitinib produced a significant reduction in the levels of secreted macrophage colony-stimulating factor (M-CSF) and cell-associated receptor activator of NF-kappaB ligand (RANKL) in both cell lines, as assessed by using specific ELISA and Western blotting techniques.	Gefitinib	28-37	TNF superfamily member 11	Homo sapiens	202-207
15623811-15	2005	In contrast, RANKL is likely to mediate the effect of estradiol on osteoclastogenesis.	Estradiol	54-63	TNF superfamily member 11	Homo sapiens	13-18
15930166-0	2005	Alpha-lipoic acid suppresses osteoclastogenesis despite increasing the receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio in human bone marrow stromal cells.	Thioctic Acid	0-17	TNF superfamily member 11	Homo sapiens	71-121
15930166-7	2005	In addition, alpha-LA-induced soluble RANKL was not inhibited by matrix metalloprotease inhibitors, indicating that soluble RANKL is produced by alpha-LA without any posttranslational processing.	Thioctic Acid	13-21	TNF superfamily member 11	Homo sapiens	38-43
15930166-7	2005	In addition, alpha-LA-induced soluble RANKL was not inhibited by matrix metalloprotease inhibitors, indicating that soluble RANKL is produced by alpha-LA without any posttranslational processing.	Thioctic Acid	13-21	TNF superfamily member 11	Homo sapiens	124-129
15930166-7	2005	In addition, alpha-LA-induced soluble RANKL was not inhibited by matrix metalloprotease inhibitors, indicating that soluble RANKL is produced by alpha-LA without any posttranslational processing.	Thioctic Acid	145-153	TNF superfamily member 11	Homo sapiens	124-129
15930166-10	2005	In addition, our findings indicate that alpha-LA-induced soluble RANKL is not produced by shedding of membranous RANKL.	Thioctic Acid	40-48	TNF superfamily member 11	Homo sapiens	65-70
15876398-9	2005	For instance sex steroids, parathyroid hormone and some interleukins are known to exert their positive or negative effects on osteoclast differentiation via the RANK/RANKL/osteoprotegrin pathway.	Steroids	17-25	TNF superfamily member 11	Homo sapiens	166-171
15885469-6	2005	RESULTS: In the presence of M-CSF, large numbers of TRAP(+) and VNR(+) multinucleated cells capable of lacunar resorption, were noted in co-cultures of monocytes and RANKL-expressing AFbs.	afbs	183-187	TNF superfamily member 11	Homo sapiens	166-171
15731115-0	2005	Reactive oxygen species stimulates receptor activator of NF-kappaB ligand expression in osteoblast.	Reactive Oxygen Species	0-23	TNF superfamily member 11	Homo sapiens	35-73
15731115-1	2005	It has been established that reactive oxygen species (ROS) such as H2O2 or superoxide anion is involved in bone loss-related diseases by stimulating osteoclast differentiation and bone resorption and that receptor activator of NF-kappaB ligand (RANKL) is a critical osteoclastogenic factor expressed on stromal/osteoblastic cells.	Reactive Oxygen Species	29-52	TNF superfamily member 11	Homo sapiens	205-243
15731115-1	2005	It has been established that reactive oxygen species (ROS) such as H2O2 or superoxide anion is involved in bone loss-related diseases by stimulating osteoclast differentiation and bone resorption and that receptor activator of NF-kappaB ligand (RANKL) is a critical osteoclastogenic factor expressed on stromal/osteoblastic cells.	Reactive Oxygen Species	29-52	TNF superfamily member 11	Homo sapiens	245-250
15731115-1	2005	It has been established that reactive oxygen species (ROS) such as H2O2 or superoxide anion is involved in bone loss-related diseases by stimulating osteoclast differentiation and bone resorption and that receptor activator of NF-kappaB ligand (RANKL) is a critical osteoclastogenic factor expressed on stromal/osteoblastic cells.	Reactive Oxygen Species	54-57	TNF superfamily member 11	Homo sapiens	205-243
15731115-1	2005	It has been established that reactive oxygen species (ROS) such as H2O2 or superoxide anion is involved in bone loss-related diseases by stimulating osteoclast differentiation and bone resorption and that receptor activator of NF-kappaB ligand (RANKL) is a critical osteoclastogenic factor expressed on stromal/osteoblastic cells.	Reactive Oxygen Species	54-57	TNF superfamily member 11	Homo sapiens	245-250
15731115-1	2005	It has been established that reactive oxygen species (ROS) such as H2O2 or superoxide anion is involved in bone loss-related diseases by stimulating osteoclast differentiation and bone resorption and that receptor activator of NF-kappaB ligand (RANKL) is a critical osteoclastogenic factor expressed on stromal/osteoblastic cells.	Hydrogen Peroxide	67-71	TNF superfamily member 11	Homo sapiens	245-250
15731115-1	2005	It has been established that reactive oxygen species (ROS) such as H2O2 or superoxide anion is involved in bone loss-related diseases by stimulating osteoclast differentiation and bone resorption and that receptor activator of NF-kappaB ligand (RANKL) is a critical osteoclastogenic factor expressed on stromal/osteoblastic cells.	Superoxides	75-91	TNF superfamily member 11	Homo sapiens	245-250
15731115-2	2005	However, the roles of ROS in RANKL expression and signaling mechanisms through which ROS regulates RANKL genes are not known.	Reactive Oxygen Species	85-88	TNF superfamily member 11	Homo sapiens	99-104
15731115-3	2005	Here we report that increased intracellular ROS levels by H2O2 or xanthine/xanthine oxidase-generated superoxide anion stimulated RANKL mRNA and protein expression in human osteoblast-like MG63 cell line and primary mouse bone marrow stromal cells and calvarial osteoblasts.	Reactive Oxygen Species	44-47	TNF superfamily member 11	Homo sapiens	130-135
15731115-3	2005	Here we report that increased intracellular ROS levels by H2O2 or xanthine/xanthine oxidase-generated superoxide anion stimulated RANKL mRNA and protein expression in human osteoblast-like MG63 cell line and primary mouse bone marrow stromal cells and calvarial osteoblasts.	Hydrogen Peroxide	58-62	TNF superfamily member 11	Homo sapiens	130-135
15731115-3	2005	Here we report that increased intracellular ROS levels by H2O2 or xanthine/xanthine oxidase-generated superoxide anion stimulated RANKL mRNA and protein expression in human osteoblast-like MG63 cell line and primary mouse bone marrow stromal cells and calvarial osteoblasts.	Superoxides	102-118	TNF superfamily member 11	Homo sapiens	130-135
15731115-6	2005	In human MG63 cells, however, we found that ROS promoted heat shock factor 2 (HSF2) binding to heat shock element in human RANKL promoter region and that HSF2, but not PKA, was required for ROS up-regulation of RANKL as revealed by KT5720 and HSF2 RNA interference transfection.	Reactive Oxygen Species	44-47	TNF superfamily member 11	Homo sapiens	123-128
15731115-6	2005	In human MG63 cells, however, we found that ROS promoted heat shock factor 2 (HSF2) binding to heat shock element in human RANKL promoter region and that HSF2, but not PKA, was required for ROS up-regulation of RANKL as revealed by KT5720 and HSF2 RNA interference transfection.	Reactive Oxygen Species	190-193	TNF superfamily member 11	Homo sapiens	211-216
15722361-9	2005	When RANKL signaling through NFATc1 was blocked with cyclosporin A, both MCP-1 and RANTES expression was down-regulated.	Cyclosporine	53-66	TNF superfamily member 11	Homo sapiens	5-10
15585657-9	2005	Therefore, we provide the first evidence demonstrating that RANKL stimulates the serine phosphorylation of STAT1 through the p38 MAPK pathway, causing MIG gene transcription and secretion, which may have a role in recruiting CXCR3-positive osteoclast precursors and osteoclasts to bone remodeling or inflammatory sites.	Serine	81-87	TNF superfamily member 11	Homo sapiens	60-65
15765187-1	2005	UNLABELLED: Human osteoblasts produce PGD(2), which acts on the DP receptor to decrease osteoprotegerin production and on the CRTH2 receptor to decrease RANKL expression and to induce osteoblast chemotaxis.	Prostaglandin D2	38-44	TNF superfamily member 11	Homo sapiens	153-158
15790738-7	2005	The PKC inhibitor, Ro-32-0432, suppressed RANKL expression in PDL cells and PTHrP-induced TRAP+ cell formation.	Ro 32-0432	19-29	TNF superfamily member 11	Homo sapiens	42-47
15618359-10	2005	COX-2 and PGE(2) stimulated osteoclastogenesis through inhibition of OPG secretion, stimulation of RANKL production by osteoblasts, and up-regulation of RANK expression in osteoclasts.	Dinoprostone	10-16	TNF superfamily member 11	Homo sapiens	99-104
15618359-14	2005	These findings provide evidence for cross-talk between the PGE(2) and IL-6 signaling enhance osteoclast differentiation via effects on the OPG/RANKL/RANK system in bone cells.	Prostaglandins E	59-62	TNF superfamily member 11	Homo sapiens	143-148
15670755-8	2005	Furthermore, YM529/ONO-5920 reduced phosphorylated extracellular signal-regulated kinase 1/2 (ERK1/2), and similarly, U0126, a mitogen-activated protein kinase kinase 1/2 inhibitor, inhibited RANKL expression.	YM 529	19-27	TNF superfamily member 11	Homo sapiens	192-197
15670755-0	2005	Nitrogen-containing bisphosphonate, YM529/ONO-5920 (a novel minodronic acid), inhibits RANKL expression in a cultured bone marrow stromal cell line ST2.	Nitrogen	0-8	TNF superfamily member 11	Homo sapiens	87-92
15790738-9	2005	Thus, PTHrP induces osteoclastogenesis by increasing the relative expression level of RANKL vs. OPG in PDL cells via a cAMP/PKA-independent pathway.	Cyclic AMP	119-123	TNF superfamily member 11	Homo sapiens	86-91
15670755-8	2005	Furthermore, YM529/ONO-5920 reduced phosphorylated extracellular signal-regulated kinase 1/2 (ERK1/2), and similarly, U0126, a mitogen-activated protein kinase kinase 1/2 inhibitor, inhibited RANKL expression.	U 0126	118-123	TNF superfamily member 11	Homo sapiens	192-197
15670755-0	2005	Nitrogen-containing bisphosphonate, YM529/ONO-5920 (a novel minodronic acid), inhibits RANKL expression in a cultured bone marrow stromal cell line ST2.	Diphosphonates	20-34	TNF superfamily member 11	Homo sapiens	87-92
15670755-0	2005	Nitrogen-containing bisphosphonate, YM529/ONO-5920 (a novel minodronic acid), inhibits RANKL expression in a cultured bone marrow stromal cell line ST2.	YM 529	36-41	TNF superfamily member 11	Homo sapiens	87-92
15670755-11	2005	This indicates that YM529/ONO-5920 inhibits GGPP biosynthesis in the mevalonate pathway and then signal transduction in the Ras-mitogen-activated protein kinase pathway, thereby inhibiting RANKL expression on ST2 cells.	YM 529	20-25	TNF superfamily member 11	Homo sapiens	189-194
15670755-0	2005	Nitrogen-containing bisphosphonate, YM529/ONO-5920 (a novel minodronic acid), inhibits RANKL expression in a cultured bone marrow stromal cell line ST2.	YM 529	42-50	TNF superfamily member 11	Homo sapiens	87-92
15670755-11	2005	This indicates that YM529/ONO-5920 inhibits GGPP biosynthesis in the mevalonate pathway and then signal transduction in the Ras-mitogen-activated protein kinase pathway, thereby inhibiting RANKL expression on ST2 cells.	YM 529	26-34	TNF superfamily member 11	Homo sapiens	189-194
15670755-0	2005	Nitrogen-containing bisphosphonate, YM529/ONO-5920 (a novel minodronic acid), inhibits RANKL expression in a cultured bone marrow stromal cell line ST2.	YM 529	60-75	TNF superfamily member 11	Homo sapiens	87-92
15670755-11	2005	This indicates that YM529/ONO-5920 inhibits GGPP biosynthesis in the mevalonate pathway and then signal transduction in the Ras-mitogen-activated protein kinase pathway, thereby inhibiting RANKL expression on ST2 cells.	geranylgeranyl pyrophosphate	44-48	TNF superfamily member 11	Homo sapiens	189-194
15670755-7	2005	The inhibition of RANKL mRNA expression was reversed when geranylgeranyl pyrophosphate (GGPP), an intermediate in the mevalonate pathway, was used in combination.	geranylgeranyl pyrophosphate	58-86	TNF superfamily member 11	Homo sapiens	18-23
15670755-11	2005	This indicates that YM529/ONO-5920 inhibits GGPP biosynthesis in the mevalonate pathway and then signal transduction in the Ras-mitogen-activated protein kinase pathway, thereby inhibiting RANKL expression on ST2 cells.	Mevalonic Acid	69-79	TNF superfamily member 11	Homo sapiens	189-194
15670755-7	2005	The inhibition of RANKL mRNA expression was reversed when geranylgeranyl pyrophosphate (GGPP), an intermediate in the mevalonate pathway, was used in combination.	geranylgeranyl pyrophosphate	88-92	TNF superfamily member 11	Homo sapiens	18-23
15670755-7	2005	The inhibition of RANKL mRNA expression was reversed when geranylgeranyl pyrophosphate (GGPP), an intermediate in the mevalonate pathway, was used in combination.	Mevalonic Acid	118-128	TNF superfamily member 11	Homo sapiens	18-23
15746983-12	2005	In human primary osteoblasts, dexamethasone dose-dependently reduced OPG and increased RANKL expression as measured by quantitative real time RT-PCR.	Dexamethasone	30-43	TNF superfamily member 11	Homo sapiens	87-92
15670755-8	2005	Furthermore, YM529/ONO-5920 reduced phosphorylated extracellular signal-regulated kinase 1/2 (ERK1/2), and similarly, U0126, a mitogen-activated protein kinase kinase 1/2 inhibitor, inhibited RANKL expression.	YM 529	13-18	TNF superfamily member 11	Homo sapiens	192-197
15777635-5	2005	In patients with tALP higher than the normal range after therapy, the OPG increase was associated with a parallel increase in RANKL levels.	talp	17-21	TNF superfamily member 11	Homo sapiens	126-131
15780952-8	2005	Pretreatment with NS398 and PD98059 also inhibited both the up-regulation of RANKL and the down-regulation of OPG expression by IL-1alpha in PDL cells.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	28-35	TNF superfamily member 11	Homo sapiens	77-82
15744818-5	2005	It was previously shown that rolipram induced the expression of TNF-related activation-induced cytokine (TRANCE, also known as RANKL, ODF, or OPGL) in osteoblasts.	Rolipram	29-37	TNF superfamily member 11	Homo sapiens	64-103
15744818-5	2005	It was previously shown that rolipram induced the expression of TNF-related activation-induced cytokine (TRANCE, also known as RANKL, ODF, or OPGL) in osteoblasts.	Rolipram	29-37	TNF superfamily member 11	Homo sapiens	105-111
15744818-5	2005	It was previously shown that rolipram induced the expression of TNF-related activation-induced cytokine (TRANCE, also known as RANKL, ODF, or OPGL) in osteoblasts.	Rolipram	29-37	TNF superfamily member 11	Homo sapiens	127-132
15744818-5	2005	It was previously shown that rolipram induced the expression of TNF-related activation-induced cytokine (TRANCE, also known as RANKL, ODF, or OPGL) in osteoblasts.	Rolipram	29-37	TNF superfamily member 11	Homo sapiens	134-137
15744818-5	2005	It was previously shown that rolipram induced the expression of TNF-related activation-induced cytokine (TRANCE, also known as RANKL, ODF, or OPGL) in osteoblasts.	Rolipram	29-37	TNF superfamily member 11	Homo sapiens	142-146
15780952-11	2005	These results suggest that IL-1alpha stimulates osteoclast formation by increasing the expression level of RANKL versus OPG via ERK-dependent PGE2 production in PDL cells.	Dinoprostone	142-146	TNF superfamily member 11	Homo sapiens	107-112
15780954-5	2005	The ability of RANKL to bind to recombinant human RANK-Fc (rhRANK-Fc) was reduced 50% by suramin in an in vitro binding assay.	Suramin	89-96	TNF superfamily member 11	Homo sapiens	15-20
15785827-6	2005	RANKL expression can be upregulated by bone-resorbing factors such as glucocorticoids, vitamin D3, interleukin 1 (IL-1), IL-6, IL-11, IL-17, tumor necrosis factor-alpha, prostaglandin E2, or parathyroid hormone-related peptide.	Cholecalciferol	87-97	TNF superfamily member 11	Homo sapiens	0-5
15530848-4	2004	In this study, we found that RANKL stimulated ROS generation in osteoclasts.	Reactive Oxygen Species	46-49	TNF superfamily member 11	Homo sapiens	29-34
16317958-6	2005	These results indicated that Leukotriene B4, elevated in many inflammatory diseases, is directly capable of inducing osteoclast formation by a RANKL-independent mechanism.	Leukotrienes	29-40	TNF superfamily member 11	Homo sapiens	143-148
15638876-14	2005	In addition, a significant positive correlation was found between serum RANKL/OPG ratios and oestradiol levels (r = 0.374, P &lt; 0.001) in Spearman correlation analysis.	Estradiol	93-103	TNF superfamily member 11	Homo sapiens	72-77
15638876-17	2005	In another multiple regression analysis, only serum oestradiol level was identified as a significant predictor for serum OPG or RANKL levels.	Estradiol	52-62	TNF superfamily member 11	Homo sapiens	128-133
15638876-20	2005	Also, our data suggest that OPG and RANKL may be mediators of the effects of oestradiol in male bone metabolism.	Estradiol	77-87	TNF superfamily member 11	Homo sapiens	36-41
16133687-4	2005	The application of 7%, 0.25-Hz CTS once a day for 4 h for 3 successive days simultaneously caused an increase of OPG synthesis and a decrease of sRANKL release and RANKL mRNA expression in osteoblasts.	castanospermine	31-34	TNF superfamily member 11	Homo sapiens	146-151
16133687-7	2005	Then, when CTS was applied once a day for 4 h for 3 successive days to osteoblasts pretreated with the p38 MAPK inhibitor SB203580 for 1 h, OPG synthesis was dose-dependently suppressed and inhibition of sRANKL release and RANKL mRNA expression was abrogated.	castanospermine	11-14	TNF superfamily member 11	Homo sapiens	205-210
16133687-7	2005	Then, when CTS was applied once a day for 4 h for 3 successive days to osteoblasts pretreated with the p38 MAPK inhibitor SB203580 for 1 h, OPG synthesis was dose-dependently suppressed and inhibition of sRANKL release and RANKL mRNA expression was abrogated.	SB 203580	122-130	TNF superfamily member 11	Homo sapiens	205-210
16686316-12	2005	In HD patients, OPGL showed a positive correlation with ALP and a negative correlation with calcium; OPG correlated positively with iP In 36 patients on HD (92.3%) and 15 patients on PD (51.7%), OPG was elevated above the normal value.	Calcium	92-99	TNF superfamily member 11	Homo sapiens	16-20
15613999-5	2005	RANK-L mRNA was isolated by using the guanidinium isothiocyanate acid phenol method.	guanidinium isothiocyanate acid phenol	38-76	TNF superfamily member 11	Homo sapiens	0-6
15613999-7	2005	RANK-L expression in each periapical sample was assessed by agarose gel electrophoresis.	Sepharose	60-67	TNF superfamily member 11	Homo sapiens	0-6
15601870-3	2005	The CCAAT box on the ODF gene is required for its transcriptional induction by vitamin D3, suggesting that NF-Y coregulates this promoter along with VDR.	Cholecalciferol	79-89	TNF superfamily member 11	Homo sapiens	21-24
15601870-5	2005	Stimulation with vitamin D3 facilitates the recruitment of VDR and p300 onto the ODF promoter, resulting in acetylation of histone H4 in an NF-Y-independent manner.	Cholecalciferol	17-27	TNF superfamily member 11	Homo sapiens	81-84
15601870-6	2005	ODF gene induction by parathyroid hormone or prostaglandin E is also dependent on NF-Y.	Prostaglandins E	45-60	TNF superfamily member 11	Homo sapiens	0-3
15530848-5	2004	Pretreatment of osteoclasts with the antioxidants N-acetyl-l-cystein and glutathione reduced RANKL-induced Akt, NF-kappaB, and ERK activation.	N-Acetyl-L-cysteine	50-68	TNF superfamily member 11	Homo sapiens	93-98
15530848-5	2004	Pretreatment of osteoclasts with the antioxidants N-acetyl-l-cystein and glutathione reduced RANKL-induced Akt, NF-kappaB, and ERK activation.	Glutathione	73-84	TNF superfamily member 11	Homo sapiens	93-98
15530848-9	2004	Taken together, our results suggest that ROS act as mediators in RANKL-induced signaling pathways and cellular events.	Reactive Oxygen Species	41-44	TNF superfamily member 11	Homo sapiens	65-70
15593184-9	2004	MTX, SSZ, infliximab, and IL-4 each inhibited the expression of RANKL in RA FLS in a dose-dependent manner, and also increased the secretion of OPG in RA FLS supernatants.	Sulfasalazine	5-8	TNF superfamily member 11	Homo sapiens	64-69
15593184-9	2004	MTX, SSZ, infliximab, and IL-4 each inhibited the expression of RANKL in RA FLS in a dose-dependent manner, and also increased the secretion of OPG in RA FLS supernatants.	Methotrexate	0-3	TNF superfamily member 11	Homo sapiens	64-69
15593184-10	2004	CONCLUSION: MTX, SSZ, infliximab, and IL-4 inhibit human osteoclastogenesis by modulating the interaction of RANKL, RANK, and OPG.	Methotrexate	12-15	TNF superfamily member 11	Homo sapiens	109-114
15605102-1	2004	OBJECTIVE: To study the expression of osteoprotegerin(OPG) and receptor activator nuclear factor kappa B ligand(RANKL) at protein level in human periodontal ligament cells (HPDLCs), and the effect of 1alpha,25(OH)(2) vitamin D(3) [1,25(OH)(2)vitD(3)] on the secretion of OPG protein in vitro.	Vitamin D	217-226	TNF superfamily member 11	Homo sapiens	112-117
16114553-0	2004	[Effect of nylestriol and levonorgestrel on the expression of Opg/OPGL in human osteosarcoma MG-63 cell lines].	Levonorgestrel	26-40	TNF superfamily member 11	Homo sapiens	66-70
16114553-0	2004	[Effect of nylestriol and levonorgestrel on the expression of Opg/OPGL in human osteosarcoma MG-63 cell lines].	nylestriol	11-21	TNF superfamily member 11	Homo sapiens	66-70
16114553-1	2004	OBJECTIVE: To determine the effect of nylestriol and levonorgestrel on mRNA expression of OPG/OPGL in MG-63 cell lines, and to explore whether the paracrine effect is involved in the regulation course.	nylestriol	38-48	TNF superfamily member 11	Homo sapiens	94-98
16114553-1	2004	OBJECTIVE: To determine the effect of nylestriol and levonorgestrel on mRNA expression of OPG/OPGL in MG-63 cell lines, and to explore whether the paracrine effect is involved in the regulation course.	Levonorgestrel	53-67	TNF superfamily member 11	Homo sapiens	94-98
16114553-2	2004	Methods Semi-quantitive RT-PCR was conducted to analyze mRNA expression of OPG/OPGL in MG-63 cell lines treated with nylestriol and levonorgestrel.	nylestriol	117-127	TNF superfamily member 11	Homo sapiens	79-83
16114553-2	2004	Methods Semi-quantitive RT-PCR was conducted to analyze mRNA expression of OPG/OPGL in MG-63 cell lines treated with nylestriol and levonorgestrel.	Levonorgestrel	132-146	TNF superfamily member 11	Homo sapiens	79-83
15389972-7	2004	Osteoclasts and osteoclast precursors from patients with Paget"s disease contain paramyxoviral transcripts and appear hyperresponsive to 1,25-(OH)2D3 and RANK ligand (RANKL).	Calcitriol	137-149	TNF superfamily member 11	Homo sapiens	167-172
15389974-4	2004	Infection with AdOPN-AS co-incident with exposure to RANKL was associated with substantial (approximately 50%) inhibition of osteoclast formation with a concomitant reduction in dentine resorption.	adopn	15-20	TNF superfamily member 11	Homo sapiens	53-58
15389974-6	2004	When the cultures were infected with AdOPN-AS after 4 days exposure to RANKL only minor effects on osteoclastogenesis were seen.	adopn-as	37-45	TNF superfamily member 11	Homo sapiens	71-76
15313187-0	2004	Vitamin A differentially regulates RANKL and OPG expression in human osteoblasts.	Vitamin A	0-9	TNF superfamily member 11	Homo sapiens	35-40
15476205-12	2004	CONCLUSION: This study provides the first evidence that novel RANKL polymorphisms were associated with an earlier age at RA onset in SE+, but not SE-, patients and that an interaction between SE-containing HLA-DRB1 and RANKL polymorphisms increased the disease penetrance, resulting in a mean age at RA onset that was 18-20 years younger.	Selenium	133-135	TNF superfamily member 11	Homo sapiens	62-67
15476205-12	2004	CONCLUSION: This study provides the first evidence that novel RANKL polymorphisms were associated with an earlier age at RA onset in SE+, but not SE-, patients and that an interaction between SE-containing HLA-DRB1 and RANKL polymorphisms increased the disease penetrance, resulting in a mean age at RA onset that was 18-20 years younger.	Selenium	133-135	TNF superfamily member 11	Homo sapiens	219-224
15363596-5	2004	Coumestrol decreased RANKL-induced formation of TRAP-positive multinucleated cells and TRAP activity dose-dependently.	Coumestrol	0-10	TNF superfamily member 11	Homo sapiens	21-26
15363596-6	2004	RANKL-stimulated RAW264.7-ERalpha cells formed resorption pits on calcium phosphate films and the pit formation was inhibited by coumestrol in a dose-dependent manner.	calcium phosphate	66-83	TNF superfamily member 11	Homo sapiens	0-5
15363596-6	2004	RANKL-stimulated RAW264.7-ERalpha cells formed resorption pits on calcium phosphate films and the pit formation was inhibited by coumestrol in a dose-dependent manner.	Coumestrol	129-139	TNF superfamily member 11	Homo sapiens	0-5
15363596-7	2004	RT-PCR analyses revealed that coumestrol (10 microM) decreased mRNA levels of calcitonin receptor (CTR) and matrix metalloproteinase-9 (MMP9) in RANKL-treated cells.	Coumestrol	30-40	TNF superfamily member 11	Homo sapiens	145-150
15363596-8	2004	In addition, pretreatment of coumestrol decreased RANKL-induced phosphorylation of extracellular signal-regulated kinases/p44/42 (ERK1/2).	Coumestrol	29-39	TNF superfamily member 11	Homo sapiens	50-55
15313187-6	2004	Thus, the RANKL/OPG ratio was markedly increased, suggesting a potential mechanism of ATRA-induced bone resorption.	Tretinoin	86-90	TNF superfamily member 11	Homo sapiens	10-15
15615494-4	2004	Skeletal estrogen agonists (including 17beta-estradiol, raloxifene, and genistein) induce osteoblastic OPG production through estrogen receptor-alpha activation in vitro, while immune cells appear to over-express RANKL in estrogen deficiency in vivo.	Estradiol	38-54	TNF superfamily member 11	Homo sapiens	213-218
15377473-9	2004	The presence of the RANK-Fc that blocks the RANK/RANKL interaction significantly inhibited HMCL-induced secretion of IL-6 and IL-11.	hmcl	91-95	TNF superfamily member 11	Homo sapiens	49-54
15615494-4	2004	Skeletal estrogen agonists (including 17beta-estradiol, raloxifene, and genistein) induce osteoblastic OPG production through estrogen receptor-alpha activation in vitro, while immune cells appear to over-express RANKL in estrogen deficiency in vivo.	Raloxifene Hydrochloride	56-66	TNF superfamily member 11	Homo sapiens	213-218
15615494-4	2004	Skeletal estrogen agonists (including 17beta-estradiol, raloxifene, and genistein) induce osteoblastic OPG production through estrogen receptor-alpha activation in vitro, while immune cells appear to over-express RANKL in estrogen deficiency in vivo.	Genistein	72-81	TNF superfamily member 11	Homo sapiens	213-218
15334457-9	2004	Up-regulation of RANKL by FGF-2 on RASFs was diminished by the removal of heparan sulfate with heparitinase.	Heparitin Sulfate	74-89	TNF superfamily member 11	Homo sapiens	17-22
14753746-0	2004	The nitrogen-containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activating TNF-alpha converting enzyme (TACE).	Nitrogen	4-12	TNF superfamily member 11	Homo sapiens	68-73
15268899-3	2004	In this report, we now show that non-antibiotic analogues of doxycycline (CMT-3) and minocycline (CMT-8) are potent inhibitors of osteoclastogenesis in vitro from human peripheral blood mononuclear cells (PBMC) stimulated with macrophage colony stimulating factor (MCSF) and receptor activator of NF-kappaB ligand (RANKL), through an action that is independent of osteoblast-osteoclast interactions.	Minocycline	85-96	TNF superfamily member 11	Homo sapiens	275-313
15268899-3	2004	In this report, we now show that non-antibiotic analogues of doxycycline (CMT-3) and minocycline (CMT-8) are potent inhibitors of osteoclastogenesis in vitro from human peripheral blood mononuclear cells (PBMC) stimulated with macrophage colony stimulating factor (MCSF) and receptor activator of NF-kappaB ligand (RANKL), through an action that is independent of osteoblast-osteoclast interactions.	Minocycline	85-96	TNF superfamily member 11	Homo sapiens	315-320
15268899-3	2004	In this report, we now show that non-antibiotic analogues of doxycycline (CMT-3) and minocycline (CMT-8) are potent inhibitors of osteoclastogenesis in vitro from human peripheral blood mononuclear cells (PBMC) stimulated with macrophage colony stimulating factor (MCSF) and receptor activator of NF-kappaB ligand (RANKL), through an action that is independent of osteoblast-osteoclast interactions.	cmt	98-101	TNF superfamily member 11	Homo sapiens	275-313
15268899-3	2004	In this report, we now show that non-antibiotic analogues of doxycycline (CMT-3) and minocycline (CMT-8) are potent inhibitors of osteoclastogenesis in vitro from human peripheral blood mononuclear cells (PBMC) stimulated with macrophage colony stimulating factor (MCSF) and receptor activator of NF-kappaB ligand (RANKL), through an action that is independent of osteoblast-osteoclast interactions.	cmt	98-101	TNF superfamily member 11	Homo sapiens	315-320
15174095-8	2004	Daidzein and estradiol increased osteoprotegerin and RANK-L secretion.	Estradiol	13-22	TNF superfamily member 11	Homo sapiens	53-59
15174095-10	2004	Daidzein and estradiol increased the membrane content of RANK-L and the nuclear content of runx2/Cbfa1.	daidzein	0-8	TNF superfamily member 11	Homo sapiens	57-63
15174095-10	2004	Daidzein and estradiol increased the membrane content of RANK-L and the nuclear content of runx2/Cbfa1.	Estradiol	13-22	TNF superfamily member 11	Homo sapiens	57-63
15275972-5	2004	The addition of the metalloprotease inhibitor KB-R8301 efficiently suppressed the release of sRANKL from activated T cells or RANKL-transfectants, and reciprocally enhanced the mRANKL expression.	KB R8301	46-54	TNF superfamily member 11	Homo sapiens	94-99
15260421-0	2004	Effects of polyethylene and TiAlV wear particles on expression of RANK, RANKL and OPG mRNA.	Polyethylene	11-23	TNF superfamily member 11	Homo sapiens	72-77
15260421-0	2004	Effects of polyethylene and TiAlV wear particles on expression of RANK, RANKL and OPG mRNA.	tialv	28-33	TNF superfamily member 11	Homo sapiens	72-77
15260421-3	2004	MATERIAL AND METHODS: We evaluated the effect of TiAIV and polyethylene particles on expression of RANK, RANKL and OPG mRNA.	Polyethylene	59-71	TNF superfamily member 11	Homo sapiens	105-110
15268899-3	2004	In this report, we now show that non-antibiotic analogues of doxycycline (CMT-3) and minocycline (CMT-8) are potent inhibitors of osteoclastogenesis in vitro from human peripheral blood mononuclear cells (PBMC) stimulated with macrophage colony stimulating factor (MCSF) and receptor activator of NF-kappaB ligand (RANKL), through an action that is independent of osteoblast-osteoclast interactions.	Doxycycline	61-72	TNF superfamily member 11	Homo sapiens	275-313
15268899-3	2004	In this report, we now show that non-antibiotic analogues of doxycycline (CMT-3) and minocycline (CMT-8) are potent inhibitors of osteoclastogenesis in vitro from human peripheral blood mononuclear cells (PBMC) stimulated with macrophage colony stimulating factor (MCSF) and receptor activator of NF-kappaB ligand (RANKL), through an action that is independent of osteoblast-osteoclast interactions.	Doxycycline	61-72	TNF superfamily member 11	Homo sapiens	315-320
15268899-3	2004	In this report, we now show that non-antibiotic analogues of doxycycline (CMT-3) and minocycline (CMT-8) are potent inhibitors of osteoclastogenesis in vitro from human peripheral blood mononuclear cells (PBMC) stimulated with macrophage colony stimulating factor (MCSF) and receptor activator of NF-kappaB ligand (RANKL), through an action that is independent of osteoblast-osteoclast interactions.	cmt	74-77	TNF superfamily member 11	Homo sapiens	275-313
15268899-3	2004	In this report, we now show that non-antibiotic analogues of doxycycline (CMT-3) and minocycline (CMT-8) are potent inhibitors of osteoclastogenesis in vitro from human peripheral blood mononuclear cells (PBMC) stimulated with macrophage colony stimulating factor (MCSF) and receptor activator of NF-kappaB ligand (RANKL), through an action that is independent of osteoblast-osteoclast interactions.	cmt	74-77	TNF superfamily member 11	Homo sapiens	315-320
15174095-8	2004	Daidzein and estradiol increased osteoprotegerin and RANK-L secretion.	daidzein	0-8	TNF superfamily member 11	Homo sapiens	53-59
15207766-13	2004	In conclusion, RANKL and OPG gene expression within the human bone microenvironment are influenced by PTH, as the ratio RANKL/OPG decreased upon PTX.	ptx	145-148	TNF superfamily member 11	Homo sapiens	15-20
15207766-13	2004	In conclusion, RANKL and OPG gene expression within the human bone microenvironment are influenced by PTH, as the ratio RANKL/OPG decreased upon PTX.	ptx	145-148	TNF superfamily member 11	Homo sapiens	120-125
15199293-6	2004	There is concomitant acid stimulation of prostaglandin production by osteoblasts, which acting in a paracrine manner increases synthesis of the osteoblastic receptor activator of nuclear factor kappa B ligand (RANKL).	Prostaglandins	41-54	TNF superfamily member 11	Homo sapiens	157-208
15199293-6	2004	There is concomitant acid stimulation of prostaglandin production by osteoblasts, which acting in a paracrine manner increases synthesis of the osteoblastic receptor activator of nuclear factor kappa B ligand (RANKL).	Prostaglandins	41-54	TNF superfamily member 11	Homo sapiens	210-215
15199293-8	2004	Both the regulation of RANKL and acid-induced calcium efflux from bone are mediated by prostaglandins.	Prostaglandins	87-101	TNF superfamily member 11	Homo sapiens	23-28
15254587-5	2004	In keeping with its antiresorptive properties, ritonavir impairs receptor activator of nuclear factor kappaB ligand-induced (RANKL-induced) activation of NF-kappaB and Akt signaling pathways, both critical to osteoclast formation and function.	Ritonavir	47-56	TNF superfamily member 11	Homo sapiens	125-130
15254587-6	2004	In particular, ritonavir is found to inhibit RANKL-induced Akt signaling by disrupting the recruitment of TNF receptor-associated factor 6/c-Src complex to lipid rafts.	Ritonavir	15-24	TNF superfamily member 11	Homo sapiens	45-50
14563699-0	2004	Nitric oxide regulates receptor activator of nuclear factor-kappaB ligand and osteoprotegerin expression in bone marrow stromal cells.	Nitric Oxide	0-12	TNF superfamily member 11	Homo sapiens	23-73
14563699-5	2004	Here, we show that treatment of ST-2 murine stromal cells with the NO donor sodium nitroprusside (100 microm) for 24 h inhibited 1,25 dihydroxyvitamin D(3)-induced RANKL mRNA to less than 33 +/- 7% of control level, whereas OPG mRNA increased to 204 +/- 19% of control.	Nitroprusside	76-96	TNF superfamily member 11	Homo sapiens	164-169
14563699-5	2004	Here, we show that treatment of ST-2 murine stromal cells with the NO donor sodium nitroprusside (100 microm) for 24 h inhibited 1,25 dihydroxyvitamin D(3)-induced RANKL mRNA to less than 33 +/- 7% of control level, whereas OPG mRNA increased to 204 +/- 19% of control.	Calcitriol	129-155	TNF superfamily member 11	Homo sapiens	164-169
14563699-8	2004	PTH-induced RANKL expression in primary stromal cells was inhibited by sodium nitroprusside, indicating that the NO effect did not require vitamin D.	Nitroprusside	71-91	TNF superfamily member 11	Homo sapiens	12-17
14743390-6	2004	Time courses showed differential activation patterns of transcription factors with early induction of FUSE binding protein 1 (FBP) and c-Jun, and later steady upregulation of NFATc1 and GABP by RANKL.	gabp	186-190	TNF superfamily member 11	Homo sapiens	194-199
15068113-0	2004	Regulatory effects of interleukin-1beta and prostaglandin E2 on expression of receptor activator of nuclear factor-kappaB ligand in human periodontal ligament cells.	Dinoprostone	44-60	TNF superfamily member 11	Homo sapiens	78-128
15068113-2	2004	We investigated the regulatory effects of interleukin-1beta (IL-1beta) and prostaglandin E2 (PGE2) on expression of RANKL in human periodontal ligament (HPDL) cells and the mechanisms involved in the PGE2 effect.	Dinoprostone	75-91	TNF superfamily member 11	Homo sapiens	116-121
15068113-2	2004	We investigated the regulatory effects of interleukin-1beta (IL-1beta) and prostaglandin E2 (PGE2) on expression of RANKL in human periodontal ligament (HPDL) cells and the mechanisms involved in the PGE2 effect.	Dinoprostone	93-97	TNF superfamily member 11	Homo sapiens	116-121
15068113-2	2004	We investigated the regulatory effects of interleukin-1beta (IL-1beta) and prostaglandin E2 (PGE2) on expression of RANKL in human periodontal ligament (HPDL) cells and the mechanisms involved in the PGE2 effect.	Dinoprostone	200-204	TNF superfamily member 11	Homo sapiens	116-121
15068113-8	2004	Endogenous PGE2 partially mediated the IL-1beta-induced RANKL mRNA expression.	Dinoprostone	11-15	TNF superfamily member 11	Homo sapiens	56-61
15068113-9	2004	Exogenously added PGE2 also stimulated RANKL expression at mRNA and protein levels in the cells.	Dinoprostone	18-22	TNF superfamily member 11	Homo sapiens	39-44
15068113-10	2004	The PGE2-stimulated RANKL expression was mediated by EP2/4 and cAMP-dependent PKA, while PKC was possibly involved in the PGE2 action.	Dinoprostone	4-8	TNF superfamily member 11	Homo sapiens	20-25
15068113-10	2004	The PGE2-stimulated RANKL expression was mediated by EP2/4 and cAMP-dependent PKA, while PKC was possibly involved in the PGE2 action.	Cyclic AMP	63-67	TNF superfamily member 11	Homo sapiens	20-25
15068113-11	2004	CONCLUSION: Human periodontal ligament cells activated with inflammatory factors such as IL-1beta and PGE2 may directly stimulate osteoclastogenesis through RANKL, which is stimulated to express by these factors.	Dinoprostone	102-106	TNF superfamily member 11	Homo sapiens	157-162
15320745-5	2004	Furthermore, vitamin K2 also inhibits the expression of the osteoclast differentiation factor (ODF)/RANK ligand, tartrate-resistant acid phosphatase activity, and mononuclear cell formation, and induces osteoclast apoptosis in vitro.	Vitamin K 2	13-23	TNF superfamily member 11	Homo sapiens	60-93
15320745-5	2004	Furthermore, vitamin K2 also inhibits the expression of the osteoclast differentiation factor (ODF)/RANK ligand, tartrate-resistant acid phosphatase activity, and mononuclear cell formation, and induces osteoclast apoptosis in vitro.	Vitamin K 2	13-23	TNF superfamily member 11	Homo sapiens	95-98
14715848-2	2004	By comparison with placebo, the soluble RANKL (sRANKL)/OPG ratio was lower in the genistein group (-69 +/- 7%; P &lt; 0.01 vs. placebo 81 +/- 24%) and in hormone replacement therapy-treated women (-11 +/- 2%; P &lt; 0.01 vs. placebo).	Genistein	82-91	TNF superfamily member 11	Homo sapiens	40-45
14753746-0	2004	The nitrogen-containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activating TNF-alpha converting enzyme (TACE).	Diphosphonates	24-38	TNF superfamily member 11	Homo sapiens	68-73
14753746-0	2004	The nitrogen-containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activating TNF-alpha converting enzyme (TACE).	Zoledronic Acid	40-55	TNF superfamily member 11	Homo sapiens	68-73
14753746-2	2004	Zoledronic acid inhibits osteoclast maturation indirectly by increasing OPG protein secretion and decreasing transmembrane RANKL expression in human osteoblasts.	Zoledronic Acid	0-15	TNF superfamily member 11	Homo sapiens	123-128
14753746-5	2004	MATERIALS AND METHODS: We examined the effect of the most potent nitrogen-containing BP available, zoledronic acid (ZOL), on the expression of RANKL and osteoprotegerin (OPG), critical factors in the regulation of OC formation and activation, in primary osteoblast (OB)-like cells derived from human bone, using flow cytometry, ELISA, semiquantitative reverse transcriptase-polymerase chain reaction (RT-PCR), in situ immunofluorescence staining, and Western blotting.	Nitrogen	65-73	TNF superfamily member 11	Homo sapiens	143-148
14753746-5	2004	MATERIALS AND METHODS: We examined the effect of the most potent nitrogen-containing BP available, zoledronic acid (ZOL), on the expression of RANKL and osteoprotegerin (OPG), critical factors in the regulation of OC formation and activation, in primary osteoblast (OB)-like cells derived from human bone, using flow cytometry, ELISA, semiquantitative reverse transcriptase-polymerase chain reaction (RT-PCR), in situ immunofluorescence staining, and Western blotting.	Diphosphonates	85-87	TNF superfamily member 11	Homo sapiens	143-148
14753746-5	2004	MATERIALS AND METHODS: We examined the effect of the most potent nitrogen-containing BP available, zoledronic acid (ZOL), on the expression of RANKL and osteoprotegerin (OPG), critical factors in the regulation of OC formation and activation, in primary osteoblast (OB)-like cells derived from human bone, using flow cytometry, ELISA, semiquantitative reverse transcriptase-polymerase chain reaction (RT-PCR), in situ immunofluorescence staining, and Western blotting.	Zoledronic Acid	99-114	TNF superfamily member 11	Homo sapiens	143-148
14753746-8	2004	In addition, the decreased transmembrane expression of RANKL could be partially reversed by a TACE inhibitor, TAPI-2.	TAPI-2	110-116	TNF superfamily member 11	Homo sapiens	55-60
15504568-8	2004	Vitamin D itself induce the formation of osteoclasts by increasing the expression of RANKL on marrow stromal cells.	Vitamin D	0-9	TNF superfamily member 11	Homo sapiens	85-90
15631341-8	2004	In whole group of patients iPTH, CAP, CIP but not CAP/CIP correlated negatively with OPGL and OPGL/OPG as well as positively with dialysis duration, OPG and AP.	ipth	27-31	TNF superfamily member 11	Homo sapiens	85-89
15631341-8	2004	In whole group of patients iPTH, CAP, CIP but not CAP/CIP correlated negatively with OPGL and OPGL/OPG as well as positively with dialysis duration, OPG and AP.	cap	33-36	TNF superfamily member 11	Homo sapiens	85-89
12944401-4	2003	Dexamethasone (Dex) at &lt;10(-8) M stimulated, but at &gt;10(-7) M depressed, receptor activator of NF-kappaB ligand (RANKL)-induced osteoclast formation synergistically with transforming growth factor-beta.	Dexamethasone	0-13	TNF superfamily member 11	Homo sapiens	79-117
14672344-11	2003	Four of the six mutations occurred in the cysteine-rich ligand-binding domain and are predicted to disrupt binding of OPG to RANKL.	Cysteine	42-50	TNF superfamily member 11	Homo sapiens	125-130
14672351-0	2003	12-O-tetradecanoylphorbol-13-acetate (TPA) inhibits osteoclastogenesis by suppressing RANKL-induced NF-kappaB activation.	Tetradecanoylphorbol Acetate	0-36	TNF superfamily member 11	Homo sapiens	86-91
14672351-0	2003	12-O-tetradecanoylphorbol-13-acetate (TPA) inhibits osteoclastogenesis by suppressing RANKL-induced NF-kappaB activation.	Tetradecanoylphorbol Acetate	38-41	TNF superfamily member 11	Homo sapiens	86-91
14672351-2	2003	Using a RAW(264.7) cell culture system and assays for NF-kappaB nuclear translocation, NF-kappaB reporter gene activity, and MAPK assays, we demonstrated that TPA inhibits osteoclastogenesis through the suppression of RANKL-induced NF-kappaB activation.	Tetradecanoylphorbol Acetate	159-162	TNF superfamily member 11	Homo sapiens	218-223
14672351-7	2003	Assays for NF-kappaB nuclear translocation, NF-kappaB reporter gene activity, protein kinase activity, and Western blotting were used to examine the effects of TPA on RANKL-induced NF-kappaB, c-Jun N-terminal kinase (JNK), and MEK/ERK and p38 signal transduction pathways.	Tetradecanoylphorbol Acetate	160-163	TNF superfamily member 11	Homo sapiens	167-172
14672351-8	2003	RESULTS: We found that TPA inhibited RANKL-induced RAW(264.7) cell differentiation into osteoclasts in a dose-dependent manner.	Tetradecanoylphorbol Acetate	23-26	TNF superfamily member 11	Homo sapiens	37-42
14672351-9	2003	Time course analysis showed that the inhibitory effect of TPA on RANKL-induced osteoclastogenesis occurs predominantly at an early stage of osteoclast differentiation.	Tetradecanoylphorbol Acetate	58-61	TNF superfamily member 11	Homo sapiens	65-70
14672351-10	2003	TPA alone had little effect on NF-kappaB activation in RAW(264.7) cells, but it suppresses the RANKL-induced NF-kappaB activation in a dose-dependent fashion.	Tetradecanoylphorbol Acetate	0-3	TNF superfamily member 11	Homo sapiens	95-100
14672351-11	2003	Interestingly, the suppressive effect of TPA on RANKL-induced NF-kappaB activation was prevented by a conventional PKC inhibitor, Go6976.	Tetradecanoylphorbol Acetate	41-44	TNF superfamily member 11	Homo sapiens	48-53
14672351-11	2003	Interestingly, the suppressive effect of TPA on RANKL-induced NF-kappaB activation was prevented by a conventional PKC inhibitor, Go6976.	Go 6976	130-136	TNF superfamily member 11	Homo sapiens	48-53
14672351-14	2003	TPA also inhibited RANKL-induced activation of ERK but had little effect on p38 activation.	Tetradecanoylphorbol Acetate	0-3	TNF superfamily member 11	Homo sapiens	19-24
14672351-15	2003	CONCLUSION: Given that NF-kappaB activation is obligatory for osteoclast differentiation, our studies imply that inhibition of osteoclastogenesis by TPA is, at least in part, caused by the suppression of RANKL-induced activation of NF-kappaB during an early stage of osteoclastogenesis.	Tetradecanoylphorbol Acetate	149-152	TNF superfamily member 11	Homo sapiens	204-209
12975380-4	2003	Using a murine osteoclast precursor cell line as well as primary human osteoclast precursors, we demonstrate that pharmacologic levels of two PIs that are linked clinically to osteopenia, ritonavir and saquinavir, abrogate a physiological block to RANKL activity, interferon-gamma-mediated degradation of the RANKL signaling adapter protein, TRAF6 (tumor necrosis factor receptor-associated protein 6) in proteasomes.	Monothiopyrophosphoric acid	142-145	TNF superfamily member 11	Homo sapiens	248-253
12975380-4	2003	Using a murine osteoclast precursor cell line as well as primary human osteoclast precursors, we demonstrate that pharmacologic levels of two PIs that are linked clinically to osteopenia, ritonavir and saquinavir, abrogate a physiological block to RANKL activity, interferon-gamma-mediated degradation of the RANKL signaling adapter protein, TRAF6 (tumor necrosis factor receptor-associated protein 6) in proteasomes.	Monothiopyrophosphoric acid	142-145	TNF superfamily member 11	Homo sapiens	309-314
12975380-4	2003	Using a murine osteoclast precursor cell line as well as primary human osteoclast precursors, we demonstrate that pharmacologic levels of two PIs that are linked clinically to osteopenia, ritonavir and saquinavir, abrogate a physiological block to RANKL activity, interferon-gamma-mediated degradation of the RANKL signaling adapter protein, TRAF6 (tumor necrosis factor receptor-associated protein 6) in proteasomes.	Saquinavir	202-212	TNF superfamily member 11	Homo sapiens	248-253
12975380-4	2003	Using a murine osteoclast precursor cell line as well as primary human osteoclast precursors, we demonstrate that pharmacologic levels of two PIs that are linked clinically to osteopenia, ritonavir and saquinavir, abrogate a physiological block to RANKL activity, interferon-gamma-mediated degradation of the RANKL signaling adapter protein, TRAF6 (tumor necrosis factor receptor-associated protein 6) in proteasomes.	Saquinavir	202-212	TNF superfamily member 11	Homo sapiens	309-314
12954625-5	2003	3) Up-regulation of ICAM-1 and RANKL on osteoblasts by beta1 stimulation was completely abrogated by pretreatment with herbimycin A and genistein, tyrosine kinase inhibitors, or transfection of dominant negative truncations of focal adhesion kinase (FAK).	herbimycin	119-131	TNF superfamily member 11	Homo sapiens	31-36
12954625-5	2003	3) Up-regulation of ICAM-1 and RANKL on osteoblasts by beta1 stimulation was completely abrogated by pretreatment with herbimycin A and genistein, tyrosine kinase inhibitors, or transfection of dominant negative truncations of focal adhesion kinase (FAK).	Genistein	136-145	TNF superfamily member 11	Homo sapiens	31-36
12944401-4	2003	Dexamethasone (Dex) at &lt;10(-8) M stimulated, but at &gt;10(-7) M depressed, receptor activator of NF-kappaB ligand (RANKL)-induced osteoclast formation synergistically with transforming growth factor-beta.	Dexamethasone	0-13	TNF superfamily member 11	Homo sapiens	119-124
12944401-8	2003	On the other hand, Dex significantly decreased the endogenous production of interferon-beta, and this cytokine depressed the RANKL-elicited DNA binding of NF-kappaB and AP-1, as well as osteoclast formation.	Dexamethasone	19-22	TNF superfamily member 11	Homo sapiens	125-130
15971575-5	2003	RANK is also expressed on mammary epithelial cells and RANKL expression in these cells is induced by pregnancy hormones, RANKL and RANK are essential for the formation of the lactating mammary gland and the transmission of maternal calcium to neonates in mammalian species.	Calcium	232-239	TNF superfamily member 11	Homo sapiens	55-60
14500543-6	2003	The RANKL-induced survival appeared to be dependent on PI 3"-kinase activity, because wortmannin and LY294002, PI 3"-kinase-specific inhibitors, blocked the RANKL-induced survival effect.	Wortmannin	86-96	TNF superfamily member 11	Homo sapiens	4-9
14500543-6	2003	The RANKL-induced survival appeared to be dependent on PI 3"-kinase activity, because wortmannin and LY294002, PI 3"-kinase-specific inhibitors, blocked the RANKL-induced survival effect.	Wortmannin	86-96	TNF superfamily member 11	Homo sapiens	157-162
14500543-6	2003	The RANKL-induced survival appeared to be dependent on PI 3"-kinase activity, because wortmannin and LY294002, PI 3"-kinase-specific inhibitors, blocked the RANKL-induced survival effect.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	101-109	TNF superfamily member 11	Homo sapiens	4-9
14500543-6	2003	The RANKL-induced survival appeared to be dependent on PI 3"-kinase activity, because wortmannin and LY294002, PI 3"-kinase-specific inhibitors, blocked the RANKL-induced survival effect.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	101-109	TNF superfamily member 11	Homo sapiens	157-162
15971575-5	2003	RANK is also expressed on mammary epithelial cells and RANKL expression in these cells is induced by pregnancy hormones, RANKL and RANK are essential for the formation of the lactating mammary gland and the transmission of maternal calcium to neonates in mammalian species.	Calcium	232-239	TNF superfamily member 11	Homo sapiens	121-126
12633785-7	2003	Osteoblasts treated with estradiol demonstrated increased RANKL protein expression at 24 h (P &lt; 0.05), but this was not maintained at 48 h. ERalpha expression was significantly increased by high-dose estradiol (P &lt; 0.01) at 24 h and dose-dependently increased at 48 h (P &lt; 0.01), while ERbeta was only increased at 24 h (P &lt; 0.01).	Estradiol	25-34	TNF superfamily member 11	Homo sapiens	58-63
14506958-7	2003	The number of tartrate-resistant acid phosphatase (TRAP)-positive multinucleated cells (MNCs) and the percentage area of lacunar resorption induced by RANKL and M-CSF were decreased when menatetrenone or geranylgeraniol was added to the cultures.	menatetrenone	187-200	TNF superfamily member 11	Homo sapiens	151-156
12858342-0	2003	Vitamin D3 supports osteoclastogenesis via functional vitamin D response element of human RANKL gene promoter.	Cholecalciferol	0-10	TNF superfamily member 11	Homo sapiens	90-95
12858342-0	2003	Vitamin D3 supports osteoclastogenesis via functional vitamin D response element of human RANKL gene promoter.	Vitamin D	54-63	TNF superfamily member 11	Homo sapiens	90-95
12858342-5	2003	Both electrophoresis mobility shift assay (EMSA) and transfection studies demonstrated that 1alpha,25(OH)(2)D(3) activated human RANKL promoter through vitamin D responsive elements (VDRE) located at -1584/-1570 by binding VDR and RXRalpha heterodimers in a ligand-dependent manner.	Vitamin D	152-161	TNF superfamily member 11	Homo sapiens	129-134
12817763-12	2003	Regression analysis showed that RANKL mRNA expression was associated negatively with the percentage of cells expressing AP (p &lt; 0.01) in vitD3- and dexamethasone-treated NHBCs.	Dexamethasone	151-164	TNF superfamily member 11	Homo sapiens	32-37
12702561-8	2003	However, doxorubicin-induced apoptosis was increased &gt;2-fold when exogenous RANKL was added.	Doxorubicin	9-20	TNF superfamily member 11	Homo sapiens	79-84
12702561-9	2003	Therefore, RANKL is necessary but not sufficient to account for early doxorubicin-induced apoptosis in CEM cells.	Doxorubicin	70-81	TNF superfamily member 11	Homo sapiens	11-16
12702561-10	2003	This finding suggests improved chemotherapeutic efficiency of the anthracyclin against susceptible malignant cells in the presence with RANKL.	anthracyclin	66-78	TNF superfamily member 11	Homo sapiens	136-141
12697741-2	2003	Thus, we isolated bone marrow mononuclear cells expressing RANKL on their surfaces by two-color flow cytometry using FITC-conjugated osteoprotegerin-Fc (OPG-Fc-FITC) as a probe.	Fluorescein-5-isothiocyanate	117-121	TNF superfamily member 11	Homo sapiens	59-64
12697741-5	2003	Moreover, in the merged groups, RANKL expression per cell correlated directly with the bone resorption markers, serum C-terminal telopeptide of type I collagen and urine N-telopeptide of type I collagen, in all three cell types and inversely with serum 17beta-estradiol for total RANKL-expressing cells.	Estradiol	253-269	TNF superfamily member 11	Homo sapiens	32-37
12630919-10	2003	Moreover, both types of vitamin K treatment decreased the expression of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor (RANKL/ODF) and enhanced the expression of osteoprotegerin/osteoclast inhibitory factor (OPG/OCIF) in the stromal cells.	Vitamin K	24-33	TNF superfamily member 11	Homo sapiens	158-163
12630919-10	2003	Moreover, both types of vitamin K treatment decreased the expression of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor (RANKL/ODF) and enhanced the expression of osteoprotegerin/osteoclast inhibitory factor (OPG/OCIF) in the stromal cells.	Vitamin K	24-33	TNF superfamily member 11	Homo sapiens	164-167
12630919-12	2003	Vitamin K might stimulate osteoblastogenesis in bone marrow cells, regulating osteoclastogenesis through the expression of RANKL/ODF more than through that of OPG/OCIF.	Vitamin K	0-9	TNF superfamily member 11	Homo sapiens	123-128
12630919-12	2003	Vitamin K might stimulate osteoblastogenesis in bone marrow cells, regulating osteoclastogenesis through the expression of RANKL/ODF more than through that of OPG/OCIF.	Vitamin K	0-9	TNF superfamily member 11	Homo sapiens	129-132
12887401-4	2003	The effect of RANKL on root resorbing activity of odontoclasts was evaluated by measuring the size of dissolved area on calcium phosphate-coated coverslips.	calcium phosphate	120-137	TNF superfamily member 11	Homo sapiens	14-19
12732166-4	2003	In this review, we provide an overview of the RANK/RANKL/osteoprotegerin system; we describe its interaction with other cellular mechanisms, through which malignant plasma cells drive osteolysis, and explain how bisphosphonates can be used to block this action.	Diphosphonates	212-227	TNF superfamily member 11	Homo sapiens	51-56
12633785-7	2003	Osteoblasts treated with estradiol demonstrated increased RANKL protein expression at 24 h (P &lt; 0.05), but this was not maintained at 48 h. ERalpha expression was significantly increased by high-dose estradiol (P &lt; 0.01) at 24 h and dose-dependently increased at 48 h (P &lt; 0.01), while ERbeta was only increased at 24 h (P &lt; 0.01).	Estradiol	203-212	TNF superfamily member 11	Homo sapiens	58-63
12633785-8	2003	The estrogen-induced protein expression of ER, OPG, and RANKL was abrogated when cells were cultured in the presence of the estrogen antagonist ICI 182780.	Fulvestrant	144-154	TNF superfamily member 11	Homo sapiens	56-61
12469211-9	2003	To determine the localization of RANKL gene transcripts in gingival tissue at the cellular level, in situ hybridization was performed using digoxigenin-labeled specific riboprobes.	Digoxigenin	140-151	TNF superfamily member 11	Homo sapiens	33-38
12364326-8	2002	CREB activity was also required for full stimulation of RANKL by oncostatin M or 1,25-dihydroxyvitamin D(3).	1,25-dihydroxyvitamin D	81-104	TNF superfamily member 11	Homo sapiens	56-61
12393684-4	2002	In addition, either anti-interleukin 6 (anti-IL-6) or anti-IL-7 antibody inhibited HMCL-induced RANKL overexpression.	hmcl	83-87	TNF superfamily member 11	Homo sapiens	96-101
12162499-3	2002	In experiments here, application of 1.8% equibiaxial strain for 6 h reduced vitamin D-stimulated RANKL mRNA expression by nearly one-half in primary bone stromal cells.	Vitamin D	76-85	TNF superfamily member 11	Homo sapiens	97-102
12477572-9	2002	These results significantly advance our understanding of the role of P2 receptors in bone, and indicate that local-acting ATP may play a pivotal role in osteoclast activation at bone-resorbing sites by inducing elevated expression of RANKL.	Adenosine Triphosphate	122-125	TNF superfamily member 11	Homo sapiens	234-239
12162499-5	2002	Adding the ERK1/2 inhibitor PD98059 30 minutes before strain delivery prevented the strain effect on RANKL mRNA expression, suggesting that activation of ERK1/2 was required for transduction of the mechanical force.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	28-35	TNF superfamily member 11	Homo sapiens	101-106
12013183-3	2002	The aim of the study was to investigate if polymethylmethacrylate-based cements are able to modulate the expression of OPG-L/OPG in MG63 cells, which are known to have high levels of OPG and inducible expression of OPG-L.	Polymethyl Methacrylate	43-65	TNF superfamily member 11	Homo sapiens	119-124
12043011-3	2002	It was the aim of this study to examine the sites of expression of RANKL and RANK in the corresponding cells of human dental hard and periodontal tissues using immunohistochemical light microscopical methods on tissue sections of 15 paraffin-embedded human deciduous teeth undergoing root resorption.	Paraffin	233-241	TNF superfamily member 11	Homo sapiens	67-72
12013183-3	2002	The aim of the study was to investigate if polymethylmethacrylate-based cements are able to modulate the expression of OPG-L/OPG in MG63 cells, which are known to have high levels of OPG and inducible expression of OPG-L.	Polymethyl Methacrylate	43-65	TNF superfamily member 11	Homo sapiens	215-220
11193242-5	2000	Many of the calciotropic hormones and cytokines, including 1,25(OH)2D3, PTH, PGE2 and IL-11, appear to act through a dual capacity to inhibit production of OPG and stimulate production of RANKL.	Calcitriol	59-70	TNF superfamily member 11	Homo sapiens	188-193
11827970-0	2002	8-Isoprostaglandin E2 enhances receptor-activated NFkappa B ligand (RANKL)-dependent osteoclastic potential of marrow hematopoietic precursors via the cAMP pathway.	8-isoprostaglandin E2	0-21	TNF superfamily member 11	Homo sapiens	68-73
11827970-0	2002	8-Isoprostaglandin E2 enhances receptor-activated NFkappa B ligand (RANKL)-dependent osteoclastic potential of marrow hematopoietic precursors via the cAMP pathway.	Cyclic AMP	151-155	TNF superfamily member 11	Homo sapiens	68-73
11863217-6	2002	Our results suggest that RANKL expression may have a role in the pathogenesis of GCTBs and in the formation of the large OC population present in these tumors.	gctbs	81-86	TNF superfamily member 11	Homo sapiens	25-30
11811551-0	2002	Periodontal ligament cells under mechanical stress induce osteoclastogenesis by receptor activator of nuclear factor kappaB ligand up-regulation via prostaglandin E2 synthesis.	Dinoprostone	149-165	TNF superfamily member 11	Homo sapiens	80-130
11811551-9	2002	In addition, cyclo-oxygenase 2 (COX-2) mRNA expression was induced by compressive force, and indomethacin inhibited the RANKL up-regulation resulting from compressive force.	Indomethacin	93-105	TNF superfamily member 11	Homo sapiens	120-125
11811551-11	2002	Exogenous PGE2 treatment increased RANKL mRNA expression in PDL cells.	Dinoprostone	10-14	TNF superfamily member 11	Homo sapiens	35-40
11811551-14	2002	Furthermore, RANKL up-regulation in mechanically stressed PDL cells was dependent on PGE2.	Dinoprostone	85-89	TNF superfamily member 11	Homo sapiens	13-18
11742876-6	2001	In advanced calcified lesions, OPG was present in bone structures, whereas OPGL was only present in the extracellular matrix surrounding calcium deposits.	Calcium	137-144	TNF superfamily member 11	Homo sapiens	75-79
11278735-6	2001	One of the TRANCE sheddases is induced by the tyrosine phosphatase inhibitor pervanadate but not by phorbol esters, whereas the other is refractory to both of these stimuli.	pervanadate	77-88	TNF superfamily member 11	Homo sapiens	11-17
11278735-6	2001	One of the TRANCE sheddases is induced by the tyrosine phosphatase inhibitor pervanadate but not by phorbol esters, whereas the other is refractory to both of these stimuli.	Phorbol Esters	100-114	TNF superfamily member 11	Homo sapiens	11-17
11160247-8	2001	Activation-induced RANKL expression is blocked by cyclosporin A, but not by dexamethasone.	Cyclosporine	50-63	TNF superfamily member 11	Homo sapiens	19-24
11123302-6	2001	The enhanced secretion of IFN-gamma mediated via TRANCE correlates with the activation of p38 mitogen-activated protein kinase and is blocked by SB203580, a p38 mitogen-activated protein kinase-specific inhibitor.	SB 203580	145-153	TNF superfamily member 11	Homo sapiens	49-55
10934644-5	2000	Stimulation by 1 alpha,25 dihydroxyvitamin D3 [1,25(OH)2D3] plus dexamethasone (Dex) augmented RANKL and diminished OPG mRNA expression in fibroblastic cells and caused the formation of numerous osteoclasts in cocultures of skin fibroblastic cells with hemopoietic cells or monocytes.	Calcitriol	15-45	TNF superfamily member 11	Homo sapiens	95-100
10934644-5	2000	Stimulation by 1 alpha,25 dihydroxyvitamin D3 [1,25(OH)2D3] plus dexamethasone (Dex) augmented RANKL and diminished OPG mRNA expression in fibroblastic cells and caused the formation of numerous osteoclasts in cocultures of skin fibroblastic cells with hemopoietic cells or monocytes.	Calcitriol	47-58	TNF superfamily member 11	Homo sapiens	95-100
10934644-5	2000	Stimulation by 1 alpha,25 dihydroxyvitamin D3 [1,25(OH)2D3] plus dexamethasone (Dex) augmented RANKL and diminished OPG mRNA expression in fibroblastic cells and caused the formation of numerous osteoclasts in cocultures of skin fibroblastic cells with hemopoietic cells or monocytes.	Dexamethasone	65-78	TNF superfamily member 11	Homo sapiens	95-100
10934644-5	2000	Stimulation by 1 alpha,25 dihydroxyvitamin D3 [1,25(OH)2D3] plus dexamethasone (Dex) augmented RANKL and diminished OPG mRNA expression in fibroblastic cells and caused the formation of numerous osteoclasts in cocultures of skin fibroblastic cells with hemopoietic cells or monocytes.	Dexamethasone	80-83	TNF superfamily member 11	Homo sapiens	95-100
19002827-6	2000	Both RANKL- andIL-1beta-induced OCL formation from pOCs wasinhibited by ZLLL-H, a peptide inhibitor ofproteasome.	benzyloxycarbonylleucyl-leucyl-leucine aldehyde	72-78	TNF superfamily member 11	Homo sapiens	5-10
10852823-6	2000	OCL formed in TRANCE also showed more rapid apoptosis than OCL in TRANCE plus TGF(beta).	ocl	0-3	TNF superfamily member 11	Homo sapiens	14-20
10852823-6	2000	OCL formed in TRANCE also showed more rapid apoptosis than OCL in TRANCE plus TGF(beta).	ocl	59-62	TNF superfamily member 11	Homo sapiens	66-72
10852823-7	2000	Like TGF(beta), incubation on bone matrix prolonged and enhanced the sensitivity of precursors to OCL-induction by TRANCE, and this was reversed by TGF(beta)sRII.	ocl	98-101	TNF superfamily member 11	Homo sapiens	115-121
10652202-3	2000	Moreover, OCL formation in RANKL was virtually abolished by soluble type II A activin receptors (ActR-II(A)), suggesting that activin A is essential for OCL formation.	ocl	10-13	TNF superfamily member 11	Homo sapiens	27-32
10652202-3	2000	Moreover, OCL formation in RANKL was virtually abolished by soluble type II A activin receptors (ActR-II(A)), suggesting that activin A is essential for OCL formation.	ocl	153-156	TNF superfamily member 11	Homo sapiens	27-32
10652202-4	2000	Activin A was most effective when precursors were exposed to RANKL and activin A simultaneously: resistance to OCL-induction that occurs when precursors are pre-incubated in M-CSF was reduced.	ocl	111-114	TNF superfamily member 11	Homo sapiens	61-66
11741951-9	2002	Furthermore, these inhibitors and the Ca(2+) chelator BAPTA-AM suppressed TRANCE-induced HUVEC migration.	1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester	54-62	TNF superfamily member 11	Homo sapiens	74-80
12210731-8	2002	Conditioned medium harvested from IL-1beta-treated XTC (containing high concentrations of OPG) inhibited RANKL-induced CD40 upregulation and cluster formation of DC.	N-Methyl-3,4-methylenedioxyamphetamine	51-54	TNF superfamily member 11	Homo sapiens	105-110
11592959-4	2001	We found that D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol (D-PDMP), a glucosylceramide synthase inhibitor, completely inhibits the osteoclast formation induced by macrophage-colony-stimulating factor and receptor activator of nuclear factor-kappa B ligand (RANKL) in a dose-dependent manner.	RV 538	14-70	TNF superfamily member 11	Homo sapiens	270-275
11592959-4	2001	We found that D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol (D-PDMP), a glucosylceramide synthase inhibitor, completely inhibits the osteoclast formation induced by macrophage-colony-stimulating factor and receptor activator of nuclear factor-kappa B ligand (RANKL) in a dose-dependent manner.	RV 538	72-78	TNF superfamily member 11	Homo sapiens	270-275
11592959-5	2001	Expression of RANK, the receptor of RANKL, induced by macrophage colony-stimulating factor, was reduced markedly in D-PDMP-treated cells.	RV 538	116-122	TNF superfamily member 11	Homo sapiens	36-41
11592959-6	2001	d-PDMP also inhibited the phosphorylation of the inhibitor of nuclear factor-kappa B and extracellular signal-regulated kinase 1/2 induced by RANKL.	d-pdmp	0-6	TNF superfamily member 11	Homo sapiens	142-147
11683411-6	2001	RANKL-ODF treatment reinforced the peripheral location of podosomes and initiated their partial fusion to larger F-actin-containing structures that displayed reduced levels of tyrosine phosphorylation.	Tyrosine	176-184	TNF superfamily member 11	Homo sapiens	0-5
11683411-6	2001	RANKL-ODF treatment reinforced the peripheral location of podosomes and initiated their partial fusion to larger F-actin-containing structures that displayed reduced levels of tyrosine phosphorylation.	Tyrosine	176-184	TNF superfamily member 11	Homo sapiens	6-9
11476953-5	2001	The stimulation of osteoclastogenesis by dexamethasone was coincident with the up-regulation of receptor activator of NF-kappaB ligand (RANKL) but down-regulation of osteoprotegerin (OPG) gene expression in stromal-like tumour cells.	Dexamethasone	41-54	TNF superfamily member 11	Homo sapiens	96-134
11476953-5	2001	The stimulation of osteoclastogenesis by dexamethasone was coincident with the up-regulation of receptor activator of NF-kappaB ligand (RANKL) but down-regulation of osteoprotegerin (OPG) gene expression in stromal-like tumour cells.	Dexamethasone	41-54	TNF superfamily member 11	Homo sapiens	136-141
11274143-7	2001	Furthermore, paraffin sections of human osteoporotic fractured bone exhibited increased RANKL immunostaining in vivo on VEC located near resorbing OCs in regions undergoing active bone turnover.	Paraffin	13-21	TNF superfamily member 11	Homo sapiens	88-93
11182380-6	2001	A function-blocking antibody to OPG and soluble human OPGL both inhibited the effect of indomethacin, leaving active osteoclasts on the bone.	Indomethacin	88-100	TNF superfamily member 11	Homo sapiens	54-58
10913332-7	2000	Recombinant human osteoprotegerin (OPG), which binds strongly to OPGL, inhibited this translocation of osteoclasts that occurred with PGE(2) and 1,25D(3), leaving integrin beta-3-negative osteoclasts on the periosteum.	Prostaglandins E	134-137	TNF superfamily member 11	Homo sapiens	65-69
10693864-8	2000	Cultured rheumatoid synovial fibroblasts efficiently induced osteoclastogenesis in the presence of 1,25(OH)2D3, which was accompanied by up-regulated expression of RANKL/ODF and decreased production of OPG/OCIF.	Calcitriol	99-110	TNF superfamily member 11	Homo sapiens	164-169
10693864-8	2000	Cultured rheumatoid synovial fibroblasts efficiently induced osteoclastogenesis in the presence of 1,25(OH)2D3, which was accompanied by up-regulated expression of RANKL/ODF and decreased production of OPG/OCIF.	Calcitriol	99-110	TNF superfamily member 11	Homo sapiens	170-173
11193242-5	2000	Many of the calciotropic hormones and cytokines, including 1,25(OH)2D3, PTH, PGE2 and IL-11, appear to act through a dual capacity to inhibit production of OPG and stimulate production of RANKL.	Dinoprostone	77-81	TNF superfamily member 11	Homo sapiens	188-193
10208850-4	1999	The present study reports that OCL formation-supporting cell line ST2 showed a greatly increased level of ODF mRNA, whereas their OCIF mRNA was drastically diminished in the presence of 1alpha, 25(OH)2-dihydroxyvitamin D3 or prostaglandin E2.	ocl	31-34	TNF superfamily member 11	Homo sapiens	106-109
10606741-5	1999	Treatment of osteoclasts with soluble RANKL resulted in translocation of NF-kappaB to the nucleus and elevation of cytosolic and nuclear calcium levels.	Calcium	137-144	TNF superfamily member 11	Homo sapiens	38-43
10380891-3	1999	Furthermore, TRANCE is expressed on osteoblasts stimulated with vitamin D3, dexamethasone, and parathyroid hormone.	Cholecalciferol	64-74	TNF superfamily member 11	Homo sapiens	13-19
10380891-3	1999	Furthermore, TRANCE is expressed on osteoblasts stimulated with vitamin D3, dexamethasone, and parathyroid hormone.	Dexamethasone	76-89	TNF superfamily member 11	Homo sapiens	13-19
10334922-9	1999	Addition of NS-398 inhibited the expression of the ODF gene in osteoblast-like cells treated with BMP-2 and IL-1alpha.	N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide	12-18	TNF superfamily member 11	Homo sapiens	51-54
10208850-8	1999	These findings indicate that reciprocal gene expression of ODF and OCIF in osteoblasts/stromal cells is essential for supporting OCL formation.	ocl	129-132	TNF superfamily member 11	Homo sapiens	59-62
10098533-10	1999	Thus, PGE2 appears to stimulate bone resorption through a direct effect on hemopoietic precursors, primarily through a synergistic effect on the ability of TRANCE to induce osteoclastic differentiation.	Dinoprostone	6-10	TNF superfamily member 11	Homo sapiens	156-162
9600092-5	1998	Treatment of human PBMCs with sODF together with M-CSF induced OCLs, which expressed tartrate-resistant acid phosphatase and vitronectin receptors, produced cAMP in response to calcitonin, and formed resorption pits on dentine slices.	Cyclic AMP	157-161	TNF superfamily member 11	Homo sapiens	30-34
10022507-4	1999	OPGL (2-50 ng/ml), in combination with CSF-1, hydrocortisone (HC), and 1,25(OH)2D3, increases the size of osteoclast-like cells on bone, as defined by the acquisition of osteoclast markers: vitronectin receptor (VR), tartrate-resistant acid phosphatase (TRAP), multinuclearity, and bone resorption.	Hydrocortisone	46-60	TNF superfamily member 11	Homo sapiens	0-4
9794488-3	1998	Each osteotropic agent, either 1,25-(OH)2D3, PTH or IL-11, promoted an increase in the ratio of ODF:OPG, with maximal stimulation occurring at 24 h, 4 h, and 8 h, respectively, and furthermore each was shown to act in a dose-dependent manner.	Calcitriol	31-43	TNF superfamily member 11	Homo sapiens	96-99
34963515-0	2022	Corrigendum to Acacetin inhibits RANKL-induced osteoclastogenesis and LPS-induced bone loss by modulating NFATc1 transcription.	acacetin	15-23	TNF superfamily member 11	Homo sapiens	33-38
32858297-7	2021	Cd exposure also upregulated the OPG/RANKL ratio in vivo and in vitro, further inhibiting osteoclast differentiation.	Cadmium	0-2	TNF superfamily member 11	Homo sapiens	37-42
32858297-8	2021	These results demonstrate that Cd causes osteoporosis in duck by inhibiting P2X7/PI3K/AKT signaling and increasing the OPG/RANKL ratio.	Cadmium	31-33	TNF superfamily member 11	Homo sapiens	123-128
33033302-3	2020	The impact of M-CSF and RANKL in the common OC co-culture was assessed for OB, FB and OK via MTT assay via DAPI control.	oc	44-46	TNF superfamily member 11	Homo sapiens	24-29
25055746-11	2015	Zoledronate increased gene expression of RANKL (4-fold).	Zoledronic Acid	0-11	TNF superfamily member 11	Homo sapiens	41-46
25055746-13	2015	TS of 10 % in combination amplified increase of RANKL ending up with a 9-fold gene expression by clodronate and high RANKL protein synthesis.	Clodronic Acid	97-107	TNF superfamily member 11	Homo sapiens	48-53
25055746-14	2015	CONCLUSIONS: This study shows for the first time that mechanical loading alters the effects of bisphosphonates on viability, apoptosis rate, and OPG/RANKL system of HPdLF dependent on the applied strength.	Diphosphonates	95-110	TNF superfamily member 11	Homo sapiens	149-154
33815591-0	2021	Long non-coding RNA receptor activator of nuclear factor-kappa B ligand promotes cisplatin resistance in non-small cell lung cancer cells.	Cisplatin	81-90	TNF superfamily member 11	Homo sapiens	20-71
33773583-0	2021	OPG/RANKL/RANK gene methylation among alcohol-induced femoral head necrosis in northern Chinese men.	Alcohols	38-45	TNF superfamily member 11	Homo sapiens	4-9
33773583-6	2021	The EpiTYPER of the Sequenom MassARRAY platform was used to detect the DNA methylation status of 132 cytosine-phosphate-guanine (CpG) sites in the OPG/RANKL/RANK gene promoter region.	cytosine-phosphate-guanine	101-127	TNF superfamily member 11	Homo sapiens	151-156
33773583-9	2021	Receiver operator characteristic (ROC) curve analysis demonstrated the methylation levels of OPG/RANKL/RANK could efficiently predict the existence of alcohol-induced ONFH.	Alcohols	151-158	TNF superfamily member 11	Homo sapiens	97-102
33773583-10	2021	CONCLUSION: Our study of Chinese men suggests that several CpG sites in the OPG/RANKL/RANK gene in peripheral blood leukocytes of patients with alcohol-induced ONFH are in an abnormal methylation state (hypermethylation tended to be more frequent).	Alcohols	144-151	TNF superfamily member 11	Homo sapiens	80-85
34906775-8	2022	Furthermore, FGF19 might enhance osteogenic differentiation via the Wnt/beta-catenin pathway and inhibit osteoclastogenesis by regulating the osteoprotegerin (OPG)/receptor activator of NF-kappaB ligand (RANKL) axis, thus attenuating the negative effect of PA in osteoblasts.	Palmitic Acid	257-259	TNF superfamily member 11	Homo sapiens	204-209
34699125-10	2022	CONCLUSION: The RANK/RANKL/OPG system may have an important role in regulating bone metabolism in TBT patients, although further studies are needed to clarify its role.	tbt	98-101	TNF superfamily member 11	Homo sapiens	21-26
34924117-8	2022	Furthermore, production of RANKL by human osteoblasts was suppressed by peficitinib but enhanced by etanercept.	peficitinib	72-83	TNF superfamily member 11	Homo sapiens	27-32
34546593-10	2021	In PI vs PM, significantly higher REL was found for Hey 1, TNF-alpha, IL-17, IL-1beta, IL-6 and RANKL.	pipermethystine	9-11	TNF superfamily member 11	Homo sapiens	96-101
34932613-2	2021	The Molecular docking data between the resveratrol and Receptor activator of nuclear factor-kappa-Beta ligand (RANKL) receptors proved that resveratrol binds tightly to the receptors, showed the highest binding affinities of -6.9, -7.6, -7.1, -6.9, -6.7, and -7.1 kcal/mol.	Resveratrol	39-50	TNF superfamily member 11	Homo sapiens	55-109
34932613-2	2021	The Molecular docking data between the resveratrol and Receptor activator of nuclear factor-kappa-Beta ligand (RANKL) receptors proved that resveratrol binds tightly to the receptors, showed the highest binding affinities of -6.9, -7.6, -7.1, -6.9, -6.7, and -7.1 kcal/mol.	Resveratrol	39-50	TNF superfamily member 11	Homo sapiens	111-116
34932613-2	2021	The Molecular docking data between the resveratrol and Receptor activator of nuclear factor-kappa-Beta ligand (RANKL) receptors proved that resveratrol binds tightly to the receptors, showed the highest binding affinities of -6.9, -7.6, -7.1, -6.9, -6.7, and -7.1 kcal/mol.	Resveratrol	140-151	TNF superfamily member 11	Homo sapiens	55-109
34932613-2	2021	The Molecular docking data between the resveratrol and Receptor activator of nuclear factor-kappa-Beta ligand (RANKL) receptors proved that resveratrol binds tightly to the receptors, showed the highest binding affinities of -6.9, -7.6, -7.1, -6.9, -6.7, and -7.1 kcal/mol.	Resveratrol	140-151	TNF superfamily member 11	Homo sapiens	111-116
34767882-8	2021	Moreover, a number of signalling pathways, such as the Wnt/beta-catenin signalling pathway, BMP/SMAD/RUNX2 signalling pathway, OPG/RANKL/RANK signalling pathway, apoptosis pathway, and transcription factors, are regulated by polysaccharides and participate in improving bone homeostasis.	Polysaccharides	225-240	TNF superfamily member 11	Homo sapiens	131-136
34948130-4	2021	To confirm whether gal-3 contributes to the regulatory effects of 1alpha,25-(OH)2D3 on osteoclastogenesis, osteoclast precursors (OCPs) were induced by macrophage colony stimulating factor (M-CSF) and receptor activator of nuclear factor kappaB ligand (RANKL).	Calcitriol	66-83	TNF superfamily member 11	Homo sapiens	201-251
34948130-4	2021	To confirm whether gal-3 contributes to the regulatory effects of 1alpha,25-(OH)2D3 on osteoclastogenesis, osteoclast precursors (OCPs) were induced by macrophage colony stimulating factor (M-CSF) and receptor activator of nuclear factor kappaB ligand (RANKL).	Calcitriol	66-83	TNF superfamily member 11	Homo sapiens	253-258
34347277-9	2021	The BP-induced abnormal shift in RANKL/OPG expression ratio in rBM-derived cells was normalized by hUC-MSCs.	Diphosphonates	4-6	TNF superfamily member 11	Homo sapiens	33-38
34719112-4	2021	For the first time, this paper reviews the evidence from in vitro and in vivo experimental models to explore the anti-inflammatory effects of BBR in periodontitis and exhibits that BBR has the high potency to exert anti-inflammatory effects by reducing expression and secretion of pro-inflammatory mediators including TNF-alpha, IL-1beta, IL-17, RANKL, MMP-2, MMP-9 and MCP-1.	Berberine	181-184	TNF superfamily member 11	Homo sapiens	346-351
34803714-4	2021	Here, we revealed that treatment with BCI attenuated RANKL-mediated osteoclast differentiation in vitro and alleviated ovariectomy-induced osteoporosis without obvious toxicity.	2-benzylidene-3-(cyclohexylamino)-2,3-dihydro-1H-inden-1-one	38-41	TNF superfamily member 11	Homo sapiens	53-58
34852310-17	2022	CONCLUSION: aPDT adjunctive to MD improved periodontal parameters i.e., plaque index, pocket depth, and crestal bone loss along with metabolic marker RANK-L in water pipe smokers compared to non piped smokers.	Water	160-165	TNF superfamily member 11	Homo sapiens	150-156
34883645-11	2021	Treatment with CA/HA/BER or CA/HA/ME downregulated RANKL and upregulated Osterix associated with a reduction in RANKL/OPG ratio, at p < 0.05.	Berberine	21-24	TNF superfamily member 11	Homo sapiens	51-56
34883645-11	2021	Treatment with CA/HA/BER or CA/HA/ME downregulated RANKL and upregulated Osterix associated with a reduction in RANKL/OPG ratio, at p < 0.05.	Berberine	21-24	TNF superfamily member 11	Homo sapiens	112-117
34883645-11	2021	Treatment with CA/HA/BER or CA/HA/ME downregulated RANKL and upregulated Osterix associated with a reduction in RANKL/OPG ratio, at p < 0.05.	methionylglutamic acid	34-36	TNF superfamily member 11	Homo sapiens	51-56
34883645-11	2021	Treatment with CA/HA/BER or CA/HA/ME downregulated RANKL and upregulated Osterix associated with a reduction in RANKL/OPG ratio, at p < 0.05.	methionylglutamic acid	34-36	TNF superfamily member 11	Homo sapiens	112-117
34867423-5	2021	Method: We assessed the efficacy of punicalin on receptor activator of nuclear factor-kappaB ligand (RANKL)-mediated osteoclast formation, F-actin ring formation, gene expression, bone resorption, nuclear factor-kappaB (NF-kappaB) as well as on mitogen-activated protein kinase (MAPK) signaling pathways and molecular docking in vitro.	punicalin	36-45	TNF superfamily member 11	Homo sapiens	49-99
34867423-5	2021	Method: We assessed the efficacy of punicalin on receptor activator of nuclear factor-kappaB ligand (RANKL)-mediated osteoclast formation, F-actin ring formation, gene expression, bone resorption, nuclear factor-kappaB (NF-kappaB) as well as on mitogen-activated protein kinase (MAPK) signaling pathways and molecular docking in vitro.	punicalin	36-45	TNF superfamily member 11	Homo sapiens	101-106
34899338-7	2021	Azilsartan significantly inhibited the receptor activator of nuclear factor-kappaB ligand (RANKL)-mediated osteoclastogenesis and downregulated the expression of osteoclast-associated markers (Nfatc1, c-Fos, and Ctsk) in vitro.	azilsartan	0-10	TNF superfamily member 11	Homo sapiens	91-96
34899338-8	2021	Furthermore, azilsartan reduced RANKL-induced ROS production by increasing the expression of nuclear factor erythroid 2-related factor 2 (Nrf2).	azilsartan	13-23	TNF superfamily member 11	Homo sapiens	32-37
34288018-3	2021	Numerous receptor-coupled signaling pathways are inhibited by artemisinins, including the receptors for interleukin-1 (IL-1), tumor necrosis factor-alpha (TNF-alpha), beta3-integrin, or RANKL, toll-like receptors and growth factor receptors.	Artemisinins	62-74	TNF superfamily member 11	Homo sapiens	186-191
34770897-3	2021	The female hormones estradiol and progesterone closely control the action of RANKL with RANK.	Estradiol	20-29	TNF superfamily member 11	Homo sapiens	77-82
34191125-8	2021	RANKL-induced mRNA expression of osteoclastic-specific genes was significantly higher in the presence of 6-shogaol.	shogaol	105-114	TNF superfamily member 11	Homo sapiens	0-5
34763194-0	2021	Acacetin inhibits RANKL-induced osteoclastogenesis and LPS-induced bone loss by modulating NFATc1 transcription.	acacetin	0-8	TNF superfamily member 11	Homo sapiens	18-23
34770897-3	2021	The female hormones estradiol and progesterone closely control the action of RANKL with RANK.	Progesterone	34-46	TNF superfamily member 11	Homo sapiens	77-82
34493695-3	2021	In vitro studies of SCPP have found by our team that it could promote osteoblast proliferation and inhibit osteoclast activity, and it has a potential inhibitory effect on aseptic loosening by suppressing the expression of RANKL and improving the expression of OPG.	scpp	20-24	TNF superfamily member 11	Homo sapiens	223-228
34676131-1	2021	Objective: Receptor activator of NF-kappabeta ligand (RANKL) is crucial for the development of hepatic insulin resistance and poor glucose uptake; therefore, inhibiting RANKL with Denosumab could improve fasting plasma glucose (FPG) and insulin (FPI).	Glucose	131-138	TNF superfamily member 11	Homo sapiens	54-59
34676131-1	2021	Objective: Receptor activator of NF-kappabeta ligand (RANKL) is crucial for the development of hepatic insulin resistance and poor glucose uptake; therefore, inhibiting RANKL with Denosumab could improve fasting plasma glucose (FPG) and insulin (FPI).	Glucose	131-138	TNF superfamily member 11	Homo sapiens	169-174
34676131-1	2021	Objective: Receptor activator of NF-kappabeta ligand (RANKL) is crucial for the development of hepatic insulin resistance and poor glucose uptake; therefore, inhibiting RANKL with Denosumab could improve fasting plasma glucose (FPG) and insulin (FPI).	Glucose	219-226	TNF superfamily member 11	Homo sapiens	54-59
34676131-1	2021	Objective: Receptor activator of NF-kappabeta ligand (RANKL) is crucial for the development of hepatic insulin resistance and poor glucose uptake; therefore, inhibiting RANKL with Denosumab could improve fasting plasma glucose (FPG) and insulin (FPI).	Glucose	219-226	TNF superfamily member 11	Homo sapiens	169-174
34795947-6	2021	Methods: We assessed the effects of Aspernolide A (AA) on osteolysis and RANKL-induced pathways activation, bone resorption and F-actin ring formation in vitro.	aspernolide A	36-49	TNF superfamily member 11	Homo sapiens	73-78
34780049-0	2021	1alpha,25-(OH)2-D3 promotes the autophagy during osteoclastogenesis by enhancing RANKL-RANK-TRAF6 signaling.	Calcitriol	0-18	TNF superfamily member 11	Homo sapiens	81-86
34780049-1	2021	As the active form of vitamin D3, 1alpha,25-(OH)2-D3 promotes receptor activator for nuclear factor-kappaB ligand (RANKL)-induced autophagy in osteoclast precursors (OCPs).	Cholecalciferol	22-32	TNF superfamily member 11	Homo sapiens	115-120
34780049-1	2021	As the active form of vitamin D3, 1alpha,25-(OH)2-D3 promotes receptor activator for nuclear factor-kappaB ligand (RANKL)-induced autophagy in osteoclast precursors (OCPs).	Calcitriol	34-52	TNF superfamily member 11	Homo sapiens	115-120
34780049-2	2021	However, the relationship between 1alpha,25-(OH)2-D3 and RANKL signaling is still unknown.	25-(oh)2-d3	41-52	TNF superfamily member 11	Homo sapiens	57-62
34780049-3	2021	This study aimed to explore whether 1alpha,25-(OH)2-D3 regulates OCP autophagy and osteoclastogenesis through RANKL signaling.	Calcitriol	36-54	TNF superfamily member 11	Homo sapiens	110-115
34780049-4	2021	Our results showed that 1alpha,25-(OH)2-D3 directly decreased OCP autophagy while significantly enhancing the ability of RANKL to promote OCP autophagy.	Calcitriol	24-42	TNF superfamily member 11	Homo sapiens	121-126
34780049-5	2021	Moreover, 1alpha,25-(OH)2-D3 not only promoted the expression of key signaling proteins in OCPs induced by RANKL but also enhanced the coimmunoprecipitation levels of RANK and TRAF6.	Calcitriol	10-28	TNF superfamily member 11	Homo sapiens	107-112
34780049-8	2021	Overall, 1alpha,25-(OH)2-D3 could upregulate RANKL-RANK-TRAF6 signaling in OCPs, thereby promoting OCP autophagy and osteoclastogenesis.	Calcitriol	9-27	TNF superfamily member 11	Homo sapiens	45-50
34650437-4	2021	In the current study, we found that RANKL dramatically induced autophagy and osteoclastogenesis, inhibition of autophagy with chloroquine (CQ) markedly attenuates RANKL-induced osteoclastogenesis.	Chloroquine	126-137	TNF superfamily member 11	Homo sapiens	163-168
34650518-7	2021	For osteokines, receptor activator of nuclear factor kappa-B ligand (RANKL), a classical regulator of bone metabolism, was recently found to play a critical role in skeletal muscle atrophy induced by chronic cigarette smoke (CS) exposure.	cigarette smoke	208-223	TNF superfamily member 11	Homo sapiens	16-67
34650518-7	2021	For osteokines, receptor activator of nuclear factor kappa-B ligand (RANKL), a classical regulator of bone metabolism, was recently found to play a critical role in skeletal muscle atrophy induced by chronic cigarette smoke (CS) exposure.	cigarette smoke	208-223	TNF superfamily member 11	Homo sapiens	69-74
34650518-7	2021	For osteokines, receptor activator of nuclear factor kappa-B ligand (RANKL), a classical regulator of bone metabolism, was recently found to play a critical role in skeletal muscle atrophy induced by chronic cigarette smoke (CS) exposure.	Cesium	225-227	TNF superfamily member 11	Homo sapiens	16-67
34650518-7	2021	For osteokines, receptor activator of nuclear factor kappa-B ligand (RANKL), a classical regulator of bone metabolism, was recently found to play a critical role in skeletal muscle atrophy induced by chronic cigarette smoke (CS) exposure.	Cesium	225-227	TNF superfamily member 11	Homo sapiens	69-74
34650437-0	2021	Nox4 Promotes RANKL-Induced Autophagy and Osteoclastogenesis via Activating ROS/PERK/eIF-2alpha/ATF4 Pathway.	Reactive Oxygen Species	76-79	TNF superfamily member 11	Homo sapiens	14-19
34650437-4	2021	In the current study, we found that RANKL dramatically induced autophagy and osteoclastogenesis, inhibition of autophagy with chloroquine (CQ) markedly attenuates RANKL-induced osteoclastogenesis.	Chloroquine	139-141	TNF superfamily member 11	Homo sapiens	163-168
34650437-6	2021	Inhibition of Nox4 by 5-O-methyl quercetin or knockdown of Nox4 with specific shRNA markedly attenuated RANKL-induced autophagy and osteoclastogenesis.	Azaleatin	22-42	TNF superfamily member 11	Homo sapiens	104-109
34650437-7	2021	Furthermore, we found that Nox4 stimulated the production of nonmitochondrial reactive oxygen species (ROS), activating the critical unfolded protein response (UPR)-related signaling pathway PERK/eIF-2alpha/ATF4, leading to RANKL-induced autophagy and osteoclastogenesis.	Reactive Oxygen Species	78-101	TNF superfamily member 11	Homo sapiens	224-229
34650437-7	2021	Furthermore, we found that Nox4 stimulated the production of nonmitochondrial reactive oxygen species (ROS), activating the critical unfolded protein response (UPR)-related signaling pathway PERK/eIF-2alpha/ATF4, leading to RANKL-induced autophagy and osteoclastogenesis.	Reactive Oxygen Species	103-106	TNF superfamily member 11	Homo sapiens	224-229
34650437-8	2021	Blocking the activation of PERK/eIF-2alpha/ATF4 signaling pathway either by Nox4 shRNA, ROS scavenger (NAC) or PERK inhibitor (GSK2606414) significantly inhibited autophagy during RANKL-induced osteoclastogenesis.	Reactive Oxygen Species	88-91	TNF superfamily member 11	Homo sapiens	180-185
34650437-8	2021	Blocking the activation of PERK/eIF-2alpha/ATF4 signaling pathway either by Nox4 shRNA, ROS scavenger (NAC) or PERK inhibitor (GSK2606414) significantly inhibited autophagy during RANKL-induced osteoclastogenesis.	nac	103-106	TNF superfamily member 11	Homo sapiens	180-185
34650437-8	2021	Blocking the activation of PERK/eIF-2alpha/ATF4 signaling pathway either by Nox4 shRNA, ROS scavenger (NAC) or PERK inhibitor (GSK2606414) significantly inhibited autophagy during RANKL-induced osteoclastogenesis.	7-methyl-5-(1-((3-(trifluoromethyl)phenyl)acetyl)-2,3-dihydro-1H-indol-5-yl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine	127-137	TNF superfamily member 11	Homo sapiens	180-185
34650437-9	2021	Collectively, this study reveals that Nox4 promotes RANKL-induced autophagy and osteoclastogenesis via activating ROS/PERK/eIF-2alpha/ATF4 pathway, suggesting that the pathway may be a novel potential therapeutic target for osteoclastogenesis-related disease.	Reactive Oxygen Species	114-117	TNF superfamily member 11	Homo sapiens	52-57
34901550-5	2022	Simultaneously, ASP VI significantly reduced the differentiation of mononuclear osteoclasts in the process of osteoclast formation induced by M-CSF and RANKL.	akebia saponin D	16-22	TNF superfamily member 11	Homo sapiens	152-157
34584694-0	2021	Supranutritional selenium suppresses ROS-induced generation of RANKL-expressing osteoclastogenic CD4+ T cells and ameliorates rheumatoid arthritis.	Selenium	17-25	TNF superfamily member 11	Homo sapiens	63-68
34584694-0	2021	Supranutritional selenium suppresses ROS-induced generation of RANKL-expressing osteoclastogenic CD4+ T cells and ameliorates rheumatoid arthritis.	ros	37-40	TNF superfamily member 11	Homo sapiens	63-68
34080298-6	2021	Further underlying mechanism investigation revealed that APS attenuated activity of MAPK signalling pathways (eg ERK, JNK and p38) and ROS production induced by RANKL.	ros	135-138	TNF superfamily member 11	Homo sapiens	161-166
34445596-0	2021	Hexosamine Biosynthetic Pathway-Derived O-GlcNAcylation Is Critical for RANKL-Mediated Osteoclast Differentiation.	Hexosamines	0-10	TNF superfamily member 11	Homo sapiens	72-77
34362147-12	2021	We propose that this correlation may be related to increased hematopoietic stress, increased consumption of nitric oxide (NO) by hemolysis, and the inhibitory effects of iron supplements on osteogenesis through the receptor activator of nuclear factor kappaB ligand (RANKL)/Osteoprotegerin pathway and the Runt-related transcription factor 2 (RUNX2) factor.	Iron	170-174	TNF superfamily member 11	Homo sapiens	215-265
34362147-12	2021	We propose that this correlation may be related to increased hematopoietic stress, increased consumption of nitric oxide (NO) by hemolysis, and the inhibitory effects of iron supplements on osteogenesis through the receptor activator of nuclear factor kappaB ligand (RANKL)/Osteoprotegerin pathway and the Runt-related transcription factor 2 (RUNX2) factor.	Iron	170-174	TNF superfamily member 11	Homo sapiens	267-272
34229744-8	2021	TBS inversely correlated with sclerostin, RANK-L, and Dkk1 circulating levels whereas directly correlated with OPG circulating levels.	tribromsalan	0-3	TNF superfamily member 11	Homo sapiens	42-48
34279472-7	2021	Significant suppression of the RANKL/OPG ratio and Kcnn4 expression among the retrieved bones of IV BP group patients was also noted.	Diphosphonates	100-102	TNF superfamily member 11	Homo sapiens	31-36
34243614-5	2021	Pitavastatin exerted dose-dependent inhibitory effects on receptor activator of nuclear factor kappa-B ligand-induced osteoclast formation, bone resorption, and osteoclast-specific marker gene expression.	pitavastatin	0-12	TNF superfamily member 11	Homo sapiens	58-109
34362362-10	2021	The RANKL:OPG ratio was downregulated by all concentrations (10 ng/ml, 40 ng/ml and 60 ng/ml) of 25(OH)D3 (mean = 0.96 +- 0.68, mean = 1.61 +- 0.66 and mean = 1.86 +- 0.78, respectively) in comparison to the control (mean 2.58 +- 1.16) (p < 0.05).	Calcifediol	97-105	TNF superfamily member 11	Homo sapiens	4-9
34217732-3	2021	Arachidonic acid (AA) and its metabolite prostaglandin E2 (PGE2) are key regulators of osteoclast differentiation via induction of the receptor activator of nuclear factor kappa-Beta ligand (RANKL) pathway.	Arachidonic Acid	0-16	TNF superfamily member 11	Homo sapiens	191-196
34217732-3	2021	Arachidonic acid (AA) and its metabolite prostaglandin E2 (PGE2) are key regulators of osteoclast differentiation via induction of the receptor activator of nuclear factor kappa-Beta ligand (RANKL) pathway.	Dinoprostone	41-57	TNF superfamily member 11	Homo sapiens	191-196
34217732-3	2021	Arachidonic acid (AA) and its metabolite prostaglandin E2 (PGE2) are key regulators of osteoclast differentiation via induction of the receptor activator of nuclear factor kappa-Beta ligand (RANKL) pathway.	Dinoprostone	59-63	TNF superfamily member 11	Homo sapiens	191-196
34217732-4	2021	Marine-derived n-3 LCPUFAs have been shown to inhibit osteoclastogenesis by decreasing the osteoprotegerin (OPG)/RANKL signalling pathway mediated by a reduction of pro-inflammatory PGE2 derived from AA.	Dinoprostone	182-186	TNF superfamily member 11	Homo sapiens	113-118
35482061-14	2022	CONCLUSIONS: The BP-stimulated increase in the level of OPG and the decrease in the level of RANKL, as well as the impact on the level of the analyzed interleukins in the bone microenvironment, may be an important element of the mechanisms limiting bone resorption.	Diphosphonates	17-19	TNF superfamily member 11	Homo sapiens	93-98
34136493-6	2021	Moreover, OMT inhibited the generation of RANKL-induced reactive oxygen species (ROS), and the upregulation of ROS could rescue the inhibition of SREBP2 by OMT.	oxymatrine	10-13	TNF superfamily member 11	Homo sapiens	42-47
34136493-6	2021	Moreover, OMT inhibited the generation of RANKL-induced reactive oxygen species (ROS), and the upregulation of ROS could rescue the inhibition of SREBP2 by OMT.	Reactive Oxygen Species	56-79	TNF superfamily member 11	Homo sapiens	42-47
34136493-6	2021	Moreover, OMT inhibited the generation of RANKL-induced reactive oxygen species (ROS), and the upregulation of ROS could rescue the inhibition of SREBP2 by OMT.	Reactive Oxygen Species	81-84	TNF superfamily member 11	Homo sapiens	42-47
34136493-6	2021	Moreover, OMT inhibited the generation of RANKL-induced reactive oxygen species (ROS), and the upregulation of ROS could rescue the inhibition of SREBP2 by OMT.	oxymatrine	156-159	TNF superfamily member 11	Homo sapiens	42-47
35412194-0	2022	Association Between Serum Selenium Concentration and OPG/RANKL/RANK Axis in Patients with Arterial Hypertension.	Selenium	26-34	TNF superfamily member 11	Homo sapiens	57-62
35412194-1	2022	The aim of the study was to determine the relationship between the serum selenium concentration (Se-S) and the blood concentrations of osteoprotegerin (OPG), receptor activator of nuclear factor kappa-Beta ligand (RANKL) and the OPG/RANKL ratio in patients with arterial hypertension.	Selenium	73-81	TNF superfamily member 11	Homo sapiens	158-212
35412194-1	2022	The aim of the study was to determine the relationship between the serum selenium concentration (Se-S) and the blood concentrations of osteoprotegerin (OPG), receptor activator of nuclear factor kappa-Beta ligand (RANKL) and the OPG/RANKL ratio in patients with arterial hypertension.	Selenium	73-81	TNF superfamily member 11	Homo sapiens	233-238
35412194-8	2022	The correlation analysis showed the negative linear relationships between Se-S and OPG (r = - 0.25, p < 0.05) and between Se-S and OPG/RANKL (r = - 0.47, p < 0.05).	se-s	122-126	TNF superfamily member 11	Homo sapiens	135-140
35412194-9	2022	Moreover, Se-S positively correlated with RANKL (r = 0.33, p < 0.05).	se-s	10-14	TNF superfamily member 11	Homo sapiens	42-47
35412194-10	2022	In regression analysis, higher body mass index (BMI), smoking and lower Se-S were independently associated with a higher OPG/RANKL ratio, while lower BMI, use of diuretics, beta-blockers and ACE inhibitors and lower OPG/RANKL ratio with effective blood pressure control.	se-s	72-76	TNF superfamily member 11	Homo sapiens	125-130
35412194-10	2022	In regression analysis, higher body mass index (BMI), smoking and lower Se-S were independently associated with a higher OPG/RANKL ratio, while lower BMI, use of diuretics, beta-blockers and ACE inhibitors and lower OPG/RANKL ratio with effective blood pressure control.	se-s	72-76	TNF superfamily member 11	Homo sapiens	220-225
34187427-0	2021	DNA methylation in the OPG/RANK/RANKL pathway is associated with steroid-induced osteonecrosis of the femoral head.	Steroids	65-72	TNF superfamily member 11	Homo sapiens	32-37
34187427-1	2021	BACKGROUND: Dysregulation of the OPG/RANK/RANKL signalling pathway is a key step in the occurrence of steroid-induced osteonecrosis of the femoral head (ONFH).	Steroids	102-109	TNF superfamily member 11	Homo sapiens	42-47
34187427-2	2021	This study aims to understand the degree of methylation of the OPG, RANK, and RANKL genes in steroid-related ONFH.	Steroids	93-100	TNF superfamily member 11	Homo sapiens	78-83
34187427-7	2021	RESULTS: In the CpG islands of the OPG, RANK, and RANKL genes in patients with steroid-related ONFH, several CpG sites with high methylation rates and high methylation levels were found.	Steroids	79-86	TNF superfamily member 11	Homo sapiens	50-55
34187427-10	2021	CONCLUSION: Methylation of certain sites in the OPG/RANK/RANKL signalling pathway increases the risk of steroid-related ONFH.	Steroids	104-111	TNF superfamily member 11	Homo sapiens	57-62
34182052-0	2022	D(-)-salicin inhibits RANKL-induced osteoclast differentiation and function in vitro.	salicin	5-12	TNF superfamily member 11	Homo sapiens	22-27
34182052-4	2022	In our research, we discovered that DSA suppressed RANKL-induced differentiation of osteoclast in vitro in a dose-dependent manner.	salicin	36-39	TNF superfamily member 11	Homo sapiens	51-56
32893332-0	2021	Correction to: Ortho-silicic Acid Inhibits RANKL-Induced Osteoclastogenesis and Reverses Ovariectomy-Induced Bone Loss In Vivo.	Silicic Acid	21-33	TNF superfamily member 11	Homo sapiens	43-48
34632163-8	2021	An appropriate Ca/P ratio in CaP can effectively promote the RANKL-RANK binding and evoke more activated NF-kappaB signaling transduction, which results in vigorous osteoclast differentiation.	Phosphorus	18-19	TNF superfamily member 11	Homo sapiens	61-66
35605887-0	2022	Preconception exposure to dibutyl phthalate (DBP) impairs spermatogenesis by activating NF-kappaB/COX-2/RANKL signaling in Sertoli cells.	Dibutyl Phthalate	26-43	TNF superfamily member 11	Homo sapiens	104-109
35545061-7	2022	Meanwhile, the CS-rGO coating could inhibit aseptic loosening and improve interfacial osseointegration through stimulating BMSCs to secrete more OPG and lesser RANKL.	Cesium	15-17	TNF superfamily member 11	Homo sapiens	160-165
35545061-7	2022	Meanwhile, the CS-rGO coating could inhibit aseptic loosening and improve interfacial osseointegration through stimulating BMSCs to secrete more OPG and lesser RANKL.	rgo	18-21	TNF superfamily member 11	Homo sapiens	160-165
35605887-0	2022	Preconception exposure to dibutyl phthalate (DBP) impairs spermatogenesis by activating NF-kappaB/COX-2/RANKL signaling in Sertoli cells.	Dibutyl Phthalate	45-48	TNF superfamily member 11	Homo sapiens	104-109
35605887-5	2022	Furthermore, experimental data showed that DBP increased COX-2 and p-p65 expression in Sertoli cells and depleting COX-2 and p-p65 by specific inhibitor NS3-98 and BAY117082 could partially abolish DBP induced up-regulation of RANKL.	ns3-98	153-159	TNF superfamily member 11	Homo sapiens	227-232
35605887-5	2022	Furthermore, experimental data showed that DBP increased COX-2 and p-p65 expression in Sertoli cells and depleting COX-2 and p-p65 by specific inhibitor NS3-98 and BAY117082 could partially abolish DBP induced up-regulation of RANKL.	3-(4-methylphenylsulfonyl)-2-propenenitrile	164-173	TNF superfamily member 11	Homo sapiens	227-232
35505281-9	2022	Furthermore, as shown by our experimental findings, Risperidone treatment inhibited the differentiation and autophagy, and promoted the apoptosis of osteoblasts, as evidenced by elevated levels of OPG, p62, cleaved PARP1, cleaved caspase-3, cleaved caspase-8, and cleaved caspase-9, and reduced levels of LC3 II/I, Beclin1, collagen I, and RANKL.	Risperidone	52-63	TNF superfamily member 11	Homo sapiens	340-345
35633138-7	2022	Therefore, understanding the correlation between the skeletal and immune systems and further revealing the roles and the cooperation between RANKL and the Th17/Treg balance will help to provide new insights for the treatment of osteoporosis.	treg	160-164	TNF superfamily member 11	Homo sapiens	141-146
35566466-3	2022	The human receptor activator of nuclear factor kappa B and its ligand-the so-called RANK-RANKL pathway-is known to play a key role in promoting osteoclasts" activation and bone depletion, and RANKL levels were shown to be higher in ACPA-positive early untreated RA patients.	arachidonylcyclopropylamide	232-236	TNF superfamily member 11	Homo sapiens	89-94
35364377-0	2022	Niloticin inhibits osteoclastogenesis by blocking RANKL-RANK interaction and suppressing the AKT, MAPK, and NF-kappaB signaling pathways.	niloticin	0-9	TNF superfamily member 11	Homo sapiens	50-55
35218446-6	2022	MATERIALS AND METHODS: Proliferation, apoptosis, differentiation and Pro-inflammatory responses of RANKL-stimulated RAW254.7 macrophage treated with or without IL-6 were measured by MTT assay, quantitative PCR assay of the expression of apoptotic genes, osteoclast differentiation markers, and pro-inflammatory genes, respectively.	monooxyethylene trimethylolpropane tristearate	182-185	TNF superfamily member 11	Homo sapiens	99-104
35451724-0	2022	Yangonin treats inflammatory osteoporosis by inhibiting the secretion of inflammatory factors and RANKL expression.	yangonin	0-8	TNF superfamily member 11	Homo sapiens	98-103
35451724-7	2022	RESULTS: Our results suggested that yangonin was able to reduce the secretion of inflammatory factors, down-regulate osteoclast-related genes such as TRAP, RANKL, cathepsin K (CTSK) and nuclear factor-activated T-cell 1 (NFATc1).	yangonin	36-44	TNF superfamily member 11	Homo sapiens	156-161
35397103-0	2022	Boric Acid Inhibits RANKL-Stimulated Osteoclastogenesis In Vitro and Attenuates LPS-Induced Bone Loss In Vivo.	boric acid	0-10	TNF superfamily member 11	Homo sapiens	20-25
35418213-11	2022	Future studies are needed to determine whether RANKL is important for the malignant transformation or transition from GCNIS to invasive tumours.	gcnis	118-123	TNF superfamily member 11	Homo sapiens	47-52
35396993-10	2022	Melatonin showed no effects on OPG or RANKL expression without mechanical strain, but increased RANKL gene expression during compression.	Melatonin	0-9	TNF superfamily member 11	Homo sapiens	96-101
35547753-8	2022	Additionally, receptor activator of nuclear factor-kappaB ligand (RANKL)-induced osteoclast differentiation and function was remarkably suppressed by 4-OI@Zn-NH-pyr.	zn-nh-pyr	155-164	TNF superfamily member 11	Homo sapiens	14-64
35547753-8	2022	Additionally, receptor activator of nuclear factor-kappaB ligand (RANKL)-induced osteoclast differentiation and function was remarkably suppressed by 4-OI@Zn-NH-pyr.	zn-nh-pyr	155-164	TNF superfamily member 11	Homo sapiens	66-71
35154427-0	2022	Capecitabine inhibits epithelial-to-mesenchymal transition and proliferation of colorectal cancer cells by mediating the RANK/RANKL pathway.	Capecitabine	0-12	TNF superfamily member 11	Homo sapiens	126-131
35406536-0	2022	Inhibiting Endothelin Receptors with Macitentan Strengthens the Bone Protective Action of RANKL Inhibition and Reduces Metastatic Dissemination in Osteosarcoma.	macitentan	37-47	TNF superfamily member 11	Homo sapiens	90-95
35154427-8	2022	Additionally, it was observed that capecitabine treatment reduced the protein expression of RANK, RANKL and OPG in HT29 cells, suggesting that capecitabine has a repressive effect on the RANK/RANKL pathway.	Capecitabine	35-47	TNF superfamily member 11	Homo sapiens	98-103
35154427-8	2022	Additionally, it was observed that capecitabine treatment reduced the protein expression of RANK, RANKL and OPG in HT29 cells, suggesting that capecitabine has a repressive effect on the RANK/RANKL pathway.	Capecitabine	35-47	TNF superfamily member 11	Homo sapiens	192-197
35154427-8	2022	Additionally, it was observed that capecitabine treatment reduced the protein expression of RANK, RANKL and OPG in HT29 cells, suggesting that capecitabine has a repressive effect on the RANK/RANKL pathway.	Capecitabine	143-155	TNF superfamily member 11	Homo sapiens	98-103
35154427-8	2022	Additionally, it was observed that capecitabine treatment reduced the protein expression of RANK, RANKL and OPG in HT29 cells, suggesting that capecitabine has a repressive effect on the RANK/RANKL pathway.	Capecitabine	143-155	TNF superfamily member 11	Homo sapiens	192-197
35154427-11	2022	These findings suggest that the regulatory role of capecitabine is at least partially mediated through the RANK/RANKL pathway in colorectal cancer.	Capecitabine	51-63	TNF superfamily member 11	Homo sapiens	112-117
35154427-12	2022	The present study demonstrated that capecitabine-induced repression of CRC is exerted by inhibiting the RANK/RANKL pathway, where this new mechanism potentially provides a novel therapeutic target.	Capecitabine	36-48	TNF superfamily member 11	Homo sapiens	109-114
35126144-0	2021	Cycloastragenol Attenuates Osteoclastogenesis and Bone Loss by Targeting RANKL-Induced Nrf2/Keap1/ARE, NF-kappaB, Calcium, and NFATc1 Pathways.	cycloastragenol	0-15	TNF superfamily member 11	Homo sapiens	73-78
35204100-6	2022	Literature data indicated that resveratrol activates sirtuin 1, and thereafter, suppresses osteoclastogenic pathways, such as the receptor activator of the nuclear factor kappa B (RANK) ligand (RANKL) pathway, and promotes osteoblastogenic pathways, such as the wingless-related MMTV integration site pathway.	Resveratrol	31-42	TNF superfamily member 11	Homo sapiens	194-199
35204100-7	2022	Further, we noted that purified polyphenols and polyphenol-rich substances or extracts exert anti-inflammatory and/or antioxidative effects, which inhibit RANKL/RANK binding via the NF-kappaB pathway, resulting in the suppression of osteoclastogenesis.	Polyphenols	32-43	TNF superfamily member 11	Homo sapiens	155-160
35204100-7	2022	Further, we noted that purified polyphenols and polyphenol-rich substances or extracts exert anti-inflammatory and/or antioxidative effects, which inhibit RANKL/RANK binding via the NF-kappaB pathway, resulting in the suppression of osteoclastogenesis.	Polyphenols	48-58	TNF superfamily member 11	Homo sapiens	155-160
35064691-6	2022	Further study revealed that the inhibition of MAT2A affected osteoclast differentiation mainly by suppressing crucial transcription factors and reactive oxygen species induced by RANKL.	Oxygen	153-159	TNF superfamily member 11	Homo sapiens	179-184
35126144-0	2021	Cycloastragenol Attenuates Osteoclastogenesis and Bone Loss by Targeting RANKL-Induced Nrf2/Keap1/ARE, NF-kappaB, Calcium, and NFATc1 Pathways.	Calcium	114-121	TNF superfamily member 11	Homo sapiens	73-78
35126144-5	2021	This study demonstrated that CAG dose-dependently inhibited osteoclast formation in receptor activator of nuclear factor-kappaB ligand (RANKL)-stimulated bone marrow macrophage (BMMs).	cycloastragenol	29-32	TNF superfamily member 11	Homo sapiens	136-141
34042278-7	2021	Androgen receptor inhibition interferes with PR agonist- and levonorgestrel-induced RANKL expression and reduces levonorgestrel-driven cell proliferation.	Levonorgestrel	61-75	TNF superfamily member 11	Homo sapiens	84-89
35096812-11	2021	Metformin inhibited osteoclast formation and accordingly downregulated the genes involved in osteoclastogenesis: RANKL, macrophage colony stimulating factor (M-CSF) and osteoclast fusion gene DC-STAMP.	Metformin	0-9	TNF superfamily member 11	Homo sapiens	113-118
34056870-7	2021	Novel mutation in TNFSF11 (RANKL) c.842T>G, p.Phe281Cys was identified in a homozygous state in both siblings.	phe281cys	46-55	TNF superfamily member 11	Homo sapiens	18-25
34056870-7	2021	Novel mutation in TNFSF11 (RANKL) c.842T>G, p.Phe281Cys was identified in a homozygous state in both siblings.	phe281cys	46-55	TNF superfamily member 11	Homo sapiens	27-32
35111053-9	2021	PBM suppressed the expression of inflammatory gene TNF and RANKL and downregulated the gene expression for VDR and proteolytic enzymes cathepsin K, MMP-8 and MMP-9.	pbm	0-3	TNF superfamily member 11	Homo sapiens	59-64
34052462-7	2021	Notably, tofacitinib treatment reduced AC hypertrophy and secretion of RANKL and IL-6.	tofacitinib	9-20	TNF superfamily member 11	Homo sapiens	71-76
33626422-3	2021	In this study, we investigated whether A-485, a highly selective catalytic p300/CBP inhibitor, could attenuate RANKL-induced osteoclast differentiation and explored the underlying molecular mechanisms.	A-485	39-44	TNF superfamily member 11	Homo sapiens	111-116
34015597-9	2021	Additional experiments showed that SB203580 (a special p38MAPK inhibitor) inhibited MMP-2, MMP-9 and RANKL/OPG expression induced by rTSP-1.	SB 203580	35-43	TNF superfamily member 11	Homo sapiens	101-106
33939240-0	2021	Galangin suppresses RANKL-induced osteoclastogenesis via inhibiting MAPK and NF-kappaB signalling pathways.	galangin	0-8	TNF superfamily member 11	Homo sapiens	20-25
33612148-7	2021	GSK5182 also attenuated RANKL-mediated expression of c-Fos and nuclear factor of activated T-cells cytoplasmic 1 (NFATc1), pivotal transcription factors for osteoclastogenesis.	GSK5182	0-7	TNF superfamily member 11	Homo sapiens	24-29
33612148-9	2021	GSK5182 strongly blocked the phosphorylation of IkappaBalpha, c-Jun N-terminal kinase, and extracellular signal-regulated kinase in response to RANKL.	GSK5182	0-7	TNF superfamily member 11	Homo sapiens	144-149
33946199-7	2021	In addition, the receptor activator of nuclear factor kappa B ligand (RANKL)/osteoprotegerin (OPG) ratio was decreased in the zinc sulfate-treated co-cultures.	Zinc Sulfate	126-138	TNF superfamily member 11	Homo sapiens	17-68
32791889-0	2021	Metformin reduces thyroid cancer tumor growth in the metastatic niche of bone by inhibiting osteoblastic RANKL productions.	Metformin	0-9	TNF superfamily member 11	Homo sapiens	105-110
32791889-15	2021	Conclusions In the microenvironment of BM, metformin effectively reduced ATC tumor growth by inhibiting cancer cell viability, blocking cancer cell induced osteoblastic RANKL production, which further activated osteoclastogenesis, and directly reduced osteoclast differentiation.	Metformin	43-52	TNF superfamily member 11	Homo sapiens	169-174
33862352-2	2021	In this study, we aimed to evaluate the efficiency of aminolevulinic acid-photodynamic therapy (ALA-PDT) against cancer of various malignancy levels, indicated by the expression level of receptor associated nuclear factor-kappaB ligand (RANKL), through the expression levels of ALA uptake transporters.	Aminolevulinic Acid	54-73	TNF superfamily member 11	Homo sapiens	187-235
33862352-2	2021	In this study, we aimed to evaluate the efficiency of aminolevulinic acid-photodynamic therapy (ALA-PDT) against cancer of various malignancy levels, indicated by the expression level of receptor associated nuclear factor-kappaB ligand (RANKL), through the expression levels of ALA uptake transporters.	Aminolevulinic Acid	54-73	TNF superfamily member 11	Homo sapiens	237-242
33862352-2	2021	In this study, we aimed to evaluate the efficiency of aminolevulinic acid-photodynamic therapy (ALA-PDT) against cancer of various malignancy levels, indicated by the expression level of receptor associated nuclear factor-kappaB ligand (RANKL), through the expression levels of ALA uptake transporters.	Aminolevulinic Acid	96-99	TNF superfamily member 11	Homo sapiens	187-235
33862352-2	2021	In this study, we aimed to evaluate the efficiency of aminolevulinic acid-photodynamic therapy (ALA-PDT) against cancer of various malignancy levels, indicated by the expression level of receptor associated nuclear factor-kappaB ligand (RANKL), through the expression levels of ALA uptake transporters.	Aminolevulinic Acid	96-99	TNF superfamily member 11	Homo sapiens	237-242
33862352-2	2021	In this study, we aimed to evaluate the efficiency of aminolevulinic acid-photodynamic therapy (ALA-PDT) against cancer of various malignancy levels, indicated by the expression level of receptor associated nuclear factor-kappaB ligand (RANKL), through the expression levels of ALA uptake transporters.	Aminolevulinic Acid	278-281	TNF superfamily member 11	Homo sapiens	187-235
33862352-2	2021	In this study, we aimed to evaluate the efficiency of aminolevulinic acid-photodynamic therapy (ALA-PDT) against cancer of various malignancy levels, indicated by the expression level of receptor associated nuclear factor-kappaB ligand (RANKL), through the expression levels of ALA uptake transporters.	Aminolevulinic Acid	278-281	TNF superfamily member 11	Homo sapiens	237-242
33946410-5	2021	EXPERIMENTAL DESIGN: Anti-human RANKL mAbs (AMG161 and AMG162) were radiolabeled with 89Zr using the bifunctional chelator DFO in high yield, purity and with intact binding affinity.	amg161	44-50	TNF superfamily member 11	Homo sapiens	32-37
33946410-5	2021	EXPERIMENTAL DESIGN: Anti-human RANKL mAbs (AMG161 and AMG162) were radiolabeled with 89Zr using the bifunctional chelator DFO in high yield, purity and with intact binding affinity.	Deferoxamine	123-126	TNF superfamily member 11	Homo sapiens	32-37
33946410-8	2021	We demonstrated specific accumulation of [89Zr]Zr-DFO-AMG162 in RANKL transduced ME-180 xenografts.	zr-dfo-amg162	47-60	TNF superfamily member 11	Homo sapiens	64-69
33946410-9	2021	In UM-SCC-22B xenograft models expressing physiological RANKL levels, [89Zr]Zr-DFO-AMG162 imaging detected significantly higher signal compared to control [89Zr]Zr-DFO-IgG2 and to RANKL negative HCT-116 xenografts.	zr-dfo-amg162	76-89	TNF superfamily member 11	Homo sapiens	56-61
33946410-9	2021	In UM-SCC-22B xenograft models expressing physiological RANKL levels, [89Zr]Zr-DFO-AMG162 imaging detected significantly higher signal compared to control [89Zr]Zr-DFO-IgG2 and to RANKL negative HCT-116 xenografts.	zr-dfo-amg162	76-89	TNF superfamily member 11	Homo sapiens	180-185
33946410-9	2021	In UM-SCC-22B xenograft models expressing physiological RANKL levels, [89Zr]Zr-DFO-AMG162 imaging detected significantly higher signal compared to control [89Zr]Zr-DFO-IgG2 and to RANKL negative HCT-116 xenografts.	zr-dfo	76-82	TNF superfamily member 11	Homo sapiens	56-61
33946410-9	2021	In UM-SCC-22B xenograft models expressing physiological RANKL levels, [89Zr]Zr-DFO-AMG162 imaging detected significantly higher signal compared to control [89Zr]Zr-DFO-IgG2 and to RANKL negative HCT-116 xenografts.	zr-dfo	76-82	TNF superfamily member 11	Homo sapiens	180-185
33946410-11	2021	CONCLUSIONS: [89Zr]Zr-DFO-AMG162 can detect heterogeneous RANKL expression in the TME of human cancer xenografts, supporting further translation of RANKL immuno-PET to evaluate tumor RANKL distribution in patients.	zr-dfo-amg162	19-32	TNF superfamily member 11	Homo sapiens	58-63
33946199-7	2021	In addition, the receptor activator of nuclear factor kappa B ligand (RANKL)/osteoprotegerin (OPG) ratio was decreased in the zinc sulfate-treated co-cultures.	Zinc Sulfate	126-138	TNF superfamily member 11	Homo sapiens	70-75
33946199-8	2021	Our results suggest that zinc sulfate enhances osteogenesis directly by promoting osteoblastic differentiation and osteogenic activities in osteoblasts and indirectly by inhibiting osteoclastic bone resorption through a reduced RANKL/OPG ratio in co-cultured osteoblasts and osteoclasts.	Zinc Sulfate	25-37	TNF superfamily member 11	Homo sapiens	228-233
33586001-8	2021	This review analyzes the interactions of PTH, P, Ca, FGF23, calcidiol, calcitriol and Klotho with the RANKL/RANKL/OPG system and the Wnt/beta-catenin, pathway and their implications in bone and cardiovascular disorders in CKD.	Calcitriol	71-81	TNF superfamily member 11	Homo sapiens	102-107
33898880-3	2021	Increasing evidence indicates that scavenging reactive oxygen species (ROS) can inhibit receptor activator of nuclear factor kappaB ligand (RANKL)-induced osteoclastogenesis and suppress ovariectomy-induced osteoporosis.	Reactive Oxygen Species	46-69	TNF superfamily member 11	Homo sapiens	140-145
33898880-3	2021	Increasing evidence indicates that scavenging reactive oxygen species (ROS) can inhibit receptor activator of nuclear factor kappaB ligand (RANKL)-induced osteoclastogenesis and suppress ovariectomy-induced osteoporosis.	Reactive Oxygen Species	71-74	TNF superfamily member 11	Homo sapiens	140-145
33403398-4	2021	In this study, we explored the effects of DMC on MDA-MB-231 cells, MCF-7 cells, and osteoclasts induced by RANKL in vitro, as well as the protective effect on bone destruction of tumor bone metastasis in vivo.	demethoxycurcumin	42-45	TNF superfamily member 11	Homo sapiens	107-112
33891990-10	2021	Both, zinc and doxycycline functionalized membranes enormously down-regulated the expression of RANKL.	Doxycycline	15-26	TNF superfamily member 11	Homo sapiens	96-101
33831806-0	2021	Hinokitiol inhibits RANKL-induced osteoclastogenesis in vitro and prevents ovariectomy-induced bone loss in vivo.	beta-thujaplicin	0-10	TNF superfamily member 11	Homo sapiens	20-25
33831806-3	2021	In this study, hinokitiol, a tropolone-related compound extracted from the heart wood of several cupressaceous plants, was found to inhibit RANKL-induced osteoclast formation and bone resorption in vitro.	beta-thujaplicin	15-25	TNF superfamily member 11	Homo sapiens	140-145
33831806-3	2021	In this study, hinokitiol, a tropolone-related compound extracted from the heart wood of several cupressaceous plants, was found to inhibit RANKL-induced osteoclast formation and bone resorption in vitro.	Tropolone	29-38	TNF superfamily member 11	Homo sapiens	140-145
33586001-8	2021	This review analyzes the interactions of PTH, P, Ca, FGF23, calcidiol, calcitriol and Klotho with the RANKL/RANKL/OPG system and the Wnt/beta-catenin, pathway and their implications in bone and cardiovascular disorders in CKD.	Calcifediol	60-69	TNF superfamily member 11	Homo sapiens	102-107
33586001-8	2021	This review analyzes the interactions of PTH, P, Ca, FGF23, calcidiol, calcitriol and Klotho with the RANKL/RANKL/OPG system and the Wnt/beta-catenin, pathway and their implications in bone and cardiovascular disorders in CKD.	Calcifediol	60-69	TNF superfamily member 11	Homo sapiens	108-113
33586001-8	2021	This review analyzes the interactions of PTH, P, Ca, FGF23, calcidiol, calcitriol and Klotho with the RANKL/RANKL/OPG system and the Wnt/beta-catenin, pathway and their implications in bone and cardiovascular disorders in CKD.	Calcitriol	71-81	TNF superfamily member 11	Homo sapiens	108-113
33785053-10	2021	After RANKL stimulation, lapatinib-resistant cells show increased NF-kappaB activation compared to their sensitive counterparts, confirming the enhanced functionality of the RANK pathway in anti-HER2-resistant breast cancer.	Lapatinib	25-34	TNF superfamily member 11	Homo sapiens	6-11
33785053-9	2021	Results in HER2-positive breast cancer cell lines recapitulate the clinical observations, with increased RANK expression observed after short-term treatment with the HER2 inhibitor lapatinib or dual anti-HER2 therapy and in lapatinib-resistant cells.	Lapatinib	181-190	TNF superfamily member 11	Homo sapiens	105-109
32997256-6	2021	Bone markers analysis shown a significant reduction of ALP/TRAP ratio due to a prednisolone-dependent stimulation of tnfsf11 (homolog of human rankl) in scales of older fish.The results evidentiated for the first time the presence of a senile male osteoporosis in lower vertebrate.	Prednisolone	79-91	TNF superfamily member 11	Homo sapiens	117-124
33785053-10	2021	After RANKL stimulation, lapatinib-resistant cells show increased NF-kappaB activation compared to their sensitive counterparts, confirming the enhanced functionality of the RANK pathway in anti-HER2-resistant breast cancer.	Lapatinib	25-34	TNF superfamily member 11	Homo sapiens	6-10
33785053-11	2021	Overactivation of the RANK signaling pathway enhances ERK and NF-kappaB signaling and increases lapatinib resistance in different HER2-positive breast cancer cell lines, whereas RANK loss sensitizes lapatinib-resistant cells to the drug.	Lapatinib	96-105	TNF superfamily member 11	Homo sapiens	22-26
33785053-11	2021	Overactivation of the RANK signaling pathway enhances ERK and NF-kappaB signaling and increases lapatinib resistance in different HER2-positive breast cancer cell lines, whereas RANK loss sensitizes lapatinib-resistant cells to the drug.	Lapatinib	199-208	TNF superfamily member 11	Homo sapiens	178-182
33785053-15	2021	CONCLUSIONS: Our data support a physical and functional link between RANK and HER2 signaling in breast cancer and demonstrate that increased RANK signaling may contribute to the development of lapatinib resistance through NF-kappaB activation.	Lapatinib	193-202	TNF superfamily member 11	Homo sapiens	141-145
32550719-2	2021	Methods: We evaluated the effect of tocotrienol on IL-17-induced receptor activator of nuclear factor kappa B ligand (RANKL) production using RA fibroblast-like synoviocyte (FLS), together with real-time polymerase chain reaction and enzyme-linked immunosorbent assay.	Tocotrienols	36-47	TNF superfamily member 11	Homo sapiens	65-116
33183068-5	2021	To the contrary, long-term use of anti-osteoporotic drugs such as bisphosphonates and Denosumab, an RANKL inhibitor, have resulted in adverse events.	Diphosphonates	66-81	TNF superfamily member 11	Homo sapiens	100-105
32550719-2	2021	Methods: We evaluated the effect of tocotrienol on IL-17-induced receptor activator of nuclear factor kappa B ligand (RANKL) production using RA fibroblast-like synoviocyte (FLS), together with real-time polymerase chain reaction and enzyme-linked immunosorbent assay.	Tocotrienols	36-47	TNF superfamily member 11	Homo sapiens	118-123
32550719-5	2021	Results: We found that IL-17 stimulated FLS to produce RANKL and tocotrienol decreased this IL-17-induced RANKL production.	Tocotrienols	65-76	TNF superfamily member 11	Homo sapiens	106-111
32550719-7	2021	When monocytes were incubated with IL-17, RANKL, IL-17-treated FLS or Th17 cells, osteoclasts were differentiated and tocotrienol decreased this osteoclast differentiation.	Tocotrienols	118-129	TNF superfamily member 11	Homo sapiens	42-47
32550719-9	2021	Conclusions: Tocotrienol inhibited IL-17- activated RANKL production in RA FLS and IL-17-activated osteoclast formation.	Tocotrienols	13-24	TNF superfamily member 11	Homo sapiens	52-57
33637048-0	2021	Administration of zoledronic acid alleviates osteoporosis in HIV patients by suppressing osteoclastogenesis via regulating RANKL expression.	Zoledronic Acid	18-33	TNF superfamily member 11	Homo sapiens	123-128
33637048-8	2021	Mechanistically, the expression of miR-302, miR-101, miR-145, RANKL, SMAD3 and PRKACB in the serum was remarkably activated by ZOL treatment.	Zoledronic Acid	127-130	TNF superfamily member 11	Homo sapiens	62-67
33637048-11	2021	CONCLUSION: The findings of this study demonstrated that administration of ZOL suppressed the expression of RANKL via modulating signaling pathways of miR-101-3p/RANKL, miR-302/PRKACB/RANKL and miR-145/SMAD3/RANKL.	Zoledronic Acid	75-78	TNF superfamily member 11	Homo sapiens	108-113
33629434-10	2021	Consistently, dMphis exhibited the lessoned capacity of adhesion to DSCs when blocking the crosstalk of RANKL-RANK between the DSCs and dMphis in vitro.	dmphis	14-20	TNF superfamily member 11	Homo sapiens	104-109
33637048-11	2021	CONCLUSION: The findings of this study demonstrated that administration of ZOL suppressed the expression of RANKL via modulating signaling pathways of miR-101-3p/RANKL, miR-302/PRKACB/RANKL and miR-145/SMAD3/RANKL.	Zoledronic Acid	75-78	TNF superfamily member 11	Homo sapiens	162-167
33637048-11	2021	CONCLUSION: The findings of this study demonstrated that administration of ZOL suppressed the expression of RANKL via modulating signaling pathways of miR-101-3p/RANKL, miR-302/PRKACB/RANKL and miR-145/SMAD3/RANKL.	Zoledronic Acid	75-78	TNF superfamily member 11	Homo sapiens	162-167
33637048-11	2021	CONCLUSION: The findings of this study demonstrated that administration of ZOL suppressed the expression of RANKL via modulating signaling pathways of miR-101-3p/RANKL, miR-302/PRKACB/RANKL and miR-145/SMAD3/RANKL.	Zoledronic Acid	75-78	TNF superfamily member 11	Homo sapiens	162-167
33637048-12	2021	Furthermore, down-regulated expression of RANKL by ZOL treatment alleviated osteoporosis in HIV-positive subjects treated with tenofovir.	Zoledronic Acid	51-54	TNF superfamily member 11	Homo sapiens	42-47
33637048-12	2021	Furthermore, down-regulated expression of RANKL by ZOL treatment alleviated osteoporosis in HIV-positive subjects treated with tenofovir.	Tenofovir	127-136	TNF superfamily member 11	Homo sapiens	42-47
33629434-10	2021	Consistently, dMphis exhibited the lessoned capacity of adhesion to DSCs when blocking the crosstalk of RANKL-RANK between the DSCs and dMphis in vitro.	dmphis	136-142	TNF superfamily member 11	Homo sapiens	104-109
33629434-11	2021	CONCLUSION: These results suggest that the interaction of RANKL-RANK up-regulates the expression of adhesion molecules on the surface of dMphis, contributing to the accumulation and residence of dMphis in human early pregnancy.	dmphis	137-143	TNF superfamily member 11	Homo sapiens	58-63
33671948-3	2021	Here, we examined the effects of PF-3845, a selective fatty acid amide hydrolase (FAAH) inhibitor, on receptor activator of nuclear factor kappa B ligand (RANKL)-mediated osteoclastogenesis, its function, and the therapeutic potential for the treatment of alveolar bone destruction in experimental periodontitis.	PF 3845	33-40	TNF superfamily member 11	Homo sapiens	102-153
33610736-10	2021	CONCLUSION: The whole salivary RANKL/OPG ratio remains high in patients with poorly-controlled type-2 DM after SRP with or without adjunct PDT.	L-seryl-AMP	111-114	TNF superfamily member 11	Homo sapiens	31-36
33671948-3	2021	Here, we examined the effects of PF-3845, a selective fatty acid amide hydrolase (FAAH) inhibitor, on receptor activator of nuclear factor kappa B ligand (RANKL)-mediated osteoclastogenesis, its function, and the therapeutic potential for the treatment of alveolar bone destruction in experimental periodontitis.	PF 3845	33-40	TNF superfamily member 11	Homo sapiens	155-160
33556550-0	2021	Bone anti-resorptive effects of coumarins on RANKL downstream cellular signaling: A systematic review of the literature.	Coumarins	32-41	TNF superfamily member 11	Homo sapiens	45-50
33556550-7	2021	RESULTS: Coumarins have been reported to downregulate RANKL-RANK signaling and various downstream signaling pathways required for osteoclast development, such as NF-kappaB, MAPK, Akt, and Ca2+ signaling, as well as pathways downstream of the nuclear factor of activated T-cells (NFATc1), including tartrate-resistant acid phosphatase (TRAP), cathepsin K (CTSK), and matrix metalloproteinase 9 (MMP-9).	Coumarins	9-18	TNF superfamily member 11	Homo sapiens	54-59
33477539-8	2021	The in vitro results showed the PCL-CM-ZnO and, to a lower extent, PCL-ZnO coated sample exhibited the best behaviour in terms of inflammatory response and receptor activator of nuclear factor kappa-B ligand (RANKL)-mediated differentiation of RAW 264.7 macrophages into osteoclasts.	pcl-zno	67-74	TNF superfamily member 11	Homo sapiens	156-207
33340772-6	2021	Findings from this study suggest the potential of Vitamin D supplementation in lowering the levels of RANKL and related markers/cytokines such as Th17 cell levels, OPG/RANKL ratio and CXCL10 pathway, which may present as a viable nutrition intervention for the management of RA.	Vitamin D	50-59	TNF superfamily member 11	Homo sapiens	102-107
33340772-6	2021	Findings from this study suggest the potential of Vitamin D supplementation in lowering the levels of RANKL and related markers/cytokines such as Th17 cell levels, OPG/RANKL ratio and CXCL10 pathway, which may present as a viable nutrition intervention for the management of RA.	Vitamin D	50-59	TNF superfamily member 11	Homo sapiens	168-173
33283899-0	2021	Association of RANK and RANKL gene polymorphism with survival and calcium levels in multiple myeloma.	Calcium	66-73	TNF superfamily member 11	Homo sapiens	24-29
33572979-8	2021	The homozygous rare CC genotype of rs9533156 (RANKL) was associated with lower 25(OH)D levels in CTRs (p = 0.032).	25(oh)d	79-86	TNF superfamily member 11	Homo sapiens	46-51
33572979-9	2021	In contrast, heterozygous AG genotype of rs2277438 (RANKL) is associated with lower 25(OH)D in the OP group (p = 0.02).	25(oh)d	84-91	TNF superfamily member 11	Homo sapiens	52-57
33572979-10	2021	Our results suggest that RANKL SNPs may impact 25(OH)D levels and that OPG SNP rs2073618A/G is a significant genetic risk factor for PMO Saudi Arabian women.	25(oh)d	47-54	TNF superfamily member 11	Homo sapiens	25-30
33494362-2	2021	The impact of glucocorticoid on the maintenance of RANK/RANKL/OPG is well explored; dexamethasone was shown to disturb the ratio between OPG and RANKL level by decreasing the expression level of OPG and increasing level of RANKL.	Dexamethasone	84-97	TNF superfamily member 11	Homo sapiens	56-61
33494362-2	2021	The impact of glucocorticoid on the maintenance of RANK/RANKL/OPG is well explored; dexamethasone was shown to disturb the ratio between OPG and RANKL level by decreasing the expression level of OPG and increasing level of RANKL.	Dexamethasone	84-97	TNF superfamily member 11	Homo sapiens	145-150
33494362-2	2021	The impact of glucocorticoid on the maintenance of RANK/RANKL/OPG is well explored; dexamethasone was shown to disturb the ratio between OPG and RANKL level by decreasing the expression level of OPG and increasing level of RANKL.	Dexamethasone	84-97	TNF superfamily member 11	Homo sapiens	145-150
33452455-0	2021	Melatonin interrupts osteoclast functioning and suppresses tumor-secreted RANKL expression: implications for bone metastases.	Melatonin	0-9	TNF superfamily member 11	Homo sapiens	74-79
33452455-4	2021	We also observed that melatonin inhibits RANKL production in lung and prostate cancer cells by downregulating the p38 MAPK pathway, which in turn prevents cancer-associated osteoclast differentiation.	Melatonin	22-31	TNF superfamily member 11	Homo sapiens	41-46
33452455-6	2021	Melatonin also substantially lowered the numbers of TRAP-positive osteoclasts in tibia bone marrow and RANKL expression in tumor tissue.	Melatonin	0-9	TNF superfamily member 11	Homo sapiens	103-108
33477539-8	2021	The in vitro results showed the PCL-CM-ZnO and, to a lower extent, PCL-ZnO coated sample exhibited the best behaviour in terms of inflammatory response and receptor activator of nuclear factor kappa-B ligand (RANKL)-mediated differentiation of RAW 264.7 macrophages into osteoclasts.	pcl-zno	67-74	TNF superfamily member 11	Homo sapiens	209-214
31971108-4	2021	Furthermore the mRNA and protein expression of OPG and RANKL and the OPG/RANKL mRNA and protein expression ratios were upregulated by ICA.	icariin	134-137	TNF superfamily member 11	Homo sapiens	55-60
33628184-0	2020	Pristimerin Suppresses RANKL-Induced Osteoclastogenesis and Ameliorates Ovariectomy-Induced Bone Loss.	pristimerin	0-11	TNF superfamily member 11	Homo sapiens	23-28
33628184-6	2020	Our results showed Pristimerin inhibited RANKL-induced osteoclast differentiation and osteoclastic bone resorption in vitro, with decreased expression of osteoclastogenesis-related markers including c-Fos, NFATc1, TRAP, Cathepsin K, and MMP-9 at both mRNA and protein levels.	pristimerin	19-30	TNF superfamily member 11	Homo sapiens	41-46
33628184-8	2020	Our in vivo experiments showed that Pristimerin remarkably ameliorated ovariectomy-induced bone loss, reduced serum levels of TNF-alpha, IL-1beta, IL-6, and RANKL, and increased serum level of osteoprotegerin (OPG).	pristimerin	36-47	TNF superfamily member 11	Homo sapiens	157-162
31971108-0	2021	Icariin stimulates hFOB 1.19 osteoblast proliferation and differentiation via OPG/RANKL mediated by the estrogen receptor.	icariin	0-7	TNF superfamily member 11	Homo sapiens	82-87
31971108-4	2021	Furthermore the mRNA and protein expression of OPG and RANKL and the OPG/RANKL mRNA and protein expression ratios were upregulated by ICA.	icariin	134-137	TNF superfamily member 11	Homo sapiens	73-78
31971108-7	2021	In conclusions, ICA can regulate bone formation by promoting cell proliferation and differentiation and upregulating the OPG/RANKL expression ratio by the ER in hFOB1.19 human osteoblast cells.	icariin	16-19	TNF superfamily member 11	Homo sapiens	125-130
33126167-0	2021	Kirenol inhibits RANKL-induced osteoclastogenesis and prevents ovariectomized-induced osteoporosis via suppressing the Ca2+-NFATc1 and Cav-1 signaling pathways.	kirenol	0-7	TNF superfamily member 11	Homo sapiens	17-22
32866421-6	2021	Interestingly, the trigger for lesion status switch from active to inactive can originate from an unanticipated RANKL immunoregulatory feedback, involving the induction of Tregs and a host response outcome with immunological tolerance features.	tregs	172-177	TNF superfamily member 11	Homo sapiens	112-117
32372176-11	2021	An inherited variant (rs7984870 CC genotype) in TNFSF11 was more likely to be associated with improvements in hot flashes in patients receiving testosterone.	Testosterone	144-156	TNF superfamily member 11	Homo sapiens	48-55
33176606-9	2021	Pretreatment with mTOR inhibitor, rapamycin, could attenuate the activation of mTOR and the secretion of RANKL in OBs.	Sirolimus	34-43	TNF superfamily member 11	Homo sapiens	105-110
33302980-5	2020	In this study, the naringin-induced OPG/RANKL effects and its underlying mechanism were studied in fibroblasts from periprosthetic membrane.	naringin	19-27	TNF superfamily member 11	Homo sapiens	40-45
33007291-10	2020	Gene expression analysis by microarrays showed that AP-002 significantly reverses the effects of RANKL-induced gene expression.	UNII-R3G3HB38O4	52-58	TNF superfamily member 11	Homo sapiens	97-102
33375370-2	2020	Calcium oscillations (Ca oscillations) are well-known phenomena in receptor activator of nuclear factor kappa B ligand (RANKL)-induced osteoclastogenesis and bone resorption via calcineurin.	Calcium	0-7	TNF superfamily member 11	Homo sapiens	67-118
33375370-2	2020	Calcium oscillations (Ca oscillations) are well-known phenomena in receptor activator of nuclear factor kappa B ligand (RANKL)-induced osteoclastogenesis and bone resorption via calcineurin.	Calcium	0-7	TNF superfamily member 11	Homo sapiens	120-125
33374546-0	2020	Bisphosphonates Reduce Smoking-Induced Osteoporotic-Like Alterations by Regulating RANKL/OPG in an Osteoblast and Osteoclast Co-Culture Model.	Diphosphonates	0-15	TNF superfamily member 11	Homo sapiens	83-88
33374546-5	2020	Our results showed that BPs were able to reduce CSE-induced osteoporotic alterations in the co-culture of osteoblasts and osteoclasts such as decreased matrix remodeling, enhanced osteoclast activation, and an up-regulated receptor activator of nuclear factor (NF)-kB-ligand (RANKL)/osteoprotegerin (OPG) ratio.	Diphosphonates	24-27	TNF superfamily member 11	Homo sapiens	276-281
33374546-6	2020	In summary, BPs may be an effective alternative therapy for reversing osteoporotic alterations in smokers, and the potential mechanism is through modulation of the RANKL/OPG ratio.	Diphosphonates	12-15	TNF superfamily member 11	Homo sapiens	164-169
32221769-0	2020	The effect of low-level laser radiation and doxycycline on the levels of osteoprotegerin and receptor activator of nuclear factor kappa-B ligand.	Doxycycline	44-55	TNF superfamily member 11	Homo sapiens	93-144
33343723-4	2020	Naringin also inhibits osteoclastogenesis by both modifying RANK/RANKL interactions and inducing apoptosis in osteoclasts in vitro.	naringin	0-8	TNF superfamily member 11	Homo sapiens	65-70
32667225-1	2020	This study is focussed on evaluating and comparing two mediators of osteoclast, osteoprotegerin (OPG) and nuclear factor-kappaB ligand (RANKL), in plasma and tissue levels in patients with steroid-induced osteonecrosis of femoral head (SIONFH).	Steroids	189-196	TNF superfamily member 11	Homo sapiens	136-141
33039968-0	2020	Carnosol attenuates RANKL-induced osteoclastogenesis in vitro and LPS-induced bone loss.	carnosol	0-8	TNF superfamily member 11	Homo sapiens	20-25
33039968-5	2020	In this study, we found that carnosol can impede RANKL-induced osteoclastogenesis via modulating the activation of NF-kappab and JNK signaling pathways in vitro.	carnosol	29-37	TNF superfamily member 11	Homo sapiens	49-54
33049108-10	2020	Moreover, metformin treatment enhanced the expression of pro-angiogenic/osteogenic growth factors BMP2 and VEGF but reduced the osteoclastogenic factor RANKL/OPG expression in SHEDs.	Metformin	10-19	TNF superfamily member 11	Homo sapiens	152-157
32221769-1	2020	The present in vitro study was conducted to investigate the effect of low-level laser (LLL) radiation and doxycycline on the levels of osteoprotegerin (OPG) and receptor activator of nuclear factor kappa-B ligand (RANKL) derived from MG-63 osteosarcoma cell line.	Doxycycline	106-117	TNF superfamily member 11	Homo sapiens	161-212
32221769-11	2020	The highest to lowest levels of RANKL was observed in the doxycycline, laser + doxycycline, control, and laser groups, respectively.	Doxycycline	58-69	TNF superfamily member 11	Homo sapiens	32-37
32221769-11	2020	The highest to lowest levels of RANKL was observed in the doxycycline, laser + doxycycline, control, and laser groups, respectively.	Doxycycline	79-90	TNF superfamily member 11	Homo sapiens	32-37
32221769-13	2020	The results of this study revealed that LLL and doxycycline reduced the RANKL/OPG ratio derived from the MG-63 osteosarcoma cell line, which may result in the diminished activity of osteoclasts and osteoclastogenesis.	Doxycycline	48-59	TNF superfamily member 11	Homo sapiens	72-77
33065485-5	2020	Therefore, the aim of the present study was to investigate and compare the influence of the anti-RANKL antibody denosumab and bisphosphonates on the gene expression of selected AMPs: human alpha-defensin-1, human alpha-defensin-3, human beta-defensin-1, and human beta-defensin-3.	Adenylyl sulfate	177-181	TNF superfamily member 11	Homo sapiens	97-102
33238590-1	2020	The bone protective effects of carotenoids have been demonstrated in several studies, and the inhibition of RANKL-induced osteoclast differentiation by lycopene has also been demonstrated.	Lycopene	152-160	TNF superfamily member 11	Homo sapiens	108-113
33207822-7	2020	Catechin effects can be directly exerted on pre-osteoclasts/osteoclasts or indirectly exerted via the modulation of mesenchymal stem cells (MSCs)/stromal cell regulation of pre-osteoclasts through activation of the nuclear factor kB (RANK)/RANK ligand (RANKL)/osteoprotegerin (OPG) system.	Catechin	0-8	TNF superfamily member 11	Homo sapiens	253-258